---
document_datetime: 2023-09-21 17:42:21
document_pages: 138
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/lixiana-epar-public-assessment-report_en.pdf
document_name: lixiana-epar-public-assessment-report_en.pdf
version: success
processing_time: 169.9523112
conversion_datetime: 2025-12-19 01:42:14.198623
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
<!-- image -->

23 April 2015 EMA/321083/2015 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Lixiana

International non-proprietary name: edoxaban

Procedure No. EMEA/H/C/002629/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                               | ..............................................7                                                           |
|--------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier                                                                                           | .....................................................................................7                    |
| 1.2. Manufacturers                                                                                                       | .....................................................................................................8    |
| 1.3. Steps taken for the assessment of the product                                                                       | ........................................................8                                                 |
| 2. Scientific discussion                                                                                                 | ..............................................................................10                          |
| 2.1. Introduction                                                                                                        | ...................................................................................................... 10 |
| 2.2. Quality aspects..................................................................................................   | 11                                                                                                        |
| 2.2.1. Introduction                                                                                                      | ................................................................................................... 11    |
| 2.2.2. Active Substance.............................................................................................     | 11                                                                                                        |
| 2.2.3. Finished Medicinal Product................................................................................        | 14                                                                                                        |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects                                                     | ............................. 17                                                                          |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                                | ...................... 17                                                                                 |
| 2.2.6. Recommendations for future quality development ...............................................                    | 17                                                                                                        |
| 2.3. Non-clinical aspects............................................................................................    | 17                                                                                                        |
| 2.3.1. Introduction                                                                                                      | ................................................................................................... 17    |
| 2.3.2. Pharmacology.................................................................................................     | 17                                                                                                        |
| 2.3.3. Pharmacokinetics ............................................................................................     | 19                                                                                                        |
| 2.3.4. Toxicology......................................................................................................  | 21                                                                                                        |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................                | 23                                                                                                        |
| 2.3.6. Discussion on non-clinical aspects .....................................................................          | 26                                                                                                        |
| 2.3.7. Conclusion on the non-clinical aspects ...............................................................            | 27                                                                                                        |
| 2.4. Clinical aspects..................................................................................................  | 28                                                                                                        |
| 2.4.1. Introduction                                                                                                      | ................................................................................................... 28    |
| 2.4.2. Pharmacokinetics ............................................................................................     | 36                                                                                                        |
| 2.4.3. Pharmacodynamics..........................................................................................        | 43                                                                                                        |
| 2.4.4. Discussion on clinical pharmacology                                                                               | .................................................................. 51                                     |
| 2.4.5. Conclusions on clinical pharmacology.................................................................             | 54                                                                                                        |
| 2.5. Clinical efficacy.................................................................................................. | 55                                                                                                        |
| 2.5.1. Dose response studies                                                                                             | ..................................................................................... 55                  |
| 2.5.2. Main studies                                                                                                      | ................................................................................................... 59    |
| 2.5.3. Discussion on clinical efficacy............................................................................       | 91                                                                                                        |
| 2.5.4. Conclusions on the clinical efficacy ..................................................................           | 105                                                                                                       |
| 2.6. Clinical safety                                                                                                     | .................................................................................................. 107    |
| 2.6.1. Discussion on clinical safety............................................................................         | 123                                                                                                       |
| 2.6.2. Conclusions on the clinical safety ....................................................................           | 124                                                                                                       |
| 2.7. Pharmacovigilance ...........................................................................................       | 124                                                                                                       |
| 2.8. Risk Management Plan......................................................................................          | 124                                                                                                       |
| 2.9. Product information..........................................................................................       | 129                                                                                                       |
| 2.9.1. User consultation ..........................................................................................      | 129                                                                                                       |
| 2.9.2. Package leaflet                                                                                                   | ............................................................................................. 129         |
| 3. Benefit-Risk Balance ........................................................................... 4.                   | 130 Recommendations...............................................................................136     |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| Abbreviation       | Definition                                                                                                                                                                      |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| ACCP               | AmericanCollege of Chest Physicians                                                                                                                                             |
| ADME               | absorption, distribution, metabolism, excretion                                                                                                                                 |
| AF                 | Atrial fibrillation                                                                                                                                                             |
| aPTT               | activated partial thromboplastin time                                                                                                                                           |
| AUC                | area under the concentration-time curve                                                                                                                                         |
| AUC 0-inf, AUC 0-∞ | area under the concentration-time curve from time zero to infinity                                                                                                              |
| AUC 0-t            | area under the concentration-time curve from time zero to time of the last quantifiable concentration                                                                           |
| BA                 | Bioavailability                                                                                                                                                                 |
| BCS                | Biopharmaceutic Classification System                                                                                                                                           |
| BE                 | Bioequivalence                                                                                                                                                                  |
| BID                | Bis in die (twice daily)                                                                                                                                                        |
| CEC                | Clinical Events Committee                                                                                                                                                       |
| CES1               | Carboxylesterase 1                                                                                                                                                              |
| CHADS 2            | Index score for stroke prediction based on the scoring system for Congestive heart failure, Hypertension, Age≥75, Diabetes, previous Stroke/Transient Ischemic Attack (doubled) |
| CHA 2 DS 2 -VASc   | Congestive heart failure or left ventricular dysfunction, Hypertension, Age≥75 (doubled), Diabetes, Stroke (doubled) - Vascular disease, Age 65-74, Sex category (female)       |
| CHF                | Congestive heart failure                                                                                                                                                        |
| CI                 | confidence interval                                                                                                                                                             |
| CLcr or CrCL       | creatinine clearance                                                                                                                                                            |
| CLr or CL R /F     | renal clearance                                                                                                                                                                 |
| CL NR /F           | non-renal clearance                                                                                                                                                             |
| CLT                | total body clearance                                                                                                                                                            |
| CLT/F or CL/F      | apparent clearance                                                                                                                                                              |
| CMAs               | critical material attributes                                                                                                                                                    |
| Cmax               | maximum concentration                                                                                                                                                           |
| Cmin               | trough concentration                                                                                                                                                            |
| CPPs               | critical process parameters                                                                                                                                                     |
| CQAs               | critical quality attributes                                                                                                                                                     |
| CRF                | Case report form                                                                                                                                                                |
| CRNM               | Clinically relevant non-major (bleed)                                                                                                                                           |
| CSED               | Common study end date                                                                                                                                                           |
| CSR                | Clinical Study Report                                                                                                                                                           |
| CT/CAT             | Computed tomography                                                                                                                                                             |
| CV                 | coefficient of variation                                                                                                                                                        |
| CYP                | cytochrome P-450                                                                                                                                                                |
| DDI                | Drug-drug interaction                                                                                                                                                           |
| DMC                | Data Monitoring Committee                                                                                                                                                       |
| DOE                | design of experiments                                                                                                                                                           |
| DVT                | Deep vein thrombosis                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Abbreviation           | Definition                                                                                                                                |
|------------------------|-------------------------------------------------------------------------------------------------------------------------------------------|
| eg                     | exampli gratia (for example)                                                                                                              |
| EOT                    | End of treatment (date)                                                                                                                   |
| F                      | absolute bioavailability                                                                                                                  |
| FDA                    | Food and Drug Administration                                                                                                              |
| FEIBA                  | Factor eight inhibitor bypassing activity                                                                                                 |
| FXa                    | Factor Xa                                                                                                                                 |
| GC                     | gas chromatography                                                                                                                        |
| HAS-BLED               | Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly |
| HPLC                   | high-performance liquid chromatography                                                                                                    |
| HPLC/MS/MS, HPLC-MS/MS | high-performance liquid chromatography with mass spectroscopy detection                                                                   |
| HR                     | Hazard ratio                                                                                                                              |
| ICH                    | International Conference of Harmonization                                                                                                 |
| ICH                    | Intracranial hemorrhage                                                                                                                   |
| IDMC                   | Independent Data Monitoring Committee                                                                                                     |
| ie,                    | id est (that is)                                                                                                                          |
| INR                    | international normalised ratio                                                                                                            |
| IPC                    | In-process control                                                                                                                        |
| IR                     | Infrared                                                                                                                                  |
| ISS                    | Integrated Summary of Safety                                                                                                              |
| ISTH                   | International Society of Thrombosis and Hemostasis                                                                                        |
| ITT                    | Intent-to-treat                                                                                                                           |
| IXRS                   | Interactive voice/web response system                                                                                                     |
| JP                     | Japanese Pharmacopoeia                                                                                                                    |
| KF                     | Karl Fischer                                                                                                                              |
| LLQ or LLOQ            | lower limit of quantitation                                                                                                               |
| LMWH                   | Low molecular weight heparin                                                                                                              |
| LSLV                   | Last subject last visit                                                                                                                   |
| LSM                    | Least squares mean                                                                                                                        |
| MS                     | Mass Spectrometry                                                                                                                         |
| NIR                    | Near Infrared Spectroscopy                                                                                                                |
| NMR                    | Nuclear Magnetic Resonance                                                                                                                |
| MACE                   | Major adverse cardiovascular events                                                                                                       |
| MedDRA                 | Medical Dictionary for Regulatory Activities                                                                                              |
| MI                     | Myocardial infarction                                                                                                                     |
| mITT                   | Modified intent-to-treat                                                                                                                  |
| mPT                    | modified prothrombin time                                                                                                                 |
| MS                     | mass spectrometry                                                                                                                         |
| NA                     | Not applicable                                                                                                                            |
| NC                     | Not calculated                                                                                                                            |
| ND                     | Not determined                                                                                                                            |
| NOAC                   | Novel oral anticoagulant                                                                                                                  |
| NVAF                   | Non-valvular atrial fibrillation                                                                                                          |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                            |
|----------------|-------------------------------------------------------|
| OATP           | Organic anion transporting peptide                    |
| PARs           | proven acceptable ranges                              |
| PAT            | Process Analytical Technology                         |
| PCC            | Prothrombin complex concentrate                       |
| PD             | pharmacodynamics                                      |
| PE             | Pulmonary embolism                                    |
| Ph. Eur.       | European Pharmacopoeia                                |
| PK             | pharmacokinetics                                      |
| P-gp           | P-glycoprotein                                        |
| PMDA           | Pharmaceuticals and Medical Devices Agency, Japan     |
| PO             | per os (oral)                                         |
| PopPK          | Population pharmacokinetics                           |
| PP             | Per Protocol                                          |
| PT             | prothrombin time                                      |
| PT             | Preferred Term                                        |
| PVC            | Polyvinyl chloride                                    |
| RH             | Relative Humidity                                     |
| RP-HPLC        | reversed phase High Performance Liquid Chromatography |
| RTRT           | real time release testing                             |
| RV             | Right ventricular                                     |
| QbD            | Quality by Design                                     |
| QD             | Quaque diem (once daily)                              |
| QID            | Four times daily                                      |
| QTc            | Corrected QT interval                                 |
| QTPP           | quality target product profile                        |
| SA             | Scientific Advice                                     |
| SAE            | Serious Adverse Event                                 |
| SC             | Subcutaneous                                          |
| SD             | standard deviation                                    |
| SEE            | Systemic embolic event                                |
| SLP            | slope of linear proportionality                       |
| SmPC           | Summary of Product Characteristics                    |
| SMQ            | Standard MedDRA query                                 |
| SOC            | System Organ Class                                    |
| TEAE           | Treatment-emergent adverse event                      |
| THR            | total hip replacement                                 |
| TIA            | Transient ischemic attack                             |
| TID            | Three times daily                                     |
| t 1/2          | half-life                                             |
| TKR            | total knee replacement                                |
| Tmax           | time of maximum observed concentration                |
| TTR            | Time in therapeutic range (refers to INR values)      |
| UFH            | Unfractionated heparin                                |
| ULN            | upper limit of normal                                 |

<div style=\"page-break-after: always\"></div>

| Abbreviation   | Definition                                      |
|----------------|-------------------------------------------------|
| UV             | Ultraviolet                                     |
| VKA            | Vitamin K antagonist                            |
| Vss            | Apparent volume of distribution at steady state |
| VTE            | Venous thromboembolism                          |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Daiichi Sankyo Europe GmbH submitted on 7 January 2014 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Lixiana, through the centralised procedure under Article 3 (2) (a) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 22 September 2011.

The applicant applied for the following indication:

- Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

-  Treatment  of  venous  thromboembolism  (VTE)  including  deep  vein  thrombosis  (DVT)  and pulmonaryembolism (PE), and prevention of recurrent VTE in adults.

## The legal basis for this application refers to:

Article 8.3 of Directive 2001/83/EC - complete and independent application. The applicant indicated that edoxaban was considered to be a new active substance.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0028/2014 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0028/2014 was not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000,  the  applicant  did  not  submit  a  critical  report  addressing  the  possible  similarity  with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Applicant's request for consideration

## New active Substance status

The applicant requested the active substance edoxaban contained in the above medicinal product to be considered as a new active substance in itself, as the applicant claims that it is not a constituent of a product previously authorised within the Union.

<div style=\"page-break-after: always\"></div>

## Scientific Advice

Scientific Advice from the EMEA was sought on 24 April 2008, 22 January 2009 and 14 April 2011 for the development of the NVAF indication. As a result of these meetings, a number of approaches were agreed and changes to the Phase 3 pivotal study made. Some of the key points are summarized hereafter: a) The doses for Phase 3 were agreed to be acceptable; b) The primary efficacy and safety endpoints were acceptable and a focus on cardiovascular and all-cause mortality was established; c) The inclusion and exclusion criteria were clarified and in particular subjects with AF secondary to severe valvular disease were excluded while subjects with bioprosthetic valves were permitted; d) The justification for the non-inferiority margin and the statistical testing to support a single pivotal study  were  not  fully  agreed.  It  was  agreed  that  the  primary  analysis  for  the  EU  would  be  the per-protocol population and the overall study period and the results would need to be consistent across the endpoints.

For  the  development  of  the  VTE  indication,  scientific  advice  was  sought  from  the  CHMP  on  24 September 2009: a) The doses for Phase 3 were agreed to be acceptable; b)The primary efficacy and safety endpoints were acceptable and a focus on cardiovascular mortality was established; c)The justification for the non-inferiority margin and the statistical testing to support a single pivotal study were not fully resolved. In response to regulatory feedback, the non-inferiority margin of the study was made more stringent so that a minimum of 70% of the efficacy of the heparin and warfarin regimen  was  maintained;  d)  A  point  of  concern  for  the  CHMP  was  the  decision  for  duration  of treatment could be taken after randomization. The applicant has been mindful of this concern in analyzing and presenting the results; e) It was agreed that the primary analysis for the EU would be the per-protocol population and the period from randomization to 30 days after the last dose and the results would need to be consistent across the endpoints.

During the current clinical  development,  the EMA Guideline on clinical investigation  of  medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation  (EMA/CHMP/341363/2014 )  has  been  drafted  and  came  into  effect  on  26th  December 2014. The compliance of the pivotal study in NVAF to the available Guideline is discussed under the efficacy endpoints. In addition, a revision of the EMA Note for Guidance on clinical investigation of medicinal  products  for  the  treatment  of  venous  thromboembolic  disease  (CPMP/EWP/563/98) is currently ongoing.

## Licensing status

Lixiana has been given a Marketing Authorisation in Japan on 21 April 2011 and in the US on 8 January 2015.

## 1.2. Manufacturers

## Manufacturer responsible for batch release

Daiichi Sankyo Europe GmbH Luitpoldstrasse 1, Pfaffenhofen, Bayern, 85276, Germany

## 1.3. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Concepcion Prieto Yerro

<div style=\"page-break-after: always\"></div>

Co-Rapporteur:   Martina Weise

- The application was received by the EMA on 7 January 2014.
- The procedure started on 26 February 2014.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 23 May 2014. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 19 May 2014 .
- PRAC Rapporteur's Risk Management Plan (RMP) Assessment Report as endorsed by PRAC on 13 June 2014.
- During the meeting on 26 June 2014, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 27 June 2014.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 18 September 2014.
- The summary report of the inspection carried out at the following site Daiichi Sankyo Europe GmbH Luitpoldstrasse 1, Pfaffenhofen, Bayern, 85276, Germanybetween 26/09/2014 and 01/10/2014 was issued on 16/12/2014.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 3 November 2014 .
- PRAC RMP Advice and assessment overview, adopted on 6 November 2014.
- During the CHMP meeting on 20 November 2014, the CHMP agreed on a list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 22 December 2014.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on 12 January 2015 .
- During the CHMP meeting on 22 January 2015, the CHMP agreed on a 2 nd  list of outstanding issues to be addressed in writing and/or in an oral explanation by the applicant.
- The applicant submitted the responses to the CHMP List of Outstanding Issues on 26 January 2015.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the 2 nd List of Outstanding Issues to all CHMP members on 9 February 2015.
- The Rapporteurs circulated the Joint updated Assessment Report on the applicant's responses to the 2 nd  List of Outstanding Issues to all CHMP members on 20 February 2015.
- During the CHMP meeting on 24 February 2015, outstanding issues were addressed by the applicant during an oral explanation before the CHMP.
- PRAC Rapporteur's Risk Management Plan (RMP) Assessment Report as endorsed by PRAC on 10 April 2015.
- During the meeting on 23 April 2015 , the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Lixiana.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Introduction

Atrial fibrillation (AF) represents the most common sustained cardiac arrhythmia, affecting more than 6 million people in Europe 1 . AF, particularly when it is persistent/permanent, predisposes patients to the development of atrial thrombi, which may embolize to the systemic circulation, being associated with a 4- to 5-fold increase in the risk of ischemic stroke and systemic embolic events (SEE) 2 . Vitamin K  antagonists  (VKA;  coumarins,  like  warfarin  and  acenocoumarol)  have  been  the  only  oral anticoagulants  available  over  the  last  60  years.  These  agents  are  effective  to  prevent  stroke  in patients with AF, but their management remains problematic due to their narrow therapeutic index and variability in drug exposure, necessitating routine coagulation monitoring, clinical surveillance, and continuous patient education 3 . Such monitoring is inconvenient for patients and medical staff, and costly for healthcare payers. As a result, approximately only half of eligible patients with AF receive oral anticoagulation with VKA.

Venous  thromboembolism  (VTE),  encompassing  deep  vein  thrombosis  (DVT)  and  pulmonary embolism  (PE),  is  the  third  leading  mortality  cause  due  to  circulatory  diseases,  only  behind  of myocardial infarction and stroke. Current guidelines recommend treating patients with acute VTE with an oral VKA for at least 3 months 4 . As VKA have a slow onset of action, overlapping with a parenteral anticoagulant  [e.g.:  low  molecular  weight  heparin  (LMWH)  or  unfractionated  heparin  (UFH)]  is needed for the initial 5-10 days of acute VTE, until appropriate anticoagulation with VKA is achieved [i.e.: international normalized ratio (INR) between 2.0 and 3.0].  LMWH are effective and safe also for the  long-term  treatment  of  VTE.  However,  they  still  require  daily  parenteral  subcutaneous  (SC) administration,  which  may  be  problematic  for  many  patients.  On  the  other  hand,  the  VKA  have several limitations, as mentioned in previous paragraph.

Direct oral anticoagulants (DOAC) are currently available in the EU and other regions for several indications, including prevention of stroke/SEE in NVAF and/or treatment of VTE: the direct thrombin inhibitor dabigatran (as etexilate) and the direct factor Xa inhibitors rivaroxaban and apixaban. Unlike VKA,  these  new  compounds  exhibit  a  predictable  dose  response  and  do  not  require  routine coagulation monitoring, but their anticoagulant effect declines quickly in case of poor compliance and no widely available coagulation monitoring tests or specific antidotes are currently available 5 . The pivotal studies conducted with the DOAC in prevention of stroke/SEE in NVAF or treatment of VTE were mainly large non-inferiority event-driven clinical trials recruiting heterogeneous populations in different  geographic  regions  and  with  different  quality  of  oral  anticoagulation  with  warfarin.  The potential influence of differences in clinical, geographic factors and quality of oral anticoagulation across studies on the relative efficacy and safety of the NOAC, as well as the clinical relevance of these differences, may be significant, particularly in NVAF indication 6 .

Edoxaban is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). The prefix 'edo' is a tribute to the old imperial city called 'Edo' (now Tokyo), while the suffix 'xaban' is the common family name of the direct factor Xa inhibitors. Factor Xa plays a pivotal role in the coagulation cascade because it sits at the junction of the intrinsic and extrinsic pathways of the coagulation  system.  Inhibition  of  FXa  is  exerting  anticoagulant  and  antithrombotic  effects  by decreasing the conversion of prothrombin to active thrombin, thereby diminishing thrombin-mediated activation of the coagulation process, including fibrin formation and platelet activation.

1 Camm AJ, et al. Eur Heart J. 2010; 31: 2369-429.

2 Camm AJ, et al. Eur Heart J. 2010; 31: 2369-429.

3 Ansell J, et al. Chest. 2008;133:160S-198S.

4 Kearon C, et al. Chest. 2012;141(2 Suppl):e419S-e494S.

5 Gómez-Outes A, et al. Curr Drug Discov Technol. 2012;9:83-104.

6  Gómez-Outes A, et al. Thrombosis. 2013:640723.

<div style=\"page-break-after: always\"></div>

Currently,  edoxaban  is  approved  in  Japan  for  prophylaxis  of  venous  thromboembolism  (VTE)  in subjects undergoing orthopedic surgeries and in the US to reduce the risk of stroke and systemic embolism (SE) in patients with NVAF and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE).

The CHMP granted the positive opinion for the following indications:

Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).

For the prevention of stroke and systemic embolism , the recommended dose is 60 mg Lixiana once daily.  For the  treatment  of  VTE  including  DVT  and  PE , and  prevention  of  recurrent  VTE ,  the recommended dose is 60 mg Lixiana once daily following initial use of heparin. For NVAF and VTE the recommended dose is 30 mg Lixiana once daily in patients with one or more of the following clinical factors: a) moderate or severe renal impairment (creatinine clearance: 15-50 ml/min); b) low body weight ≤60 kg; c) concomitant use of the following P-glycoprotein (P-gp) inhibitors: ciclosporine, dronedarone, erythromycin, ketoconazole.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as immediate release tablets containing 15 mg, 30 mg or 60 mg of edoxaban tosilate as active substance.

Other ingredients are:

Tablet core: mannitol (E421), pregelatinised starch, crospovidone, hydroxypropylcellulose, magnesium stearate (E470b);

Film-coat: hypromellose (E464), macrogol 8000, titanium dioxide (E171), talc, carnauba wax, iron oxide yellow (E172), iron oxide red (E172).

The product is available in PVC/aluminium blisters.

## 2.2.2. Active Substance

## General information

The chemical name of edoxaban tosilate is N -(5-chloropyridin-2-yl)N '-[(1 S ,2 R ,4 S )-4

( N , N -dimethylcarbamoyl)-

2-(5-methyl-4,5,6,7-tetrahydro[1,3]thiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl]oxamide mono(4-methylbenzenesulfonate) monohydrate and it has the following structure:

<div style=\"page-break-after: always\"></div>

<!-- image -->

The chemical structure of edoxaban tosilate has been confirmed by elemental analysis, spectroscopic techniques (UV, IR,  1 H and  13 C NMR), mass spectrometry and single X-ray structure analysis.

The active substance is a white to pale yellowish-white non-hygroscopic crystalline powder which is practically  insoluble  in  isopropanol  and  ethyl  acetate,  slightly  soluble  in  water,  ethanol  and acetonitrile, soluble in methanol and freely soluble in DMSO and N , N -dimethylformamide.

Edoxaban  exhibits  stereoisomerism  due  to  the  presence  of  three  chiral  centres.  The  chirality  of edoxaban is determined by the synthesis of the relevant starting material and is controlled by the specification of this starting material.

Edoxaban tosilate exists in two polymorphic forms, form I (thermodynamically most stable form) and form II. The crystalline form consistently produced by the proposed synthetic route is form I. In addition, the results from the stability studies conducted on edoxaban tosilate show no evidence of conversion between form I to form II.

## Manufacture, characterisation and process controls

Edoxaban  tosilate  is  synthesized  by  two  manufacturers  in  a  three  arm  convergent  synthesis comprising  six  main  stages  using  well-defined  starting  materials  with  acceptable  specifications, followed by crystallization and milling. However, at the time of opinion the HPLC method developed to test one of the starting materials was not capable of identifying its oxalate counter ion. Therefore, the applicant is recommended to develop a specific test for the identification of the oxalate in this starting material.  The  stereocentres  introduced  in  this  starting  material  are  stable  to  epimerization  in subsequent synthetic steps.

The particle size of edoxaban tosilate affects its dissolution and is therefore a critical quality attribute (CQA) of the finished product. Several design of experiments (DOEs) were conducted to determine the optimal crystallization process and milling conditions leading to the desired particle size distribution. These included the evaluation of three critical process parameters: pulverization hammer revolution, separator rotor revolution and flow rate. Based in these studies, proven acceptable ranges (PARs) were defined for these parameters. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin and characterised. A potentially genotoxic reagent is used in the final synthetic step. It was stated that this reagent converts to a non-mutagenic compound under the subsequent acidic crystallisation conditions, and also in the acidic stomach environment when orally administered. However, no specific analytical method for quantification of this reagent is available. The applicant provided data demonstrating that the reagent is genotoxic in vitro , but not in a series of in vivo studies and therefore, no further in vivo mutagenicity studies are required and this reagent can be considered as a class 4 impurity according to ICH M7.

<div style=\"page-break-after: always\"></div>

Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting materials and reagents have been presented and are acceptable with the exception of potential benzene in some organic solvents. The applicant is recommended to develop a GC method to test potential benzene levels in ethanol, methanol, isopropyl alcohol and n -hexane and update their specifications if required.

## Specification

The  active  substance  specification  includes  tests  for  appearance,  identity  (IR,  RP-HPLC),  assay (RP-HPLC), impurities (RP-HPLC, chiral HPLC), residual solvents (GC), water content (KF), heavy metals (JP), residue on ignition (Ph. Eur.), particle size distribution (Ph. Eur.) and microbial limits (Ph. Eur.).

The  analytical  methods  used  have  been  adequately  described  and  non-compendial  methods appropriately validated in accordance with the ICH guidelines.

The method from the Japanese Pharmacopeia (JP) used for the determination of heavy metals was cross validated against Ph. Eur. monograph, confirming the applicability of both methods as a limit test method for heavy metals in edoxaban tosilate drug substance.

Batch analysis data on fifteen pilot scale batches manufactured during the development program and five commercial scale batches of the active substance were provided. The results were within the specifications and consistent from batch to batch.

## Stability

Stability data on three pilot scale batches of active substance from a development site and three commercial scale batches from one of the proposed manufacturers stored in a container closure system representative of that intended for the market for up to 36 months (pilot scale batches) or up to 6 months (commercial scale batches) months under long term conditions at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided.  The following parameters were tested: appearance, colour, optical rotation, identification, assay, related substances, residual solvents, water content, particle size distribution, crystallinity, thermal analysis and microbial purity. The analytical methods used were the same as for release and are stability indicating. For the additional tests performed as part of primary stability studies, which are not part of the release/shelf-life specification, (colour, optical rotation, some related substances, crystallinity, thermal analysis and microbial purity), adequate validation data have been provided. All results were within the proposed specification, and no differences were observed in stability behaviour between the pilot and the commercial scale batches.

Forced degradation studies were performed by exposing solutions of active substance to acid, base, oxidant and solid samples to heat and humidity (25 ºC /33% RH, 25 ºC /93% RH, 40 ºC /75% RH), heat (60 ºC) or light. The results from these studies demonstrated that the active substance is stable to all tested conditions in the solid state but degrades in solution.

In  addition,  one  pilot-scale  batch  was  exposed  to  light  as  defined  in  the  ICH  Guideline  on photostability testing of new drug substances and products. The appearance of the drug substance remained as 'white powder' following exposure to the light conditions. There was no observed change in the impurity profile throughout the study, specifically no new degradation products were observed and no change enantiomeric and stereoisomeric content was detected, confirming that edoxaban tosilate is photostable.

The stability results indicate that the drug substance manufactured by the proposed suppliers is sufficiently stable. The stability results justify the proposed retest period in the proposed container.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and pharmaceutical development

The drug product is presented as film-coated, immediate-release tablets available in three strengths: 15 mg, 30 mg and 60 mg.

The  quality  target  product  profile  (QTPP)  was  defined  as  immediate  release  film-coated  tablets containing  15  mg,  30  mg  or  60  mg  of  edoxaban,  which  can  be  discriminated  visually  (by  size, film-coating  colour  and  debossed  information),  and  meet  compendial  and  other  relevant  quality standards.

The  critical  quality  attributes  identified  were  assay,  uniformity  of  dosage  units,  dissolution, appearance, identity and impurities. Prior knowledge, DOE and mathematical models were applied to identify critical material attributes (CMAs) and critical process parameters (CPPs).

Since edoxaban tosilate is a low solubility compound, studies were conducted to evaluate the impact of its particle size on the drug product dissolution rate and content uniformity. The results from these studies showed that the particle size of the active substance had an impact on the dissolution rate, but not on the content uniformity. Therefore, edoxaban tosilate particle size is reduced during the last step of the manufacturing process of the active substance by milling. X-ray powder diffraction studies confirmed that the polymorphic form I is not changed during the drug product manufacturing process.

The selection of excipients and their target concentrations was conducted using a computer system that identified the initial formulation, followed by a diluent selection study, a disintegrant selection study and DOE to determine the final target concentration for the binder, disintegrant and lubricant based on their impact on dissolution performance and tablet hardness. Additionally, a compatibility study using binary mixtures of excipient-drug substance was performed to evaluate the stability of the potential formulations. Based on these studies, mannitol and pregelatinised starch were selected as diluents, crospovidone as disintegrant, hydroxypopyl cellulose as binder and magnesium stearate as lubricant.

Optimisation  of  the  film  coating  was  next  undertaken.  Colouring  agents  were  incorporated  to differentiate the tablet strengths for commercial use.

All excipients used are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur. standards. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

The  pharmaceutical  development  was  conducted  using  Quality  by  Design  (QbD)  principles.  The applicant proposed some 'in-house' terminology which slightly deviated from that one included in ICH guidelines. This is not acceptable and was clarified during the assessment process.

In particular, according to ICH guidance, design spaces are built from CPPs and CMAs of the input materials.  However,  the  applicant  instead  proposed  design  spaces  for  three  drug  product  CQAs, (content uniformity, assay and dissolution), built from CMAs of the output materials (in this case, intermediates) so that they were scale independent. Since the applicant defines the design spaces based on CMAs of intermediates in the manufacturing process and not on input parameters, the ICH definition is not met. However, no regulatory flexibility in terms of process parameters as described in ICH Q8-Q10 was claimed.

Prior knowledge and preliminary hazard analysis (PHA) and failure mode and effects analysis (FMEA) risk assessments were applied to identify CMAs of the API, excipients and in-process materials, and the  impact  of  the  manufacturing  process  unit  operations  (granulation,  blending,  tableting  and film-coating) on the CQAs. PHA and FMEA risk assessments were also performed to identify the CPPs

<div style=\"page-break-after: always\"></div>

which need to be controlled to ensure that the CMAs remain within their target ranges, which in turn ensure that the CQAs of the finished product are attained.

The design spaces were developed at pilot scale. The verification of the design space for content uniformity and assay was performed at commercial scale, but only with the 15 mg strength. The verification of the design space for dissolution was performed with all three strengths, but only at one third of commercial scale. Taking into account that the CMAs of the design spaces are scale independent the verification is considered sufficient.

The formulation used during clinical studies is the same that the used for marketing.

With  regards  to  dissolution  method  development,  a  study  was  conducted  to  evaluate  which  pH medium had the best discriminatory capability when varying typical CMAs. The results from these studies demonstrated that the selected pH had adequate discriminatory capability whilst maintaining sink conditions.

The  primary  packaging  is  a  PVC/aluminum  blister.  The  material  complies  with  Ph.  Eur.  and  EC requirements. The choice of the container closure system has been validated by stability data and is adequate for the intended use of the product.

## Manufacture of the product and process controls

The manufacturing process of Lixiana tablets consists of four main steps: fluid bed granulation; blending; tableting; film-coating. The tablets are manufactured from a common granulate and are quantitatively proportional. The process is considered to be a standard manufacturing process

As described under the pharmaceutical development section the CQAs of Lixiana tablets are ensured by controlling CMAs within defined design spaces. The control strategy for commercial batches uses process  analytical  technology  (PAT)  to  ensure  the  intermediate  CMAs  are  met.  It  has  been demonstrated that these CMAs act as surrogates for Lixiana CQAs which in turn allows a real time release testing (RTRT) strategy to be employed. In addition, some traditional in-process controls (IPCs) are also conducted to verify that each unit operation is carried out as planned.

A hybrid approach for process validation as described in the 'Guideline on process validation for finished products -information and data to be provided in regulatory submissions (EMA/CHMP/CVMP/QWP/BWP/70278/2012-Rev1)' has been followed. Traditional process validation has  been  followed  for  non-critical  manufacturing  steps,  and  a  continuous  process  verification approach for critical steps. A process validation scheme has been provided. To demonstrate and verify that the CQAs meet the specification, extensive in-line and at-line controls including PAT have been established.

It has been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner.

## Product specification

The finished product specifications include appropriate tests for this kind of dosage form and comprise appearance, identification (NIR, UV-Vis, HPLC), assay (NIR/gravimetry, HPLC), related substances (HPLC), uniformity of dosage units (NIR/gravimetry, Ph. Eur.), dissolution (NIR/laser diffraction/gravimetry/ thickness, Ph. Eur.), water content (KF), and microbial control (Ph. Eur.).

The absence on a test for enantiomer and stereoisomers content has been adequately justified based on the results from the stability studies.

The finished product is released onto the market through a combination of end product testing and RTRT. The strategy for RTRT has been described in detail, and verification tests against secondary

<div style=\"page-break-after: always\"></div>

methods have been adequately described. Parallel data comparing RTRT with equivalent end product release testing at commercial scale has also been provided.

Relevant information regarding chemometric model development, data collection, model calibration, method verification and model maintenance was provided. RTRT has been established for all the CQAs. Content uniformity, assay and dissolution would be monitored by the design spaces developed.

Batch analysis results are provided for batches of 15 mg (8 pilot, 1 commercial scale), 30 mg (6 pilot, 1 commercial scale) and 60 mg (8 pilot, 1 commercial) tablets confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

Analytical  procedures  have  been  adequately  described  and  validated  according  to  the  ICH  QR2 guideline  and  the  EMA  guideline  on  the  use  of  Near  Infrared  Spectroscopy  (NIRS)  by  the pharmaceutical industry.

## Stability of the product

Stability data on three pilot scale batches of finished product of each strength stored under long term (25 ºC / 60% RH) and intermediate (30 ºC /75% RH) conditions for up to 24 months, and under accelerated conditions (40 ºC / 75% RH) for up to 6 months according to the ICH guidelines were provided. The batches of medicinal product are representative of those proposed for marketing and were packed in the primary packaging proposed for marketing.

Samples were tested for appearance, assay, related substances, enantiomeric impurity, stereosisomer, dissolution, water content and microbial purity. The analytical procedures used are stability indicating.

Stress stability studies were also conducted on Lixiana bulk tablets for all three dosage strengths. Bulk tablets were stored at 60 °C in amber glass bottles closed and tested at the initial time-point and after 1 and 2 months. Bulk tablets of all three dosage strengths were stored in an open dish at 40 °C/75% RH and tested after 1, 2 and 3 months.

No  significant  changes  in  the  tested  parameters  appearance,  assay,  related  substances  and dissolution were reported under any of the conditions described above. An increase of the water content was observed but had no influence on the quality of the drug product.

In addition, one batch of each strength was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products showing that the product is photostable and no special protection from light is required.

In order to simulate short term temperature excursions during transportation, Lixiana tablets packed in the primary packaging material as well as in bulk containers were stored at 60 ºC for 7 days, and were subjected to a temperature cycling study over a period of 12 days.  No significant changes in the tested parameters were observed.

A freeze-thaw stability study on tablets stored in double aluminium blisters or aluminium/PVC blisters as  well  as  in  bulk  containers  was  also  conducted.  Samples  were  stored  under  thermal  cycling conditions for 12 days at alternating temperatures of 40 ºC (12 hours) and -20 ºC (12 hours). No significant changes in the tested parameters were observed, and the proposed transport conditions are therefore supported.

Based on available stability data, the shelf-life as stated in the SmPC is acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

<div style=\"page-break-after: always\"></div>

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Lixiana  is  presented  as  an  immediate-release  film-coated tablets  containing  15,  30  or  60  mg  of edoxaban tosilate as active substance.  Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The applicant has applied QbD principles in the development of the finished product and their manufacturing process. Design spaces based on critical material attributes have been proposed for assay, content uniformity and dissolution. The design spaces have been adequately verified. The applicant has applied for Real Time  Release  Testing  (RTRT)  for  the  drug  product  using  Near  Infra-Red  (NIR)  method  for identification,  assay  and  uniformity  of  dosage  units.  The  results  of  tests  carried  out  indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined  in  the  SmPC.  Physicochemical  and  biological  aspects  relevant  to  the  uniform  clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendations for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

-The applicant is recommended to introduce either a IR or HPLC identification test for oxalic acid in the relevant starting material.

-The applicant is recommended to develop a GC method to test potential benzene levels in ethanol, methanol, isopropyl alcohol and n-hexane and update their specifications.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

In vitro and in vivo primary pharmacology studies with edoxaban tosilate hydrate were conducted by the Applicant in order to elucidate its mechanism of action and assess its anticoagulant effect. In the primary pharmacology studies, inhibitory activities of edoxaban tosilate hydrate on factor Xa and the prothrombinase complex and its selectivity for factor Xa were examined in vitro to elucidate the mechanism of action. Edoxaban tosilate hydrate inhibited human factor Xa with a Ki value of 0.561 nM, and it also inhibited rabbit or cynomolgus monkey factor Xa with similar Ki values of 0.457 and 0.715 nM, respectively, whereas inhibition of rat factor Xa had an about 10-fold higher Ki value of 6.98 nM.

Detailed analysis of enzyme kinetics demonstrated that edoxaban tosilate hydrate is a competitive inhibitor  of  factor  Xa.  Although  edoxaban,  rivaroxaban  and  apixaban  have  different  chemical

<div style=\"page-break-after: always\"></div>

structures, X-ray analysis demonstrated that the binding sites for all three substances on factor Xa involve 2 distinct sites (S1 and S4), i.e. that the binding sites for these substances are at least overlapping  if  not  identical.  These  observations  might  be  of  relevance  for  the  development  of antagonists for factor Xa inhibitors.

The anticoagulant effect of the product (prolongation effect on clotting time) was assessed in vitro, as well as the inhibition of activity of factor Xa derived from mutant factor X and the pharmacological activities of several metabolites. Metabolites D21-1402-0201 and D21-2135-0101 prolonged PT in human and rat plasma, with CT2 values similar to those of edoxaban tosilate hydrate.

Antithrombotic effects of the drug were examined in vivo using five rat thrombosis models. In rat models of venous thrombosis and venous stasis thrombosis, pre-treatment with a single oral dose of edoxaban tosilate hydrate dose-dependently inhibited venous thrombosis and exerted anti-Xa activity in plasma at a minimum effective dose of 2.5 and 0.5 mg/kg, respectively, whereas the dose required for PT prolongation was 12.5 mg/kg. In the rat A-V shunt model, the drug inhibited thrombosis in a dose-dependent manner at single oral doses of 2.5 mg/kg or more, and in a rat DIC model, the drug showed a dose-dependent anticoagulant effect at single oral doses of 0.1 mg/kg or more, along with inhibition  of  platelet  consumption,  the  increase  of  thrombin-antithrombin  III  complex,  and  the decrease of fibrinogen.

It is remarkable that edoxaban inhibited factor Xa activity in rats with an IC50 value of 7 nM, whereas much higher concentrations (in the micromolar range) were required to inhibit thrombus formation in rat thrombosis models. Similar observations have been made previously (Hara et al. 1995), that the factor Xa inhibitor DX-9065a potently inhibited human factor Xa, but that a much higher dose was required to inhibit thrombus formation in a rat thrombosis model. The higher potency for edoxaban regarding inhibition of factor Xa activity when compared to inhibition of thrombus formation in rat thrombosis models was explained by the Applicant by the higher amount of factor Xa generated during thrombus formation in the in vivo thrombosis models.

Edoxaban tosilate hydrate was compared to anticoagulant drugs warfarin and enoxaparin in a rat model of venous thrombosis, showing that edoxaban tosilate hydrate significantly prevents venous thrombosis, like warfarin sodium and enoxaparin sodium, although the onset of action was more rapid after  treatment  with  edoxaban  tosilate  hydrate  than  with  warfarin  sodium  in  these  models.  In addition, in a rat model of venous thrombosis treatment, edoxaban tosilate hydrate, enoxaparin sodium and fondaparinux sodium reduced the thrombus weight in a dose-dependent manner.

In  conclusion,  orally  administered  edoxaban  tosilate  hydrate  has  the  potential  to  treat  venous thrombosis similar to warfarin, enoxaparin and fondaparinux, which have different mechanisms of action.

## Secondary pharmacodynamic studies

Several in vitro and in vivo secondary pharmacology studies were conducted by the Applicant. In vitro pharmacological activity of 10 μM edoxaban tosilate hydrate was tested on 63 receptors, channels, transporters and enzymes. Edoxaban showed significant affinity for histamine H2 and opioid binding sites, although the concentration evaluated in the study (10 μM) was about 16 times the exposure in patients given edoxaban at dose of 60 mg, and no clinical relevance is expected.

In the secondary pharmacology studies conducted by the Applicant, edoxaban tosilate hydrate at 100 μM  had  no  effect  on  aggregation  of  human  platelets  induced  by  collagen,  the  thromboxane  A2 receptor  agonist  U46619  or  ADP.  It  inhibited  thrombin-induced  aggregation  of  human  washed platelets. In addition, in a rat bleeding model, edoxaban tosilate hydrate prolonged the bleeding time to a lesser extent than warfarin sodium and enoxaparin sodium, achieving a higher therapeutic index (BT2/ED50). In human plasma or whole blood, anticoagulant activities of edoxaban tosilate hydrate

<div style=\"page-break-after: always\"></div>

were significantly suppressed by coagulants recombinant factor VIIa, Feiba TM  and PPSB®-HT. Lastly, in a rat plantar bleeding model, tranexamic acid did not affect the prolonged bleeding time and PT induced by a supratherapeutic dose of edoxaban tosilate hydrate. However, the CHMP was concerned whether there is progress in the development of specific antidotes which are able to antagonize the effects of edoxaban tosilate hydrate on blood coagulation (e.g. factor Xa mutants lacking enzymatic activity). This was discussed further in the clinical section (Pharmacodynamic interactions with other medicinal products or substances).

## Safety pharmacology programme

The potential adverse effects of edoxaban tosilate hydrate on vital functions have been investigated in  a  battery  of  safety  pharmacology  studies  on  the  central  nervous,  cardiovascular,  respiratory systems and on renal function. The highest dose of 200 mg/kg or the highest concentration of 20 μg/mL used in these studies correspond to 200-times or 58-times, respectively, the recommended clinical dose of a 60 mg of edoxaban tosilate hydrate or its corresponding Cmax value of 0.347 μg/mL. One safety pharmacology study (Study 20020556) was performed in conscious cynomolgus monkeys in order to investigate the effects of edoxaban tosilate hydrate on the central nervous system, the respiratory system and on the cardiovascular system. In addition, one study was performed in order to investigate the effects of edoxaban tosilate hydrate on the central nervous system in mice, one study was performed in order to investigate the effects of edoxaban tosilate hydrate on renal function in rats, and two in-vitro studies (hERG, action potential assay in ventricular papillary muscles from guinea pig) were performed in order to investigate the effect of edoxaban tosilate hydrate on cardiac electrophysiology. No clinically relevant effects were observed in these studies. Edoxaban tosilate hydrate at oral doses of 200 mg/kg did neither affect the function of the central nervous system of mice and monkeys, the respiratory system of monkeys nor the renal function of rats. Edoxaban tosilate hydrate at concentrations of up to 20 µg/ml had no effect on hERG currents or on action potential (AP) parameters in right ventricular guinea pig papillary muscles. Edoxaban tosilate hydrate at oral doses of up to 200 mg/kg did not affect blood pressure, heart rate or ECG parameters in conscious unrestrained cynomolgus monkeys.

## Pharmacodynamic drug interactions

No  nonclinical  studies  of  pharmacodynamic  drug  interactions  were  conducted  because  clinical interaction studies with aspirin, naproxen and warfarin were undertaken.

## 2.3.3. Pharmacokinetics

In-vivo  nonclinical  pharmacokinetic  (PK)  studies  of  edoxaban  tosilate  hydrate  were  performed primarily in rats and cynomolgus monkeys, which were also used in the toxicology studies. PK were evaluated using oral or intravenous doses of unlabelled or 14C-labelled edoxaban tosilate hydrate, which were dissolved in a solution in 0.5% methylcellulose aqueous solution. In-vitro nonclinical PK studies were performed with 14C-edoxaban tosilate hydrate using animal and human plasma/blood. For D21-2393, a human specific metabolite, the nonclinical PK studies were also performed to assess protein binding and tissue distribution using 14C-labeled D21-2393.

After single oral administration of edoxaban tosilate to rats and cynomolgus monkeys, edoxaban was absorbed with a bioavailability of about 40% in rats and 55% in monkeys, and the plasma edoxaban concentration increased rapidly. After reaching Cmax, edoxaban concentration declined in a biphasic manner with elimination t½ of 0.67 to 5.05 h in rats and 1.55 to 6.59 h in cynomolgus monkeys. Repeat dosing for 2 weeks in rat and 4 weeks in cynomolgus monkeys did not markedly increase edoxaban exposure, although rats treated daily with edoxaban for 4 weeks showed an increase in Cmax and AUC0-24h. However, according to the Applicant, in the clinical studies there is no evidence

<div style=\"page-break-after: always\"></div>

that repeated dosing altered the exposure to edoxaban, indicating that steady state exposure is attained within 3 days in humans.

Tissue distribution of edoxaban tosilate hydrate was evaluated in albino and pigmented rats and cynomolgus monkeys. Edoxaban showed a broad tissue-distribution of radioactivity except for central nerve system in all species tested. In pigmented rats and monkeys, higher levels of radioactivity were found in the eyeball and skin than in other tissues, with a t½ for radioactivity in the eyeball of pigmented rats of approximately 260 h. These data indicate that edoxaban and/or its metabolites may have an affinity to melanin-containing tissues. However, the in vitro phototoxicity studies and the 39-week or 52-week repeated-dose oral toxicity studies in cynomolgus monkeys did not show any photosafety issue.

For the investigation of paediatric population, the tissue distribution of radiolabelled edoxaban tosilate was  studied  in  infant,  juvenile  and  adult  rats.  Infant  albino  rats  exhibited  higher  radioactivity concentrations in blood and tissues than those in juvenile and adult rats after a single oral dose of 14 C-edoxaban tosilate hydrate.

The  plasma  protein  binding  of  edoxaban  in  animals  and  humans  (31.6%-56.6%)  suggests  that edoxaban is unlikely to interact with other drugs via this mechanism.

In vitro metabolism studies conducted by the Applicant are included in the clinical dossier.

Quantitative metabolite profiles of edoxaban in rats and cynomolgus monkeys were investigated with 14 C-edoxaban label B, so the labelled position would not be released by metabolism. After an oral dose  of 14 C-edoxaban  to  rats  and  monkeys,  unchanged  edoxaban  was  the  major  radioactive compound in plasma, and it was primarily excreted as unchanged in both species. These data indicate that metabolism makes a minor contribution to the clearance of edoxaban so that any inhibition of drug-metabolizing  enzymes  is  unlikely  to  affect  its  PK.  The  main  metabolite  in  human  plasma, D21-2393, was not detected in rat or cynomolgus monkey plasma.

Edoxaban and its metabolites were excreted into urine, bile (tested only in rats) and faeces in rats and cynomolgus monkeys. In rats, at least 24% of the radioactivity excreted into the bile was reabsorbed, suggesting that enterohepatic circulation may occur. Radioactivity was secreted into milk in rats.

A  study  using mdr1a/1b knock-out  mice  showed  that  edoxaban  is  a  substrate  for  mouse  P-gp mdr1a/1b, which plays a role in the restricted brain uptake of edoxaban. In consistency with that, an in vitro transcellular transport study using Caco-2 cells demonstrated that edoxaban is a substrate of human P-gp MDR1.

The tissue distribution of D21-2393, the main metabolite in human plasma, was investigated using infant  (PND4),  juvenile  (3  weeks  old)  and  adult  (6  weeks  old)  rats  of  albino  (male  Wistar)  and pigmented (male Brown Norway) strains. Adult rats exhibited rapid elimination of 14 C-D21-2393-derived radioactivity in blood and tissues; the radioactivity concentrations in the blood and tissues in infant and juvenile rats were higher than that in adult rats. The remaining radioactivity in the eyeball and skin observed at 24 h post-dose in infant and juvenile pigmented rats suggested an affinity of D21-2393 to melanin-containing tissues; however, the affinity seems to be less potent compared to edoxaban, which showed long retention of radioactivity in melanin-containing tissues.

The  higher  blood  and  tissue  concentrations  of  both  edoxaban  and  its  main  human  metabolite D21-2393 in infant and juvenile compared to adult rats have been explained by the Applicant by the immature development of drug metabolizing enzymes (cytochrome P450 3A4 for edoxaban) and transporters (P-glycoprotein for edoxaban, organic anion transporting peptides (OATP) and other hepatic transporters for D21-2393.

<div style=\"page-break-after: always\"></div>

In conclusion, the nonclinical PK studies indicate that edoxaban is absorbed rapidly, has a broad tissue distribution with a high affinity for melanin-containing tissues and is eliminated mainly as a parent compound via hepatic/renal excretion and with limited metabolic elimination.

## 2.3.4. Toxicology

The toxicology of edoxaban tosilate hydrate has been evaluated in single- and repeated-dose toxicity studies in rats and cynomolgus monkeys, genotoxicity studies, carcinogenicity studies in mice and rats, reproductive and developmental toxicity studies in rats and rabbits, a juvenile toxicity study in rats,  and  other  special  toxicity  studies  including  photosafety,  ocular  toxicity  (eye  function  test), haemolysis  and  vascular  irritation  studies.  Potential  toxicity  of  the  human  specific  metabolite D21-2393 was also evaluated in repeated-dose oral toxicity  studies  in  rats,  in-vitro  and  in-vivo genotoxicity studies, embryo-fetal developmental toxicity and juvenile toxicity studies in rats.

## Single dose toxicity

In  single-dose  toxicity  studies  performed  in  rats,  edoxaban  tosilate  hydrate  did  not  show  toxic changes at doses of up to 2000 mg/kg. In single-dose toxicity studies performed in cynomolgus monkeys, prolongations of PT and APTT and a decrease in factor X activity were observed at doses of 200 and 400 mg/kg, and the lethal dose of edoxaban tosilate hydrate was above 400 mg/kg.

## Repeat dose toxicity

In  repeated dose oral toxicity studies in rats, a small number of focal hemorrhagic lesions were observed  in  the  pancreas,  lung  and  thymus  given  edoxaban  tosilate  hydrate  at  doses  ≥  20 mg/kg/day. These focal incidences were considered to be an extension of the pharmacological activity of edoxaban. In the 26-week repeated dose oral toxicity study in rats, the death of a female animal in the highest dose group was considered by the Applicant not related to the treatment.

Since  pharmacological  activity  of  edoxaban  tosilate  hydrate  for  the  cynomolgus  monkey  was comparable to that for the human, cynomolgus monkey was considered as an appropriate species for toxicological assessment. In repeated dose oral toxicity studies in cynomolgus monkeys, hemorrhagic findings and anaemia were noted in some animals at ≥15 mg/kg/day, leading to a deteriorated animal condition or animal deaths. According to the Applicant, these findings related to the exaggerated pharmacological action of edoxaban tosilate hydrate are considered the primary adverse effect and the only dose-limiting toxicity for this compound. This conclusion was acknowledged by the CHMP.

Intravenous toxicity studies to support a clinical study for absolute bioavailability were conducted in rats and cynomolgus monkeys. The hemorrhagic findings in these studies were consistent with the findings observed after oral administration.

## Genotoxicity

A standard battery of genotoxicity tests has been perfomed with edoxaban tosilate hydrate. Although edoxaban tosilate hydrate caused numerical chromosome aberrations in vitro studies using Chinese hamster  lung  cells  and  human  lymphocytes  at  1250  μg/mL  or  more  and  313  μg/mL  or  more, respectively, the drug did not show any genotoxic potential in an in vitro micronucleus test using human lymphocytes and in three in vivo studies with different tissues (bone marrow micronucleus test in rats and cynomolgus monkeys, liver micronucleus test in rats, unscheduled DNA synthesis in rat liver).

The doses in these in vivo studies are similar to those administered to rats in single dose toxicity studies and higher than those in repeated dose toxicity studies, thus, it is considered that the plasma exposure is sufficient. In addition, in distribution studies in rats the peak levels of radioactivity in the

<div style=\"page-break-after: always\"></div>

liver and bone marrow were about 6 and 2 times higher than in the plasma, respectively. Taken together, edoxaban is not considered to have a relevant in-vivo genotoxic potential.

## Carcinogenicity

The  carcinogenic  potential  of  edoxaban  tosilate  hydrate  was  evaluated  in  medium-term  liver carcinogenesis bioassay in rats, and standard 2-year mouse and rat carcinogenicity studies. The dose selection and study design elements for the 2-year carcinogenicity studies in mice and rats were based on 13 week repeated-dose toxicity studies performed in mice and rats.

The carcinogenicity studies in mice and rats did not reveal any increase in neoplastic effects. The deviation  from  GLP  in  the  rat  study  AN07-C0020-R01  (some  tissues  fixed  in  expired  modified Davidson's fixative) is not considered relevant for the scientific validity of the study. In addition, the medium term liver carcinogenesis bioassay in rats showed that edoxaban is not associated with tumor promotion potential in the liver.

## Reproduction Toxicity

Reproductive toxicity studies have been performed in rats and rabbits. Edoxaban showed no effects on  fertility  and  early  embryonic  development  in  rats  at  doses  of  up  to  1000  mg/kg/day.  The embryo-foetal development study in rats did not reveal any malformations in the foetuses, although a slight increase in post-implantation loss was observed at 300 mg/kg/day (approximately 49 times the MRHD). The study in rabbits also showed an increase in post-implantation losses, and an increase in the incidence of variations in the gall bladder at ≥200 mg/kg/day (approximately 65 times the MRHD) and increases in the incidence of 13 th full ribs and 27 presacral vertebrae at 600 mg/kg/day. According to literature, the presence of gall bladder variations in rabbits is a species characteristic, and it is attributed to a paternal contribution. Regarding the incidence of 13 th full ribs and 27 presacral vertebrae, the usefulness of these endpoints in predicting risk for the human population is complex and has not been well studied or validated, and it has been suggested that these findings might simply reflect species-specific anatomic variations, without detrimental effects on salubrity.

In the final report of the fertility and early embryonic development study in rats (20030552) atrophy of the testis and epididymis was observed in several animals (1 in the control group, 1 in the 100 and 300 mg/kg/day group and 2 in the 1000 mg/kg/day group). This finding was also detected in one animal  in  the  highest  dose  group  in  the  preliminary  study  20030165.  However,  literature  data produced both by Charles River Inc. and by other researchers show that there is a large variation of the testis and epididymis weights in Crj:CD(SD)IGS rats, as well as spontaneous seminiferous tubular atrophy, leading to atrophy of the testis and epididymis. The incidence of atrophy of the testis and epididymis in the fertility and early embryonic development studies in rats are comparable to that of the published data.

The margin of safety at the NOAEL derived from the embryo-fetal development studies (rats and rabbits), based on the maximum recommended clinical dose of 60 mg per total body surface area in mg/m 2 , is about 16 - 19. Although no AUC data were obtained in these studies, this is not considered an issue because the margin of safety based on dose is appropriate. In addition, in the study in rabbits (2004002) the achieved Cmax is much higher than the Cmax in humans (5830 vs 347 ng/mL).

In an oral study for effects on prenatal and postnatal development including maternal function in rats, vaginal bleeding in dams was observed at 30 mg/kg/day. Lower avoidance response in the shuttle box test was observed on the first day of examination in female offspring, but disappeared afterwards. In the  juvenile  toxicity  study  in  rats,  edoxaban  tosilate  hydrate  did  not  induce  any  toxicologically significant effect on postnatal development and growth, organ development, skeletal development, or sexual maturation. The observation that in the embryo-fetal development study pharmacodynamic effects occurred after 10 days, while in the fertility and development study no effects occurred after

<div style=\"page-break-after: always\"></div>

an even longer and higher dosing scheme has been explained by the Applicant by the timing of dosing during pregnancy. In conclusion, there is a potential for reproductive toxicity and an intrinsic risk of bleeding exists for humans. Consequently a contraindication for use during pregnancy was included in the SmPC.

## Toxicokinetic data

Regarding  toxicokinetics,  some  safety  margins  are  low  (repeated  dose  toxicity  in  monkeys, reproductive and maternal toxicity in rats have a margin of safety based on the AUC of 1.6). However, this was not considered an issue because the toxicity findings are mostly produced by an exacerbated pharmacological effect.

## Local Tolerance

To support a clinical study for absolute bioavailability, local tolerance of edoxaban tosilate hydrate lyophilized product for injection was evaluated in the in-vitro hemolysis and rabbit vascular irritation tests. The local tolerance studies conducted by the Applicant showed no haemolytic action on human blood nor irritation potential on the rabbit auricular vasculature.

## Other toxicity studies

## Phototoxicity studies

Phototoxicity  NRU  and  photochromosomal  aberration  tests  did  not  show  a  potential  phototoxic potential for edoxaban tosilate hydrate. In addition, there was no evidence of adverse effects on eye function  or  morphology  of  the  eye  in  cynomolgus  monkeys  after  a  39-week  repeated  dosing  of edoxaban tosilate hydrate at 15 mg/kg/day.

## Studies with human specific metabolite D21-2393

The Applicant has conducted general toxicity, genotoxicity, reproductive toxicity and juvenile toxicity studies with human specific metabolite D21-2393. The exposures achieved in all studies are much higher than the ones in humans treated with the maximum recommended dose of 60 mg (data from study DU176b-PRT019. In the general toxicity, genotoxicity, embryofoetal development and juvenile toxicity studies in rats no treatment related changes were noted. Regarding metabolite D21-3231, a study conducted by the Applicant showed that rats are exposed to D21-3231 and the potential toxicity of the metabolite has been assessed in the toxicity studies conducted with edoxaban tosilate hydrate.

## 2.3.5. Ecotoxicity/environmental risk assessment

As required by the given guidelines the applicant provided an environmental risk assessment (ERA) for the active ingredient edoxaban tosylate in accordance with the Guideline on environmental risk assessment of medicinal products for human use (EMEA/CHMP/SWP/4447/00) . Since in Phase I of the procedure the action limit of 0.01 µg/L is exceeded, a detailed Phase II Tier A and Tier B assessment was  performed  to  assess  the  potential  risk  to  surface  water,  the  sewage  treatment  plant, water-sediment system, groundwater and micro-organisms. Laboratory studies on the environmental fate and effects of edoxaban tosylate were conducted following appropriate OECD Guidelines and under GLP conditions. On the basis of the obtained study results and the calculated PEC/PNEC values it can be concluded that the medicinal product Lixiana is unlikely to represent a concern for daphnids and  fishes.  However,  it  was  assessed  that  edoxaban  is  persistent  in  the  environment.  The environmental  risk  assessment  could  not  be  finalized  since  an  adsorption-desorption  study  in

<div style=\"page-break-after: always\"></div>

accordance  with  OECD106  and  a  valid  OECD  201  growth  inhibition  test  for  algae  were  still  not available.

Table 1. Summary of main study results

| Substance (INN/Invented Name): edoxaban tosylate                    | Substance (INN/Invented Name): edoxaban tosylate   | Substance (INN/Invented Name): edoxaban tosylate                                                                                                  | Substance (INN/Invented Name): edoxaban tosylate   | Substance (INN/Invented Name): edoxaban tosylate   | Substance (INN/Invented Name): edoxaban tosylate                               |
|---------------------------------------------------------------------|----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------|----------------------------------------------------|--------------------------------------------------------------------------------|
| CAS-number (if available):                                          | CAS-number (if available):                         | CAS-number (if available):                                                                                                                        | CAS-number (if available):                         | CAS-number (if available):                         | CAS-number (if available):                                                     |
| PBT screening                                                       |                                                    | Result                                                                                                                                            |                                                    |                                                    | Conclusion                                                                     |
| Bioaccumulation potential- log K ow                                 | OECD107                                            |                                                                                                                                                   |                                                    |                                                    | no study was provided                                                          |
| PBT-assessment                                                      |                                                    |                                                                                                                                                   |                                                    |                                                    |                                                                                |
| Parameter                                                           | Result relevant for conclusion                     |                                                                                                                                                   |                                                    |                                                    | Conclusion                                                                     |
| Bioaccumulation                                                     | log K ow                                           |                                                                                                                                                   |                                                    |                                                    | no study was provided                                                          |
|                                                                     | BCF                                                |                                                                                                                                                   |                                                    |                                                    | not assessed                                                                   |
| Persistence                                                         | DT50 or ready biodegradability                     | DT50 (12°C) sediment                                                                                                                              | =126                                               | days in                                            | P                                                                              |
| Toxicity                                                            | NOEC or CMR                                        | OECD201                                                                                                                                           | is not valid                                       |                                                    | not assessed                                                                   |
| PBT-statement :                                                     | The compound is                                    | considered as P                                                                                                                                   |                                                    |                                                    |                                                                                |
| Phase I                                                             |                                                    |                                                                                                                                                   |                                                    |                                                    |                                                                                |
| Calculation                                                         | Value                                              | Unit                                                                                                                                              |                                                    |                                                    | Conclusion                                                                     |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.3 µg/l                                           | µ g/L                                                                                                                                             |                                                    |                                                    | > 0.01 threshold (Y)                                                           |
| Other concerns (e.g. chemical class)                                |                                                    |                                                                                                                                                   |                                                    |                                                    | (N)                                                                            |
| Phase II Physical-chemical properties and fate                      | Phase II Physical-chemical properties and fate     | Phase II Physical-chemical properties and fate                                                                                                    | Phase II Physical-chemical properties and fate     | Phase II Physical-chemical properties and fate     | Phase II Physical-chemical properties and fate                                 |
| Study type                                                          | Test protocol                                      | Results                                                                                                                                           |                                                    |                                                    | Remarks                                                                        |
| Adsorption-Desorption                                               | OPPTS 835.1110                                     | K oc = 14                                                                                                                                         |                                                    |                                                    | value only acceptable in Phase II Tier A                                       |
| Ready Biodegradability Test                                         | OECD 301                                           | 23% (28d)                                                                                                                                         |                                                    |                                                    | not readily biodegradable                                                      |
| Aerobic and Anaerobic Transformation in Aquatic Sediment systems    | OECD 308                                           | DT 50, water(20°C) = DT 50, sediment (20°C) = DT 50 sediment (12°C) = DT 50, whole system (20°C) %shifting to 60.7 (day 14) TP: D21-3231-0101 10% | 1.1d sediment                                      | 59.1d 126.1d = 6.1d = >                            | P, significant shifting to the sediment, test on sediment organism is required |
| Phase IIa Effect studies                                            |                                                    |                                                                                                                                                   |                                                    |                                                    |                                                                                |
| Study type                                                          | Test protocol                                      | Endpoint                                                                                                                                          | value                                              | Unit                                               | Remarks                                                                        |
| Daphnia sp . Reproduction Test                                      | OECD 211                                           | NOEC                                                                                                                                              | 5570                                               | µg/L                                               | Daphnia magna                                                                  |
| Fish, Early Life Stage Toxicity Test/ Species                       | OECD 210                                           | NOEC                                                                                                                                              | 2320                                               | µg/L                                               | Pimephales promelas                                                            |
| Activated Sludge, Respiration Inhibition Test                       | OECD 209                                           | EC                                                                                                                                                |                                                    | µg/L                                               | remained questions                                                             |
| Phase IIb Studies                                                   |                                                    |                                                                                                                                                   |                                                    |                                                    |                                                                                |
| Sediment dwelling organisms                                         | OECD 218                                           | NOEC                                                                                                                                              | 704 (real conc.)                                   | mg/ L                                              | Chironomus riparius                                                            |
| Substance (INN/Invented Name):                                      | Substance (INN/Invented Name):                     | Substance (INN/Invented Name):                                                                                                                    | Substance (INN/Invented Name):                     | Substance (INN/Invented Name):                     | Substance (INN/Invented Name):                                                 |
| CAS-number (if available):                                          | CAS-number (if available):                         | CAS-number (if available):                                                                                                                        | CAS-number (if available):                         | CAS-number (if available):                         | CAS-number (if available):                                                     |
| PBT screening                                                       |                                                    | Result                                                                                                                                            |                                                    |                                                    | Conclusion                                                                     |
| Bioaccumulation potential- log K ow                                 | OECD107 or …                                       |                                                                                                                                                   |                                                    |                                                    | Potential PBT (Y/N)                                                            |

<div style=\"page-break-after: always\"></div>

| PBT-assessment                                                                               | PBT-assessment                                                                                                      | PBT-assessment                                                                                                      | PBT-assessment                                                                                                      | PBT-assessment                                                                                                      | PBT-assessment                                                                                                      |
|----------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------|
| Parameter                                                                                    | Result relevant for conclusion                                                                                      |                                                                                                                     |                                                                                                                     |                                                                                                                     | Conclusion                                                                                                          |
| Bioaccumulation                                                                              | log K ow                                                                                                            |                                                                                                                     |                                                                                                                     |                                                                                                                     | B/not B                                                                                                             |
| Persistence                                                                                  | BCF                                                                                                                 |                                                                                                                     |                                                                                                                     |                                                                                                                     | B/not B                                                                                                             |
|                                                                                              | DT50 or ready biodegradability                                                                                      |                                                                                                                     |                                                                                                                     |                                                                                                                     | P/not P                                                                                                             |
| Toxicity                                                                                     | NOEC or CMR                                                                                                         |                                                                                                                     |                                                                                                                     |                                                                                                                     | T/not T                                                                                                             |
| PBT-statement :                                                                              | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT | The compound is not considered as PBT nor vPvB The compound is considered as vPvB The compound is considered as PBT |
| Phase I                                                                                      | Phase I                                                                                                             | Phase I                                                                                                             | Phase I                                                                                                             | Phase I                                                                                                             | Phase I                                                                                                             |
| Calculation                                                                                  | Value                                                                                                               | Unit                                                                                                                | Unit                                                                                                                | Unit                                                                                                                | Conclusion                                                                                                          |
| PEC surfacewater , default or refined (e.g. prevalence, literature)                          |                                                                                                                     | µ g/L                                                                                                               | µ g/L                                                                                                               | µ g/L                                                                                                               | > 0.01 threshold (Y/N)                                                                                              |
| Other concerns (e.g. chemical class)                                                         |                                                                                                                     |                                                                                                                     |                                                                                                                     |                                                                                                                     | (Y/N)                                                                                                               |
| Phase II Physical-chemical properties and fate                                               | Phase II Physical-chemical properties and fate                                                                      | Phase II Physical-chemical properties and fate                                                                      | Phase II Physical-chemical properties and fate                                                                      | Phase II Physical-chemical properties and fate                                                                      | Phase II Physical-chemical properties and fate                                                                      |
| Study type                                                                                   | Test protocol                                                                                                       | Results                                                                                                             | Results                                                                                                             | Results                                                                                                             | Remarks                                                                                                             |
| Adsorption-Desorption                                                                        | OECD 106 or …                                                                                                       | K oc =                                                                                                              | K oc =                                                                                                              | K oc =                                                                                                              | List all values                                                                                                     |
| Ready Biodegradability Test Aerobic and Anaerobic Transformation in Aquatic Sediment systems | OECD 301 OECD 308                                                                                                   | DT 50, water = DT 50, sediment = DT 50, whole system =                                                              | DT 50, water = DT 50, sediment = DT 50, whole system =                                                              | DT 50, water = DT 50, sediment = DT 50, whole system =                                                              | Not required if readily biodegradable                                                                               |
| Phase IIa Effect studies                                                                     | Phase IIa Effect studies                                                                                            | Phase IIa Effect studies                                                                                            | Phase IIa Effect studies                                                                                            | Phase IIa Effect studies                                                                                            | Phase IIa Effect studies                                                                                            |
| Study type                                                                                   | Test protocol                                                                                                       | Endpoint                                                                                                            | value                                                                                                               | Unit                                                                                                                | Remarks                                                                                                             |
| Algae, Growth Inhibition Test/ Species                                                       | OECD 201                                                                                                            | NOEC                                                                                                                |                                                                                                                     | µg/L                                                                                                                | species                                                                                                             |
| Daphnia sp . Reproduction Test                                                               | OECD 211                                                                                                            | NOEC                                                                                                                |                                                                                                                     | µg/L                                                                                                                |                                                                                                                     |
| Fish, Early Life Stage Toxicity Test/ Species                                                | OECD 210                                                                                                            | NOEC                                                                                                                |                                                                                                                     | µg/L                                                                                                                | species                                                                                                             |
| Activated Sludge, Respiration Inhibition Test                                                | OECD 209                                                                                                            | EC                                                                                                                  |                                                                                                                     | µg/L                                                                                                                |                                                                                                                     |
| Phase IIb Studies                                                                            | Phase IIb Studies                                                                                                   | Phase IIb Studies                                                                                                   | Phase IIb Studies                                                                                                   | Phase IIb Studies                                                                                                   | Phase IIb Studies                                                                                                   |
| Bioaccumulation                                                                              | OECD 305                                                                                                            | BCF                                                                                                                 |                                                                                                                     | L/kg                                                                                                                | %lipids:                                                                                                            |
| Aerobic and anaerobic transformation in soil                                                 | OECD 307                                                                                                            | DT50 %CO2                                                                                                           |                                                                                                                     |                                                                                                                     | for all 4 soils                                                                                                     |
| Soil Micro organisms: Nitrogen Transformation Test                                           | OECD 216                                                                                                            | %effect                                                                                                             |                                                                                                                     | mg/ kg                                                                                                              |                                                                                                                     |
| Terrestrial Plants, Growth Test/ Species                                                     | OECD 208                                                                                                            | NOEC                                                                                                                |                                                                                                                     | mg/ kg                                                                                                              |                                                                                                                     |
| Earthworm, Acute Toxicity                                                                    | OECD 207                                                                                                            | NOEC                                                                                                                |                                                                                                                     | mg/                                                                                                                 |                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| Tests                         |           |      | kg     |         |
|-------------------------------|-----------|------|--------|---------|
| Collembola, Reproduction Test | ISO 11267 | NOEC | mg/ kg |         |
| Sediment dwelling organism    |           | NOEC | mg/ kg | species |

In the context of the obligation of the MAH to take due account of technical and scientific progress, the CHMP recommends the following points to be addressed: (1) to provide an adsorption study for soils in accordance with OECD 106, (2) to submit a valid OECD 201 study for algae.

## 2.3.6. Discussion on non-clinical aspects

The Applicant conducted in vitro and in vivo pharmacology studies with edoxaban tosilate to elucidate its mechanism of action and assess its anticoagulant effect. Edoxaban tosilate and some metabolites were able to prolong PT in human and rat plasma. Antithrombotic effects of edoxaban tosilate were examined in vivo in several rat thrombosis models, showing anti-Xa activity in plasma and thrombosis inhibition in a dose-dependent manner.

Edoxaban  tosilate  hydrate  was  compared  to  anticoagulant  drugs  warfarin,  enoxaparin  and fondaparinux in several rat models, although the mechanism of action of edoxaban is more similar to that of authorized new oral anticoagulants: apixaban and rivaroxaban. In these models, edoxaban tosilate  hydrate  significantly  prevented  venous  thrombosis,  like  warfarin  sodium  and  enoxaparin sodium, although the onset of action was more rapid after treatment with edoxaban tosilate hydrate than with warfarin.

The safety pharmacology studies on central nervous, cardiovascular and respiratory systems, and on renal function, did not reveal any clinically relevant effects. Several in vitro and in vivo secondary pharmacology studies were conducted by the Applicant. In vitro pharmacological activity of 10 μM edoxaban  tosilate  hydrate  was  tested  on  63  receptors,  channels,  transporters  and  enzymes. Edoxaban  showed  significant  affinity  for  histamine  H2  and  opioid  binding  sites,  although  the concentration evaluated in the study (10 μM) was about 16 times the exposure in patients given edoxaban at dose of 60 mg, and no clinical relevance is expected.

PK studies were conducted in rats and cynomolgus monkeys treated orally or intravenously with edoxaban  tosilate  hydrate.  After  single  oral  administration  of  edoxaban  tosilate  to  rats  and cynomolgus monkeys, edoxaban was absorbed with a bioavailability of about 40% in rats and 55% in monkeys, and the plasma edoxaban concentration increased rapidly. After reaching Cmax, edoxaban concentration declined in a biphasic manner with elimination t½ of 0.67 to 5.05 h in rats and 1.55 to 6.59 h in cynomolgus monkeys. Repeat dosing for 2 weeks in rat and 4 weeks in cynomolgus monkeys did not markedly increase edoxaban exposure. In distribution studies, edoxaban showed a broad tissue distribution except for central nervous system. High levels of radioactivity were found in the eyeball and skin in pigmented rats and monkeys, although phototoxicity and general toxicity studies did not show any photosafety issue.

The main metabolite in human plasma, D21-2393, was not detected in rat or cynomolgus monkey plasma; therefore, specific PK and toxicity studies were conducted with this metabolite. In infant and juvenile rats, concentrations of both edoxaban and this main metabolite D21-2393 were much higher than those in adults. This fact was explained by the immature development of drug metabolizing enzymes and transporters.

General  toxicity  studies  with  edoxaban  tosilate  hydrate  were  conducted  in  rats  and  cynomolgus monkeys. Since pharmacological activity of edoxaban tosilate hydrate for the cynomolgus monkey was comparable to that for the human, cynomolgus monkey was considered as an appropriate species for  toxicological  assessment.  In  both  species,  all  findings  were  related  to  the  exaggerated

<div style=\"page-break-after: always\"></div>

pharmacological action of the test item, such as haemorrhagic lesions in some organs and anaemia. These adverse effects are considered the only dose-limiting toxicity for edoxaban tosilate hydrate. Regarding  toxicokinetics,  some  safety  margins  are  low  (repeated  dose  toxicity  in  monkeys, reproductive and maternal toxicity in rats have a margin of safety based on the AUC of 1.6). However, this was not considered an issue because the toxicity findings are mostly produced by an exacerbated pharmacological effect.

Although edoxaban tosilate hydrate caused numerical chromosome aberrations in vitro studies using Chinese hamster lung cells and human lymphocytes at 1250 μg/mL or more and 313 μg/mL or more, respectively, the drug did not show any genotoxic potential in an in vitro micronucleus test using human lymphocytes and in three in vivo studies with different tissues (bone marrow micronucleus test in rats and cynomolgus monkeys, liver micronucleus test in rats, unscheduled DNA synthesis in rat liver). In addition, in the carcinogenicity studies no increase in neoplastic effects was found.

The  embryo-foetal  development  study  in  rats  did  not  reveal  any  malformations  in  the  foetuses, although a slight increase in post-implantation loss was observed at 300 mg/kg/day (approximately 49 times the MRHD). The study in rabbits showed an increase in post-implantation losses, and an increase in the incidence of variations in the gall bladder at ≥200 mg/kg/day (approximately 65 times the  MRHD)  and  increases  in  the  incidence  of  13 th full  ribs  and  27  presacral  vertebrae  at  600 mg/kg/day. However, the presence of gall bladder variations in rabbits is a species characteristic, and it is attributed to a paternal contribution. Regarding the incidence of 13 th full ribs and 27 presacral vertebrae, the usefulness of these endpoints in predicting risk for the human population is complex and has not been well studied or validated, and it has been suggested that these findings might simply reflect species-specific anatomic variations, without detrimental effects on salubrity.

In the juvenile toxicity study in rats, edoxaban tosilate hydrate did not induce any toxicologically significant effect on postnatal development and growth, organ development, skeletal development, or sexual maturation.

The Applicant has conducted general toxicity, genotoxicity, reproductive toxicity and juvenile toxicity studies with human specific metabolite D21-2393. No treatment related changes were noted.

The environmental risk assessment could not be finalized because two studies were still not available.

## Assessment of paediatric data on non-clinical aspects

A PIP was agreed for edoxaban tosilate hydrate (EMEA-000788-PIP02-11-M02). The Applicant has conducted all the non-clinical studies required in the PIP, both with edoxaban tosilate hydrate and with metabolite D21-2393.

## 2.3.7. Conclusion on the non-clinical aspects

The pharmacologic, pharmacokinetic, and toxicological characteristics of edoxaban tosilate hydrate are  well  characterized  and  the  non-clinical  package  presented  by  the  Applicant  is  considered appropriate. However, the environmental risk assessment could not be finalized because two studies were still not available (see List of Recommendations).

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

This submission includes 43 clinical pharmacology studies to characterise the PK and PD profile of edoxaban, while the efficacy and safety in each of the two requested indications is mainly based on two large pivotal  Phase  III  studies:  one  in  NVAF  (ENGAGE-AF:  21,105  patients)  and  one  in  the treatment of (acute) VTE (Hokusai VTE: 8,292 patients), and supported by 6 phase II studies in NVAF (n= 2045 patients).

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The  applicant  has  provided  a  statement  to  the  effect  that  clinical  trials  conducted  outside  the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

<div style=\"page-break-after: always\"></div>

## Table 2: Phase 1 Clinical Pharmacology Studies

| Study identifier   | Type of study                                                 | Study objective                                                  | Study design and type of control                                                | Test product(s) Dosage regimen, route of administration                                                                                                                 | No. of subjects                                                                   | Duration of treatment                        |
|--------------------|---------------------------------------------------------------|------------------------------------------------------------------|---------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------|
| PRT001             | Healthy subject PK Initial tolerability Comparative BA and BE | Safety, tolerability, assess PK/PD                               | Single-blind, randomized, placebo-controlled scending single and multiple doses | Single dose: Edoxaban 10 mg, 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg PO; Placebo PO Multiple dose (10 days): Edoxaban 90 mg QD, 60 mg BID, 120 mg QD, PO; Placebo QD PO | Single dose: Edoxaban - 68, Placebo- 17 Multiple dose: Edoxaban - 27, Placebo - 9 | 1 day (single dose); 10 days (multiple dose) |
| PRT002             | Intrinsic factor PK (effect of age and gender)                | Safety, tolerability, assess PK/PD                               | Single-blind, randomized, placebo-controlled, multiple doses                    | Edoxaban 90 mg QD PO, Placebo QD PO                                                                                                                                     | Edoxaban: 18 Placebo: 6                                                           | 9 days (Days 1, 3 to 10)                     |
| PRT003             | Healthy subject PD PK/PD                                      | Assess PD using shed blood model, PK                             | Open-label, randomized, parallel group, placebo and active controlled           | Edoxaban 30 mg, 60 mg, 120 mg PO; Fondaparinux 2.5 mg SC Placebo PO                                                                                                     | Edoxaban: 60 Fondaparinux: 20 Placebo: 20                                         | Single dose                                  |
| PRT004             | BA                                                            | Assess PK, regional drug absorption                              | Open-label, randomized, 4-way pharmacoscintigraph ic crossover                  | Edoxaban: 60 mg tablet PO; 60 mg powder or liquid via Enterion TM capsule PO                                                                                            | 8                                                                                 | Single dose x 4                              |
| PRT005 (CLN005)    | Healthy subject PD PK/PD                                      | Assess PD using an ex vivo model of thrombosis                   | Open-label, single center, assessor blind, ex vivo study                        | Edoxaban 60 mg PO                                                                                                                                                       | 12                                                                                | Single dose                                  |
| PRT008             | BA                                                            | Food effect on PK                                                | Open label, randomized, two-treatment, two-period, two-sequence crossover       | Edoxaban 60 mg PO                                                                                                                                                       | 16 (Japanese) 16 (Caucasian)                                                      | Single dose x 2                              |
| PRT009             | Healthy subject PD PK/PD                                      | Assess PD in ex vivo thrombin generation and platelet activation | Open label, randomized, active-comparator, no-treatment controlled              | Edoxaban 60 mg BID PO Dalteparin 5000IU QD SC Ximelagatran 24 mg BID PO                                                                                                 | Edoxaban: 10 Dalteparin: 10 Ximelagatran: 10 No treatment: 10                     | 4 days                                       |
| PRT010 (J02)       | Intrinsic factor PK (effect of race)                          | Safety, tolerability, assess PK/PD                               | Randomized, single blind, placebo-controlled, repeated dose                     | Edoxaban 60 mg BID PO, 120 mg QD PO, Placebo BID/QD PO                                                                                                                  | Edoxaban: 18 Placebo: 6                                                           | 9 days (Days 1, 3 to 10)                     |

<div style=\"page-break-after: always\"></div>

| Study identifier   | Type of study                           | Study objective                                                                                              | Study design and type of control                                                   | Test product(s) Dosage regimen, route of administration                           | No. of subjects                                                | Duration of treatment                               |
|--------------------|-----------------------------------------|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------------------------|
| PRT012             | Extrinsic factor PK                     | Assess PK/PD, interaction with esomeprazole                                                                  | Randomized, open label, crossover                                                  | Edoxaban: 60 mg tablet PO; 60 mg oral solution Esomeprazole: 20 mg capsule QD PO  | 32 (16 oral tablet, 16 oral solution)                          | Edoxaban: single dose x 2 Esomeprazole:4 days x 2   |
| PRT013 (CLN013)    | BA                                      | Assess PK, colonic permeability                                                                              | Open-label, randomized, 2-way pharmacoscintigraph ic crossover                     | Edoxaban: 30 mg tablet PO; 30 mg granules with 50 mg fumaric acid granules via TM | 10                                                             | Single dose x 2                                     |
| PRT014             | Healthy subject PD PK/PD                | Assess PK/PD, interaction with digoxin                                                                       | Open-label, randomized, dual sequence, parallel group                              | Edoxaban 60 mg QD PO Digoxin 0.25 mg QD PO                                        | 48 (24 in each sequence)                                       | 7-14 days (7 days monotherapy + 7 days combination) |
| PRT016             | Extrinsic factor PK                     | Assess PK, interaction with ketoconazole                                                                     | Open-label, randomized, 2-period, 2-treatment, crossover                           | Edoxaban 60 mg PO Ketoconazole 400 mg QD PO                                       | 40                                                             | Edoxaban: Single dose x 2 Ketoconazole: 7 days      |
| PRT017             | Healthy subject PD PK/PD                | Assess bleeding time, PK/PD, interaction with aspirin                                                        | Randomized, double blind, 2-cohort, 2- period, 2-way crossover                     | Edoxaban 60 mg QD PO Aspirin 325 mg QD PO                                         | 56 (28 in each cohort) (54 treated w. edoxaban)                | 5 days in one cohort; 5 days x 2 in another cohort  |
| PRT019             | Healthy subject PK Initial tolerability | Assess mass balance (excretion) and metabolite, PK                                                           | Open label, nonrandomized                                                          | [ 14 C]-Edoxaban 60 mg oral solution, 2.2 MBq (0.57 mSv)                          | 6                                                              | Single dose                                         |
| PRT020 (J01)       | Intrinsic factor PK (effect of race) BA | Safety, tolerability, assess PK/PD, food effect on PK in Japanese                                            | Randomized, single blind, placebo controlled, single dose, crossover (food effect) | Edoxaban 30, 60, 90, 120, 150 mg PO Placebo PO                                    | Edoxaban: 45 (Japanese); 27 (Caucasian) Placebo: 15 (Japanese) | Single dose Single 60 mg dose x 2 for food effect   |
| PRT021             | Healthy subject PD PK/PD                | Assess effect of therapeutic and supratherapeutic exposure to edoxaban on QTc interval, safety, tolerability | Randomized, placebo and active controlled crossover                                | Edoxaban 90 mg QD PO; Edoxaban 180 mg QD PO; Placebo PO; Moxifloxacin 400 mg PO   | 9 (Caucasian) 64 (62 treated w edoxaban)                       | Single dose for each treatment                      |

<div style=\"page-break-after: always\"></div>

| Study identifier   | Type of study                        | Study objective                                                        | Study design and type of control                                                                                                                      | Test product(s) Dosage regimen, route of administration                               | No. of subjects                                                           | Duration of treatment                                                                |
|--------------------|--------------------------------------|------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|---------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| A-U120             | Intrinsic factor PK                  | Assess PK, varying degrees of renal impairment versus healthy subjects | Open-label, parallel group,                                                                                                                           | Edoxaban 15 mg PO                                                                     | 32 (various degrees of renal impairment); 8 (healthy                      | Single dose                                                                          |
| C-U122             | Healthy subject PD PK/PD             | Safety, assess PK                                                      | Randomized, double blind, placebo-controlled All subjects pretreated with open-label dose adjusted warfarin for 6-16 days, followed by a 24-h washout | Edoxaban 60 mg QD PO Placebo QD PO                                                    | Edoxaban: 48 enrolled ( 43 treated) Placebo: 24 Warfarin pretreatment: 72 | 5 days                                                                               |
| A-A123             | Intrinsic factor PK (effect of race) | Safety, tolerability, assess PK/PD                                     | Randomized, single blind, placebo controlled, multiple dose                                                                                           | Edoxaban 60 mg BID PO; Placebo BID PO                                                 | Edoxaban: 8; Placebo: 3                                                   | 9 days (single dose on Days 1 and 10, and BID doses on Days 3 to 9)                  |
| A-U127             | Healthy subject PD PK/PD             | Assess bleeding time, PK, interaction with low-dose aspirin            | Open-label, randomized, 3-period, 3-treatment, crossover                                                                                              | Aspirin 100 mg + edoxaban 60 mg QD PO; Edoxaban 60 mg QD PO; Aspirin 100 mg QD PO     | 36                                                                        | 5 days for each treatment period                                                     |
| A-U128             | Healthy subject PD PK/PD             | Assess bleeding time, PK, interaction with naproxen                    | Open-label, randomized, 3-way crossover                                                                                                               | Naproxen 500 mg BID PO + edoxaban 60 mg PO; Edoxaban 60 mg PO; Naproxen 500 mg BID PO | 34                                                                        | Edoxaban: single dose x 2; Naproxen: BID for 2 days x 2                              |
| A-U129             | Extrinsic factor PK                  | Assess PK interaction with quinidine                                   | Open-label, randomized, 2-period, 2-treatment, crossover                                                                                              | Edoxaban 60 mg QD PO; Quinidine 300 mg TID PO                                         | 42 (40 treated w. edoxaban)                                               | Edoxaban: a single dose + QD for 4 days; Quinidine: single dose x 3 + TID for 2 days |
| A-U130             | Extrinsic factor PK                  | Assess PK interaction with verapamil                                   | Open-label, randomized, 2-period, 2-treatment, crossover                                                                                              | Edoxaban 60 mg QD PO; Verapamil 240 mg QD PO                                          | 34 (33 treated w. edoxaban)                                               | Edoxaban: a single dose + QD for 4 days; Verapamil: a single dose +                  |
| A-U131             | Extrinsic factor PK                  | Assess PK interaction with amiodarone                                  | Open label, one sequence crossover                                                                                                                    | Edoxaban 60 mg PO; Amiodarone 400 mg QD PO                                            | 30                                                                        | Edoxaban: single dose x 2; Amiodarone: QD for 4 days                                 |

<div style=\"page-break-after: always\"></div>

| Study identifier   | Type of study          | Study objective                                                                      | Study design and type of control                                   | Test product(s) Dosage regimen, route of administration                                      | No. of subjects                                          | Duration of treatment                                                          |
|--------------------|------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------|----------------------------------------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------------|
| A-E132             | Extrinsic factor PK    | Assess PK interaction with erythromycin                                              | Open-label, randomized, 2-period, 2-treatment,                     | Edoxaban 60 mg PO; Erythromycin 500 mg QID PO                                                | 36 (33 treated w. edoxaban)                              | Edoxaban: single dose x 2; Erythromycin: QID for 8 days                        |
| A-E133             | Extrinsic factor PK    | Assess PK interaction with atorvastatin                                              | Open-label, randomized, 2-period, 2-treatment, crossover           | Edoxaban 60 mg PO; Atorvastatin 80 mg QD PO                                                  | 32 (30 treated w. edoxaban)                              | Edoxaban: single dose x 2; Atorvastatin QD for 8 days                          |
| A-E134             | Intrinsic factor PK    | Compare PK in subjects with mild or moderate hepatic impairment vs. healthy subjects | Open label, parallel group                                         | Edoxaban 15 mg PO                                                                            | 17 subjects with hepatic impairment; 16 healthy subjects | Single dose                                                                    |
| A-J135             | BA                     | Food effect on PK                                                                    | Open-label, randomized, 2-period, 2-sequence, crossover            | Edoxaban 30 mg PO                                                                            | 34                                                       | Single dose x 2                                                                |
| A-U136             | Extrinsic factor PK    | Assess PK interaction with enoxaparin                                                | Open-label, randomized, 4-period, 4-treatment, crossover           | Edoxaban 60 mg PO; Enoxaparin 1 mg/kg SC                                                     | 40 (39 treated w. edoxaban)                              | Edoxaban: single dose x 3; Enoxaparin: single dose x 3                         |
| A-U137             | Extrinsic factor PK    | Assess PK interaction with rifampin                                                  | Open-label, nonrandomized, 2- treatment, 2-period, single sequence | Edoxaban 60 mg PO; Rifampin 600 mg QD PO                                                     | 34                                                       | Edoxaban: single dose x 2; Rifampin QD for 7 days                              |
| A-U138             | Extrinsic factor PK    | Assess PK interaction with ciclosporine                                              | Open-label, randomized, 2-period, 2-treatment, crossover           | Edoxaban 60 mg PO; Cyclosporin 500 mg PO                                                     | 34                                                       | Edoxaban: single dose x 2; Ciclosporine: single dose                           |
| A-U139             | BA Extrinsic factor PK | Assess absolute bioavailability; effect of quinidine on edoxaban PK                  | Open-label, randomized, 3-period, 3-treatment, crossover           | Edoxaban 60 mg PO; Edoxaban 30 mg IV Quinidine 300 mg Q8H PO                                 | 36                                                       | Edoxaban tablet: single dose; Edoxaban single injection x 2; Quinidine: 4 days |
| A-U140             | Comparative BA and BE  | Compare bioavailability of 2 formulations of edoxaban                                | Open-label, randomized, 2-period, 2-treatment, 2-way crossover     | Edoxaban (proposed commercial formulation) 60 mg PO; Edoxaban (current formulation) 60 mg PO | 44                                                       | Single dose x 2 (Single dose x 1 for each formulation)                         |

<div style=\"page-break-after: always\"></div>

| Study identifier   | Type of study            | Study objective                                                                                       | Study design and type of control                                      | Test product(s) Dosage regimen, route of administration                                                                                                           |   No. of subjects | Duration of treatment                                                                                                         |
|--------------------|--------------------------|-------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------|
| A-U141             | Extrinsic factor PK      | Assess PK interaction with dronedarone under fed                                                      | Open-label, randomized, 2-period, 2-treatment,                        | Edoxaban 60 mg PO; Dronedarone 400 mg BID PO                                                                                                                      |                34 | Edoxaban: single dose x 2; Dronedarone: BID for 7 days                                                                        |
| A-U142             | Comparative BA and BE    | Assess bioequivalence, round shape tablet versus current tablet formulation                           | Open-label, randomized, 2-treatment, 4-period, 2-sequence, replicated | Edoxaban (current tablet) 60 mg PO; Edoxaban (round shaped tablet) 60 mg PO                                                                                       |                30 | Single dose x 4 (single dose x 2 for each formulation)                                                                        |
| A-U145             | Comparative BA and BE    | Compare bioavailability of 4 formulations of edoxaban                                                 | Open-label, randomized, 4-period, 4-treatment, crossover              | Edoxaban (current tablet) 60 mg PO; Edoxaban (teardrop shaped tablet) 60 mg PO; Edoxaban (oblong shaped tablet) 60 mg PO; Edoxaban (round shaped tablet) 60 mg PO |                28 | Single dose x 4 (Single dose x 1 for each formulation)                                                                        |
| A-U146             | Intrinsic factor PK      | Evaluate effect of hemodialysis on PK                                                                 | Open-label, randomized, 2-way crossover                               | Edoxaban 15 mg PO                                                                                                                                                 |                10 | Single dose x 2                                                                                                               |
| A-U147             | BA                       | Evaluate dose proportionality of edoxaban PK                                                          | Open-label, randomized, 3-way crossover                               | Edoxaban 15 mg, 30 mg, 60 mg PO                                                                                                                                   |                48 | Single dose x 3 (Single dose x 1 for each dose)                                                                               |
| A-U148             | BA                       | Evaluate effect of high-fat meal on edoxaban PK                                                       | Open-label, randomized, 2-way crossover                               | Edoxaban 60 mg PO                                                                                                                                                 |                36 | Single dose x 2                                                                                                               |
| A-U150             | Healthy subject PD PK/PD | Effect of prothrombin complex concentrate (PCC) on edoxaban anticoagulation activity                  | 2-cohort, placebo controlled, randomized 3-treatment, 3-way crossover | Edoxaban 60 or 180 mg PO; 25 and 50 IU/kg doses of PCC IV; Placebo IV (PCC and placebo were given in a blinded manner.)                                           |                24 | Single dose x 3 (Single dose x 1 for each treatment)                                                                          |
| A-U151             | Healthy subject PD PK/PD | Evaluate PT and aPTT in subjects treated with edoxaban alone or preceded by dabigatran or rivaroxaban | Open-label, randomized, 3- treatment, 3-way crossover                 | Edoxaban: 60 mg QD PO; Dabigatran 150 mg BID PO; Rivaroxaban 20 mg QD PO                                                                                          |                24 | Edoxaban: QD for 4 days (Tx A), single dose on Day 4 (Tx B or C); Dabigatran BID or Rivaroxaban QD on Days 1 to 3 (Tx B or C) |

<div style=\"page-break-after: always\"></div>

| Study identifier   | Type of study            | Study objective                                                             | Study design and type of control                     | Test product(s) Dosage regimen, route of administration      |   No. of subjects | Duration of treatment                                                                            |
|--------------------|--------------------------|-----------------------------------------------------------------------------|------------------------------------------------------|--------------------------------------------------------------|-------------------|--------------------------------------------------------------------------------------------------|
| A-E152             | Healthy subject PD PK/PD | Evaluate PT in subjects treated with edoxaban alone or preceded by apixaban | Open-label, randomized, 2-treatment, 2-way crossover | Edoxaban 60 mg QD PO; Apixaban 5 mg BID PO                   |                18 | Edoxaban: QD for 4 days (Tx A), single dose on Day 4 (Tx B); Apixaban: BID on Days 1 to 3 (Tx B) |
| A-U153             | Healthy subject PD PK/PD | Collect plasma samples to validate the STA-Liquid Anti-Xa assay             | Open-label, randomized, parallel group               | Edoxaban 15 mg, 60 mg, 90 mg, 180 mg PO                      |                24 | Single dose                                                                                      |
| A-U156             | Extrinsic factor PK      | Assess PK, interaction with esomeprazole                                    | Open-label, randomized, 2-way crossover              | Edoxaban: 60 mg tablet PO; Esomeprazole: 40 mg capsule QD PO |                34 | Edoxaban: single dose x 2; Esomeprazole: 5 days x 2                                              |

## Table 3. Phase II clinical studies with edoxaban in patients with NVAF.

| Typeof Study   | Study Identifier Location of Study Report   | Objective(s)of theStudy   | StudyDesign andTypeof Control                                                                                                                                  | TestProduct(s); Dosage Regimen; Routeof Administration         | Numberof Subjects                                                        | Healthy Subjects or Diagnosis ofPatients   | Durationof Treatment   | Study Status; Type of Report   |
|----------------|---------------------------------------------|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------|--------------------------------------------|------------------------|--------------------------------|
| Safety         | PRT018 5.3.5.1 NVAF                         | Safetyversus warfarin     | Randomized. parallelgroup. multicenter, double-blind edoxaban, open-label active controlled                                                                    | Edoxaban: 30mgQDPO; 30mgBIDPO 60mgQDPO; 60mgBIDPO WarfarinQDPO | Edoxaban: 30mgQD 235; 30 mgBID 244 60mgQD 234; 60mgBID 180 Warfarin- 250 | Patients with non-valvular AF              | 3months (12 weeks)     | Completed CSR                  |
| Safety         | C-J225 5.3.5.1 NVAF                         | Safetyversus warfarin     | Randomized, parallelgroup, multicenter, double-blind edoxaban, open-label active controlled (includinga warfarin run-in period tocheck PT-INRbefore treatment) | Edoxaban: 30mgQDPO; 45mgQDPO; 60mgQDPO; WarfarinQDPO           | Edoxaban: 30mgQD 130; 45 mg QD 134; 60mgQD 130 Warfarin_- 125            | Patientswith non-valvular AF               | 12weeks                | Completed CSR                  |

<div style=\"page-break-after: always\"></div>

| Safety         | C-J226 5.3.5.1 NVAF   | Safetyversus warfarin    | Randomized, parallel group. multicenter, double-blind edoxaban, open-label active controlled   | Edoxaban: 30mgQDPO; 60mgQDPO WarfarinQDPO                                                                                                                                         | Edoxaban: 30 mgQD 79; 60mgQD- 80 Warfarin-75                    | Patients with non-valvular AF                            | 3 months (12 weeks)                                                      | Completed CSR   |
|----------------|-----------------------|--------------------------|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------------------------|-----------------|
| Dose-titration | J03 5.3.5.2 NVAF      | Safety                   | Open-label, multicenter, dose escalation study                                                 | Edoxaban: 30mgBIDPO: 45 mg BID PO;: 60mgBIDPO                                                                                                                                     | Edoxaban:32 30mgBID 32; 45 mg BID 29; 60mgBID 26                | Patientswith non-valvular AF                             | 10weeks: 30mgBID for 2 weeks, 45 mg BID for 4 weeks, 60mgBID for 4 weeks | Completed CSR   |
| Dose-titration | J05 5.3.5.2 NVAF      | Safety                   | Open-label, multicenter, dose escalation study                                                 | Edoxaban: 5 mgQDPO; 15mgQDPO; 30mgQDPO                                                                                                                                            | Edoxaban:24 5 mgQD 24; 15 mg QD 23; 30mgQD 23                   | Patientswith non-valvular AF                             | 6weeks: 5 mgQD for 2weeks, 15mgQDfor 2weeks, 30mgQDfor 2 weeks           | Completed CSR   |
| Safety         | C-J307 5.3.5.2 NVAF   | Safetyinpatients withSRI | Open-label, parallel group                                                                     | Edoxaban: SRI-15 mgQD PO; Normal/mildrenal impairment 30mg(low dose), 60 mg (high dose) QDPO (Dosehalvedfor subjectwithlow body wt (≤60kg) oronconcomitant verapamilor quinidine) | 93 SRI:50 Nomal/ mild renal impairment: Lowdose 22 High dose 21 | Patients with non-valvular AF and severerenal impairment | 12weeks                                                                  | Completed CSR   |

Table 4. Phase III clinical studies with edoxaban in the requested indications

| Type of Study       | Study Identifier Location of Study Report   | Objective(s) of the Study                            | StudyDesign and Type of Control                                                                           | Test Product(s); Dosage Regimen; Routeof Administration                                                                                                                                                                                                                                                                                                                                                  | Numberof Subjects                                                                      | Healthy Subjects or Diagnosis ofPatients   | Duration of Treatment                                                                                                                                   | Study Status; Type of Report   |
|---------------------|---------------------------------------------|------------------------------------------------------|-----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Efficacy and Safety | C-U301 (ENGAGE AF-TIMI 48) 5.3.5.1 NVAF     | Efficacy and safety, Non-inferiority versus warfarin | Randomized, multicenter, double-blind, double dummy, parallel group, active controlled                    | Edoxaban: 30mgQDPO; 60 mgQDPO Dosehalvedfor subject with moderaterenal impairment(CrCL ≥30and≤50 mL/min),1ow body wt(≤60 kg), oronconcomitant verapamil, quinidine, dronedarone. Warfarin:QDPO Dose adjusted to maintain INR between2.0 and                                                                                                                                                              | 21,105 enrolled, 21,026 treated Edoxaban: 30 mgQD- 7002; 60 mg QD- 7012 Warfarin: 7012 | Patients with documented AF                | From randomizat iontothe common study end date (CSED) visit. Median of 916,904,and 904daysfor edoxaban 30mg. edoxaban 60 mg. and warfarin, respectively | Completed CSR                  |
| Efficacyand Safety  | D-U305 (Hokusai VTE) 5.3.5.1 VTE            | Efficacy and safety, Non-inferiority versus warfarin | Randomized, multicenter, multinational, double-blind, matching placebo, parallel group, active controlled | 3.0,inclusive. LMWH/Edoxaban: LMWHSCfor ≥5days,followed by edoxaban 60 mgQDPO; (Edoxabandose halved for subj. withmoderate renalimpairment [CrCL≥30 and ≤50mL/min],1ow bodywt[≤60kg], oronconcomitant strongP-gp inhibitor[eg, verapamil, quinidine]). LMWH/Warfarin: LMWHSCand warfarin QD PO for≥5days, followed by warfarinQDPO; (Warfarin dose adjusted to maintainINR between 2.0and 3.0,inclusive) | 8292 enrolled, 8240treated Edoxaban: 4118 Warfarin: 4122                               | Patientswith symptomatic DVT and/or PE     | Aminimum of3months upto12 months Median of 267 and 266 days for edoxaban and warfarin, respectively.                                                    | Completed CSR                  |

## Analytical Methods

Statement on GLP compliance and bio-analytical audits is given.

The validation reports included all validation parameters for full validation of an analytical method according to the FDA Guideline for 'Industry, Bioanalytical Method Validation stability. In general, the

<div style=\"page-break-after: always\"></div>

pre-study validations of all the bioanalytical methods were consistent and demonstrated an adequate precision and accuracy (both intra- and inter-day) within the calibrated range, which showed an adequate selectivity,  matrix  effect  and  carry-over,  although  in  June  2011,  the  MHRA  conducted inspections at the Rushden (UK) laboratory of Quotient and identified irregularities in some of the bioanalytical data. Details of the specific data irregularities identified the affected bioanalytical and clinical studies, and the comprehensive remediation undertaken, are summarized in a Remediation Report (TMBA001). In addition, all amendments were reviewed by GLP or GCP inspectors prior to being sent to the study sponsor. At the end of this process the applicant was satisfied that all relevant data had been assessed and a risk assessment had been carried out which showed minimal impact on study conclusions.

Dilution of samples was necessary (different dilution factors have been validated).

The established long-term stability at -20 °C for all analytes (including analytes in the DDI studies) covers  the  maximum  period  of  study  sample  storage  with  the  following  exception:  for  ENGAGE AF-TIMI 48 study (U301), PK samples from subjects were analyzed and reported, even though the collection-to-analysis time could have exceeded validated long-term storage stability period (up to 793 days under -20 ºC, longer storage time not tested).

In general, the analysis of study samples is acceptable and the re-analysis of the study samples were well justified and handled, although some samples reanalysis were carried due to PK reason. For the PK re-assayed, the original values have been reported in the most cases. For the other, the mean concentration was reported. It could be acceptable take into account that these samples do not correspond to values near tmax and it is not a BE study.

All results for ISR samples were within the 20% acceptance limits, although not in all studies the ISR was  performed  (for  BE  study  the  ISR  has  been  performed).  This  is  acceptable  as  the  ISR  was performed in others studies using the same analytical methods in the same analytical site.

## 2.4.2. Pharmacokinetics

The  edoxaban  has  low  solubility  and  low  permeability  and  is  classified  as  Biopharmaceutics Classification  System  (BCS)  Class  IV.  The  formulation  strategy  focused  on  developing  an  oral immediate-release tablet. The proposed commercial formulations are 15, 30, and 60 mg tablets. The 15 and 30 mg tablets were used in the Phase 3 pivotal studies and are the same as the commercial tablets except for a change in the colouring agent. The 60 mg tablet has been demonstrated to be bioequivalent to 2 x 30 mg tablets (U142). The bioequivalence of the 15 mg tablets was not tested in vivo , but is assumed as the criteria regarding manufacture process, qualitative composition, ratio between amounts of active substance and excipients and the comparative dissolution profiles are fulfilled  according  to  section  4.1.6  of  the EMA  Guideline  on  the  investigation  of  bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **) .

## Absorption

## Site of absorption

Edoxaban is absorbed with peak plasma concentrations within 1 - 2 hours. The absolute bioavailability is  approximately  62%.  Edoxaban  is  primarily  absorbed  (approximately  85%)  in  the  upper gastrointestinal tract and is poorly soluble at pH of 6.0 or higher. Compared with oral administration of edoxaban tablets, exposure to edoxaban following delivery in the distal small bowel was about 15% and in the ascending colon about 7%. Administering the compound as a liquid (thus eliminating the limitation of pH dependent solubility) or with an acid (fumaric acid; to reduce pH below 6.0 and thus maximize  solubility)  did  not  greatly  improve  the  absorption  from  the  ascending  colon.  Thus,  in subjects with achlorhydria or conditions and concomitant drugs that increase stomach pH higher than

<div style=\"page-break-after: always\"></div>

6, edoxaban solubility and dissolution rate may be reduced, thereby affecting total absorption of edoxaban.

## Bioavailability

The proposed commercial formulations for the 15 mg and 30 mg tablets have the same composition as the Phase 3 tablets, with the exception of the colorants used in the film coats. Additionally, a 60 mg tablet has been developed for commercial use.

The bioavailability of edoxaban was evaluated in four studies (PRT001, U145, U139 and U147) and is described below.

| Study (No. Subjects)   | Objectives of the Studies                                    | Dose/Formulation                                                  |
|------------------------|--------------------------------------------------------------|-------------------------------------------------------------------|
| PRT001                 | Relative bioavailability, dose- proportionality, food effect | Yellow film coated 60 mg tablet (commercial formulation)          |
| PRT001                 | Relative bioavailability, dose- proportionality, food effect | 60 mg/ Oral solution (160 mL 0.375 mg/mL [60 mg])                 |
| U145                   | Pilot bioavailability study of 60 mg tablet formulations     | Teardrop, round and oblong 60 mg tablets                          |
| U145                   | Pilot bioavailability study of 60 mg tablet formulations     | Yellow film coated 30 mg tablet (Phase 3 formulation) (reference) |
| U139                   | Absolute bioavailability                                     | Yellow film coated 30 mg tablet (Phase 3 formulation)             |
| U139                   | Absolute bioavailability                                     | 30 mg (IV) Lyophilized product for infusion, 10 mg per vial       |
| U147 1                 | Dose proportionality of edoxaban 15, 30 and 60 mg tablets    | Yellow film coated 15 mg tablet (Phase 3 formulation)             |
| U147 1                 | Dose proportionality of edoxaban 15, 30 and 60 mg tablets    | Yellow film coated 30 mg tablet (Phase 3 formulation)             |
| U147 1                 | Dose proportionality of edoxaban 15, 30 and 60 mg tablets    | Yellow film coated 60 mg tablet (Commercial formulation)          |

1 For assessment of this study, please refer to dose-proportionality section

Oral administration of a 60 mg dose to a fasting subject results in peak plasma concentrations of 309±97 ng/mL (arithmetic mean±standard deviation [SD]) occurring within 1 to 2 h (study U151); this Cmax was slightly higher on average than after the same dose in study U147.

The absolute bioavailability of edoxaban is about 62% (geometric mean, study U139).

Under fasting conditions, the relative bioavailability of edoxaban from a tablet formulation (white uncoated tablet) is almost 100% with respect to a solution (study PRT 001).

The PK profile of edoxaban is similar for single and multiple dosing (study PRT 001). Steady-state is achieved within 3 days of dosing,  with minimal accumulation upon once daily dosing (less than 2-fold). At steady-state, a 60 mg dose results in peak concentrations of 303±88 ng/mL at median (range) 1.5 h (0.5 to 4.00 h). The steady-state exposure is 1990±403 ng·h/mL (AUCtau) with trough concentrations of 15.5±3.98 ng/mL (study U151). At the 60 mg bid dose level, the pre-dose and 4 hours post-dose concentrations after the evening dose on Day 9 were similar to after the morning dose, suggesting no diurnal variation in the pharmacokinetics of DU-176.

## Influence of food

The effect of food on the rate and extent of exposure of single doses of edoxaban has been examined in several studies. In the pivotal food effect study (study U148) administration of a high-fat meal did not significantly affect the total exposure of edoxaban (approx. 10%; upper bound 90% CI&lt;125% of fasted from the 60 mg tablets; however, the maximum concentration (Cmax) of edoxaban increased by 40%, when dosed with a high-fat meal. In general, a variable food effect (4% to 77% increase) was observed in Cmax, but no significant effect was seen on total exposure. The high-fat meal also delayed the  time  to  peak  concentration  by  about  0.5h;  however,  in  the  pivotal  Phase  3  clinical  studies edoxaban was dosed without regards to food as the observed PK differences were not expected to have a significant impact on PD of edoxaban. Therefore no recommendation is made for edoxaban to be taken with or without food.

<div style=\"page-break-after: always\"></div>

## Effect of gastric pH

The effect of gastric pH on edoxaban pharmacokinetics was evaluated in a drug-interaction study with esomeprazole  40  mg  QD,  which  elevates  the  mean  24-hour  gastric  pH  to  4.33.  Single  dose administration of oral 60 mg edoxaban 2 hours after the fifth dose of esomeprazole 40 mg QD resulted in a 33% decrease in peak concentrations of edoxaban, with 90% CI falling below the 80 to 125% limit, and the total exposure decreased by 12% with 90% CI completely within the 80 to 125% limit (study U156).

## Distribution

Distribution of edoxaban appears to be biphasic, probably due to enterohepatic circulation, with a steady-state volume of distribution of 107±19.9 L (study U139). While the intravenous (IV) half-life is about 7 h (U139), the oral half-life is between 10 to 14 h, suggesting a higher terminal phase volume (Vz). This indicates that the gut distribution and redistribution phases contributing to Vz following  oral  administration  result  in  a  longer  oral  apparent  half-life  which  could  be  due  to enterohepatic  recirculation.  The  inter-  and  intra-subject  variability  for  clearance  and  volume  of distribution of edoxaban is low (&lt;30%). In vitro plasma protein binding was approximately 54-57% (study 20040272). In addition, plasma protein binding of edoxaban was measured at 2 h, 6 h and 12 h after a single dose of 90 mg and 120 mg of edoxaban (study PRT001). At the 90-mg and 120-mg doses, the plasma protein binding ranged from 40% to 59%, and remained relatively constant over time and individual values at 2 hours post-dose ranged between approximately 37 to 59% across the two dose levels.

## Elimination

The elimination of endoxaban includes both renal and non-renal pathways. In healthy volunteers both pathways contribute equally (~50%) to the total clearance of edoxaban  after iv dosing (U139). Edoxaban is primarily eliminated unchanged in urine and through biliary secretion (PRT019); with metabolism contributing to a lesser extent towards total clearance of edoxaban. In healthy subjects, edoxaban is the predominant excreted component in urine, accounting for 35% (range 27.4% to 46%) of the administered dose indicating that the renal excretion is a significant component of the total clearance. The renal clearance for total radioactivity was 9.69 ± 0.997 L/h, which is higher than glomerular  filtration  rate  suggesting  active  secretion  in  kidney.  In  feces,  62%  (range  55.2%  to 73.0%) total radioactivity is detected; 49% of the administered dose appears to be as parent drug. As the  absolute  bioavailability  is  approximately  61.8%  (Study  U139).  Therefore  the  unchanged edoxaban detected in the feces was a result of both unabsorbed drug and hepatobiliary excretion of systemically absorbed drug. The total clearance of edoxaban is 21.8±3.03 L/h and the renal clearance of edoxaban was 14.2 ± 3.4 L7H. An in vitro uptake study in suspended fresh human hepatocytes provides  suggests  that  edoxaban  is  not  a  substrate  for  the  OATP  class  of  uptake  transporters, including OATP1B3.

## Metabolism

Unchanged edoxaban is the predominant form in plasma. Edoxaban is metabolised via hydrolysis (mediated  by  carboxylesterase 1),  conjugation  or  oxidation  by  CYP3A4/5  (&lt; 10%).  A  total  of  7 metabolites have been detected in plasma; 3 have anticoagulant activity (D21-2393 [human specific metabolite],  D21-1402,  D21-2135).  In  healthy  subjects,  D21-2393  (M4)  is  the  most  abundant metabolite (approximately 10% of parent drug exposure), followed by D21-3231 (&lt; 10%), D21-1402 (&lt;5%), and D21-2135 (low amounts).  D21-1402,  D21-2135,  D21-2393  and  edoxaban  inhibited human FXa with IC50 values of 6.9, 2.7, 1.8 and 3.0 nM, respectively.

The  amount  of  total  metabolites  detected  in  urine  and  feces  was  approximately  5  and  4%, respectively, indicating further metabolism of these metabolites and/or small volumes of distribution

<div style=\"page-break-after: always\"></div>

corresponding  to  higher  plasma  concentrations  relative  to  those  in  urine  and  feces.  Overall, metabolism appears to play a modest role in the elimination of edoxaban.

## Dose proportionality and time dependencies

Based on the studies submitted, the increases in peak and total exposures were slightly less than dose proportional  between 15 and 60 mg but this lack  of dose proportionality was not considered of relevant magnitude. Hence it can be concluded that edoxaban displays approximately dose-proportional pharmacokinetics for doses of 15 mg to 60 mg in healthy subjects. Population PK modelling (TMPP014) of pooled Phase 1 data from 5 studies, for doses of 10, 15, 30, 60, 90, 120, 150 and  180  mg  indicates  a  slightly  less  than  dose-proportional  dose-exposure  relationship.  The population estimate of F1 (model-based relative bioavailability) was found to remain constant for the dose range of 10 mg to 30 mg, but decreased with increasing doses at higher dose levels. For doses above 30 mg, every 30-mg increase in dose was associated with a 6.7% decrease in F1, presumably due to a decreased dissolution rate.

In study PRT001, the PK profile of edoxaban is similar for single and multiple dosing. Steady-state is achieved within 3 days of dosing,  with minimal accumulation upon once daily dosing (less than 2-fold). The mean accumulation ratio at steady-state for maximum (peak) concentration (Cmax) is 1.07 and for area under the concentration-versus-time curves AUCtau (over tau, the dosing interval of 24 h), is 1.14. At the 60 mg bid dose level, the pre-dose and 4 hours post-dose concentrations after the evening dose on Day 9 were similar to after the morning dose, suggesting no diurnal variation in the pharmacokinetics of DU-176.

## Intra- and inter-individual variability

In study PRT001 it was stated, that inter-subject variability in the pharmacokinetics of edoxaban was low  for  AUC0-∞  and  moderate  for  Cmax.  Similar  variability  was  assumed  for  the  intra-subject variability.  The  inter-  and  intra-subject  variability  for  clearance  and  volume  of  distribution  of edoxaban is low (&lt;30%).

## Pharmacokinetics in target population

Population PKs indicates very similar PK of edoxaban in healthy subjects and in patients. The PopPK simulations did not indicate clinically relevant differences.

## Special populations

## Impaired renal function

Results  from  a  targeted  study  in  renal  impairment  show  that  edoxaban  AUC0-inf increased  by approximately 32%, 74% and 72% in subjects with mild, moderate and severe renal impairment but not  on  dialysis,  respectively,  compared  to  healthy  subjects.  Edoxaban  AUC0-inf increased  by approximately  93%  in  subjects  with  ESRD  on  peritoneal  dialysis.  A  study  in  ESRD  patients  on intermittent hemodialysis suggests that hemodialysis does not significantly remove edoxaban from the blood. The PopPK modelling based on data from the Phase 3 study in AF showed that AUC0-24,ss increase  on  average  by  25%,  57%  and  97%  in  subjects  with  mild,  moderate  and  severe  renal impairment.  The following posology is recommended in the proposed SPC: subjects with normal renal function and mild renal impairment (CrCL &gt; 50 mL/min) are recommended to receive edoxaban doses of  60  mg  once  daily,  while  for  subjects  with  moderate  or  severe  renal  impairment  (CrCL  15-50 mL/min) a 50% dose reduction is recommended. In patients with ESRD (CrCL &lt;15 mL/min) or on dialysis, the use of edoxaban is not recommended. Based on the results from the renal impairment study  and  the  PopPK  modelling  based  on  data  from  the  Phase  3  study  in  AF  the  dosing recommendations in renal impairment seem adequate.

## Impaired hepatic function

<div style=\"page-break-after: always\"></div>

The targeted phase I study in patients with hepatic impairment suggest that administering a single dose of 15 mg of edoxaban to subjects with mild or moderate hepatic impairment (Child-Pugh A and B) is unlikely to affect edoxaban exposure to a clinically relevant extent. Subjects with severe hepatic impairment have not been studied. It should be however noted that 15 mg is not the proposed therapeutic dose (60 mg). Therefore definitive conclusions regarding the need for dose adjustment in subjects with hepatic impairment can not be concluded from this study. The following posology in hepatic impairment is recommended in the proposed SPC: No dose adjustment is proposed in patients with mild or moderate hepatic impairment and edoxaban is not recommended in patients with severe hepatic impairment. Edoxaban is contraindicated in patients with hepatic disease associated with coagulopathy and clinically relevant bleeding risk.

## Weight

The effect of body weight has been evaluated using Population PK analyses. Allometrically scaled body weight was included on all disposition parameters for edoxaban in the Population PK analyses based on phase I data, characterizing an increase in disposition parameters with increasing body weight. In the phase 2 study C-J225 Japanese subjects with body weight ≤ 60 kg treated with edoxaban had higher incidence of bleeding than those with body weight &gt;60 kg. Therefore, it was decided that patients with low body weight ≤ 60 kg would receive half of the dose in the phase 3 studies. The population PK analysis based on data from the phase 3 study in AF shows that total exposure is predicted to be 13% higher and peak exposure is predicted to be approximately 40% higher in a typical non-asian patient with normal renal function weighing 55 kg with respect to a patient weighing 84 kg. With the proposed dosing, subjects weighing &lt; 60 kg seems under exposed compared to subjects &gt; 60 kg (almost half exposure). Despite lower exposures, the Applicant has shown that both the ENGAGE AF and Hokusai VTE studies did not reveal any clinically relevant increases in stroke/SEE event rates relative to warfarin for subjects randomized to a reduced dose of edoxaban due to body weight ≤ 60 kg.  Furthermore, predicted PK data in different body weight groups show that the 25 th to 75 th  percentiles from the subgroups ≤ 60 kg, ≤ 50 kg and ≤ 40 kg overlap. It worth mentioning that the majority of the target population in standard clinical practice will have in addition some degree of impairment  in  renal  function  and  associated  risk  factors  for  bleeding.  Therefore,  in  the  low body-weight population, the main concern is bleeding due to potential overexposure rather than a potential lack of efficacy. Therefore the Applicant's conclusion not to change the weight cut off for dose adjustment is accepted. . For 60 mg QD the plasma concentrations of edoxaban in patients with Body weight &gt; 140 kg in relation to all patients in ENGAGE AF-TIMI 48 was reduced to ~60% for Cmax, ~65% for AUC0-24,ss and ~70% for Cmin. A weak trend to a reduced efficacy of edoxaban 60 mg OD versus warfarin in heavy patients weighing &gt;100 kg is visible (stroke/SEE, HR: 1.12; 95%CI: 0.70 to 1.78; mITT, overall study period) compared with patients weighing ≤ 100 kg (stroke/SEE, HR: 0.83; 95%CI: 0.70 to 0.98; mITT, overall study period). However, the HR in heavy patients is based on a small number of primary events (38 vs 33) and the efficacy of edoxaban 60 mg compared with warfarin appears to be maintained even in heavy patients (interaction p-value = 0.24).

## Gender and Age

Regarding gender and age, a phase I study was performed to assess the PK profiles of edoxaban in healthy females and healthy elderly males. Although it is not possible to draw definitive conclusions from this study due to the reduced sample size, edoxaban pharmacokinetics does not appear to be markedly affected by gender, when differences in body weight are taken into account. Regarding age, the small increase in AUC and the decrease in clearance observed in this study in elderly males are probably due to the decrease in renal function  with age. The effect of gender has been further evaluated using population PK analyses. After accounting for body weight, gender does not appear to have a relevant effect on edoxaban PK. Thus, no dose modification is proposed based on gender. The effect of age has also been further evaluated using PK data from pivotal studies and from Population PK analyses. These analyses suggest that, after accounting for renal function, age does not have a

<div style=\"page-break-after: always\"></div>

clinically significant effect on edoxaban PK. The analyses were consistent in the subgroups 65-74 years, 75-84 years and older than 85 years. As such, no dose reduction is recommended based upon age alone.

## Race

There are very limited data originating from phase I / PK studies. Japanese and Caucasian male subjects were examined in the studies PRT020 and PRT008. Additional information is provided in PopPK-analyses/modelling. PK is sufficiently characterised for Caucasian subjects. Minor differences to Japanese subjects are considered of no clinical relevance. Descriptive PK-data provided for races other than Caucasians or Japanese from pivotal trials suggest that race has no significant impact on the edoxaban exposure.

Table 4:

Summary of Predicted Cmarin Different Dose and Subject Groups [a] (TMPPoo8 Addendum)

<!-- image -->

| Exposure group                          | Mean   | Median   | 25h percentile   | 75h percentile   | Min   | Max   | Observation   |
|-----------------------------------------|--------|----------|------------------|------------------|-------|-------|---------------|
| Observationswithnon-dose-adjusted60mgQD | 216.9  | 216.8    | 188.3            | 245.7            | 74.87 | 382.4 | 10272         |
| Age subgroup                            |        |          |                  |                  |       |       |               |
| <65 years                               | 196.3  | 196.8    | 169.7            | 221.8            | 74.87 | 349.9 | 3362          |
| ≥65 and<75 years                        | 220.8  | 220.8    | 193.9            | 247.8            | 77.12 | 353.0 | 3787          |
| 2 75 and< 85 years                      | 233.7  | 233.8    | 207.8            | 260.4            | 115.3 | 382.4 |               |
| 2 85 years                              | 247.4  | 247.7    | 225.1            | 273.1            | 144.6 | 335.0 | 168           |
| Body weight subgroup                    |        |          |                  |                  |       |       |               |
| 2100kg                                  | 230.7  | 229.0    | 207.7            | 254.3            | 95.18 | 382.4 | 7860          |
| >100 and≤ 120 kg                        | 181.2  | 183.5    | 169.8            | 194.8            | 81.37 | 255.8 | 1721          |
| >120 and≤ 140kg                         | 155.9  | 157.2    | 147.2            | 166.7            | 85.83 | 209.4 | 485           |
| >140 kg                                 | 132.0  | 131.1    | 123.0            | 141.5            | 74.9  | 178.2 | 206           |
| Race subgroup                           |        |          |                  |                  |       |       |               |
| White/Caucasian                         | 216.2  | 215.7    | 187.4            | 245.2            | 74.87 | 382.4 | 8818          |
| Black/AfricanAmerican                   | 205.4  | 196.6    | 167.3            | 239.6            | 90.69 | 328.0 | 125           |
| NativeHawaiianorOtherPacificIslander    | 203.1  | 203.6    | 202.7            | 207.7            | 175.3 | 225.0 | 9             |
| Other                                   | 234.5  | 236.7    | 208.7            | 263.9            | 93.35 | 348.3 | 335           |
| Asian (ENGAGE AF study)                 | 219.0  | 220.8    | 195.3            | 244.9            | 89.14 | 332.5 | 978           |
| Missing                                 | 169.6  | 138.6    | 123.1            | 225.6            | 110.0 | 241.2 | 7             |

Table 5: Summary of Predicted Cmin in Different Dose and Subject Groups [a] (TMPPo08)

| Exposure group                           | Mean   | Median   | 25h percentile   | 75th percentile   | Min   | Max   | Observation   |
|------------------------------------------|--------|----------|------------------|-------------------|-------|-------|---------------|
| Observationswithnon-dose-adjusted60mgQD  | 28.13  | 27.26    | 21.99            | 33.68             | 5.672 | 67.58 | 10272         |
| Age subgroup                             |        |          |                  |                   |       |       |               |
| ≤ 65 years                               | 22.94  | 22.02    | 18.66            | 26.20             | 7.243 | 61.85 | 3362          |
| ≥65 and≤75 years                         | 28.53  | 27.83    | 23.21            | 33.31             | 5.672 | 63.33 | 3787          |
| ≥ 75 and ≤ 85 years                      | 32.98  | 32.76    | 27.65            | 37.87             | 11.16 | 67.58 | 2955          |
| ≥ 85 years                               | 37.75  | 38.42    | 33.33            | 42.54             | 13.87 | 58.53 | 168           |
| Body weight subgroup                     |        |          |                  |                   |       |       |               |
| ≤100 kg                                  | 29.37  | 28.83    | 23.30            | 34.93             | 8.083 | 67.58 | 7860          |
| >100 and≤ 120 kg                         | 25.03  | 23.88    | 19.95            | 29.15             | 5.672 | 57.06 | 1721          |
| >120 and≤ 140 kg                         | 22.36  | 21.62    | 18.93            | 25.09             | 8.361 | 48.42 | 485           |
| >140 kg                                  | 20.45  | 20.17    | 17.07            | 23.69             | 8.963 | 31.43 | 206           |
| Race subgroup                            |        |          |                  |                   |       |       |               |
| White/Caucasian                          | 28.00  | 27.05    | 21.91            | 33.54             | 5.672 | 67.58 | 8818          |
| Black/African American                   | 27.92  | 26.17    | 23.48            | 32.38             | 13.85 | 59.60 | 125           |
| Native Hawaiian or Other PacificIslander | 23.55  | 21.92    | 18.05            | 29.36             | 17.29 | 32.91 | 9             |
| Other                                    | 29.73  | 29.32    | 23.15            | 35.63             | 9.698 | 52.43 | 335           |
| Asian (ENGAGE AF study)                  | 28.88  | 28.64    | 22.39            | 34.42             | 8.713 | 60.03 | 978           |
| Missing                                  | 19.39  | 18.70    | 18.22            | 22.40             | 11.50 | 24.26 | 7             |

<div style=\"page-break-after: always\"></div>

Table 6: Summary of Predicted AUCo-24,ss in Different Dose and Subject Groups [a] (TMPP008)

<!-- image -->

| Exposure group                               | Mean   | Median   | 25h percentile   | 75h percentile   | Min   | Max   | Observation   |
|----------------------------------------------|--------|----------|------------------|------------------|-------|-------|---------------|
| Observations with non-dose-adjusted 60 mg QD | 2055   | 2035     | 1771             | 2323             | 946.1 | 3862  | 10272         |
| Age subgroup                                 |        |          |                  |                  |       |       |               |
| ≤65 years                                    | 1795   | 1764     | 1575             | 1981             | 946.1 | 3713  | 3362          |
| 2 65 and ≤ 75 years                          | 2088   | 2074     | 1845             | 2309             | 1002  | 3394  | 3787          |
| ≥75 and≤85years                              | 2283   | 2267     | 2042             | 2525             | 1320  | 3862  | 2955          |
| ≥ 85 years                                   | 2490   | 2496     | 2263             | 2664             | 1911  | 3468  | 168           |
| Body weight subgroup                         |        |          |                  |                  |       |       |               |
| ≤100kg                                       | 2175   | 2151     | 1924             | 2409             | 1096  | 3862  | 7860          |
| >100 and≤ 120 kg                             | 1746   | 1714     | 1579             | 1900             | 1002  | 2896  | 1721          |
| >120 and≤140kg                               | 1522   | 1495     | 1394             | 1628             | 1073  | 2296  | 485           |
| >140 kg                                      | 1327   | 1330     | 1200             | 1445             | 946.1 | 1754  | 206           |
| Race subgroup                                |        |          |                  |                  |       |       |               |
| White/Caucasian                              | 2036   | 2014     | 1754             | 2296             | 946.1 | 3862  | 8818          |
| Black/AfricanAmerican                        | 1964   | 1918     | 1641             | 2246             | 1215  | 3255  | 125           |
| NativeHawaiian or OtherPacificIslander       | 1822   | 1734     | 1664             | 2100             | 1585  | 2127  | 9             |
| Other                                        | 2195   | 2173     | 1941             | 2499             | 1262  | 3144  | 335           |
| Asian (ENGAGE AF study)                      | 2194   | 2192     | 1950             | 2461             | 1260  | 3134  | 978           |
| Missing                                      | 1543   | 1326     | 1297             | 1949             | 958.1 | 2027  | 7             |

## Pharmacokinetic interaction studies Effects of other substances on edoxaban:

The potential for  other  drugs  to  affect  edoxaban  exposure  seems  to  be  primarily  related  to  the inhibition  of  P-gp.  In  vivo  DDI  studies  with  drugs  known  to  inhibit  P-gp  have  been  conducted. Ketoconazole, ciclosporine, quinidine, verapamil, erythromycin and dronedarone, increased edoxaban AUC by 87%, 73%, 77%, 53%, 85% and 85%, respectively. Cmax increased by 89%, 74%, 85%, 53%, 68% and 46%. Based on these results, a 50% dose reduction was initially recommended by the Applicant when edoxaban is co-administered with P-gp inhibitors. However, in respect to the clinical efficacy and safety data gained with verapamil or amiodarone comedication (see Discussion on Clinical Pharmacology) and the similarity of the influence of verapamil, amiodarone and quinidine on edoxaban PK, it is considered appropriate to administer edoxaban at a dose of 60 mg once daily when these drugs are a concomitant medication unless additional factors such as impaired renal function or low body weight have to be taken into account.

An in vivo study with the P-gp inducer rifampicin showed that edoxaban AUC decreased by 34% and Cmax  was  comparable.  In  spite  of  the  decrease  in  edoxaban  total  extent  of  exposure,  the pharmacodynamic effect was not significantly influenced by the co-administration with rifampicin. This  finding  is  likely  due  to  the  observed  increase  in  the  total  exposure  to  active  metabolites D21-2393 and D21-1402, which can be explained by the OATP1B1 inhibition and by the strong CYP3A induction produced by rifampicin. Based on these results, no dose modification is proposed by the Applicant when edoxaban is administered with rifampicin.

## Effects of edoxaban on other substances:

Enzyme inhibition potential has been studied in vitro and the results suggest that a clinically relevant inhibition by edoxaban of the CYP enzymes most commonly involved in drug metabolism is not likely. Predictions based on the PBPK model suggest that a clinically relevant drug-drug interaction via edoxaban  CYP3A4  induction  is  unlikely.  A in  vitro study  was  considered  negative  for  CYP2B6 induction.

Regarding inhibition  of  efflux  transport  proteins,  edoxaban  effect  on  P-gp  mediated  transport  of digoxin has been investigated. The results in vitro show that the net flux ratio of digoxin decreases with increased concentrations of edoxaban. However, results from an in vivo study with digoxin show that a clinically relevant effect of edoxaban on the PK of digoxin is not likely.

Results of the AM14-C0053-R01 'in vitro' study showed no effect of edoxaban on BCRP transport.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Pharmacodynamics

## Mechanism of action

Edoxaban is a highly selective, direct and reversible inhibitor of factor Xa, the serine protease located in  the  final  common  pathway  of  the  coagulation  cascade.  Edoxaban  inhibits  free  factor  Xa,  and prothrombinase  activity.  Inhibition  of  factor  Xa  in  the  coagulation  cascade  reduces  thrombin generation, prolongs clotting time and reduces the risk of thrombus formation.

## Primary and Secondary pharmacology

In vitro, edoxaban inhibits the human FXa in a concentration-dependent and competitive manner. In human studies, it has rapid onset of action with anticoagulant effects, as measured by biomarkers such  as  Factor  Xa  activity,  thrombin  generation  (TG)  parameters,  prothrombin  time  (PT)  and activated partial thromboplastin time (aPTT), observed soon after first dose administration.

Inhibition of FXa in the coagulation cascade reduces thrombin generation and prolongs clotting time and  reduces  thrombus  formation.  The  inhibitory  effects  of  edoxaban  on  human  FXa  and prothrombinase complex were evaluated in several studies. Anticoagulant activity of edoxaban was measured in human plasma through activated partial thromboplastin time (aPTT), prothrombin time (PT), expressed as International Normalised Ratio (INR), and thrombin time (TT).

The biomarkers measured during clinical development include D-dimer, anti-FXa activity, PT, aPTT, Intrinsic FX activity, prothrombin fragments F1 and F2 (F1+2), prothrombinase-induced clotting time (PiCT), thrombin generation, thrombin-antithrombin III complex (TAT) and β-thromboglobulin (β-TG). PT and aPTT were measured in most of the clinical pharmacology studies as part of PD or safety assessment. Additional biomarkers were measured in specific clinical pharmacology studies to further characterize the PD effects of edoxaban.

The PD biomarkers of edoxaban have been characterized in many Phase 1 clinical pharmacology studies  from  healthy  subjects  (PRT001,  PRT003,  PRT005,  PRT009)  to  characterize  the  biological effects of edoxaban.

Edoxaban has a concentration dependent response on PT, aPTT, anti-FXa, TGA, D-dimer and F1+2.

PRT001: In this randomized, single-blind, placebo-controlled two part study, single ascending doses (SAD) of 10 mg, 30 mg, 60 mg, 90 mg, 120 mg, and 150 mg of edoxaban were administered to 85 healthy adult males aged 18-51 years to evaluate the PK and PD of edoxaban (PRT001-SAD and PRT001-MAD). In part two of the study, 36 healthy male subjects received 90 mg QD, 60 mg BID, or 120 mg QD for 10 days. Single oral doses of edoxaban from 10 mg to 150 mg resulted in rapid increase in anti-FXa activity and rapid prolongation of PT and aPTT.

For all dose levels, the median time at which maximal activity was observed was between 1.0 to 3.0 h  postdose.  On  average,  maximum  observed  activity  for  PT,  aPTT  and  anti-FXa  increased  in  a dose-dependent manner over the dose range studied. Recovery to predose values was dose-dependent with return to baseline by 24 to 36 h postdose in all subjects.

## Table PD-01: Pharmacodynamic Parameters after Single Oral Administration of Edoxaban or Placebo (PRT001-SAD)

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                    |              | Placebo            | Edoxaban Dosea    | Edoxaban Dosea    | Edoxaban Dosea    | Edoxaban Dosea    | Edoxaban Dosea    | Edoxaban Dosea    |
|--------------------|--------------|--------------------|-------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
| Biomarker          | PD Parameter | (N=17)             | 10 mg (N=10)      | 30mg (N=10)       | 60 mga (N=10)     | 90 mg (N=9)       | 120 mg (N=9)      | 150 mg (N=9)      |
| PT                 | Amx (s)      | 14.7 ±1.20         | 15.5±1.13         | 21.9±2.02         | 28.2±4.70         | 33.8 ± 7.71       | 31.8± 5.77        | 39.5±8.29         |
| PT                 | tAmsx (h)b   | 6.00 (0.00, 48.00) | 3.00 (0.50, 6.02) | 1.00 (1.00, 2.00) | 1.02 (0.50, 3.00) | 1.00 (0.50, 2.02) | 1.00 (0.50, 2.00) | 1.02 (0.50,2.00)  |
| PT                 | Ax (s)       | 0.741±0.600        | 1.91±0.458        | 7.20 ±2.04        | 14.0 ± 4.40       | 19.0± 7.07        | 18.0±5.44         | 24.4± 7.84        |
| aPTT               | Amx (s)      | 33.6±4.03          | 38.0±4.03         | 45.7 ± 8.50       | 54.3 ± 15.2       | 52.6± 7.97        | 56.2±6.52         | 58.0 ±8.64        |
| aPTT               | tAmxx (h)b   | 6.00 (0.00, 48.00) | 3.00 (0.50, 6.02) | 1.00(1.00,2.00)   | 1.03 (1.00, 3.00) | 3.00 (1.00, 3.02) | 2.00 (0.50, 3.00) | 2.00 (1.00,3.00)  |
| aPTT               | Amx (s)      | 1.96 ±2.12         | 3.27± 0.835       | 10.7 ±3.97        | 18.2± 8.15        | 20.4± 5.45        | 22.1 ±4.26        | 24.1 ± 7.11       |
| Anti-FXa activity* | Amax (IU/mL) |                    | 0.435 ±0.160      | 2.09 ±0.384       | 3.80±0.971        | 8.14±4.86         | 9.14 ± 3.30       | 10.7±4.94         |
| Anti-FXa activity* | tAm.x (h)b   |                    | 2.00 (0.50, 6.02) | 1.00 (0.50, 3.00) | 1.02 (0.50, 3.00) | 1.00 (1.00, 2.00) | 1.00 (0.50, 2.00) | 2.00 (0.50, 3.00) |

Source:PRT001-SAD Table12.1,Table12-4 andTable12.8.

Datapresentedasarithmeticmean±SD

a:Includes subjects from Group C only (participated in 2 treatmentpeniods and receiveda single dose of 60mg of edoxaban orplaceboas tablet in thefasted state)

b: Median (Min, Max)

c: Little or noactivities were observed at baseline or postdose in subjectswho received placebo.

anti-FXa = anti factor Xa;aPTT = activatedpartial thromboplastin time;

Amx = maximum observed achivity value; AAmx = maximum observed achivity value change from baseline;

PT = prothrombin time; tAmax = time of maximum observed activity value.

PRT003: An open label, randomised, placebo and positive controlled (Fondaparinux). The primary objective of this study was to investigate the effect of administration of different doses (30, 60 and 120 mg) of oral edoxaban on inhibition of thrombin generation and platelet activation by using the shed  blood  model.  Edoxaban  caused  a  rapid  and  marked  reduction  in  the  thrombin  generation markers, F1+2 and TAT in shed blood, at dose levels of 30 to 120 mg. The maximum inhibition appeared to be reached at the 120 mg dose level. There was no apparent drug-related effect of edoxaban on venous F1+2 levels, and edoxaban  caused a rapid and variable reduction in venous TAT levels at dose levels of 30 to 120 mg. High between-subject variability in venous F1+2 and TAT data confounded the interpretation. Edoxaban caused a rapid and marked reduction in the marker of platelet activation, â-TG in shed blood, at dose levels of 30 to 120 mg. The between-subject variability in  venous â-TG data was high for edoxaban. Edoxaban caused a rapid and marked dose-related prolongation of the venous blood coagulation parameters, APTT, PT and PT-INR, and induction of venous Anti FXa activity at dose levels of 30 to 120 mg. There was no apparent drug-related effect of edoxaban on shed blood volume. Furthermore, high between-subject variability was observed.

PRT005: an open label, single center, assessor blind, ex vivo study. The primary objective of this study was to investigate the antithrombotic effects following a single oral dose of 60 mg edoxaban using a human model of thrombus formation. The secondary objective of the study was to analyze the pharmacological effects of edoxaban using thrombin generation measurement, anti-factor Xa activity, and standard coagulation parameters (PT/INR and aPTT). Pharmacological effects were assessed in relation to plasma concentrations of edosaban at time 0 (pre-dosing), 1.5, 5 and 12 h (post-dosing). Edoxaban 60 mg oral dose reduced ex vivo thrombus formation under high-and low shear rate conditions, prolonged clotting time in subjects´ plasma, and inhibited clotting factor Xa.

PRT009 and PRT018: Two studies investigated both, QD and BID dosing (study PRT009 in elderly healthy  subjects  and  study  PRT018  in  patients  with  NVAF).  In  both  studies  through  levels  of pharmacodyamic parameters (especially anti-FXa activity) were markedly higher after BID dosing. Therefore, the effect on pharmacodynamic parameters does not seem to be maintained throughout the dosing interval after QD dosing, at least at the 30 mg dose level. Overall, the low anticoagulant action after about 12 hours after QD dosing has to be discussed in the clinical context, also taking into account the higher bleeding rates with BID dosing.

TMCP-Peds-001 (DSNER1): This study tested the effect on plasma biomarkers of coagulation of ex-vivo treatment with edoxaban (6 concentrations: 12.5, 25, 50, 100, 200 and 500 ng/ml) and rivaroxaban (5 concentrations: 12, 36, 108, 216 and 540 ng/ml) using blood samples from umbilical

<div style=\"page-break-after: always\"></div>

cord (n=10) and healthy adult volunteers (n=5). The PD performance of edoxaban in plasma from ex-vivo-treated cord blood was not significantly different from that in plasma from ex-vivo-treated adult blood for any parameter investigated, which included Prothrombin time (PT), activated partial thromboplastin time (aPTT), Anti-Factor Xa (Anti-FXa), Intrinsic Factor X (Intrinsic FX) Thrombin Generating Activity (TGA): Peak (TGA-Peak); lag time (TGA-lag), time to peak (TGA-time to peak), endogenous thrombin potential (TGA-ETP) and velocity index (TGA-VI). In summary, there was no significant  difference  in  the  anticoagulant  activity  of  edoxaban  in  cord  and  adult  plasma.  In  an addendum  to  this  study,  it  was  reported  that  the  percentage  increase  of  INR  following  ex-vivo treatment with edoxaban did not differ significantly in samples derived from adult versus cord blood treated.

## Secondary pharmacology

PRT021: A phase 1, randomized, single-dose, placebo and active controlled crossover (moxifloxacin 400 mg) study to evaluate a thorough QTC study with edoxaban in healthy subjects.

The primary objective of this study was to assess the effect of therapeutic and supratherapeutic plasma exposures of edoxaban on the QTc interval duration after administration of single oral doses of  90  mg  and  180  mg.  Blood  was  collected  for  the  determination  of  plasma  concentrations  for edoxaban for up to 48 hours post-dose in each period. The primary endpoint for this study was the time-matched difference in QTcI (individual correction method) interval of each active treatment group  (edoxaban  90  mg,  edoxaban  180  mg  dose,  and  moxifloxacin)  and  placebo  after  baseline adjustment.  The  main  objective  of  the  QTc  analysis  was  to  determine  whether  edoxaban  has  a threshold pharmacologic effect on cardiac repolarization, as detected by QT/QTc prolongation.

Since the positive control (moxifloxacin) met the criteria for the QTc prolongation of greater than 5 msec at the specified time points, the thorough QTc study is valid to detect conclusively the potential edoxaban to cause changes in ∆QTcI intervals. Edoxaban did not have a threshold pharmacologic effect on cardiac repolarization. The upper bounds of 95% one-sided CIs for the least-squares mean of the placebo-corrected QTcI change from time-matched baseline did not exceed 4 msec at any time point after dosing for either dose level (90 mg and 180 mg). The results showed no relationship between plasma concentrations of edoxaban and ∆QTcI values up to DU-176b concentrations of 857 ng/mL.

In summary, doses of edoxaban had no clinically relevant QTc effect as compared to placebo, and this can be considered a negative thorough QT/QTc study.

## Relationship between plasma concentration and effect

In  healthy  volunteers: In study PRT001, A linear correlation was observed between edoxaban plasma concentrations and PT, aPTT and anti-FXa activity (Figure 2.1).

## Figure PD-01: Relationship Between Plasma Concentrations of Edoxaban and pharmacodynamic Endpoints (PRT001)

Source:PRT001-MADFigure11-19toFigure11-24

<div style=\"page-break-after: always\"></div>

<!-- image -->

In  patients: There are two Phase 3 pivotal studies of efficacy and safety, one of them in NVAF (ENGAGE-AF) and the other one in patients with VTE (Hokusai-VTE), in which plasma samples were obtained and therefore a relationship between plasma and efficacy/safety could be tempted. The first substudy (TMPP009) describes the plasma exposure response of edoxaban and efficacy (time to first occurrence of stroke or SEE, ischemic stroke or SEE and hemorrhagic stroke) and safety endpoints (time to first occurrence of major bleeding) (Figures PD-02 and PD-03). This substudy demonstrated statistically significant exposure response relationships using a median model prediction for major bleeding (minimum concentration), stroke or SEE (average concentrations), and ischemic stroke or SEE  (average  concentration),  but  not  for  hemorrhagic  stroke.  By  appliying  a  logistic  regression model, the period of time that intrinsic factor  Xa  was  maintained  at  15%  or  less  was  the  most significant factor for bleeding. As such, the duration of factor FXa suppression exceeding a certain threshold value seems to be more accountable for bleeding risk than the magnitude of suppression. This may explain the observed increase in bleeding after the 30 mg and 60 mg BID dosing regimens compared to QD dosing of edoxaban in phase II trials.

Figure PD-02: Probability of a Major Bleeding Event Within 1 Year in an Edoxaban Subject Versus Minimum Exposure (Cmin) of Edoxaban (TMPP009)

Figure PD-03\\_ Probability of a Stroke or SEE Within 1 year in an Edoxaban Subject Versus Average Exposure (Cav) of Edoxaban (TMPP009)

<div style=\"page-break-after: always\"></div>

<!-- image -->

The second substudy (TMPP011) describes the plasma exposure response of edoxaban and efficacy endpoint  of  symptomatic  recurrent  venous  thromboembolic  event  (recurrent  VTE)  and  safety endpoint of clinically relevant bleeding (CRB). This study identifieda statistically significant exposure response relationship using a median model prediction for recurrent VTE (average concentration), but no statistically significant exposure response relationship was detected for CRB (Figures PD-04 and PD-05).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| for a typical edoxaban subject (no risk factors). The gray shaded area shows the 90% prediction interval. The distributions represent the predicted (from the   | for a typical edoxaban subject (no risk factors). The gray shaded area shows the 90% prediction interval. The two distributions represent the predicted (from the   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## Pharmacodynamic interactions with other medicinal products or substances

As  an  anticoagulant,  edoxaban  has  the  potential  to  interact  with  other  drugs  that  influence  the coagulation system. Co-administration of edoxaban with acetylsalicylic acid, naproxen, or digoxin showed additive effects on bleeding time prolongation compared to the administration of edoxaban alone, without additionally affecting platelet aggregation.

The interaction studies with aspirin (high and low doses), naproxen or digoxinare:

PRT014: A  phase  I,  randomized,  open-label,  dual  sequence,  parallel  group  study  assessing  the pharmacodynamic effects of the co-administration of digoxin and edoxaban in healthy volunteers. The objective of this study was to evaluate the pharmacodynamics (PD) of multiple daily 60 mg edoxaban doses for seven days followed by its co-administration with multiple 0.25 mg digoxin dose for the subsequent seven days. lood samples for PD parameters, were collected over 24 hours on Day 7 (monotherapy) and on Day 14 (combination therapy). Maximal increases in coagulation parameters were noted at approximately 2 hours after the last dose following concomitant administration of edoxaban and digoxin. The maximum decrease in the rate of thrombin generation and the maximum anti-factor Xa activity occurred 2 hours after the last dose. PT, INR, aPTT, all CAT-TGT parameters, and  anti-factor  Xa  (FXa)  activity  were  summarized  with  descriptive  statistics.  The  combination therapy of digoxin and edoxaban increased the maximal plasma concentration of digoxin by 28% and increased the maximal plasma concentration of edoxaban by 16%, without affecting the total extent of exposure. The combination therapy (edoxaban and digoxin) and the monotherapy with edoxaban resulted  in  a  similar  increase  of  the  standard  coagulation  parameters  (INR,  PT  and  aPTT).  The thrombin  generation  was  slightly  decreased,  and  the  induction  of  anti-factor  Xa  activity  slightly increased. A strong positive correlation was observed between plasma concentrations of edoxaban and  anti-Factor  Xa  activity.  These  results  were  not  unexpected  based  on  previous  non-clinical pharmacology studies that showed edoxaban to be a potent and direct inhibitor of Factor Xa (FXa) that prolongs clotting  (PT and aPTT) in plasma.

U128: A phase I, open-label, randomized, 3-way crossover study to assess the effect of naproxen on the  pharmacodynamics of edoxaban. The objective of  this  study  was  to  determine  the  effect  of co-administration of naproxen (500 mg BID) and edoxaban (60 mg) on bleeding time, and on global coagulation variables (aPTT, PT/INR, and Intrinsic Factor Xa), compared to when each drug was administered alone. Serial blood samples were collected on Day 1 at pre-dose (baseline for each respective period) and on Day 2, measured at various time points up to 24 hours postdose.

Bleeding Time: Both edoxaban and naproxen had an effect on prolongation of bleeding time was most pronounced when both drugs were administered together.

Pharmacodynamic Markers: Graphical data analysis demonstrated correlations between the peak plasma concentrations of edoxaban, administered with or without naproxen, and PT, INR, aPTT and Intrinsic  FXa.  Similar  prolongation  effects  from  baseline  were  observed  for  the  coagulation biomarkers PT, INR, aPTT and Intrinsic FXa, measured at various time points up to 24 hours postdose on Day 2, when edoxaban was administered with or without naproxen. The prolongation effect of edoxaban  on  the  coagulation  biomarkers  PT,  INR,  aPTT  and  Intrinsic  FXa  was  not  significantly influenced by co-administration with naproxen.

<div style=\"page-break-after: always\"></div>

PRT017: A phase I, two-cohort, double-blind, randomized, 2-way crossover study in healthy subjects to assess the effect of high dose aspirin on pharmacodynamics of edoxaban. The objectives of this study were to assess the effect of co-administration of high dose aspirin (325 mg) and edoxaban (60 mg) on bleeding time, and the effect of co-administration of aspirin on the pharmacodynamics (PD) edoxaban. Serial blood samples were collected on Day 1 (baseline) and on predose on Day 5 until 24 hours post dose.

Bleeding Time: These results showed that both edoxaban and high dose aspirin have an effect on prolongation of bleeding time was generally most pronounced when both drugs were administered together. Results for changes in bleeding time from baseline were consistent with an additive effect for the prolongation of bleeding time between edoxaban and aspirin.

Pharmacodynamics: The effects of edoxaban and aspirin (administered alone or as a combination therapy)  on  coagulation  were  measured  using  activated  partial  thromboplastin  time  (aPTT), prothrombin time (PT), anti-factor Xa (FXa) activity, prothrombinase induced clotting time (PiCT), and calibrated automated  thrombogram-thrombin  generation  time  (CAT-TGT)  for thrombin generation. In all treatments that included edoxaban either as a monotherapy or as a combination therapy with aspirin, similar increases from baseline were noted for most coagulation parameters following dose administration on Day 5. The pharmacodynamics of edoxaban do not appear to be influenced by the co-administration of aspirin.

U127: A phase I, randomized, 3-way crossover, open-label study in healthy subjects to assess the effect of low dose aspirin on pharmacodynamics of edoxaban. The objectives of this study were to assess the effect of co-administration of low dose aspirin (100 mg) and edoxaban (60 mg) on bleeding time,  and  the  effect  of  co-administration  of  aspirin  on  PT,  aPTT,  INR  and  anti-FXa  activity  of edoxaban. Serial blood samples were collected on Day 1 (baseline) and measured at various time points up to 24 hours post-dose on Day 5, when edoxaban was administered with or without aspirin.

Bleeding  Time: concomitant  administration  of  100  mg  aspirin  and  edoxaban  results  in  greater prolongation of bleeding time, comparing with either drug administered alone. Results for changes in bleeding time from baseline were consistent with an additive effect for the prolongation of bleeding time between edoxaban and aspirin.

Pharmacodynamics: PD analyses were performed in order to determine the effect of co-administration of edoxaban and low dose aspirin on the coagulation parameters aPTT (Time), aPTT (Ratio), PT (Time), PT Rate (%), INR and Intrinsic FXa. No significant difference was observed in coagulation effects when edoxaban was administered with low dose aspirin (Treatment A) compared to its administration alone (Treatment B). Aspirin had no apparent effect on coagulation biomarkers after 5 days of once daily doses of 100 mg. These results were consistent with the similar prolongation effects observed relative to baseline, based on the peak change and percent change from baseline results, for both treatments. These results supported the hypothesis that the effect of edoxaban on the coagulation biomarkers would not be significantly influenced by co-administration with aspirin. The  effect  of  edoxaban  on  the  coagulation  biomarkers  PT,  INR,  aPTT  and  Intrinsic  FXa  was  not significantly influenced by co-administration with aspirin.

## Effects of coagulation markers when switching from rivaroxaban, dabigatran, or apixaban to edoxaban:

U122: A phase I, randomized, double blind study to assess the pharmacodynamics of edoxaban in healthy  subjects  who  have  recently  discontinued  warfarin.  The  objectives  of  this  study  were  to

<div style=\"page-break-after: always\"></div>

determine the effect of warfarin on biomarkers of anticoagulation in healthy subjects who were dosed to achieve an INR of 2 to 3, and to compare the effect of edoxaban to placebo on biomarkers of anticoagulation in healthy subjects who have recently discontinued warfarin. Serial blood samples for PD markers were collected at baseline (predose on Day 1) and from predose up to 12 hours post dose on the last day of warfarin dosing (prior to administration of edoxaban or placebo). The administration of a single edoxaban 60 mg dose 24 hours after the last warfarin dose prolonged the lag time to thrombin  formation  or  clotting  time.  A  positive  correlation  was  observed  between  plasma concentrations of edoxaban and clotting time as measured by the clotting time factors PT, INR and PICT. A strong positive correlation was observed between plasma concentrations of edoxaban and anti Factor Xa activity.

U151: A  phase  I,  open-label,  randomized,  crossover  study  to  assess  the  pharmacodynamics edoxaban (60 mg) in healthy subjects after switching from dabigatran (150 mg BID) or rivaroxaban (20 mg). The objectives of this study were to evaluate the prothrombin time (PT) and the activated partial  thromboplastin  time  (aPTT)  profile  in  healthy  subjects  treated  with  edoxaban  alone  or preceded by rivaroxaban or dabigatran, and to assess the effect of edoxaban alone or preceded by rivaroxaban  and  dabigatran  on  additional  pharmacodynamic  (PD)  assays.  PD  assessments  were based on the following biomarkers: PT, aPTT, anti-FXa, TGA parameters, bleeding time, and ecarin clotting time (ECT). Serial blood samples were collected during each treatment edoxaban switching on Day 4, and also during treatment edoxaban only on Day 1, for assessment of PD parameters related to edoxaban. The PD parameters for PT, aPTT, anti-Fxa, ETP peak thrombin after a single edoxaban dose preceded by rivaroxaban were comparable to those parameters after 4 consecutive daily doses of edoxaban. The PD parameters for anti-FXa, ETP, peak thrombin after a single edoxaban dose preceded by dabigatran were comparable to those parameters after four consecutive daily doses of edoxaban, but for PT was higher. Switching from rivaroxaban to edoxaban 24 h after the last rivaroxaban dose resulted in similar anticoagulant effects of edoxaban in all PD assays upon switching as upon multiple dosing of edoxaban. Switching from dabigatran to edoxaban resulted in higher anticoagulant  effects  of  edoxaban  for  aPTT,  PT,  and  the  thrombin  generation  parameters  most sensitive to dabigatran (TGA lag time, TGA time to peak) when dosed 12 h after a dabigatran dose.

E152: A phase I, open-label, 2-treatment, 2-way crossover study to assess the pharmacodynamics edoxaban (60 mg) in healthy subjects after switching from apixaban (5 mg BID). The objectives of this study were to evaluate the prothrombin time (PT) in healthy volunteers treated with edoxaban alone or preceded by apixaban, and to assess the effect of edoxaban alone or preceded by apixaban on  additional  pharmacodynamic  (PD)  assays:  activated  partial  thromboplastin  time  (aPTT), anti-factor Xa (anti-FXa) activity, thrombin generation assay (TGA) parameters. The prothrombin time (PT) observed for apixaban BID followed by edoxaban was comparable to that observed for edoxaban alone on day 4. The other biomarkers anti-FXa, INR, ETP, peak thrombin after edoxaban were  comparable  across  study  days  in  Treatment  edoxaban  alone  (Days  1  and  4)  and  across treatments switching from apixaban. Switching from apixaban to edoxaban at the next scheduled dosing time of apixaban should be feasible, as anticoagulant effects of edoxaban upon switching are similar to multiple dosing of edoxaban.

## Reversal of anticoagulant effects

Study U150 investigated the potential of two concentrations of a 3-factor PCC (factors FII, IX and X) as reversal agents for edoxaban. Both doses of edoxaban (60 and 180 mg) inhibited endogenous thrombin potential (ETP, one of the TGA parameters), an effect that was rapidly reversed (within 0.5 h  after  administration  of  PCC)  by  both  doses  of  PCC  (25  and  50  IU/kg).  The  effect  was  more pronounced for the 60 mg dose group. At 0.5 h after administration of PCC, the LSM values for change

<div style=\"page-break-after: always\"></div>

from baseline for TGA-ETP were -1047, -546 and -611, respectively for 60 mg edoxaban dose alone, or edoxaban with 25 or 50 IU/kg PCC. For the 180 mg edoxaban dose, the change from baseline in TGA-ETP was -1644, -975 and - 1970, respectively with edoxaban alone, or edoxaban with 25 or 50 IU/kg PCC. Both doses of PCC resulted in a more rapid return to baseline for both doses of edoxaban (~3h), than for edoxaban alone (&gt;72h). However, PCC did not substantially reverse the effect of edoxaban on PT, INR or aPTT prolongation relative to placebo. Both doses of PCC did not appear to have any effect on change from baseline for anti-FXa.

Hence,  administration  of  25  or  50  IU/kg  3-factor  PCC  with  edoxaban  60  or  180  mg  did  not substantially accelerate reversal of PT, INR or aPTT prolongation relative to placebo. A reversal was demonstrated for ETP. No dose-dependency with respect to the effect on ETP (between 25 IU/ kg and 50 IU/ kg) was observed.

## Genetic differences in PD response

Exploratory  pharmacogenomics  analyses  demonstrate  that  there  is  no  demonstrable  effect  of VKORC1 or CYP2C9 genotype on bleeding events in edoxaban treated subjects, although in warfarin treated  subjects,  the VKORC1 1639 AA subjects appeared to have a higher frequency ofbleeding events that the GG or GA genotypes. Common genetic variants in the VKORC1 and CYP2C9 genes that are known to affect warfarin sensitivity had no effect on bleeding in subjects treated with edoxaban.

## 2.4.4. Discussion on clinical pharmacology

## Pharmacokinetics

A large amount of PK data was generated, as PK-data were not only available from the 43 phase 1 studies but from phase 2 and phase 3 studies as well. In general, PK was considered characterised properly. This includes absorption, distribution, metabolism and excretion (ADME), influence of food and gastric pH, renal and hepatic insufficiency.

Time dependency of edoxaban PK in general was characterised properly. There is a bi-exponential decline of the plasma profile. The half-life estimates were variable across studies. A pooled population PK (PopPK) analysis of 8 Phase 1, 1 Phase 2 and 2 Phase 3 studies of edoxaban characterized the PK of edoxaban using a two-compartment model, giving an estimated half-life of about 12.5 h. In some studies, sparse sampling after 12 hours may have led to a shorter calculated half-life (e.g. t1/2 = 5.5 - 7.5 h in study U147). When edoxaban is dosed 60 mg QD, Cmax is about 20 - fold the value of Ctrough. As a linear  correlation  is  observed  between  edoxaban  plasma  concentrations  and  PT,  aPTT,  and anti-FXa activity the QD dosing was considered not justified from the PK point of view. A BID or even three  times  a  day  (TID)  dosing  scheme  could  be  more  favourable.  The  chosen  QD-dosing  was addressed as well in the PD, clinical efficacy and safety sections of this assessment report.

The targeted phase I study in patients with hepatic impairment suggested that administering a single dose of 15 mg of edoxaban to subjects with mild or moderate hepatic impairment (Child-Pugh A and B)  is  unlikely  to  affect  edoxaban  exposure  to  a  clinically  relevant  extent.  In  light  of  the  results obtained in this study and considering the importance of renal clearance in edoxaban elimination, the Applicant's conclusion regarding no need for dose adjustment in subjects with mild or moderate hepatic impairment was considered acceptable.

In general, the PK interactions profile is characterised properly. Though amiodarone and verapamil show comparable modifications of edoxaban PK, a dose reduction of edoxaban by 50 % was initially suggested  if  co-administered  with  verapamil  but  not  when  co-administered  with  amiodarone,  a decision mainly based on Cmin calculations. However, clinical phase III data indicate that efficacy of edoxaban  was  unsatisfactory  with  dose  reduction  by  50  %  in  patients  receiving  verapamil  or

<div style=\"page-break-after: always\"></div>

quinidine. In ENGAGE AF-TIMI 48, subgroup analyses for these patients indicated a numerically better efficacy of warfarin. The concern is supported by the POP PK analyses. C min ss values were 28.13 ng/ml (n = 10272) for the 60 mg qd dose and 16.24 ng/ml (n = 335) for the 30 mg qd dose in the presence of a P-gp inhibitor. In respect to the clinical efficacy and safety data gained with verapamil or  amiodarone  co-medication  and  the  similarity  of  the  influence  of  verapamil,  amiodarone  and quinidine on edoxaban PK, it was considered appropriate to administer edoxaban at a dose of 60 mg once daily when these drugs are a concomitant medication unless additional factors such as impaired renal function or low body weight have to be taken into account. The SmPC section 4.5 was modified accordingly. Co-administration of edoxaban with the p-gp inducer rifampicin led to a decrease in mean edoxaban AUC and a shortened half-life, with possible decreases in its PD effects. Therefore, edoxaban should be used with caution when co-administered with P-gp inducers.

## Population pharmacokinetics

In general, the population PK analysis was considered acceptable. Presented goodness of fit plots was not easy to interpret since scaling was not optimal. Prediction-corrected Visual Predictive Checks (pcVPCs)  were  considered  acceptable  and  bootstrap  (n=100)  results  show  good  agreement. Compared to the results of the non-compartmental analysis (NCA), clearance was underestimated in the normal renal function group and overestimated in the severely renally impaired group. This might indicate an underprediction of the influence of CrCl on edoxaban clearance (CL). Edoxaban seems to undergo an enterohepatic recirculation. A second peak can be seen in the concentration-time profiles. The second peak was more pronounced in patients with mild or moderate renal function compared to those with normal or severe renal function. The model seems to underestimate the influence of renal function since compared to NCA values which ranged from 34.8 to 17.9 L/h from normal to severe renal function; the final model only predicted a range between 31.4 and 20.5 L/h.

Influence of P-gp inhibitors was discussed with the Phase 1 POPPK model. It was mentioned that taking into account the relation of each P-gp inhibitor separately was more adequate than including a class effect of P-gp inhibitors. In the Phase 3 POPPK model, P-gp inhibitors were introduced as a class and the effect on absolute bioavailability (F) and CL remains unclear. A more differentiated conclusion on the necessity of dose adjustment and its extent with the different P-gp inhibitors was not possible with the actual data. The following recommendations were finaly agreed to be included in the SmPC with regards to the concomitant use of edoxaban and P-gp inhibitors: (1) in patients concomitantly taking  edoxaban  and  the  following  P-gp  inhibitors:  ciclosporine,  dronedarone,  erythromycin,  or ketoconazole,  the  recommended  dose  was  agreed  to  be  30  mg  of  edoxaban  once  daily  (50% reduction as compared to the usual recommended edoxaban dose of 60 mg once daily); (2) no dose reduction was recommended for concomitant use of amiodarone, quinidine or verapamil; (3) the use of Lixiana with other P-gp inhibitors including HIV protease inhibitors has not been studied. The effect of P-gp inhibitors, pre-specified for dose-adjustment on the PK of edoxaban, differed to the effect of P-gp inhibitors with no dose-adjustment on the PK of edoxaban. The applicant considered the slight non-proportionality of the PK of edoxaban not relevant for a different influence of different P-gp inhibitors on edoxaban exposure, especially because dose reduction was only done by 50% and not from 60 mg to 15 mg.

Eta-shrinkage values were high in the Phase 3 studies. This has to be kept in mind when evaluating the  exposure  -  response  relation  since  estimated  exposure  values  for  individual  persons  will  be shrunk  to  the  typical  population  parameters.  Thus,  the  variability  in  the  exposure  will  not  be adequately captured, but will be lower than real.

<div style=\"page-break-after: always\"></div>

Summarizing the results of the population PK analyses, the relevance of the influence of concomitant P-gp inhibitors could not be finally assessed.

## Pharmacodynamics

The effect of edoxaban on anti-Xa activity was assessed in multiple clinical trials. The PD effects of edoxaban  include  induction  of  venous  anti-FXa  activity  at  dose  levels  of  30  to  120  mg,  the prolongation of clotting tests such as PT/INR, and aPTT, as well as edoxaban 60 mg reduced ex vivo thrombus formation. Edoxaban has no apparent direct effect on platelet activation or on endothelial activation.

A  linear  correlation  was  observed  between  edoxaban  plasma  concentrations  and  PT,  aPTT  and anti-FXa activity in healthy subjects (study PRT001). In patients with NVAF, there was a statistically significant exposure response relationship for major bleeding (minimum concentration), stroke or SEE (average concentrations), and ischemic stroke or SEE (minimum concentration), but not for hemorrhagic  stroke  (TMPP009).  In  patients  with  acute  VTE,  there  was  a  statistically  significant exposure  response  relationship  for  recurrent  VTE  (average  concentration),  but  no  statistically significant exposure response relationship was detected for CRB (TMPP011).

As  an  anticoagulant,  edoxaban  has  the  potential  to  interact  with  other  drugs  that  influence  the coagulation system. Co-administration of edoxaban with acetylsalicylic acid, naproxen, or digoxin showed additive effects on bleeding time prolongation compared to the administration of edoxaban alone, without additionally affecting platelet aggregation. The prolongation effect of edoxaban on the coagulation  biomarkers  PT,  INR,  aPTT  and  intrinsic  FXa  was  not  significantly  influenced  by co-administration with these drugs.

Available data support that edoxaban does not affect the QTc interval: the lower bound of the 95% CI for the placebo-adjusted change in QTc after treatment with moxifloxacin was &gt;5 msec, confirming assay sensitivity.  The  upper  bound  of  the  95%  CI  for  the  placebo-adjusted  differences  for  both edoxaban doses were &lt; 4 msec, indicating that edoxaban had no relevant effect on the QTc interval.

The effect on PD parameters seems not to be maintained throughout the dosing interval after QD dosing (e. g. study PRT003). Two studies investigated both, QD and BID dosing (study PRT009 in elderly healthy subjects and study PRT018 in patients with NVAF, please refer to clinical part of this AR). In both studies through levels for PD parameters (especially anti-FXa activity) were markedly higher after BID dosing. Overall, the low anticoagulant action beyond 12 hours after QD dosing has to be discussed in the clinical context, also taking into account the higher bleeding rates with BID dosing. Overall, the choice of the QD dosing regimen is considered justified with regard to the increase in bleeding risk observed after BID dosing. The impact of lower doses than 30 mg BID, which might have exhibited the most favourable B/R profile, cannot be assessed since such doses were not investigated. Further discussion on this issue was not considered necessary given the clinical study data available.

PD interaction studies have been performed with edoxaban and digoxin, naproxen and low- and highdose ASA. The results from these studies did not reveal any unexpected PD interactions. Adequate warnings were included in the SmPC  with respect to co-administration of agents with anti-haemostatic properties (e. g. naproxen). The present wording recommends against the chronic concomitant use of naproxen but permits short term treatment, which is acceptable. Since high dose ASA (325 mg) increased the steady state Cmax and AUC of edoxaban by 35% and 32%, respectively, and was not permitted in the phase III trials, the wording in section 4.5 has been amended as follows:

\"'The concomitant chronic use of high dose ASA (325 mg) with edoxaban is not recommended. Concomitant  administration  of  higher  doses  than  100  mg  ASA  should  be  only  performed  under medical supervision '.

<div style=\"page-break-after: always\"></div>

Switching from various anticoagulants to edoxaban was examined in healthy subject studies, trough effects  on  PD  markers  of  coagulation.  Based  on  the  study  results,  switching  from  enoxaparin, warfarin,  rivaroxaban  and  apixaban  can  be  initiated  at  the  next  scheduled  dosing  time  of  the preceding anticoagulant. The proposal to start warfarin when the INR is &lt;2.5 was accepted. Switching from the factor II inhibitor (dabigatran) to edoxaban is recommended at the next scheduled dosing time of dabigatran (12 h after the last dose of dabigatran). Switching from dabigatran to edoxaban resulted in higher anticoagulant effect of edoxaban as evidenced by aPTT when dosed 12 hours after dabigatran dose (this effect normalized at about 24 hours). Section 5.1 of the SmPC was updated to reflect that when switching from dabigatran to edoxaban in clinical pharmacology studies, higher aPTT activity was observed after edoxaban administration with prior dabigatran treatment compared to that after treatment with edoxaban alone. This was considered to be due to the carry-over effect of dabigatran treatment, however, this did not lead to a prolongation of bleeding time.

## Development of the reversal agent for edoxaban

Study U150 investigated the potential of two concentrations of a 3-factor PCC (factors FII, IX and X) as a reversal agent for edoxaban. This study showed differential effects on PT prolongation, anti-FXa (no reversal) and endogenous thrombin potential (ETP) (reversal). No dose-dependency with respect to the effect on ETP (between 25 IU/ kg and 50 IU/ kg) was observed. Furthermore, unlike warfarin, it is unclear which biomarker correlates best with clinical anticoagulation status and bleeding.

Overall, further investigations on other potential reversal agents and biomarkers for monitoring are considered necessary. Study U158 was a 2-part study, that was performed in healthy subjects to assess the use of a punch-biopsy to evaluate edoxaban effects on bleeding (Part 1), and then to evaluate the reversal effects of a 4-factor PCC (Part 2). Results of study U158 are promising in that a 4- factor PCC (licensed in the EU) could be useful to reverse the anticoagulant effect of edoxaban. PER977 is a small, synthetic molecule designed to bind to factor Xa inhibitors (edoxaban, rivaroxaban and apixaban) and to the oral thrombin inhibitor dabigatran through non-covalent hydrogen bonding and charge-charge interactions. Study PER977 was a first in human study which assessed the safety and the effect on anticoagulation reversal of PER977 when administered alone and after a 60 mg dose of the factor X inhibitor edoxaban. Results from this phase 1 study are also promising. Two phase 2 studies,  investigating  the  reversal  of  anticoagulant  effect  of  edoxaban  with:  (1)  aripazine  (CSR planned for July 2015) and (2) andexanet alfa (sponsored by another company, supported by the applicant),  are  currently  underway.  All  studies  are  included  in  the  agreed  RMP.  Overall,  the development program for a reversal agent was considered comprehensive.

Polymorphisms in the genes associated with the determinants of PD (variants in the VKORC1 and CYP2C9 genes), that are known to affect warfarin sensitivity had no effect on bleeding in subjects treated with edoxaban.

## 2.4.5. Conclusions on clinical pharmacology

The PK properties of edoxaban have been generally well characterised. Regarding interaction of edoxaban with other drugs, the overall PK, efficacy and safety data indicates that a dose-adjustment of edoxaban 60 mg is not required when coadministered with verapamil, quinidine or amiodarone.

The PD properties of edoxaban are adequately characterized and are within expected for a direct FXa inhibitor. Overall, the development program for a reversal agent was considered reasonable and comprehensive and has to be followed as specified in the agreed RMP.

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies

A total of 6 phase-II studies (3 controlled and 2 uncontrolled studies) were conducted in patients with NVAF. Overall, the studies included 2045 patients receiving at least one dose of study drug (safety population). Of them, 1595 were treated with several oral dosing regimes of edoxaban, ranging from 5 mg OD to 60 mg BID, and 450 patients received warfarin as active control. The Phase 2 studies in subjects with NVAF were not designed to evaluate efficacy; they were safety studies of short term treatment (up to 3 months) and relatively small sample size, with the exception of study PRT-018 (n=1146), which is described below.

## Study PRT-018: A Phase 2, randomized, parallel group, multi-center, multi-national study for the evaluation of safety of four fixed dose regimens of DU-176b in subjects with non-valvular atrial fibrillation

Study Period: First subject first visit date: 02 Jul 2007; Last subject last follow-up date: 10 Jun 2008 Study Center(s): A total of 107 investigative sites randomized subjects in this study. This study was conducted  (randomized  subjects)  at  23  investigative  sites  in  North  and  South  America,  18 investigative sites in Eastern, Western, and Central Europe, 32 investigative sites in Russia, and 34 investigative sites in Ukraine.

Phase of Development: Phase 2

Study objectives: The primary objective was to evaluate the safety of four fixed dose regimens of DU-176b (30 mg once daily [qd], 30 mg twice daily [bid], 60 mg qd, and 60 mg bid) in subjects with non-valvular  atrial  fibrillation  (NVAF).  Warfarin  was  included  as  an  active  control.  Evaluation  of bleeding  events  and  liver  enzyme/bilirubin  abnormalities  were  the  primary  focus  of  the  safety evaluation.

Secondary objectives included the following:

- Evaluation of the incidence of major adverse cardiovascular events (MACE): stroke (ischemic or hemorrhagic), SEE, myocardial infarction (MI), cardiovascular death, and hospitalization for any cardiac condition
- Evaluation  of  the  effects  on  biomarkers  of  thrombus  formation:  D-dimer  and  prothrombin fragments 1 and 2 (F1 and F2).
- Evaluation of the PK of DU 176 including known metabolites in subjects receiving DU-176b.
- Evaluation  of  the  effects  on  PD  biomarkers  (anti  FXa  activity,  endogenous  FXa  activity, prothombin time [PT], international normalized ratio [INR], prothrombinase induced clotting time [PiCT], and thrombin generation using the calibrated automated thrombogram [CAT-TG]) in subjects receiving DU-176b.

Study  Design/Methodology: This  was  a  randomized,  double-blind  (DU-176b)  and  open-label (warfarin), parallel group, multi-center, multi-national study. Male and female subjects, 18 to 85 years of age, inclusive, with NVAF and at least a moderate yearly risk of stroke (based on the CHADS2 index score) were randomly assigned to 1 of 5 treatment groups (4 fixed doses of DU-176b or warfarin) in a 1:1:1:1:1 ratio. The Investigator, all subjects, and the Sponsor were blinded to the exact DU-176b dose regimen, but not to whether the assigned treatment was DU-176b or warfarin. Subjects randomized into the study received 1 of the following active treatments: DU-176b 30 mg qd; DU-176b 30 mg bid;DU-176b 60 mg qd; DU-176b 60 mg bid (only subjects randomized before 14 Jan 2008); Warfarin tablets (open-label) qd with dose adjusted to maintain an INR between 2.0 and 3.0, inclusive. Treatments were administered for 3 months (see figure below).

## Figure E01. Schematic diagram of PRT-018 study design.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Abbreviations:qd=oncedaily:bid=twicedaily.

Note:DU-176b60mgbiddoseregimenWasteminatedbyIDMCrecommendationon14Jan2008

An Independent Data Monitoring Committee (IDMC) of external experts was organized to monitor the study data in an unblinded manner while the study was ongoing. The purpose of the IDMC was to protect the safety of the subjects and to advise the Sponsor in case of any signals of safety concern. In  addition,  an  independent  Clinical  Events  Committee  (CEC)  was  organized  to  evaluate  and adjudicate all bleeding events based upon review of blinded data. The CEC adjudicated all bleeding events and categorized them as major, clinically relevant nonmajor, or minor bleeding based on pre-specified definitions.

Table E02. Disposition of subjects in study PRT-018

|                                     | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   |            |
|-------------------------------------|--------------------|--------------------|--------------------|--------------------|------------|
| Numberofsubjects                    | 30mgqd             | 30mgbid            | 60mgqd             | 60mgbil            | Warfarin   |
| Randomized                          | 235                | 245                | 235                | 180                | 251        |
| Safety analysisset, n (%)           | 235 (100.0)        | 244 (99.6)         | 234 (99.6)         | 180 (100.0)        | 250 (99.6) |
| Perprotocol analysis set, n (%)     | 235 (100.0)        | 243² (99.2)        | 234 (99.6)         | 180 (100.0)        | 250 (99.6) |
| n (%)with major protocoldeviations  | 0 (0.0)            | 1* (0.4)           | 0 (0.0)            | 0 (0.0)            | 0 (0.0)    |
| Pharmacodynamic analysis set, n (%) | 230 (97.9)         | 236 (96.3)         | 228 (97.0)         | 170 (94.4)         | 244 (97.2) |

a:Subject(ID#:4001/0002)was excluded from the perprotocol analysis set for a majorprotocol deviation(randomizeddoseand treateddosewerenotthesameperCRF);however,after unblinding,itwasfoundthatthissubjectdidreceivetherandomizeddose.Inanycase,per protocolanalyseswerenotconducted.

Note:Percentages arebasedonthenumberofrandomizedsubjects.

Source:Table15.1.1.

## Results:

A total of 1146 patients were enrolled. Of them 1143 patients received at least one dose of study drug (safety population). The mean age ranged from 64.7 to 66.0 years. The mean weight ranged from 87.75  kg  to  88.95  kg.  Most  subjects  were  male  (~60%).  Most  of  the  subjects  (~60%)  were warfarin-naïve and approximately half of the subjects were on aspirin therapy at study entry. The majority of subjects were Caucasian (~98.0%) and from Eastern Europe (over 90%). Across all treatment groups, ~36% of subjects had a CHADS2 score ≥ 3, ~20% of subjects had diabetes, ~95% of subjects had hypertension, ~65% of subjects had ischemic heart disease, ~90% of subjects had heart failure, and ~20% had a past stroke or TIA.

Major  Adverse  Cardiovascular  Events  (Efficacy): The  incidence  of  MACE  was  2.4%  for warfarin-treated subjects and 2.5% across all DU-176b treated subjects.

Safety: Overall, DU-176b 30 mg qd and 60 mg qd dosage regimens were well tolerated with lower or similar incidences of bleeding compared with warfarin therapy (see table). Subjects treated with DU-30 mg bid and 60 mg bid regimens had higher bleeding incidences compared with subjects on warfarin therapy. The DU-176b 60 mg bid regimen was considered unsafe by the IDMC due to an unfavourable benefit/risk ratio, and was terminated early. Subjects treated with DU-176b 30 mg qd

<div style=\"page-break-after: always\"></div>

and 60 mg qd regimens had lower bleeding incidences than those treated with the 30 mg bid or 60 mg bid regimens.

Table E03. Bleeding events in study PRT-018

<!-- image -->

|                                    | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   |                  |
|------------------------------------|--------------------|--------------------|--------------------|--------------------|------------------|
| BleedingCategory                   | 30mgqd (N=235)     | 30mgbid (I=244)    | 60 mgqd (=234)     | 60mgbid (N=180)    | Warfarin (I=250) |
| AllBleeding，n(%)                   | 13 (5.5)           | 31 (12.7)          | 17 (7.3)           | 33 (18.3)          | 20 (8.0)         |
| p-value                            | 0.367              | 0.104              | 0.864              | 0.002              |                  |
| MajororCRnon- majorbleeding, n (%) | 7 (3.0)            | 19 (7.8)           | 9 (3.8)            | 19 (10.6)          | 8 (3.2)          |
| p-value                            | 1.000              | 0.029              | 0.807              | 0.002              |                  |
| Majorbleeding,n (%)                | 0 (0.0)            | 5 (2.0)            | 1 (0.4)            | 6 (3.3)            | 1 (0.4)          |
| p-value                            | 1.000              | 0.119              | 1.000              | 0.023              |                  |

The overall incidence of liver enzyme and bilirubin abnormalities was low in this study and there was no significant difference between treatment groups.

Table E04. Liver abnormalities in study PRT-018

<!-- image -->

|                                 | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   | DU-176bDailyDose   |                  |
|---------------------------------|--------------------|--------------------|--------------------|--------------------|------------------|
| LaboratoryTest                  | 30mgqd (N=235)     | 30mgbid (N=244)    | 60mgqd (=234)      | 60mgbid (=180)     | Warfarin (N=250) |
| AnyElevation                    | 5 (2.1)            | 4 (1.6)            | 8 (3.4)            | 7 (3.9)            | 8 (3.2)          |
| ALT,N                           | 230                | 235                | 229                | 172                | 245              |
| Total≥3xULN                     | 3 (1.3)            | 2 (0.9)            | 6 (2.6)            | 3 (1.7)            | 3 (1.2)          |
| AST,N                           | 230                | 235                | 229                | 172                | 245              |
| Total≥3xULN                     | 2 (0.9)            | 2 (0.9)            | 3 (1.3)            | 2 (1.2)            | 2 (0.8)          |
| TBL,N                           | 230                | 235                | 229                | 172                | 245              |
| Total≥2xULN                     | 2 (0.9)            | 3 (1.3)            | 1 (0.4)            | 5 (2.9)            | 4 (1.6)          |
| ALTand/orAST,N                  | 230                | 235                | 229                | 172                | 245              |
| ALTorAST≥3x ULN                 | 3 (1.3)            | 2 (0.9)            | 7 (3.1)            | 3 (1.7)            | 4 (1.6)          |
| (ALTorAST)and TBL,N             | 230                | 235                | 229                | 172                | 245              |
| (ALT/AST≥3X ULN)and(TBL≥2x ULN) | 0 (0.0)            | 1 (0.4)            | 0 (0.0)            | 1 (0.6)            | 0 (0.0)          |

There were two subjects (Subject IDs: 20060002 and 40290006 [1 in each of the DU-176b bid groups]) who experienced concomitant but not persistent elevations of ALT or AST ≥ 3 x ULN and TBL ≥ 2 x ULN. At the same time as the elevated ALT/A ST and TBL, both subjects also had ALP &gt; 2 x ULN, suggesting cholestasis rather than drug-induced hepatocellular injury. Independent hepatologists' review of these cases concluded that one subject had acute cholecystitis and the other had a dilated bile duct confounded by chronic heart failure, intermittent hypotension, and anemia.

Deaths: Fourteen subjects (6 [2.6%] in the 30 mg qd DU-176b group, 4 [1.6%] in the30 mg bid DU-176b group, 1 [0.4%] in the 60 mg qd DU-176b group, 0 in the 60 mg bid DU-176b group, and 3 [1.2%] in the warfarin group) died during the study: 8 deaths occurred while the subject was on study drug, 5 occurred as a results of events during the post-treatment follow-up period, and 1 occurred during the follow-up period as a result of an event that began the day after the last dose of study drug (i.e., on the last day of the treatment period). All deaths resulted from cardiovascular conditions such as MI, coronary artery disease, cardiac failure, stroke, pulmonary embolism, or sudden death.

PK: The pharmacometric analyses were conducted to better understand the PK across the study population,  the  relationship  between  PK  parameters  and  bleeding  incidence  relationship  and  the differences  in  bleeding  incidences  (DU-176b  bid  regimens  vs.  DU-176b  qd  regimens).  These pharmacometric analyses confirmed similar total exposure expressed as AUCss between the DU-176b

<div style=\"page-break-after: always\"></div>

60 mg qd and 30 mg bid regimens. In addition, logistic regression analyses indicated that the steady state minimum (trough) concentrations (Cmin,ss) best predicted the probability of bleeding.

Overall, the edoxaban 30 mg and 60 mg once daily regimes were safe and well tolerated by subjects with AF treated for 3 months in this Phase 2 study. There was a higher bleeding risk with twice-daily administration. The DU-176b 60 mg bid regimen was considered unsafe by the IDMC due to an unfavourable benefit/risk ratio, and had to be terminated early as a consequence. Logistic regression analyses indicated that the steady state minimum (trough) concentrations (Cmin,ss) best predicted the probability of bleeding.

## Dose selection for phase III:

Three elements were considered by the applicant to support the proposed dose. Firstly, to select doses for the Phase 3 pivotal study that were likely to have a 10 to 20% reduction in bleeding when compared to warfarin at no potential cost of efficacy (no numerical increase in thrombotic events and similar effect on PD biomarkers). The second step was to identify a priori subjects who would have increased drug exposure and potentially increased risk of bleeding and hence benefit from dose reduction. The final step was to use the Phase 3 data to identify the optimal dose regimen, validate the dose reduction criteria and identify any other groups who may be at high risk of bleeding who would benefit from a lower dose.

A large Phase 2 study (PRT018) in NVAF subjects compared edoxaban 30 mg QD, 30 mg BID, 60 mg QD, and 60 mg BID and warfarin. All the regimens showed the potential for adequate efficacy based on PD biomarkers but the once daily regimens showed a similar or better bleeding profile when compared with warfarin. The DU-176b 60 mg BID regimen was considered unsafe by the IDMC due to an unfavourable benefit/risk ratio, and had to be terminated early as a consequence. The findings were supported by PK/bleeding modeling which showed that Cmin rather than AUC or Cmax was the driver of bleeding events. Based on these data, both 30 mg QD and 60 mg QD were taken forward in the NVAF Phase 3 pivotal study.

To identify factors for dose reduction, data from two Phase 2 NVAF studies in subjects (PRT018 and J225)  plus  DDI  studies  were  evaluated  by  clinical  assessment  and  pharmacometric  modeling (TMPP004). In univariate analysis, age and sex had a significant effect but dropped out of multivariate analysis, which identified three independent factors (moderate to severe renal impairment, weight &lt; 60 kg and concomitant use of P-gp inhibitors) that would increase exposure to edoxaban and also potentially increase the risk of bleeding compared with warfarin. Looking at these factors individually and in combination, a 50% dose reduction was selected so that in subjects with one or more of these factors the bleeding risk would be similar to the overall population while efficacy would be maintained. Supporting data with regard to weight was obtained from the subsequently completed study J226. The rationale for the Phase 3 dose section in NVAF was discussed with the CHMP and accepted.

The dose justification for edoxaban in VTE is essentially the same as for NVAF except that there were no dose finding studies in VTE and the clinical considerations of use with heparin and the increased risk of under anticoagulation that could lead to fatal pulmonary embolism. The standard of care for comparison was parenteral heparin with concomitant warfarin titrated to an INR of 2 to 3. For VTE, only the 60 mg dose was selected because of the increased thrombotic load in VTE and the need for intensive anticoagulation in a treatment setting rather than in NVAF, where the aim is prevention of thromboembolic events. Therefore weight was given to ensuring a dose was selected that would ensure efficacy while still being able to demonstrate a 10% reduction in bleeding.

<div style=\"page-break-after: always\"></div>

This  bridging  approach,  using  principally  data  from  NVAF  and  VTE  prophylaxis  subjects  for  dose selection of VTE treatment, was discussed with CHMP, as was the rationale for the dose reduction and the selection of the single 60 mg dose for VTE.

The  study  C-J307  in  93  patients  with  several  degrees  of  renal  function,  showed  that  the administration of 15 mg of DU-176b for 12 weeks in Japanese patients with SRI did not result in a marked increase in bleeding compared to the low dose or high dose of DU-176b (30 mg OD and 60 mg OD, respectively) in patients with Normal/MiRI. The plasma concentrations in the subjects with SRI (15 mL/min ≤ CLCR &lt; 30 mL/min) receiving 15 mg of DU-176b overlapped considerably with those concentrations in the subjects with Normal/MiRI receiving the 30 mg OD dose or 60 mg OD dose of DU-176b. These data support the use of halved doses of edoxaban in patients with moderate-severe renal impairment (CrCL 15 - 50 mL/min).

With respect to hepatic safety, in at least two phase II studies (PRT-018 and J225) there was at least one subject on edoxaban that showed concurrent elevations of AST (GOT) or ALT (GPT) ≥3 times the ULN and total bilirubin ≥2 times the ULN, with no corresponding cases reported in the warfarin control group.

## 2.5.2. Main studies

## ENGAGE AF: Prevention of stroke and SEE in patients with non-valvular atrial fibrillation

## Methods

The efficacy data supporting the use of edoxaban for reducing the risk of stroke and SEE in subjects with NVAF are provided by the pivotal Phase 3 ENGAGE AF study (n=21,105 randomized patients; 21,006 received at least one dose) in which 7002 subjects were treated with edoxaban 30 mg (15 mg reduced), 7012 subjects were treated with edoxaban 60 mg (30 mg reduced) and 7012 with warfarin. ENGAGE  AF  was  an  event-driven,  randomized,  double-blind, double-dummy,  multinational, multicenter, parallel-group study.

Figure E-02. ENGAGE-AF TIMI 48 study design

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Study Participants

Inclusion/exclusion criteria: ENGAGE AF enrolled male or female subjects ≥21 years of age with documented NVAF (including paroxysmal, persistent,  or  permanent  AF)  within  the  preceding  12 months and in whom anticoagulation therapy was indicated and planned for the duration of the study. Subjects who were receiving or had received prior anticoagulant (e.g.: VKA experienced) and/or antiplatelet  therapies  were  eligible,  as  well  as  subjects  who  were  naive  to  anticoagulant  and/or antiplatelet therapy. In addition, eligible subjects were required to have a CHADS2 index score ≥ 2. VKA experienced was defined as current users as well as former users who took VKA for greater than 2 months. VKA naïve were those subjects who received ≤ 2 months of VKA therapy before study entry.  Given that these definitions are not homogeneous across trials in NVAF, current EMA Guideline on clinical investigation of medicinal products for prevention of stroke and SEEs in patients with non-valvular  atrial  fibrillation  (EMA/CHMP/341363/2014) recommends  sensitivity  analyses  using different definitions of VKA-naïve users in order to be able to compare with other studies. In this regard, the applicant was requested to show the main efficacy and safety results using other previous definitions of VKA naïve: a) VKA use for &lt; 6 weeks immediately before entry into the trial; b) patients not on a VKA at randomization; c) patients who had never been on a VKA. Subjects with mitral valve stenosis  (moderate to severe), unresected atrial myxoma or a mechanical heart valve were not allowed in the study. The intention of the sponsor/investigators was to represent 'the typical NVAF population encountered in clinical practice' at the time in which the study was designed (clinical overview; module 2.5). However, this statement contrasts with the 25 exclusion criteria applied in the ENGAGE AF study. It is recognised that many of these exclusion criteria are standard for clinical trials, while  others  are  known  general  contraindications  for  anticoagulation.  However,  some  exclusion criteria may deserve specific commentaries. Patients with a mechanical heart valve were excluded from ENGAGE AF, but subjects with bioprosthetic heart valves and/or valve repair could have been included. The applicant proposes a warning stating that 'Edoxaban has not been studied in patients with mechanical heart valves. Therefore, use of edoxaban is not recommended in these patients.' It is  implicit  in  the  proposed  warning  that  edoxaban  could  therefore  be  used  in  patients  with bioprosthetic heart valves and/or valve repair. The applicant was requested to describe the efficacy and safety data available from patients with bioprosthetic heart valves and/or valve repair from ENGAGE AF. If the data are not robust, the warning should be extended to 'prosthetic heart valves' in line with the wording approved for Xarelto (rivaroxaban).  Subjects with severe renal insufficiency (calculated CrCL &lt;30 mL/min) were excluded. In the proposed SmPC the non-recommendation of use was for patients with end-stage renal disease (calculated CrCL &lt;15 mL/min). Despite patients with CrCl between 15 and 30 were not included in the ENGAGE study, the applicant had additional data in these patients from study C-J307 (see dose-finding studies). The results of this study supported a recommendation of use for edoxaban in patients with severe renal impairment not in end-stage renal disease. At the end the it was agreed that in patients with moderate or severe renal impairment (CrCL 15 - 50 mL/min), the recommended dose is 30 mg Lixiana once daily while in patients with end stage renal disease (ESRD) (CrCL &lt; 15 mL/min) or on dialysis, the use of Lixiana is not recommended

Thromboembolic  risk  stratification: Current  guidelines  recommend the use of CHA2DS2-VASC instead  of  CHADS2  score.  Compared  with  the  CHADS2  score,  the  CHA2DS2-VASC  score  markedly increases the number of AF patients for whom OAC is recommended. Therefore it is important to determine  by  randomized  trials  if  this  major  paradigm  shift  to  greater  use  of  OAC  using  the CHA2DS2-VASC  scoring  improves  patient  outcomes.  The  CHMP  has  agreed  the  wording  of  the indication  in  NVAF  for  other  NOACs,  which  includes  patients  with  a  CHADS2  index  score  ≥  1 (approximately equivalent to current CHA2DS2-VASC score ≥ 2, in which anticoagulation is indicated as  per  current  ESC  guidelines)  (de  Caterina  et  al.  Eur  Heart  J.  2012;  33:2719-47).  The  CHMP approach has accepted to widen the target population from CHADS2 index score ≥ 2 (at least 2 points in CHADS2 tested in pivotal clinical trials) to CHADS2 index score ≥ 1 ('with one or more risk factors' generally not tested in clinical trials) in previous applications for NOACs. Therefore the wording of the

<div style=\"page-break-after: always\"></div>

requested indication for edoxaban was also accepted, as it is identical to that of the other compounds. However,  as  patients  with  CHADS2  index  score=1  were  excluded  from  the  single  pivotal  study ENGAGE-AF but are already included in the wording of the indication (e.g.: patients with only one of the following risk factors: age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II), the applicant justified why the extrapolation of the available data from high risk CHADS2 score ≥2 to CHADS 2 score =1 could be acceptable and discussed whether further studies are planned with edoxaban to generate clinical data in these patients at lower risk of stroke. The CHMP accepted the justification.

## Treatments

In ENGAGE-AF, Eligible subjects were randomized to edoxaban 30 mg, edoxaban 60 mg, or warfarin (1:1:1 ratio)  using  stratified  randomization.  Within  each  CHADS2  stratum,  subjects  were  further stratified with respect to factors requiring edoxaban dosage reduction. In both edoxaban treatment groups, the dosage regimen was halved for subjects with one or more of moderate renal impairment (CrCL ≥ 30 mL/min and ≤ 50 mL/min as calculated using the Cockroft-Gault formula), low body weight  (≤  60  kg)  or  for  subjects  on  specified  concomitant  medications  (verapamil,  quinidine, dronedarone). Each enrolled subject was to be treated with the study drug from randomization to the Common Study End Date (CSED) visit; this visit had to be within 90 days of the announced CSED (determined by the accrual rate of primary endpoint events), and it was the final dose day for all subjects. At the end, a total of 21105 subjects were randomized, and median duration of treatment exposure was 2.5 years and median duration of follow-up in the study was 2.8 years. Warfarin was the active blinded control and was provided by the Sponsor. International Normalized Ratio (INR) measurements were to be performed using uniform Point-of-Care (POC) devices supplied to all study sites. Warfarin doses were to be adjusted to maintain an INR of 2.0 to 3.0, inclusive. A Japan specific amendment was created to allow Investigator's in Japan to comply with Japanese guidelines for warfarin management in subjects age 70 years or older. In those Japanese subjects, the dose of warfarin was to be adjusted to maintain an INR of 2.0 to 2.5. Treatment regimes tested in the ENGAGE AF study are deemed appropriate.

## Objectives

## Outcomes/endpoints

Primary endpoint: as in other similar trials, the primary efficacy endpoint in ENGAGE-AF was a net clinical endpoint mixing thromboembolic events (ischemic/undefined stroke, SEE) and haemorrhagic stroke. As a result, there has been double-counting of primary efficacy/safety events (thromboembolism/major bleeding) regarding haemorrhagic stroke (included in both main efficacy and  safety  endpoints).  Current EMA Guideline  on  clinical  investigation  of  medicinal  products  for prevention of stroke and SEEs in patients with non-valvular atrial fibrillation (EMA/CHMP/341363/2014) stresses the importance of excluding haemorrhagic stroke from the main efficacy endpoint. In this regard, the applicant provided the results of the primary endpoint with the thromboembolic events excluding haemorrhagic strokes. On the other hand, the definition of ischemic stroke/TIA used in ENGAGE-AF is unclear. In recent years, there has been a change in the diagnostic approach of TIA and ischaemic Stroke (from a time-based definition to a tissue-based definition), depending on the absence or presence of signs of brain infarction on neuroimaging. In current EMA Guideline (EMA/CHMP/341363/2014), it is recommended to adjudicate suspected strokes and TIAs as a group and to follow a tissue-based definition. A suspected TIA should be adjudicated as stroke if there is positive neuroimaging confirming a cerebral infarction, even if the duration of symptoms is of less  than  24  hours  [American  Heart  Association  (AHA)  and  American  Stroke  Association  (ASA) definition of TIA; Standardized Data Collection for Cardiovascular Trials (SDCCT) Initiative definition]. The  occurrence  of  a  TIA  (transient  episode  of  focal  neurological  dysfunction  without  positive neuroimaging) should not be part of the composite stroke endpoint, instead it is recommended to

<div style=\"page-break-after: always\"></div>

assess this as a secondary efficacy endpoint. In this regard, the applicant clarified the approach used in  ENGAGE  AF  to  differentiate  between  ischaemic  stroke  and  TIA  (time-based  definition  or tissue-based definition) and provided with appropriate sensitivity analysis with different definition of ischaemic stroke (including or excluding TIA with positive neuroimaging as being an ischaemic stroke) (tissue-based and time-based definitions, respectively).

Secondary variables: A number of secondary variables were included (each of the components of the main outcome; composite of stroke, SEE, and CV mortality; MACE, which is the composite of non-fatal MI, non-fatal stroke, non-fatal SEE, and death due to CV cause or bleeding; Composite of stroke, SEE, and all-cause mortality). These endpoints are considered acceptable.

## Sample size

## Randomisation

An Interactive voice/web response system (IXRS) was used. Eligible subjects in ENGAGE-AF were stratified by CHADS2 risk score (2 and 3 versus ≥4). Within each CHADS2 stratum, subjects were stratified further for factors (calculated CrCL ≥50 mL/min and ≤30 mL/min, low body weight ≤60 kg], concomitant  verapamil  or  concomitant  quinidine)  that  required  dosage  reduction  of  edoxaban. Randomisation methods in ENGAGE-AF are deemed appropriate.

## Blinding (masking)

The ENGAGE study used a double-blind design, which is the one recommended by the guideline EMA/CHMP/341363/2014. Blinding/masking methods are deemed appropriate.

## Statistical methods

Statistical methods applied in the ENGAGE AF study are considered acceptable. ENGAGE AF was event driven.  A  total  of  at  least  448  events  were  required.  Sample  size  calculation  is  endorsed.  The non-inferiority margin (HR &lt;1.38) is comparable to that used in ARISTOTLE study with apixaban and more  restringing  than  the  1.46  used  in  the  RE-LY  and  ROCKET-AF  study  with  dabigatran  and rivaroxaban. The time to first stroke/SEE event (primary endpoint) in ENGAGE-AF was analyzed using the Cox proportional hazards model including treatment groups and 2 dichotomized stratification factors as covariates (CHADS2 2-3 versus 4-6; full dose versus reduced dose in a given treatment group). The applicant focused its main analysis (non-inferiority) in a modified ITT population during the 'on-treatment period'. However, the applicant also tested non-inferiority in the PP population during the overall study period according to CHMP recommendations during scientific advice, as well as in the PP population 'on-treatment', which is in agreement with the recent CHMP Guideline on clinical investigation of medicinal products for prevention of stroke and SEEs in patients with NVAF (EMA/CHMP/341363/2014) that states that 'the analysis to show non-inferiority should include the primary  endpoint  events  while  taking  study  drug  including  a  period  of  3  days  after  study  drug discontinuation (on-treatment analysis). Sensitivity analyses should include events occurring 1 week and 1 month after study drug discontinuation in order to investigate a possible early rebound increase in thromboembolism after treatment cessation.'In order to control the studywise type-I error rate of two-sided α=0.05 for non-inferiority, each of these 2 comparisons (60 mg or 30 mg versus warfarin) were  performed  at  the  statistical  significance  level  of  two-sided  α=0.025,  respectively,  which  is endorsed.  The  analysis  of  superiority  was  only  planned  for  the  comparison  between  the  60  mg edoxaban dose and warfarin and only if  non-inferiority was first established for that group. The significance level of α=0.01 for superiority was selected by the sponsor because this was a single pivotal study. This was endorsed by the CHMP. The planned applicant's analysis to show superiority (ITT,  overall  study  period)  was  consistent  with  the  approach  stated  in  the  EMA  Guideline (EMA/CHMP/341363/2014). Exploratory analyses of subgroups were conducted depending on at least 14 patient/study characteristics. These analyses are discussed under 'ancillary analyses' subsection.

<div style=\"page-break-after: always\"></div>

## Results

## Participant flow

<!-- image -->

Note:CompletedsubjectsincludedeathsaftertheCSEDannoumcement.

Abbreviations:CSED:commonstudyenddate.

completedCSEDVisit. Source data:Tables14.1.1.1,14.1.1.5,14.1.1.7,and 14.1.5.2

A total of 21,105 subjects who were randomized (7034, 70135, and 7036 in the edoxaban 30 mg, edoxaban 60 mg, and warfarin treatment groups, respectively) (ITT). 21,026 subjects were treated with study drug (7002, 7012, and 7012 in the edoxaban 30 mg, edoxaban 60 mg, and warfarin treatment groups, respectively) (mITT). 20,970 subjects who were treated with study drug and had no major protocol violations (6982, 6995, and 6993 in the edoxaban 30 mg, edoxaban 60 mg, and warfarin treatment groups, respectively) (PP set).

## Conduct of the study

A  total  of  46  countries  from  6  regions  (North  America,  Latin  America,  Western  Europe,  Eastern Europe, Asia Pacific and South Africa, and Japan) randomized subjects in this study. A total of 1420 investigational study sites screened at least 1 subject and 1393 study sites randomized at least 1 subject  in  this  study.  The  rate  of  screening  failures  was  relatively  low  (17%).  There  were  few differences between the ITT, mITT and PP populations, with a difference between populations of less than 50 subjects per group. O nly one patient was lost to follow-up, which is a signal of good quality of study oversight. There were 7 amendments with extensive major changes in the protocol of the ENGAGE-AF study. In particular, amendment 3 could have implications on the quality of management in warfarin control group and dosing errors. As a result, it was unknown if the changes made in the protocol before and after amendment 3 could have had implications on study results. The applicant showed the analyses of the main efficacy and safety outcomes in the ENGAGE AF study (edoxaban 60 mg vs. warfarin) in the subgroup of patients recruited before and after amendment 3 (29-Jul-2010). On the positive side, it seems that these amendments were based on gained experience from other contemporary studies in AF (e.g.: RE-LY, ROCKET-AF, ARISTOTLE). For example, in amendment 1, transition from blinded study drug to open-label warfarin was clarified and added explanation/instruction for use of transition study drug kit. This issue may have resulted in less tromboembolic events during the transition from edoxaban to warfarin after the end of study.

## Baseline data

Population included in ENGAGE AF was an old population (mean 72 years; 40% &gt; 75 years; 17% &gt; 80 years) at high risk of stroke (mean CHADS2 score of 2.8; 53% of subjects had a CHADS2 score ≥ 3).

Completed studymeans

<div style=\"page-break-after: always\"></div>

There  was  no  representation  of  patients  with  CHADS2  score  0-1.The  majority  of  subjects  were Caucasian (81%) and male (62%). Overall, mean body weight was 84 kg and 10% of subjects had body weight ≤60 kg. Approximately 18% of subjects had a body weight &gt;100 kg. Overall, the mean BMI was 29.5 kg/m2, with approximately 60% of subjects having a BMI ≤ 30 kg/m2.

In all 3 treatment groups, CrCL was ≤50 mL/min in approximately 19% of subjects. The percentage of VKA naive subjects was 41% overall. Overall, 52% of subjects had permanent, 23% had persistent, and 25% had paroxysmal AF.

The  percentage  of  subjects  from  each  region  was  comparable  among  the  treatment  groups. Approximately half of the subjects were from Europe (Eastern Europe 34% and Western Europe 15%), 22% from North America, 13% from Latin America, 11% from Asia/Pacific and South Africa (excluding Japan), and 5% from Japan.

More than 65% of subjects were receiving ACE inhibitors or ARBs, or beta blockers, and about 60% were taking diuretic agents. Other more frequent medications used included lipid lowering agents (approximately 48%), aspirin (approximately 30%), calcium channel blockers (approximately 31%), and  amiodarone  (approximately  12%).  Quinidine/verapamil  was  used  by  &lt;4%  of  subjects  at randomization.

## Table E-19: Demographic and Baseline Characteristics - mITT (safety) analysis set

<div style=\"page-break-after: always\"></div>

|                                                  | Edoxaban30mg (15mgDosAdj)   | Edoxaban60mg (30mg DosAdj)   | Warfarin (N=7012)      |
|--------------------------------------------------|-----------------------------|------------------------------|------------------------|
| Age (years), n                                   | (N=7002) 7002               | (N=7012) 7012                | 7012                   |
| Mean                                             | 70.6                        | 70.6                         | 70.5                   |
| SD                                               | 9.31                        | 9.51                         | 9.44                   |
| Median                                           | 72.0                        | 72.0                         | 72.0                   |
| Minimum                                          | 27                          | 25                           | 27                     |
| Maximum                                          | 95                          | 96                           | 95                     |
| =65yearsn(%)                                     | 5218 (74.5)                 | 5182 (73.9)                  | 5143 (73.3)            |
| =75 years n(%)                                   | 2789 (39.8)                 | 2838(40.5)                   | 2805 (40.0)            |
| = s0 years n(%)                                  | 1197 (17.1)                 | 1177 (16.8)                  | 1195 (17.0)            |
| Gender,n(%)                                      | 7002                        | 7012                         | 7012                   |
| Male                                             | 4284(61.2)                  | 4353 (62.1)                  | 4383 (62.5)            |
| Female                                           | 2718(38.8)                  | 2659 (37.9)                  | 2629 (37.5)            |
| Race,n（%）[a]                                     | 7001                        | 7012                         | 7012                   |
| Caucasian                                        | 5650 (80.7)                 | 5679 (81.0)                  | 5679 (81.0)            |
| Black                                            | 94 ( 1.3)                   | 96 ( 1.4)                    | 88 ( 1.3)              |
| Asian                                            | 975 (13.9)                  | 956 (13.6)                   | 963 (13.7)             |
| Other                                            | 282 ( 4.0)                  | 281 ( 4.0)                   | 282 ( 4.0)             |
| Edoxaban/PlaceboDoseAdjustedat Randomization,n() | 7002                        | 7012                         | 7012                   |
| Yes                                              | 1774 (25.3)                 | 1776 (25.3)                  | 1780 (25.4)            |
| No                                               | 5228 (74.7)                 | 5236 ( 74.7)                 | 5232 (74.6)            |
| CrCL（mL/min),n（%)[b]                             | 6961                        | 6954                         | 6973                   |
| ≤30 30-=50                                       | 42 ( 0.6)                   | 70 (1.0)                     | 51 (0.7)               |
| 50 -≤80                                          | 1274 (18.2) 3034 ( 43.3)    | 1287 (18.4) 2985 (42.6)      | 1297(18.5) 3030 (43.2) |
| >= 80                                            | 2611(37.3)                  | 2612(37.3)                   | 2595 (37.0)            |
| Weight (kg),n (%)[c]                             | 9669                        | 7007                         | 7007                   |
| 50                                               | 148 ( 2.1)                  | 158 ( 2.3)                   | 172 ( 2.5)             |
| = 60                                             | 692 ( 9.9)                  | 681 ( 9.7)                   | 697 ( 9.9)             |
| > 60                                             | 6304 (90.0)                 | 6326 (90.2)                  | 6310(90.0)             |
| Mean (SD)                                        | 83.9 (20.11)                | 84.2 (20.40)                 | 83.7(20.09)            |
| BMII, n (%)[c]                                   | 6976                        | 6985                         | 6984                   |
| 30                                               | 4160 (59.4)                 | 4116 (58.7)                  | 4238 ( 60.4)           |
| 30                                               | 2816(40.2)                  | 2869 (40.9)                  | 2746 (39.2)            |
| Mean (SD)                                        | 29.5(5.93)                  | 29.6(6.05)                   | 29.3 ( 5.89)           |
| YerapamilorQuinidineUseat Randomization,n(%)[d]  | 7002                        | 7012                         | 7012                   |
| Yes                                              | 259 ( 3.7)                  | 257 ( 3.7)                   | 241 ( 3.4)             |
| No                                               | 6743 (96.3)                 | 6755 (96.3)                  | 6771 (96.6) 7012       |
| CHADS2, n (%)[e] 2-3                             | 7002 5437 (77.6)            | 7012 5401 (77.0)             | 5422 (77.3)            |
| 4-6                                              | 1559 (22.3)                 | 1606 (22.9)                  | 1585 (22.6)            |
| >=3                                              | 3705 (52.9)                 | 3784(54.0)                   | 3686 (52.6)            |
| 0                                                | （0°0）0                      | 0(0.0)                       | 1 (<0.1)               |
| 1                                                | 6 (-0.1)                    | 5 (-0.1)                     | 4 (≤0.1)               |
| 2                                                | 3291 (47.0)                 | 3223 (46.0)                  | 3321 (47.4) 2101(30.0) |
| 3 4                                              | 2146 (30.6)                 | 2178 (31.1)                  | 1072 (15.3)            |
| 5                                                | 1077 (15.4) 399 (5.7)       | 1123 (16.0) 397 ( 5.7)       | 424 ( 6.0)             |
| 6                                                | 83 ( 1.2)                   | 86 (1.2)                     | 89 ( 1.3)              |
|                                                  |                             | 7012                         |                        |
| VKA Use,n (%)[f]                                 | 7001                        |                              | 7012                   |
| Naive                                            | 2857 (40.8)                 | 2879 (41.1)                  | 2888 (41.2)            |
| Experienced                                      | 4144 (59.2) 7001            | 4133 (58.9) 7012             | 4124 (58.8) 7010       |
| Iype of Atrial Fibrillation, n (%) Paroxysmal    | 1827(26.1)                  | 1747 ( 24.9)                 | 1774 (25.3)            |
| Persistent                                       | 1581 (22.6)                 | 1645 (23.5)                  | 1624 (23.2)            |
| Pemanent                                         | 3593(51.3)                  | 3620 (51.6)                  | 3612 (51.5) 7012       |
| Region, n(%)                                     | 7002                        | 7012                         | 1556 (22.2)            |
| NorthAmerica                                     | 1550 (22.1)                 | 1559 (22.2)                  |                        |
|                                                  |                             |                              | 1297 (18.5)            |
| USA. LatinAmerica                                | 1308 (18.7) 882 (12.6)      | 1288 (18.4) 884 (12.6)       | 885 (12.6) 1070 (15.3) |
| WestemEurope                                     | 1075 (15.4)                 | 1075 (15.3)                  | 2378(33.9)             |
| EastemEurope                                     | 2369(33.8)                  | 2374(33.9)                   |                        |
| Asia/PacificandSouthAfricaExcluding Japan)       | 789(11.3)                   | 784(11.2)                    | 786(11.2)              |
| Japan                                            | 337(4.8)                    | 336(4.8)                     | 337 (4.8)              |

heartfailure,Hypertension,Age,Diabetes,previousStroke/Transientischemicattack),CrCL

Abbreviations:DosAdj-DoseAdjusted,CHADS=Scoringsysteforstokeriekstatification(Congestive

clearance,VKA=Vitamin-Kantagonist,BMiI=bodymassindex. [a]:Subjectscouldonlyselectlrace.Other'waschosenifnoneoftheotherprespecifiedcate cories applied,orifthesubjectwaswultiracial.

[e]: WeightandBMfIaredenivedfrominformationrecordedintheeCRF

creatinine

[]: CiCLiederivedfiominfommationrecordedinCentralLaborLocal Labresults.

[d]:Verapamil/QuinidineuseatrandomizationisderivedfrominformationrecordedinboththeIXRSandthe eCRF.Ifatleast1sourceindicatesVerapamil/Quinidineuse,thenthesubjectiscountedasYes,else No'.

VKAExperiencedisdefinedasCunentUsers'aswellasFomerUsers'whotookVKAforgreaterthan2 months.VKANaiveisdefinedbythecomplementofVKAExperiencedforthosesubjectswitheCRF data present.

[e]: CHADS=derivedindexscoreforstrokepredictionperinfonmationrecordedintheeCRF

Sowrcedata:Table14.1.3.1

## Numbers analysed

Table E-14: Disposition of Subjects and Study Completion Status, ITT Analysis Set

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                 | Edoxaban 30mg (15mg DosAdj) (=7034) n (%)   | Edoxaban 60mg (③0mg DosAdj) (N=7035) n (%)   | Warfarin (N=7030) n (%)   | Overall (N=21105) n (%)   |
|---------------------------------|---------------------------------------------|----------------------------------------------|---------------------------|---------------------------|
| Treated[a]                      | 7002(99.5)                                  | 7012(99.7)                                   | 7012(99.7)                | 21026 (99.6)              |
| CompletedCSEDVisit[b]           | 6250 (88.9)                                 | 6228 (88.5)                                  | 6157(87.5)                | 18635(88.3)               |
| DeathOnorAfterCSED Announcement | 9 (0.1)                                     | 14 ( 0.2)                                    | 20 ( 0.3)                 | 43 ( 0.2)                 |
| DidNotCompleteCSEDVisit[b]      | 784 (11.1)                                  | 807(11.5)                                    | 879 (12.5)                | 2470 (11.7)               |
| Death(PriorToCSED Announcement) | 706 (10.0)                                  | 730 (10.4)                                   | 789 (11.2)                | 2225 (10.5)               |
| WithdrewConsent                 | 77 ( 1.1)                                   | 77 (1.1)                                     | 90 ( 1.3)                 | 244 ( 1.2)                |
| Losttofollowup[c]               | 1 (<0.01)                                   | 0(0.0)                                       | 0(0.0)                    | 1 (<0.01)                 |

[a]:Treated'representsrandomizedsubjectswhoreceived1ormoredosesofstudydrug

[c]:Subject1014-0003,fromaUSAsiteandrandomizedtoEdoxaban30mgnotdoseadjusted,isincluded

[b]:CompletedandDidNotComplete(andreasons)comefromtheFinalStatuseCRF.Completedsubjects includedeathsonoraftertheCSEDannouncementbutpriortotheCSEDVisit.

inthisrow.ThesubjectdidnotcompleteCSED-VisitandinformationontheFinalStatuseCRFpage ismissing.SiteclosedandthenthesubjectrefusedtotransfertoanothersitepriortotheCSED

annoimcement.

Souurcedata:Tables14.1.1.5and14.1.1.7

## Outcomes and estimation

Edoxaban (or matching edoxaban placebo for the warfarin group) compliance was assessed by percentage  of  doses  taken  (≥80%  versus  &lt;80%)  at  each  compliance  visit  (every  3  months). Treatment compliance (more than 80% of tablets taken; i.e.: 6 or less tablets missed per month) was &gt; 98% in almost all timepoints with the exception of Month 45 (98% and 93% for edoxaban 30 mg OD and 60 mg OD, respectively).Warfarin compliance was assessed by the percentage of time subjects INR was within the range of 2.0 - 3.0. The mean time in therapeutic range (TTR) (INR: 2-3) was 64.9% (median 68.4%), which is comparable to contemporary studies like RE-LY (mean: 64.4%; median 67%) or ARISTOTLE (mean: 62.2%; median: 66%) and higher than in ROCKET-AF (mean: 55.2%; median: 58%) ( Gómez-Outes, et al. Thrombosis. 2013; 640723 ). As expected, the more frequent deviation was undercoagulation, with a 22.8% of the time below therapeutic range (INR&lt;2). The percent time above therapeutic range (INR&gt;3) was 12.4% (mean values). By regions, North America, Western Europe and Japan had a mean TTR of 70.2%, 68.3% and 70.3% respectively. Eastern Europe had a mean of 62.5%, Latin America had a mean TTR of 61.5%, and Asia/Pacific and South Africa  (excluding  Japan)  had  a  mean  TTR  of  58.10%.  These  data  indicate  that  quality  of anticoagulation with warfarin was relatively good in western Europe, North America and Japan, and of a poorer quality in eastern Europe, Latin America, Asia/Pacific (excluding Japan) and South Africa. The correlation between quality of anticoagulation and efficacy is further discussed under 'ancillary analyses'.

Non-inferiority of edoxaban 60 mg was shown in the primary sponsor's analysis of all strokes/SEE (mITT, on-treatment) as well as in the sensitivity analysis for ischemic stroke/SEE according to CHMP guideline on NVAF (PP, on-treatment), but superiority was not shown for the previous mentioned endpoints in the ITT population in the overall study period (see below). On the contrary, although the main  sponsor's  analysis  suggested  non-inferiority  of  edoxaban  30  mg  versus  warfarin  on  all strokes/SEE, the sensitivity analysis using ischemic stroke/SEE (CHMP guideline) showed inferiority of the low edoxaban dose versus warfarin:

- a) Stroke  and  SEE  -Non-inferiority,  mITT,  on-treatment  (study  protocol): In  the  mITT on-treatment  period  (main  sponsor's  analysis),  adjudicated  stroke  or  SEE  occurred  in  253 subjects in the edoxaban 30 mg group (1.61% per year), 182 subjects in the edoxaban 60 mg group (1.18% per year), and 232 subjects in the warfarin group (1.50% per year). Compared to warfarin-treated subjects, the HR in the edoxaban 60 mg group was 0.79 (97.5% CI: 0.632, 0.985, p&lt;0.0001 for non-inferiority) and in the edoxaban 30 mg group was 1.07 (97.5% CI: 0.874, 1.314, p=0.0055 for non-inferiority).

<div style=\"page-break-after: always\"></div>

Table E-29: Adjudicated Primary Endpoint (Stroke or SEE), mITT Analysis Set On-Treatment (Non-Inferiority) and Overall Study Period

<!-- image -->

| PrimaryEndpoint                    | Edoxaban 30mg (15mgDosAdj) (N=7002)   | Edoxaban 30mg (15mgDosAdj) (N=7002)   | Edoxaban 60mg (30mgDosAdi) (N=7012)   | Edoxaban 60mg (30mgDosAdi) (N=7012)   | Warfarin (N=7012)   | Warfarin (N=7012)    | Edoxaban30mg (15mgDosAdj) VsWarfarin   | Edoxaban30mg (15mgDosAdj) VsWarfarin   | Edoxaban60mg (30mgDosAdj) vsWarfarin   | Edoxaban60mg (30mgDosAdj) vsWarfarin   |
|------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------|----------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| FirstStrokeorSEE                   | events #of                            | EventRate (14/%) [a]                  | events #of                            | EventRate (14/%) [a]                  | events #of          | EventRate (%/yr) [a] | (97.5% CI) HR                          | value[b] p-                            | (97.5% CI) HR                          | value[b] p-                            |
| mITTAnalysisSet OnTreatmentPeriod  | 253                                   | 1.61                                  | 182                                   | 1.18                                  | 232                 | 1.50                 | 1.07 (0.874,1.314)                     | 0.0055                                 | 0.79 (0.632,0.985)                     | <0.0001                                |
| mITTAnalysisSet OverallStudyPeriod | 382                                   | 2.04                                  | 292                                   | 1.55                                  | 336                 | 1.80                 | 1.13 (0.955, 1.336)                    | 0.0074                                 | 0.86 (0.719,1.029)                     | <0.0001                                |

Abbreviations:DosAdj=DoseAdjusted,HR=HazardRatioversusWarfarin,CI=ConfidenceInterval,mITT=Modified

Intent-to-Treat,SEE=SystemicEmbolicEvent,yr=year.

[a]:Theeventrate(%/yr)is calculatedas #ofevents/subject-yearexposure.

[b]:Thetwo-sidedp-valueisbasedonthenon-inferioritymarginof1.38

Sourcedata:Tables14.2.1.1and14.2.1.2

Highlighted in yellow: main analysis set to show non-inferiority included in the protocol (ITT, on-treatment)

Table E-33: Components and Select Subcomponents of the Primary Endpoint, mITT Analysis Set - On-treatment Period

|                           | Edoxaban 60 mg     | Edoxaban 60 mg   | Warfarin   | Warfarin        | Edoxaban 60 mg vs Warfarin   | Edoxaban 60 mg vs Warfarin   |
|---------------------------|--------------------|------------------|------------|-----------------|------------------------------|------------------------------|
| Event                     |                    | % per year [a]   |            | %6 per year [a] | HR (95% CI)                  | p-value                      |
| mITT Analysis Set         | N-7012             | N-7012           | N-7012     | N-7012          |                              |                              |
| On-TreatmentPeriod        | On-TreatmentPeriod |                  |            |                 |                              |                              |
| First Stoke               | 174                | 1.13             | 219        | 1.41            | 0.80 (0.655.0.975)           | 0.0273                       |
| Ischemie Stroke           | 135                | 0.87             | 144        | 0.93            | 0.94 (0.746, 1.193)          | 0.6258                       |
| Hemonhagic Stroke         | 40                 | 0.26             | 76         | 0.49            | 0.53 (0.362,0.778)           | 0.0012                       |
| Fatal Stoke               | 45                 | 0.29             | 43         | 0.28            | 1.05 (0.694, 1.602)          | 0.8038                       |
| Disabling Stroke          | 35                 | 0.23             | 41         | 0.26            | 0.86 (0.548.1.349)           | 0.5107                       |
| First SEE                 | 8                  | 0.05             | 13         | 0.08            | 0.62 (0.257, 1.497)          | 0.2884                       |
| First SEE/Ischemic Stroke | 143                | 0.93             | 157        | 1.01            | 0.92 (0.730, 1.149)          | 0.4495                       |

Note : Disabling is based on the Rankin score (3 to 5) supplied by the Investigator as well as taking into accoumt if the stroke event was adjudicated as fatal. Rankin score 3 = Moderate disability requiring some help, but able to wallk without assistance; 4 = Moderately severe disability, umable to wallk without assistance and uwable to attend to own bodily needs without assistance; 5 = Severe disability, bedridden, imcontinent,and requiningconstantnuursingcare and attention.

[a]: The event rate (% per yt) is caleulated as number of events/subject-year exposue.

Souce: U301, Table 14.2.1.13; U301, Table 14.2.1.18; U301, Table 14.2.1.10; U301, Table 14.2.1.15

- b) Ischemic Stroke/SEE - Non-inferiority, PP, on-treatment (endpoint and population set recommended to show non-inferiority in the NVAF Guideline EMA/CHMP/341363/2014): the event rate for ischemic stroke and SEE was the similar in both the edoxaban 60 mg group and the warfarin group (0.93% vs. 1.01% per year), with an HR of 0.92 (95% CI: 0.73 to 1.15) (97.5% CI: 0.71 to 1.23). More subjects in the edoxaban 30 mg group experienced ischemic stroke/SEE compared with the warfarin group (event rate of 1.49% and 1.01% per year, respectively), with an HR of 1.47 (95% CI: 1.20 to 1.80) .
- c) Stroke and SEE - Superiority, ITT, overall study period (study  protocol): In the ITT population (Overall Study Period), fewer subjects in the edoxaban 60 mg group experienced stroke or SEE than the warfarin group (1.57% and 1.80% per year, respectively), with an HR of 0.87 (99% CI: 0.709, 1.068, 95% CI: 0.744, 1.017) but the p-value (p=0.0807) was not below the protocol-specified value of statistical significance for superiority (p&lt; 0.01).

Table E-31: Adjudicated Primary Endpoint (Stroke or SEE), ITT Analysis Set - Overall Study Period (Superiority)

<div style=\"page-break-after: always\"></div>

<!-- image -->

ITT=Intent-to-Treat,SEE=SystemicEmbolicEvent,yr=year.

Abbreviations:DosAdj=DoseAdjusted,HR=HazardRatioversusWarfarin,CI=ConfidenceInterval,

[a]:Theeventrate(%/yr)iscalculatedas#ofevents/subject-yearexposure.

Souurcedata:Table14.2.1.7

Highlighted in yellow: main analysis to show superiority (study protocol and EMA/CHMP/341363/2014). The applicant chose a 99%CI for the main analysis given that this was a single pivotal trial.

- d) Ischemic Stroke/SEE -Superiority, ITT, overall study period (endpoint and population set recommended to show superiority in the NVAF Guideline EMA/CHMP/341363/2014): the event rate for ischemic stroke and SEE was the similar in both the edoxaban 60 mg group and the warfarin group (1.33% vs. 1.36% per year), with an HR of  0.98  (99% CI: 0.78 to 1.23; p = 0.7903). More subjects in the edoxaban 30 mg group experienced ischemic stroke/SEE compared with the warfarin group (event rate of 1.89% and 1.36% per year, respectively), with an HR of 1.39 (99% CI: 1.12 to 1.72; p &lt; 0.0001) .

Stroke/SEE during temporary interruptions: The percentage of subjects with 1 or more study drug interruptions (&gt; 3 consecutive days during which the subject did not take study drug) was 62.5%, 61.8%, and 65.5%, respectively, among the edoxaban 60 mg, edoxaban 30 mg, and the warfarin  treatment  groups.  Thromboembolic  events  occurring  during  temporary  interruptions (starting Day 4 of each interruption period to resumption of study drug after each interruption)were not included in the 'on-treatment analysis' of non-inferiority. There were 117 stroke/SEE events on edoxaban 60 mg and 112 stroke/SEE events on warfarin during temporary interruptions (starting Day 4 of each interruption period to resumption of study drug after each interruption). However, when corrected by exposure, the yearly event rate was quite similar (edoxaban 3.06 %/yr vs. warfarin 3.04 %/yr). All-cause, cardiovascular mortality events, hemorrhagic strokes and intracranial bleed events were  lower  in  the  edoxaban  60-mg  group  compared  with  the  warfarin  group  during  temporary interruptions.

Stroke/SEE after the end of study (study drug discontinuation): The percentage of subjects with adjudicated events after 3 days was low and similar in the three treatment groups (0.2%). From day 4 to 30 after end of study, the percentage of patients with stroke was 1.3%, 1.8% and 1.4% in the edoxaban 60 mg OD, edoxaban 30 mg OD and warfarin, respectively. These data indicate that the management of oral anticoagulation after study drug discontinuation in ENGAGE AF was appropriate. Edoxaban dose reduction was only one of the 4 key components for the transition plan from edoxaban to VKA. There were 4 key components: 1) selection of the oral anticoagulant (VKA or an NOAC) by the treating physician and patient; 2) a 14-day transition kit of modified-dose edoxaban for patients randomized to edoxaban (30 mg once daily for patients in whom the edoxaban dose was not reduced before the end-of-trial visit and 15 mg once daily for patients in whom the edoxaban dose had been reduced  before  the  end-of-trial  visit,  regardless  of  randomized  edoxaban  drug  assignment)  or matching placebo for patients randomized to warfarin; 3) early and frequent INR testing (≥3 tests during the first 2 weeks); and 4) use of a VKA titration algorithm [Ruff et al. J Am Coll Cardiol. 2014;64:576-84].

Control of INR during transition from edoxaban to warfarin was optimal in ENGAGE AF, and this is likely to be the main cause of the low rate of stroke and bleeding seen during the transition procedure. Frequent international normalized ratio (INR) testing and algorithm directed warfarin dosing allowed an INR ≥ 2 to be achieved promptly without giving a loading dose of warfarin. Median time to INR ≥

<div style=\"page-break-after: always\"></div>

2.0 was 9 days in patients transitioned from edoxaban to warfarin in ENGAGE-AF. By 30 days after the end of the trial, 98% of patients transitioned from edoxaban to warfarin had ≥ 2.0 therapeutic INR value in ENGAGE AF. In spite of the limitations of across study comparisons, these data compare favourably to those in contemporary trials (i.e.: ROCKET-AF). In order to ascertain the contribution of edoxaban in this process, the applicant modelled factor Xa activity over the 24-hour dosing period for the doses used in the ENGAGE AF study (TMPP008) and showed that even the 15 mg dose has some antithrombotic effect, although lower than that of a full therapeutic dose, as expected. The offset of activity lags the fall in plasma edoxaban concentration and hence there is more sustained activity of edoxaban over the 24-hour period than the pharmacokinetics would suggest. Simulations made by the  applicant  suggest  that  the  projected  incidence  in  ischemic  stroke  for  the  15-mg  dose  in monotherapy (≈2%/yr), although higher than that of warfarin (≈1%/yr), may retain some clinical effectiveness in absolute terms, as the estimated background risk untreated is 6 %/year (CHADS2 score  3).  However,  it  is  worth  mentioning  that  edoxaban  15  mg  is  not  to  be  administered  in monotherapy, but concomitantly with warfarin during the switching procedure. One of the problems for the other DOACs transition regimens was not only a lack of ischemic protection, but, importantly, of an increased rate of bleeding. This is the reason for the ENGAGE AF protocol to include provisions intended  to  mitigate  the  risk  of  bleeding  expected  for  those  patients  who  were  taking  two  oral anticoagulants concomitantly. On the other hand, SmPC information has been amended to reflect more accurately the switching process used in ENGAGE-AF.  An additional warning has been deemed necessary to prevent from treatment with suboptimal 15 mg dose in monotherapy and to make clear that the 15 mg dose isonly indicated in the process of switching from Lixiana 30 mg to VKA (patients with presumed increased exposure), together with an appropriate VKA dose (SmPC).

Secondary  outcomes: analyses  of  composite  (first-event)  endpoint  of  stroke,  SEE,  and  CV mortality, the endpoint of MACE, and the composite endpoint of stroke, SEE, and all-cause mortality were generally consistent with the analysis of the main endpoint of all strokes/SEE.

Dose-response in efficacy: The trend for superiority of the high edoxaban dose (60 mg OD) versus warfarin for the primary endpoint is supported by secondary analyses of patients with fatal strokes (80 vs. 86) disabling strokes (54 vs. 57), recurrent stroke/SEE events (5 vs. 8; mITT analysis set on-treatment period) and analysis of the composite of stroke, SEE and TIA (edoxaban 60 mg 1.69% per year vs. warfarin 1.92% per year; HR: 0.88; 95%CI: 0.746 to 1.042; mITT on-treatment period; main sponsor's analysis). On the contrary, the edoxaban 30 mg dose shows a trend for inferiority versus warfarin in the analysis of pure thromboembolic events (ischemic stroke/SEE as well as in MI). The trend for inferior efficacy of edoxaban 30 mg OD versus warfarin is also supported by the higher number of disabling strokes (82 and 57 subjects in edoxaban 30 mg group and the warfarin group, respectively),  in  the  number  of  patients  with  who  had  ≥  2  occurrences  of  the  primary  efficacy endpoint (21 and 8 subjects in edoxaban 30 mg group and the warfarin group, respectively; mITT analysis set on-treatment period) as well as by the high number of events when TIA was added to stroke and SEE (edoxaban 30 mg event rate 2.28% per year vs warfarin 1.92% per year; HR: 1.19; 95%CI: 1.021 to 1.389; mITT on-treatment period; primary sponsor's analysis). However, there was a trend for superiority of edoxaban 30 mg versus warfarin in the reduction of haemorrhagic stroke and CV mortality (mainly due to the reduction in fatal bleedings), which might be of interest in patients at high risk of bleeding.

Potential for dose adjustment in patients at high risk of bleeding: At the time of balancing efficacy and safety, the 60 mg edoxaban dose (with reduction to 30 mg in case of increased exposure) was considered the edoxaban dose with the best benefit-risk balance in NVAF. However, given the significant reduction of bleeding with the 30 mg edoxaban dose, the applicant discussed whether a dose reduction to 30 mg OD (in addition to those patients with moderate renal impairment and/or low

<div style=\"page-break-after: always\"></div>

body  weight  ≤  60  kg  and/or  concomitant  verapamil,  quinidine  or  dronedarone)  should  also  be considered in patients at high risk of bleeding (please see Discussion on Clinical Efficacy section). Exploratory analyses of subgroups in ENGAGE-AF were conducted by INR/TTR level by centre and quartiles as well as by at least 14 patient/study characteristics. Efficacy data in subgroups are difficult to interpret by the inclusion of haemorrhagic stroke in the analyses. In this respect, the applicant was requested and provided the analyses of subgroups of efficacy by INR/TTR level (center and quartiles) and by patient/study characteristics excluding haemorrhagic stroke (i.e.: including only ischemic stroke and SEE) using the same analysis sets as in the ENGAGE study report. Subgroup analyses by patient/study characteristics showed a generally consistent effect of edoxaban in most subgroups, with the exception of subgroups by renal function and geographic region in which the interaction  p-values  were  significant  for  both  edoxaban  doses  versus  warfarin.  The  HR  for  the edoxaban 60 mg group compared with the warfarin group for Western Europe was 1.47 (95%CI: 0.89-2.45; mITT, on-treatment) and for the subgroup with CrCL ≥ 80 mL/min was 1.41 (95%CI: 0.97-2.06).  The  main  primary  endpoint  results  in  ENGAGE-AF  study  seem  to  be  driven  by  an increased stroke/SEE rate with warfarin in Asia/Pacific/South Africa and Latin America (2.33% and 2.60%, respectively), which contrasts with the 1.13% yearly rate of stroke/SEE found in western Europe.  In  general,  subgroup  analyses  of  ENGAGE-AF  for  INR  level  and  geographic  region  are consistent with a recent meta-analysis of subgroups of RE-LY (dabigatran vs. warfarin), ROCKET-AF (rivaroxaban vs. warfarin) and ARISTOTLE (apixaban vs. warfarin) (Gómez-Outes et al. Thrombosis. 2013; 640723). In all these studies, the good results of the new anticoagulants were mainly at expenses  of  increased  stroke/SEE  rates  with  warfarin  in  Asia  and  Latin  America.  However,  the interaction by region seems more pronounced in the ENGAGE-AF study than in the other studies. In addition, the poorer results of edoxaban in the group of normal renal function versus impaired renal function for the primary endpoint was a novel finding (see also \"Efficacy data and additional analyses\" in the Discussion).

## Figure E-08: Forest Plot of Primary Endpoint (Stroke or SEE) by Baseline Characteristics for Edoxaban 60 mg Group Versus Warfarin, mITT Analysis Set - On-Treatment Period

<div style=\"page-break-after: always\"></div>

<!-- image -->

Note:Needatleast5subjectswitheventsinagroupfor aforestplot andpvalue.

Note:NativeHawaiian/PacificIslanderandAmericanIndian/AlaskanNativearenotpresented undei Racebecause thenumbersare small.

Source:Table14.2.5.1

<div style=\"page-break-after: always\"></div>

Figure E-08: Forest Plot of Primary Endpoint (Stroke or SEE) by Baseline Characteristics for Edoxaban 60 mg Group Versus Warfarin, mITT Analysis Set - On-Treatment Period (Continued)

<!-- image -->

Note:Need atleast5subjectswitheventsinagroupforaforestplot andpvalue.

Source:Table14.2.5.1

<div style=\"page-break-after: always\"></div>

Figure E-09: Forest Plot of Primary Endpoint (Stroke or SEE) by Baseline Characteristics for the Edoxaban 30 mg Group Versus Warfarin, mITT Analysis Set - On-Treatment Period

<!-- image -->

| Subgroup             | Edoxaban3omg (15mgDosAdj) n/M(%/yr)   | n/M(%/yr) Warfarin             | Hazard Ratio forStrokeorSEE and95%CI   | Interaction P-valuofor   |
|----------------------|---------------------------------------|--------------------------------|----------------------------------------|--------------------------|
| Age                  |                                       |                                |                                        |                          |
| <75                  | 144/ 4213 （1.46)                      | 117/ 4207 (1.19)               |                                        | 0.1397                   |
| >=75                 | 109/ 2789 （1.85)                      | 115/ 2805 (2.02)               |                                        |                          |
| Gender               |                                       |                                |                                        |                          |
| Male                 | 144/ 4284 (1.48)                      | 144/ 4383 (1.46)               |                                        | 0.4794                   |
|                      | 1.09/ 2718 (1.80)                     | 88/ 2629 (1.55)                |                                        |                          |
| Race                 |                                       |                                |                                        |                          |
|                      | 201/ 5650 (1.57)                      | 171/ 5679 (1.35)               |                                        |                          |
| Blaok                | 2/ 94 (1.05)                          | 1/ 88 (0.60)                   |                                        |                          |
| Asian                | 43/ 975 (1.98)                        | 48/ 963 (2.30)                 |                                        |                          |
|                      | 5/ 257 (0.91)                         | 11/ 265 (2.00)                 |                                        |                          |
| Dose At Rand         |                                       |                                |                                        |                          |
| Yes                  | 85/ 1774 (2.36)                       | /LL 1780 (2.21)                |                                        | 0.9872                   |
| No                   | 168/ 5228 (1.38)                      | 155/ 5232 (1.29)               |                                        |                          |
| CrCL (mL/min)        |                                       |                                |                                        |                          |
| <30                  | 2/ 42 (5.19)                          | 1/ 51 (1.83)                   |                                        | 0.0077                   |
| 30 一 <=50            | 58/ 1280                              | 49/ 1305 (1.97)                |                                        |                          |
| >50 <80              | (2.32) 116 / 3052 (1.67)              | 135/ 3048                      |                                        |                          |
| >-80                 | /LL 2628                              | (2.00) 47/ 2608 (0.76)         |                                        |                          |
| Verap/Quin Use At    | (1.23)                                |                                |                                        |                          |
| Yes                  | 16/ 240 (3.02)                        | 3/ 222 (0.58)                  |                                        |                          |
| No                   | 6762 (1.56)                           | 229/ 6790 (1.53)               |                                        |                          |
| Weight (kg) <=40     | 2/ 12 (9.21)                          | 0/ 16 (0.00)                   |                                        |                          |
| >40                  | 251/ 0669 (1.60)                      | 232/ 9669 (1.50)               |                                        |                          |
| <=60                 | 37/ 692 (2.65)                        | 32/ 698 (2.41)                 |                                        | 0.8947                   |
| >60                  | 216/ 6310 (1.50)                      | 200/ 6314 (1.41)               |                                        |                          |
| VKAUse At Rand Naive | 104/ 2857 (1.66)                      | 107/ 2888 (1.77)               |                                        | 0.1565                   |
|                      | 149/ 4144                             |                                |                                        |                          |
| CHADS2 score         | (1.57)                                | 125/ 4124 (1.32)               |                                        |                          |
| <=3                  | 161/ 5.443 (1.29)                     | 147/ 5427 (1.20)               |                                        | 0.9573                   |
| >3                   | 92/ 1559 (2.83)                       | 85/ 1585 (2.62)                |                                        |                          |
| -2                   | 83/ 3291                              | 3321                           |                                        |                          |
|                      | (1.08) (2.12)                         | 72/ (0.94)                     |                                        |                          |
| >=3 Priox Stxoke/TIA | 170/ 3705                             | 160/ 3686 (2.05)               |                                        |                          |
| Yes                  | 1.18/ 666T (2.73)                     | 107/ 1983 (2.51)               |                                        | 0.9516                   |
| No                   | 135/ 5003 (1.18)                      | 125/ 5029 (1.11)               |                                        |                          |
| Pr1or                |                                       |                                |                                        |                          |
| Yes                  | 95/ 1309 (3.41)                       | 84/ 1321 (2.98)                |                                        | 0.6033                   |
| No                   | 158/ 5692 (1.22)                      | 148/ 5691 (1.17)               |                                        |                          |
| Prior TIA            |                                       |                                |                                        |                          |
| Yes                  | /0E 820 (1.65)                        | 32/ 793 (1.85)                 |                                        | 0.3499                   |
| No                   | 223/ 6182 (1.60)                      | 200/ 6219 (1.45)               |                                        |                          |
| Prior CHF            |                                       |                                |                                        |                          |
| Yes                  | 134/ 3962 (1.52)                      | 127/ 4038 (1.44)               |                                        | 0.9853                   |
| No                   | 119/ 3040 (1.71)                      | 105/ 2974                      |                                        |                          |
| Prior ension         |                                       | (1.57)                         |                                        |                          |
| Yes                  | 229/ 6545 (1.55)                      | 215/ 6566 (1.47)               | 1                                      | 0.3912                   |
| No                   | 24/ 457 (2.49)                        | 17/ 446 (1.83)                 |                                        |                          |
| Pxiox                |                                       |                                |                                        |                          |
|                      | 89/ 2533                              | 69/ 2516                       |                                        |                          |
| Yes No               | (1.54) 164/ 4469 (1.64)               | (1.23) 163/ 4496 (1.64)        |                                        | 0.2404                   |
| Type of AE           |                                       |                                |                                        |                          |
|                      | 58/ 1827                              | 43/ 1774 (1.10)                |                                        | 0.6268                   |
| stent                | (1.43) 56/ 1581 (1.58)                | 56/ 1624 (1.58)                |                                        |                          |
|                      | 139/                                  | 3612                           |                                        |                          |
|                      | (1.71)                                |                                |                                        |                          |
|                      |                                       | 133/ (991)                     |                                        |                          |
| Region               |                                       |                                |                                        |                          |
| North America        | 39/ 1550 (1.13)                       | 42/ 1556 (1.21)                |                                        | 0.0299                   |
| USA                  | 33/ 1308 (1.14)                       | 34/ 1297 (1.16)                |                                        |                          |
| Latin                | 34/ 882 (1.82)                        | 42/ 885 (2.33)                 |                                        |                          |
|                      | 40/ 1075 (1.75) 94/ 2369 (1.67)       | 25/ 1070 (1.13)                |                                        |                          |
| and SA               | 28/ 789 (1.63)                        | 68/ 2378 (1.22) 42/ 786 (2.60) |                                        |                          |
| Asia/Pao Japan       | 18/ LEE (2.24)                        | 13/ 337 (1.56)                 | 0 2                                    |                          |

<div style=\"page-break-after: always\"></div>

Subgroup  analyses  of  stroke/SEE  by  INR/TTR  level  suggest  that  the  effect  size  (reduction  of stroke/SEE by edoxaban) decreases as the quality of anticoagulation in the control group increases (i.e.: in centers with TTR &gt; 60% and when INR/TTR is above the fourth quartile, &gt;73.9%). When the TTR data are examined by quartiles for the edoxaban 60 mg group compared to warfarin, the HR for the primary endpoint in the 1st, 2nd, and 3rd quartile was 0.80, 0.73, and 0.74, respectively, and for the 4th quartile was 1.07 (95%CI: 0.65-1.75). For the edoxaban 30 mg group compared to warfarin, the HR for 1st, 2nd, 3rd, and 4th quartiles were 0.82, 1.02, 1.22, and 1.30 (95%CI: 0.81-2.09), respectively.  These  data  are  within  expected  on  the  light  of  previous  studies  with  novel  oral anticoagulants in NVAF.

Table E-42: Primary Endpoint (Stroke or SEE) by Center Level INR TTR, mITT Analysis Set - On-Treatment Period

Abbreviations:DosAdj=DoseAdjusted,HR=Hazard RatioversusWarfarin,CI=ConfidenceInterval,yr=year,INR=Intemational Normalized

<!-- image -->

| PrimaryEndpoint               | Edoxaban 30mg (15mgDosAdi) (N=7002)   | Edoxaban 30mg (15mgDosAdi) (N=7002)   | Edoxaban 60mg (30mgDosAdj) (N=7012)   | Edoxaban 60mg (30mgDosAdj) (N=7012)   | Warfarin (N=7012)       | Warfarin (N=7012)       | Edoxaban 30mg (15mg DosAdj) VsWarfarin   | Edoxaban 60mg (30mg DosAdj) Vs Warfarin   |
|-------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------|-------------------------|------------------------------------------|-------------------------------------------|
| FirstStrokeorSEE              | n/[a]                                 | EventRate (%/yr)[b]                   | n/M[a]                                | EventRate (%/y)[b]                    | m/M[a]                  | EventRate (%/y)[b]      | HR (95% C1)                              | HR (95% C1)                               |
| CenterswithTTR>66.4%(Median)  | 110/3273                              | 1.46                                  | 73/3277                               | 1.00                                  | 94/3402                 | 1.19                    | 1.24 (0.944,1.639)                       | 0.85 (0.623,1.148)                        |
| CenterswithTTR<=66.4%(Median) | 134/3509                              | 1.72                                  | 107/3517                              | 1.39                                  | 138/3602                | 1.82                    | 0.93 (0.737,1.185)                       | 0.77 (0.595,0.986)                        |
| pvaluefortheinteraction       | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction | pvaluefortheinteraction | 0.1243                                   | 0.6275                                    |
| CenterswithTTR>=60%           | 175/4990                              | 1.54                                  | 120/4960                              | 1.09                                  | 155/5191                | 1.30                    | 1.19 (0.955,1.472)                       | 0.84 (0.661,1.065)                        |
| CenterswithTTR<60%            | 69/1792                               | 1.77                                  | 60/1834                               | 1.51                                  | 77/1813                 | 2.14                    | 0.81 (0.584,1.119)                       | 0.71 (0.503,0.989)                        |
| pvaluefortheinteraction       | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction | pvaluefortheinteraction | 0.0559                                   | 0.4114                                    |

Ratio,mITT=ModifiedIntent-to-Treat,TTR=TimeinTherapeuticRange,SEE=SystemicEmbolicEvent.

[a]:nisthenumberofevents,Misthetotalnumberofsubjectsonwhomtheinformationisavailableforthatsubgroup

Note:All INRs takenwhile on-treatment,excluding the initiai 7daysof studymedicationareconsidered.

[b]:Theeventrate(%/yr)iscalculated as #ofevents/subject-yearexposure.

Sourcedata:Table14.2.5.10

Table E-43: Primary Endpoint (Stroke or SEE) by Quartiles of INR TTR, mITT Analysis Set On-Treatment Period

Abbreviations:DosAdj=DoseAdjusted,HR=Hazard RatioversusWarfarin,CI=ConfidenceInterval,yr=year,INR=IntemationalNormalized

<!-- image -->

| PrimaryEndpoint               | Edoxaban 30mg (15mgDosAdj) (N=7002)   | Edoxaban 30mg (15mgDosAdj) (N=7002)   | Edoxaban 60mg (30mgDosAdj) (N=7012)   | Edoxaban 60mg (30mgDosAdj) (N=7012)   | Warfarin (N=7012)       | Warfarin (N=7012)       | Edoxaban30mg (15mgDosAdi) VsWarfarin   | Edoxaban60mg (30mgDosAdj) vsWarfarin   |
|-------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-------------------------|-------------------------|----------------------------------------|----------------------------------------|
| QuartilesofINRTTR             | n/[a]                                 | EventRate [(%)                        | n/I[a]                                | EventRate [q(/%)                      | n/I[a]                  | EventRate (%/yr)[b]     | HR (95% C1)                            | HR (95% C1)                            |
| 1stQuartile(<=57.7%)          | 54/1406                               | 1.78                                  | 51/1413                               | 1.68                                  | 57/1406                 | 2.07                    | 0.82 (0.563,1.183)                     | 0.80 (0.547, 1.164)                    |
| 2ndQuartile (>57.7%t0<=66.4%) | 80/2103                               | 1.69                                  | 56/2104                               | 1.21                                  | 81/2196                 | 1.68                    | 1.02 (0.747, 1.387)                    | 0.73 (0.516, 1.020)                    |
| BrdQuartile (>66.4%t0<=73.9%) | 71/1906                               | 1.63                                  | 42/1908                               | 0.99                                  | 63/2038                 | 1.35                    | 1.22 (0.871, 1.717)                    | 0.74 (0.500, 1.090)                    |
| 4thQuartile(>73.9%)           | 39/1367                               | 1.23                                  | 31/1369                               | 1.02                                  | 31/1364                 | 0.95                    | 1.30 (0.814, 2.092)                    | 1.07 (0.648, 1.751)                    |
| pvaluefortheinteraction       | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction               | pvaluefortheinteraction | pvaluefortheinteraction | 0.3384                                 | 0.6372                                 |

Ratio,mITT=ModifiedIntent-to-Treat,TTR=TimeinTherapeuticRange,SEE=SystemicEmbolicEvent.

[b]:Theeventrate(%/yr)iscalculatedas#ofevents/subject-yearexposure.

[a]:nisthenumber ofevents,Misthe total number of subjectsonwhom theinformationis availablefor thatsubgroup.

Note:AllINRstakenwhileon-treatment,excluding theinitial7daysofstudymedicationare considered

Sourcedata:Table14.2.5.10

## HOKUSAI VTE: Treatment of VTE including DVT and PE, and prevention of recurrent VTE

## Methods

The efficacy and safety of edoxaban in reducing the risk of symptomatic recurrent VTE in subjects with documented acute symptomatic DVT and/or PE is primarily based upon the large Phase 3 Hokusai VTE study in which 4118 subjects were treated with edoxaban 60 mg (30 mg reduced) and 4122 with warfarin  for  3-12  months  (all  patients  received  heparin-based  initial  treatment  for  5-12  days). Hokusai VTE was an event-driven, Phase 3, multinational, multicenter, randomized, double-blind, matching placebo, parallel-group, event-driven non-inferiority study to evaluate the benefits and risks of edoxaban in reducing the risk of symptomatic recurrent VTE in subjects with documented acute symptomatic DVT and/or PE. At least 40% of subjects had to present with PE.

<div style=\"page-break-after: always\"></div>

Figure E-03. Hokusai-VTE study design

<!-- image -->

## Study Participants

Inclusion/exclusion criteria: HOKUSAI-VTE  enrolled  male  or  female  adult  subjects  with symptomatic DVT and/or PE documented by objective methods. Exclusion criteria were similar to other contemporary trials. Patients with active cancer (in which LMWH treatment instead of VKA is recommended), active liver disease, severe renal impairment or pregnancy were excluded, as well as those with contraindications to anticoagulation (e.g.: active bleeding) or treatment with potent P-gp inhibitors. Patients could have temporary risk factors only (such as trauma, surgery, immobilization, estrogen therapy, etc.) for which a 3-month treatment may suffice, or all others (e.g.: intrinsic factors), for which a longer treatment may be needed.

## Treatments

In HOKUSAI-VTE, eligible subjects were randomized to (LMW)heparin/edoxaban or (LMW)heparin/warfarin  using  stratified  randomization.  All  patients  received  initial  therapy  with open-label  enoxaparin  or  unfractionated  heparin  for  at  least  5  days.  Edoxaban  or  warfarin  was administered in a double-blind, double-dummy fashion. Edoxaban (or placebo) was started after discontinuation of initial heparin. Edoxaban was administered at a dose of 60 mg orally once daily, taken with or without food, or at a dose of 30 mg once daily in patients with a creatinine clearance of 30 to 50 ml per minute or a body weight of 60 kg or less or in patients who were receiving concomitant treatment with potent P-glycoprotein inhibitors. The study was designed with the aim of broadening applicability to real-world practice and encouraging the enrolment of all patients, including those with extensive disease, by specifying that treatment should be initiated with the proven, global standard of parenteral heparin; that the dose of the study drug should be halved in patients perceived to be at higher risk for bleeding (e.g., those with renal impairment or low body weight); and that physicians should be allowed to adjust the duration of treatment after 3 months according to their clinical judgment or in keeping with evolving evidence. Dosing in the experimental group (heparin lead-in followed by edoxaban) is similar to the dosing selected for dabigatran trials in acute VTE (RE-COVER I and II), but different from the single drug approach (no need for heparin lead-in, using higher doses of the new anticoagulant during the first weeks and followed by a lower maintenance dose) used in rivaroxaban trials (EINSTEIN DVT and PE) and apixaban pivotal trial in acute VTE (AMPLIFY). This is an important difference in dosing between edoxaban and the other Factor Xa inhibitors. In order to avoid medication errors, it should be stated in section 4.2 of the SmPC that Lixiana is to be started

<div style=\"page-break-after: always\"></div>

following  initial  use  of  heparin  (subcutaneous  low-molecular-weight  heparin  or  intravenous unfractionated heparin) for at least 5 days.

Treatment regimes tested in the HOKUSAI-VTE study are in general deemed appropriate. However, study duration was left to the investigator. Although it was endorsed that this approach may mimic standard practice, it was considered unfortunate that a second randomisation, or a second study was not performed in patients having received anticoagulation after 3-6 months, in order to generate randomised clinical data versus placebo or active comparator in the setting of extended treatment of VTE (i.e.: as conducted in the EINSTEIN-ext with rivaroxaban, RE-MEDY and RE-SONATE study with dabigatran or the AMPLIFY-ext study with apixaban). However, the design and analysis (mITT Overall versus On-Treatment) of the study allowed for assessment of the extension of therapy/the secondary prevention of VTE without the need for a formal 'extension' study. Furthermore this 'extension' study within Hokusai was performed with an active comparator-warfarin rather than placebo allowing a more robust comparison as to the real world risk benefit if continued therapy. As such the indication for  both  the  active  treatment  of  acute  VTE  and  secondary  prevention  of  recurrent  VTE  were demonstrated with the Hokusai VTE study with up to 12 months of therapy. Therefore, it was agreed that a separate \"extension\" study was not warranted.

## Objectives

## Outcomes/endpoints

The primary efficacy outcome in HOKUSAI-VTE was symptomatic recurrent VTE (i.e., the composite of DVT, non-fatal PE, and fatal PE). The secondary efficacy outcome added was the same but adding all-cause mortality. The main analysis set was the mITT during the overall study period (12 months). CEC  adjudication  results  was  the  basis  of  the  analyses.  The  objective  criteria  used  to  confirm recurrent VTE are in line with those used in contemporary studies in the acute treatment of VTE and are considered acceptable. In this regard, the CHMP Guidance on clinical investigation of medicinal products for the treatment of venous thromboembolic disease [CPMP/EWP/563/98] published in 2000 (now in revision), states that if, in exceptional cases, recurrent VTE events diagnosed only by clinical symptoms are followed by acute, new antithrombotic therapy, such events could be considered for inclusion in the endpoint only after adjudication by the clinical events committee. The applicant has confirmed  that  approximately  8%  of  primary  efficacy  events  were  adjudicated  events  without confirmatory imaging. These events mainly included VTE-related deaths. However, the events were equally distributed in both groups and sensitivity analysis excluding these events (HR: 0.90: 95%CI: 0.69-1.16) yielded very similar results than the main analysis (HR: 0.89; 95%CI: 0.70-1.13), thus supporting non-inferiority of edoxaban under different assumptions.

## Randomisation

Randomisation in HOKUSAI-VTE study was stratified by presenting diagnosis (PE and DVT only), Baseline risk factors (temporary risk factors vs. all others), and need for edoxaban dose reduction to 30  mg  (yes,  no).  An  Interactive  voice/web  response  system  (IXRS)  was  used.  Randomisation methods in HOKUSAI-VTE study are considered acceptable.

## Blinding (masking)

The HOKUSAI-VTE study used a double-blind design, which is in line of the one used in the recent RE-COVER  studies  with  dabigatran  and  AMPLIFY  study  with  apixaban  (EINSTEIN  studies  with rivaroxaban followed an open-label design). Blinding/masking methods are deemed appropriate.

## Statistical methods

HOKUSAI-VTE was event driven. A total of at least 220 events were required. Sample size calculation is  endorsed.  The  primary  efficacy  analysis  of  the  HOKUSAI-VTE  study  was  based  on  a  modified Intent-to-Treat (mITT) Analysis Set (subjects who are randomized and received at least one dose of

<div style=\"page-break-after: always\"></div>

study  drug)  using  all  primary  efficacy  events  (symptomatic  recurrent  VTE)  that  occurred  in  the 12-month study period. The time to the first event of the composite primary efficacy outcome was analyzed using a Cox proportional hazards model including treatment and the stratification factors as covariates. The experimental regime was considered non-inferior to the comparator if the upper limit of  the  95%CI for the HR was less than 1.5. The non-inferiority margin (HR &lt;1.50) is the more restrictive one use in recent studies with novel oral anticoagulants in the treatment of VTE (1.80 in AMPLIFY; 2.0 in EINSTEIN studies; 2.75 in RE-COVER studies). During discussion with the CHMP SA procedure, it was advised that the preferred assessment for non-inferiority of the primary endpoint, recurrent VTE (the composite endpoint of DVT, non-fatal PE and fatal PE), was the treatment period plus 30 days tested using the PP analysis set; although the mITT analysis for the overall study period was also important. The sponsor decided to maintain the main analysis of non-inferiority in the mITT in the overall study period but planned sensitivity analyses for non-inferiority and superiority in the mITT and PP population at different study time points (on-treatment period; treatment +30 days period; first 90 days). In the CHMP view, primary analysis of non-inferiority should have been focused on recurrent VTE in the PP population on-treatment. However, this analysis has been provided at least as sensitivity analysis, which is endorsed. The superiority analysis should have focused on recurrent VTE + all-cause mortality in a pure ITT population (randomized patients) in the overall study period. However, as the proportion of randomized patients that were excluded from the mITT population was less than 1% (see 'participant flow'), the mITT analysis conducted by the applicant was considered appropriate for  the  analysis  of  superiority.  Superiority  was  tested  for  the  secondary  endpoint  of symptomatic recurrent DVT, non-fatal symptomatic recurrent PE, and all-cause mortality (mITT, overall study period). An α=0.01 two-sided was chosen and the analysis was based on the mITT Analysis  Set  using  the  same  proportional  hazard  model  as  for  the  primary  efficacy  analysis. Exploratory  analyses  of  subgroups  were  conducted  depending  on  at  least  16  patient/study characteristics.

## Results

## Participant flow

Populations analysed: A total of 8292 subjects were randomized and assigned to the edoxaban (N=4143) or warfarin (N=4149) treatment groups, and a total of 8240 subjects were treated with edoxaban (N=4118) or warfarin (N=4122) (mITT set).

There was no screening period in Hokusai VTE, which is consistent with the acute and serious nature of the event to be treated. The critical study qualification work-up was conducted outside of the study as a matter of routine for the management of VTE. These procedures were deemed acceptable if done within 48 hours before randomization. . Of the 8,240 mITT subjects, 65 (0.8%) subjects withdrew consent and 11 (0.1%) were lost to follow up.

## Figure E-05: Enrollment and Study Completion Outcomes

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Recruitment

## Conduct of the study

A total of 439 investigational study sites in 37 countries randomized at least one subject in this trial. The countries were classified into 10 regions (South Europe, Central Europe, Nordic, Eastern Europe, China/Japan, Western Europe, Other Asian, Australia-New Zealand, South Africa/South America, and United States and Canada).

There were 4 amendments to the original protocol of the HOKUSAI-VTE study dated 24 Aug 2009. It is unlikely that the amendments had impact the integrity of the study.

## Baseline data

The baseline characteristics of the patients included in the HOKUSAI-VTE study were similar in the two study  groups.  The  mean  age  was  56  years  and  the  majority  of  subjects  were  males  (57%). Approximately 41% of patients presented PE as index event. Risk factors for VTE were transient in 28% of patients. Intented treatment duration was 3 months in 6% of patients, 6 months in 37% of patients and 12 months in 57% of patients.

Table E-24: Demographic and Baseline Characteristics, mITT Analysis Set

<div style=\"page-break-after: always\"></div>

<!-- image -->

|                                        | Edoxaban N=4118 m ()   | Warfarin N=4122) m (0)   | Overall N=8240 n (96)   |
|----------------------------------------|------------------------|--------------------------|-------------------------|
| Age (years)                            |                        |                          |                         |
| Mean (SD)                              | 55.7(16.28)            | 55.9(16.17)              | 55.8(16.23)             |
| Median                                 | 57.0                   | 57.0                     | 57.0                    |
| Minimum                                | 18                     | 18                       | 18                      |
| Maximum                                | 106                    | 95                       | 106                     |
| <65 years                              | 2784 (67.6)            | 2752 (66.8)              | 5536 (67.2)             |
| 65years                                | 1334 (32.4)            | 1370 (33.2)              | 2704(32.8)              |
| 75 years                               | 560 (13.6)             | 544 (13.2)               | 1104 (13.4)             |
| 80 years                               | 252 ( 6.1)             | 265 ( 6.4)               | 517 ( 6.3)              |
| Gender                                 | 4118                   | 4122                     | 8240                    |
| Male                                   | 2360 (57.3)            | 2356 (57.2)              | 4716 (57.2)             |
| Female                                 | 1758 (42.7)            | 1766 (42.8)              | 3524 (42.8)             |
| Race                                   | 4109                   | 4115                     | 8224                    |
| Caucasian                              | 2867 (69.6)            | 2895 (70.2)              | 5762 ( 69.9)            |
| Black                                  | 156 ( 3.8)             | 144( 3.5)                | 300 (3.6)               |
| Asian                                  | 866 (21.0)             | 861 (20.9)               | 1727(21.0)              |
| Other                                  | 220 ( 5.3)             | 211 ( 5.1)               | 435 ( 5.3)              |
| PresentingDiagnosis (IXRS)             |                        |                          |                         |
| PulmonaryEmbolism                      | 1671 (40.6)            | 1679 (40.7)              | 3350 ( 40.7)            |
| withDVT                                | 611 (14.8)             | 560 (13.6)               | 1171 (14.2)             |
| withoutDVT                             | 1060(25.7)             | 1119 (27.1)              | 2179 (26.4)             |
| DVTOnly                                | 2447 ( 59.4)           | 2443(59.3)               | 4890(59.3)              |
| Risk Factors (IXRS)                    |                        |                          |                         |
| Temporary                              | 1132 (27.5)            | 1140 (27.7)              | 2272 (27.6)             |
| Other                                  | 2986 (72.5)            | 2982(72.3)               | 5968(72.4)              |
| IntendedTreatment Duration             |                        |                          |                         |
| 3Months                                | 221 ( 5.4)             | 245 ( 5.9)               | 466 (5.7)               |
| 61onths                                | 1555 (37.8)            | 1502 (36.4)              | 3057(37.1)              |
| 12Months                               | 2339 (56.8)            | 2371 (57.5)              | 4710(57.2)              |
| Edoxaban30mgdoseat Randomization(IxRS) |                        |                          |                         |
| Yes                                    | 733 (17.8)             | 719 (17.4)               | 1452 (17.6)             |
| No                                     | 3385(82.2)             | 3403(82.6)               | 6788 (82.4)             |
| WeightatRandomization                  |                        |                          |                         |
| (IXRS)Cg) =60                          | 524 (12.7)             | 519 (12.6)               | 1043 (12.7)             |
| 60                                     | 3594(87.3)             | 3603(87.4)               | 7197 (87.3)             |
| CreatinineClearanceat                  |                        |                          |                         |
| Randomization(IXRS) (mL /min)          |                        |                          |                         |
| =30 to =50                             | 268 ( 6.5)             | 273 ( 6.6)               | 541 ( 6.6)              |
| >50                                    | 3850(93.5)             | 3849(93.4)               | 7699(93.4)              |
| VerapamilorQuinidine                   |                        |                          |                         |
| UseatRandomization IXRS)               |                        |                          |                         |
| Yes                                    | 26 ( 0.6)              | 25（ 0.6)                 | 51( 0.6)                |
| No                                     | 4092(99.4)             | 4097(99.4)               | 8189(99.4)              |
| Region                                 |                        |                          |                         |
| WestemEuurope                          | 680 (16.5)             | 679 (16.5)               | 1359 (16.5)             |
| SouthEurope                            | 586 (14.2)             | 590 (14.3)               | 1176 (14.3)             |
| Central Euurope                        | 468 (11.4)             | 464 (11.3)               | 932 (11.3)              |
| EastemEurope                           | 483 (11.7)             | 485 (11.8)               | 968(11.7)               |
| Nordic                                 | 174 ( 4.2)             | 180(4.4)                 | 354 ( 4.3) 693 (8.4)    |
| China/Japan                            | 349 (8.5) 106 (2.6)    | 344 (8.3)                |                         |
| Japan OtherAsian                       | 501 (12.2)             | 103 ( 2.5) 503 (12.2)    | 209 ( 2.5) 1004(12.2)   |
| Australia/NewZealand                   | 145 ( 3.5)             | 145 ( 3.5)               | 290 (3.5)               |
| SouthAfrica/South                      | 316 (7.7)              | 312 (7.6)                | 628 (7.6)               |
| America                                | 416(10.1)              | 420(10.2)                | 836(                    |
| USA/Canada                             |                        |                          | 10.1)                   |

Note:RiskFactors and PresentingDiagnosis areper theInvestigatoratRandomization.RiskFactors are categorized temporary (e.g., trauma, surgery, immobilization, estrogen therapy, etc.) vs all others. Source:Table14.1.1.3.Table14.1.3.1.andTable14.1.5.4

Abbreviations:DVT=deepveinthrombosis,IxRS=Interactivevoice/webresponsesystem,N=numberof subjectsinanalysisset,n=numberofsubjectsmeetingeventcriteria,SD=standarddeviation. Note:Doseallocation,creatinineclearance,andverapamil/quinidineuseisderivedfrominfomation recorded intheIXRSatrandomization.

The regions throughout Europe enrolled the majority of subjects. Approximately 17% of subjects required the 30 mg edoxaban at randomization due to body weight ≤ 60 kg (10%), CrCL 30-50 mL/min (4%), or for the use of quinidine/verapamil (0.5%). Post- randomization requirement for 30 mg edoxaban/edoxaban placebo occurred in 123 subjects (68 for edoxaban and 55 for edoxaban placebo (active warfarin), respectively. Approximately 17.6% of subjects had their dose adjusted at randomization. Approximately 8% of the dose reductions were due to concomitant medication with P-gp inhibitors. However, only 0.8% is due to concomitant treatment of with the examples given in the protocol (verapamil, quinidine or dronedarone). The numerically more important subgroup was

<div style=\"page-break-after: always\"></div>

the group of azole antifungals, macrolides and 'other' (4.6% including captopril, carvedilol, diltiazem, felodipine, ticagrelor, and ranolazine, among others).

Numbers analysed

Table E-17: Number of Subjects in Analysis Sets - All Randomized Subjects

|                                            | Edoxaban N=4143 n (%)   | Warfarin N=4149 n (%)   |
|--------------------------------------------|-------------------------|-------------------------|
| Randomized                                 | 4143                    | 4149                    |
| Never Received Study Drug                  | 25 ( 0.6)               | 27 ( 0.7)               |
| mITT (Treated)                             | 4118 (99.4)             | 4122 (99.3)             |
| DosedButExcludedFromPerProtocol            | 61 ( 1.5)               | 44 ( 1.1)               |
| SubjectsExperiencingTreatmentMisallocation | 0 ( 0.0)                | 0 ( 0.0)                |
| IndexEventNotConfirmedbyCECAdjudication    | 61 ( 1.5)               | 44 ( 1.1)               |
| PerProtocol                                | 4057 (97.9)             | 4078 (98.3)             |
| Safety [a]                                 | 4118 (99.4)             | 4122 (99.3)             |

Abbreviations:mITT=modifiedIntent-to-Treat(treatedsubjects),N=number(overall),n=numberwithin asubsetofsubjects.

[a] Based on actual treatment received. There were no treatment misallocations in Hokusai VTE

Source:Table14.1.1.5

Major protocol deviations were reported in 23% of patients (Table 14.1.2.1 of the HOKUSAI-VTE study  report).  Most  of  them  (16%)  corresponded  to  the  use  of  disallowed  medications  (mainly disallowed  NSAIDs)  that  impacts  the  evaluation  of  main  efficacy/safety  endpoints,  followed  by pretreatment for more than 48 hours with therapeutic dosages of anticoagulant treatment before randomisation (4%). However, it was not endorsed that patients with major protocol deviations were excluded from the PP analysis. Only patients for whom the index DVT or PE event at baseline could not be confirmed by the CEC were excluded from the PP population. This was considered inconsistent with the criteria followed in the ENGAGE-AF study, in which patients with all major protocol violations were excluded from the PP population. In summary, the original PP analysis of the applicant (not excluding all  major  protocol  violations)  favoured  the  demonstration  of  non-inferiority  of  edoxaban  versus warfarin in efficacy. However, non-inferiority was also demonstrated after conducting a \"true\" PP analysis (excluding all major protocol violations).

## Outcomes and estimation

Treatment  compliance: Compliance  with  edoxaban  or  matching  placebo  was  analyzed  as  the percentage of doses taken (≥ 80% to ≤ 120% of the planned number of doses) during the study treatment period. In the edoxaban and edoxaban placebo groups, 93.6% and 93.3% of subjects in the mITT Analysis Set On-Treatment period were within the compliance range of ≥ 80% to ≤ 120%). This analysis suggests that the definition of compliance was quite insensitive to detect differences that could be of relevance (e.g.: a patient could have been declared compliant missing 5 consecutive doses per month). In this regard, sensitivity analyses were requested by narrower intervals of percentaje of doses taken (5-10% intervals), but could not be provided by the Applicant as the data as collected did not have sufficient granularity. The Applicant noted that compliance was high in both studies and it cannot  be  refuted  with  the  data  available.  Compliance  with  warfarin  was  analyzed  by  using  the subjects'duration of time in the INR therapeutic range (2.0 to 3.0) during the study treatment period. The  mean time in  the  therapeutic  range  (TTR)  was  63.5%  (median:  65.6%).  The  overall  mean percent  of  reported  INR  measurements  that  were  &lt;  2.0  was  18.9%  and  &gt;  3.0  was  17.6%, respectively. The mean TTR in HOKUSAI-VTE (63.5%) was above the upper range of TTRs reported in contemporary studies (from 57% in RE-COVER II to 62.7% in EINSTEIN PE). Therefore, in the overall study population, quality of anticoagulation was reasonable good.The correlation between quality of anticoagulation by region/center and efficacy is further discussed under 'ancillary analyses'.

Non-inferiority of edoxaban 60 mg was shown in the primary sponsor's analysis of symptomatic recurrent VTE (mITT, overall study period) as well as in the sensitivity analysis for symptomatic

<div style=\"page-break-after: always\"></div>

recurrent  VTE  (PP,  on-treatment),  but  superiority  was  not  shown  for  the  secondary  endpoint  of symptomatic recurrent VTE and all-cause death (mITT, overall study period. In addition, there was a huge  difference in the number  of  VTE  events  'on-treatment'  and  'overall  study period' (approximately half of total primary events occurred post-treatment) (see below):

- Recurrent VTE, mITT, overall study period (main non-inferiority analysis): Symptomatic recurrent VTE occurred in a total of 130 subjects (3.2%) in the edoxaban group, compared to 146 (3.5%) subjects in the warfarin group, during the Overall Study Period. The Hazard Ratio (HR) for the edoxaban group vs. the warfarin group was 0.89 (95% CI: 0.703, 1.128). The upper bound of the 95% CI is 1.128, which was below the pre-specified non-inferiority margin of 1.5, and the difference  between  edoxaban  and  warfarin  in  the  time  to  first  occurrence  of  adjudicated symptomatic  recurrent  VTE  was  statistically  significant  for  non-inferiority  (p&lt;0.0001)  (Table 11.2).

Table E-38: Primary Endpoint (Adjudicated Symptomatic Recurrent VTE), mITT Analysis Set - Overall Study Period

| PrimaryEndpoint[a]                              | Edoxaban N=4118     | Warfarin N=4122     |
|-------------------------------------------------|---------------------|---------------------|
| All Subjects with Recurrent VTE, n (%)          | 130 ( 3.2)          | 146 ( 3.5)          |
| HR Edoxaban vs. Warfarin (95% C1) [b]           | 0.89 (0.703, 1.128) | 0.89 (0.703, 1.128) |
| p-value (for non-inferiority) [b, c]            | <0.0001             | <0.0001             |
| p-value (for superiority) [b]                   | 0.3362              | 0.3362              |
| Iype of First Recurrent VTE, n (%)              |                     |                     |
| PEWith/WithoutDVT                               | 73 ( 1.8)           | 83 ( 2.0)           |
| PE-Related Deaths                               | 24 ( 0.6)           | 24 ( 0.6)           |
| Fatal PE                                        | 4 (<0.1)            | 3 (<0.1)            |
| Unexplained Death (and VTE cannot be ruled out) | 20 ( 0.5)           | 21 ( 0.5)           |
| Non-Fatal PE                                    | 49 (1.2)            | 59 (1.4)            |
| With DVT                                        | 2 (<0.1)            | 2 (≤0.1)            |
| Without DVT                                     | 47 ( 1.1)           | 57 ( 1.4)           |
| DVT Only                                        | 57 ( 1.4)           | 63 ( 1.5)           |

Abbreviations:DVT =deep vein thrombosis,HR =Hazard Ratio vs.warfarin,CI= confidence interval, mITT=modifiedIntent-to-Treat,N=number of subjects in mITT analysis set,n =number of subjectswith events,PE=pulmonary embolism,VTE=venous thromboembolicevent.

[a] The primary efficacy endpoint is symptomatic recurrent VTE (i.e., the composite endpoint of DVT, non-fatal PE, and fatal PE). Only CEC adjudication results are considered for this summary.

[b] The HR, two-sided CI are based on the Cox proportional hazards regression model including treatment and the following randomization stratification factors as covariates: presenting diagnosis (PE with or without DVT; DVT only), baseline risk factors (temporary factors, all others), and the need for 30 mg edoxaban/edoxabanplacebodose atrandomization (yes/no).

[c] The p-value is for the pre-defined non-inferiority margin of 1.5.

Note: Events are included in the Overall study period if they occurred on or after the randomization date up to Day 365.

Source:Table 14.2.1.1.

The Kaplan-Meier curves (figure below) provide further support that continued exposure, remaining on therapy (Ontreatment versus Overall population) is associated with decreased recurrence and both analyses (ontreatment and overall population) favors edoxaban versus warfarin. The main issue during HOKUSAI-VTE regarding duration of therapy, looking at post-treatment recurrences, was that many  patients  would  have  been  benefited  from  longer  treatment  durations  of  anticoagulation. Furthermore, the Kaplan Meier curves are linear data and there is long-term safety data from the ENGAGE AF. Due to the above mentioned reasons, it was agreed not to limit the duration of treatment of VTE to the 1 year tested with edoxaban in HOKUSAI-VTE.

Figure: Kaplan-Meier curves for recurrent VTE in Hokusai VTE

<div style=\"page-break-after: always\"></div>

<!-- image -->

DataSource:U305.Figure14.2.1.33.Figure14.2.1.43

- Sensitivity analyses for non-inferiority: In the PP Analysis Set, a total of 64 subjects (1.6%) in the edoxaban group vs. 80 (2.0%) subjects in the warfarin group had recurrent VTE during the on-treament study period. The Hazard Ratio (HR) for non-inferiority was 0.80 (95% CI: 0.58, 1.12).  The  upper  bound  of  the  95%  CI  was  1.12,  which  was  below  the  pre-specified non-inferiority margin of 1.5. All of the remaining sensitivity analyses of non-inferiority for the mITT Analysis Set, Overall Study Period and PP analysis set, excluding unexplained deaths for which VTE could not be ruled out and assessing the potential impact of missing data are all consistent with the results of the primary analysis.

Table E-39: Efficacy Analyses Across Multiple Analysis Sets and Study Periods

|                                                                   | Edoxaban     | Warfarin     | Edoxabanvs.Warfarin   | Edoxabanvs.Warfarin   |
|-------------------------------------------------------------------|--------------|--------------|-----------------------|-----------------------|
| RecurrentVTE mITTAnalysisSet[a]                                   | N=4118 n (%) | N=4122 n (%) | HR (95% C1) [b]       | p-value [c]           |
| mITTAnalysis Set, Overall Study Period (Primary efficacy)         | 130 ( 3.2)   | 146 ( 3.5)   | 0.89 (0.703, 1.128)   | <0.0001               |
| mITTAnalysisSet,OverallStudy Periodexcludingunexplaineddeaths [p] | 110( 2.7)    | 125( 3.0)    | 0.88 (0.682,1.138)    | <0.0001               |
| mITTAnalysisSet,OverallStudy Impact of Missing Data [e]           | 132 ( 3.2)   | 147 ( 3.6)   | 0.90 (0.710, 1.136)   | <0.0001               |
| RecurrentVTEPPAnalysisSet[a]                                      | N=4057 n (%) | N=4078 n (%) | HR (95% C1) [b]       | p-value [c]           |
| PPAnalysisSet-On-TreatmentStudy Period                            | 64 ( 1.6)    | 80 ( 2.0)    | 0.80 (0.577, 1.113)   | <0.0001               |
| PPAnalysisSet-Treatment+30Days StudyPeriod                        | 87 ( 2.1)    | 102 ( 2.5)   | 0.85 (0.642, 1.137)   | <0.0001               |
| PPAnalysisSet-1st90days                                           | 54 ( 1.3)    | 71 (1.7)     | 0.76 (0.536, 1.088)   | <0.0001               |
| PP Analysis Set, Treatment+30 Days excludingunexplained deaths[d] | 74 ( 1.8)    | 89 ( 2.2)    | 0.83 (0.611, 1.133)   | <0.0001               |

Abbreviations: CI = confidence interval, HR =hazard ratio, mITT =modified Intent-to-Treat, N =number of subjects in the analysis set, n = number of subjects with events, PP =per protocol, VTE = venous thromboembolism.

[a]RecurrentVTE=recurrentsymptomaticDVT,non-fatalPE,fatal PE andunexplaineddeathforwhich

PEcouldnotberuledout

[b]TheHR and two-sided CI arebased on the Coxproportional hazards regression model including treatment and the following randomization stratification factors as covariates:presenting diagnosis (PE with or without DVT, DVT only), baseline risk factors (temporary factors, all others), and the need for 30mgedoxaban/edoxabanplacebodose atrandomization(yes,no).

[c] The p-value is based for a non-inferiority margin of 1.5.

[d]RecurrentVTE excludingunexplained deathfor whichVTE could not be ruled out;recurrent VTE=recurrentsymptomaticDVT,non-fatalPE,fatalPEonly.

[e] Imputation for missing data as defined in the statistical analysis plan.

Source:Table14.2.1.1,Table14.2.1.2,Table14.2.1.4,Table14.2.1.5,Table14.2.1.12,Table14.2.1.23, andTable14.2.1.24.

<div style=\"page-break-after: always\"></div>

- Additional sensitivity analysis to show non-inferiority: In the original PP analysis (not excluding  all  major  protocol  violations  but  only  those  patients  without  confirmed  VTE  at baseline) there were 4057 patients on edoxaban and 4078 patients on warfarin. The HR for recurrent VTE was 0.85 (0.64 to 1.14; treatment+30 days). In the revised \"true\" PP analysis (excluding all major protocol violations) there are 3116 patients on edoxaban and 3143 patients on warfarin. The HR of edoxaban versus warfarin for recurrent VTE is 0.95 (0.68 to 1.33; treatment+30 days), thus confirming non-inferiority (p-value 0.0040). In summary, the original PP analysis of the applicant (not excluding all major protocol violations) favoured the  demonstration  of  non-inferiority  of  edoxaban  versus  warfarin  in  efficacy.  However, non-inferiority was also demonstrated after conducting a \"true\" PP analysis (excluding all major protocol violations).
- Time onset of recurrent VTE events: There was a huge difference in the number of recurrent VTE events between the PP on-treatment analysis (edoxaban 64 events vs warfarin 80 events) and the mITT overall study period analysis (130 events vs 146 events), which indicates that approximately half of the events during overall study period (66 events in each group) occurred after  anticoagulant  treatment  had  been  stopped.  On  the  one  hand,  it  is  reassuring  that  no differences  in  rebound  thromboembolism  were  noticed  between  groups  and  therefore  the non-inferiority of edoxaban vs. warfarin on-treatment was sustained at 12 months. On the other hand, it questions whether duration of anticoagulant therapy was generally insufficient during the trial.
- Recurrent VTE and all-cause mortality, mITT analysis set, overall study period (main superiority  analysis): The  composite  endpoint  of  recurrent  VTE  and  all-cause  mortality occurred in 228 of subjects (5.5%) in the edoxaban group and in 228 subjects (5.5%) in the warfarin group (HR: 1.00; 95% CI: 0.832, 1.200, p=0.9933). Although recurrent VTE (DVT or PE) favoured  numerically  to  edoxaban  versus  warfarin,  there  was  a  numerical  imbalance  in  the number of deaths in the  overall  study  period  of  the  HOKUSAI-VTE  study  (edoxaban  122  vs warfarin 106), thus leading to a hazard ratio of 1.00. Analysing the timecourse of deaths, there was not an imbalance in on-treament deaths (edoxaban 35 vs warfarin 33). The imbalance was attributed to an excess in deaths due to infectious disease in the edoxaban arm after treatment had been stopped. This imbalance was not seen in the ENGAGE-AF study in a population with AF, which may indicate a chance finding. Deaths are also discussed under safety.

<div style=\"page-break-after: always\"></div>

Table E-40: Adjudicated Secondary Endpoint (Recurrent VTE and All-cause Mortality), mITT Analysis Set - Overall Study Period

Abbreviations:CI=ConfidenceInterval, DVT =Deep vein thrombosis,HR =Hazard Ratiovs.Warfarin, N =number of subjects in analysis set, n =number of subjects meeting event criteria, PE =Pulmonary

| SecondaryEndpoint[a]                                        | Edoxaban N=4118     | Warfarin N=4122     |
|-------------------------------------------------------------|---------------------|---------------------|
| All SubjectsWithRecurrent VTE or All-CauseMortality, n (%)  | 228 ( 5.5)          | 228 ( 5.5)          |
| HREdoxabanvs.Warfarin(95%C1)[b]                             | 1.00 (0.832, 1.200) | 1.00 (0.832, 1.200) |
| p-value [b]                                                 | 0.9933              | 0.9933              |
| Type of Initial Recurrent VTE or All-Cause Mortality, n (%) |                     |                     |
| All-CauseMortality                                          | 122 ( 3.0)          | 106 ( 2.6)          |
| VTE-RelatedDeath                                            | 24 (<0.1)           | 24 (<0.1)           |
| FatalPE                                                     | 4 (≤0.1)            | 3 (<0.1)            |
| UnexplainedDeath(andVTEcannotberuledout)                    | 20 ( 0.5)           | 21 ( 0.5)           |
| Other Death[c]                                              | 98 (2.4)            | 82 ( 2.0)           |
| Non-Fatal PE                                                | 49 (1.2)            | 59 (1.4)            |
| WithDVT                                                     | 2 (<0.1)            | 2 (<0.1)            |
| Without DVT                                                 | 47 ( 1.1)           | 57 ( 1.4)           |
| DVT Only                                                    | 57 (1.4)            | 63 ( 1.5)           |

embolism,VTE=Venous thromboembolicevent.

[a]ThesecondaryefficacyendpointissymptomaticrecurrentVTE(i.e.,thecompositeendpointof symptomaticrecurrentDVT,non-fatalsymptomaticrecurrentPE,andall-causemortality). [b] The HR and two-sided CI are based on the Cox proportional hazards regression model including treatmentand thefollowingrandomizationstratificationfactors ascovariates:presentingdiagnosis (PE with or without DVT,DVTonly),baseline riskfactors(temporaryfactors,allothers),and theneed for 30 mg edoxaban/edoxaban placebo atrandomization (yes,no),p-value α =0.01[two-sided]. Note:Eventsareincludedin the Overallstudyperiod if theyoccurredonor after therandomizationdateup to Day365.

[c] Of\"Other Deaths\",infectious disease was the cause of death in 25(0.6%)subjects in theedoxaban group vs.12 (0.2%) in the warfarin group (Table 12.21)

Note: CEC adjudication results only are considered for this summary.

Source:Table14.2.2.1.

Net clinical outcome (composite of symptomatic recurrent DVT, nonfatal symptomatic recurrent PE, Major bleeding, and All-cause mortality) occurred in 138 subjects (3.4%) in the edoxaban group and 158 subjects (3.9%) in the warfarin group (HR: 0.87; 95% CI: 0.696, 1.099; p = 0.2515). However, these results correspond to a secondary PP analysis on-treatment, and not to the main analysis in the mITT, overall study period, which may have biased the results in favour of edoxaban, as  post-treatment  deaths  were  not  included.  For  the  shake  of  consistency,  the  applicant  was requested to show the results of net clinical outcome in HOKUSAI-VTE using the same approach as in the main analysis of the primary endpoint (i.e.: in the mITT population, overall study period). The HR and 95% CIs for the net clinical outcome using this approach (HR: 1.00; 95%CI: 0.85-1.18) suggest that  both  edoxaban  and  warfarin  (both  with  lead  in  parenteral  anticoagulant)  are  equivalent strategies for VTE treatment. The SmPC, section 5.1, has been amended accordingly .

Subgroup analyses in  HOKUSAI-VTE: The effect of edoxaban was generally consistent across subgroups tested in the HOKUSAI-VTE study. Overall, of the 55 comparisons presented from 18 subgroup  analyses,  most  (45)  resulted  in  a  point  estimate  favouring  edoxaban.  Statistically significant interaction was only found for fragile vs. non-fragile patients. Edoxaban effect was better in fragile than in non-fragile patients. In general, the effects of edoxaban were also better (although not statistically significant interaction was found) in index PE, age &gt; 75 years and history of cancer, which is reassuring.

Regarding the quality of oral anticoagulation, the edoxaban group had a relative reduction in risk for recurrent VTE compared to warfarin for subjects at centers TTR &lt; 60% (HR: 0.89; 95% CI: 0.574, 1.364) and also at centers with TTR ≥60% (HR: 0.87; 95% CI: 0.653, 1.153). The Hazard Ratio for the edoxaban group for centers with INR-TTR &gt;55.8 ≤64.0% was 0.77 (95% CI: 0.496, 1.205).

<div style=\"page-break-after: always\"></div>

Figure E-10: Forest Plot of Primary Endpoint (Recurrent VTE) by Subgroup, mITT Analysis Set - Overall Study Period

<!-- image -->

Fragilepopulation=atrandomization:age≥75yearsand/orbodyweight≤5okgand/orCrCL 30-50mL/min

Source:Table14.2.5.1,Table14.2.5.7.

Subgroups by renal function: In the subgroup of patients with normal renal function (CrCL ≥ 80 mL/min), no significant differences between edoxaban and warfarin were found in recurrent VTE (3.3% vs. 3.2%), major bleeding (0.8% vs. 1.0%) or all-cause mortality (1.8% vs. 2.1%). Looking at the  overall  benefit-risk  in  terms  of  the  net  clinical  outcome  (recurrent  VTE,  major  bleeding  and all-cause mortality) there is considerable overlap between the CrCL subgroups and no statistical difference is apparent between the treatments, including the subgroup of patients with CrCL ≥ 80 mL/min (3.1% vs. 3.2%; HR: 0.96; 95%CI: 0.71 to 1.29).

Subgroups  by  treatment  duration: There  was  significant  disagreement between  planned  and actual treatment duration. Of the subjects intended for treatment of 3 months 55.7% received 3 months  of  treatment,  whereas  24.4  %  received  3-6  months  of  treatment,  19.9%  received  &gt;

<div style=\"page-break-after: always\"></div>

6-months of treatment and 10.0% received a full 12-months of treatment. Edoxaban demonstrated non-inferiority to warfarin for the 6- and 12-month intended treatment duration subjects. The HR for the primary efficacy endpoint, recurrent VTE (HR; 95%CI; mITT, overall study period) was 1.34 (0.52-3.41) in the 3-month intended treatment duration, 0.80 (0.57-1.12) in the 6-month intended treatment duration (edoxaban 62/1555 vs warfarin 75/1502) and 0.94 (0.66-1.34) in the 12-month intended treatment duration (edoxaban 58/2339 vs. warfarin 63/2371). In the 3-month intended treatment duration the HR was 1.34 but was associated with a small sample size and numerically very few events (edoxaban 10/221 vs. warfarin 9/245).

## Summary of main studies

The following tables summarise the efficacy results from the main studies supporting the present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Table E-45. Summary of efficacy for trial ENGAGE-AF TIMI 48

Title: A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-center, Multi-national Study for Evaluation of Efficacy and Safety of DU-176b (Edoxaban) Versus Warfarin in Subjects with Atrial Fibrillation,  Effective  aNticoaGulation  with  factor  xA  next  GEneration  in  Atrial  Fibrillation  (ENGAGE AF-TIMI 48)

| Study identifier   | DU176b-C-U301 (ENGAGE AF-TIMI 48)                                                                                                                                                                                                                                                        | DU176b-C-U301 (ENGAGE AF-TIMI 48)                                                                                                                                                                                                                                                                                        |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design             | This was an event-driven, Phase 3, multi-national, multi-center, randomized, double-blind, double-dummy, parallel-group study in subjects with documented AF within the preceding 12 months and in whom anticoagulation therapy was indicated and planned for the duration of the study. | This was an event-driven, Phase 3, multi-national, multi-center, randomized, double-blind, double-dummy, parallel-group study in subjects with documented AF within the preceding 12 months and in whom anticoagulation therapy was indicated and planned for the duration of the study.                                 |
|                    | Duration of main phase: Duration of Run-in phase:                                                                                                                                                                                                                                        | Event-driven (until approximately 672 targeted primary endpoint events were collected). Median duration of treatment: 2.5 years Median subject-year follow-up: 2.8 years. First subject randomized: 19 Nov 2008 Start of study close-out procedures: 22 January 2013. Last subject completed: 24 May 2013 not applicable |
| Hypothesis         | Non-inferiority (both edoxaban doses vs. warfarin; HR <1.38), then superiority (only edoxaban high dose vs. warfarin)                                                                                                                                                                    | Non-inferiority (both edoxaban doses vs. warfarin; HR <1.38), then superiority (only edoxaban high dose vs. warfarin)                                                                                                                                                                                                    |
| Treatments groups  | Edoxaban 60 mg OD (experimental)                                                                                                                                                                                                                                                         | Randomized (ITT analysis set): 7035 Treated (mITT, safety analysis): 7012 Per-protocol: 6995                                                                                                                                                                                                                             |
| Treatments groups  | Edoxaban 30 mg OD (experimental)                                                                                                                                                                                                                                                         | Randomized (ITT analysis set): 7034 Treated (mITT, safety analysis): 7002 Per-protocol: 6982                                                                                                                                                                                                                             |
| Treatments groups  | Warfarin dose-adjusted (INR: 2.0-3.0) (control)                                                                                                                                                                                                                                          | Randomized (ITT analysis set): 7036 Treated (mITT, safety analysis): 7012 Per-protocol: 6993                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions     | 07 Aug 2013                   | 07 Aug 2013                            | Warfarin (dose-adjusted)               | Warfarin (dose-adjusted)               |                                        |                                        |                                        |
|-------------------------------|-------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Endpoints and definitions     | 7002                          | 7002                                   | 7012                                   | 7012                                   | 1.18% per year (182 subjects)          | 1.18% per year (182 subjects)          | 1.18% per year (182 subjects)          |
| Endpoints and definitions     | 1.61% per year (253 subjects) | 1.61% per year (253 subjects)          | Hazard ratio versus warfarin (97.5%CI) | Hazard ratio versus warfarin (97.5%CI) | 0.79 (0.632 to 0.985, p<0.0001 for     | 0.79 (0.632 to 0.985, p<0.0001 for     | 0.79 (0.632 to 0.985, p<0.0001 for     |
| Treatment group               | Edoxaban 60 mg OD             | Edoxaban 60 mg OD                      | Edoxaban 60 mg OD                      | Edoxaban 60 mg OD                      | Edoxaban 60 mg OD                      | Edoxaban 60 mg OD                      | Edoxaban 60 mg OD                      |
| Number of                     | Number of                     | Number of                              | Number of                              | Number of                              | Number of                              | Number of                              | Number of                              |
| 6995                          | 6995                          | Ischemic stroke/SEE (rate per 100      | Ischemic stroke/SEE (rate per 100      | Ischemic stroke/SEE (rate per 100      | Ischemic stroke/SEE (rate per 100      | Ischemic stroke/SEE (rate per 100      | Ischemic stroke/SEE (rate per 100      |
| 0.93% per year (143 subjects) | 0.93% per year (143 subjects) | Hazard ratio versus warfarin (95%CI)** | Hazard ratio versus warfarin (95%CI)** | Hazard ratio versus warfarin (95%CI)** | Hazard ratio versus warfarin (95%CI)** | Hazard ratio versus warfarin (95%CI)** | Hazard ratio versus warfarin (95%CI)** |
| 0.92 (0.73 to 1.15)           | 0.92 (0.73 to 1.15)           | 1.47 (1.20 to 1.80)                    | 1.47 (1.20 to 1.80)                    | -                                      | -                                      |                                        |                                        |

<div style=\"page-break-after: always\"></div>

| Analysis description                                        | Primary Analysis of superiority (study protocol)               | Primary Analysis of superiority (study protocol)               | Primary Analysis of superiority (study protocol)               | Primary Analysis of superiority (study protocol)               |
|-------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|
| Analysis population and time point                          | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) |
| description Descriptive statistics and estimate variability | Treatment group                                                | Edoxaban 60 mg OD                                              | Edoxaban 30 mg OD                                              | Warfarin (dose-adjusted)                                       |
| description Descriptive statistics and estimate variability | Number of subjects                                             | 7035                                                           | 7034                                                           | 7036                                                           |
| description Descriptive statistics and estimate variability | Primary endpoint All strokes/SEE(rate per 100 patient-years)   | 1.57% per year (296 subjects)                                  | 2.04% per year (383 subjects)                                  | (1.80% per year (337 subjects)                                 |
| description Descriptive statistics and estimate variability | Hazard ratio versus warfarin (99%CI)                           | 0.87 (0.709, 1.068, p=0.0807 for superiority)                  | 1.13 (0.933 to 1.371, p=0.0980 for superiority)                | -                                                              |
| Analysis description                                        | Primary Analysis of superiority (CHMP guideline)*              | Primary Analysis of superiority (CHMP guideline)*              | Primary Analysis of superiority (CHMP guideline)*              | Primary Analysis of superiority (CHMP guideline)*              |
| Analysis population and time point description              | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) | Intention-to-treat, overall study period (time to first event) |
| Descriptive statistics and estimate variability             | Treatment group                                                | Edoxaban 60 mg OD                                              | Edoxaban 30 mg OD                                              | Warfarin (dose-adjusted)                                       |
| Descriptive statistics and estimate variability             | Number of subjects                                             | 7035                                                           | 7034                                                           | 7036                                                           |
| Descriptive statistics and estimate variability             | Ischemic stroke/SEE (rate per 100 patient-years)               | 1.33% per year (251 subjects)                                  | 1.89% per year (356 subjects)                                  | (1.36% per year (255 subjects)                                 |
| Descriptive statistics and estimate variability             | Hazard ratio versus warfarin (99%CI)                           | 0.98 (0.78 to 1.23, p=0.7903)                                  | 1.39 (1.12 to 1.72, p<0.0001)                                  | -                                                              |
| Analysis description                                        | Secondary variables (ITT, overall study period)                | Secondary variables (ITT, overall study period)                | Secondary variables (ITT, overall study period)                | Secondary variables (ITT, overall study period)                |
| Descriptive statistics and estimate variability             | Treatment group                                                | Edoxaban 60 mg                                                 | Edoxaban 30 mg                                                 | warfarin                                                       |
| Descriptive statistics and estimate variability             | Number of subject                                              | N = 7035                                                       | N= 7034                                                        | N = 7036                                                       |
| Descriptive statistics and estimate variability             | Stroke, SEE or CV mortality(rate per 100 patient-years)        | 3.85% per year (728 subjects)                                  | 4.23% per year (796 subjects)                                  | 4.43% per year (831 subjects)                                  |
| Descriptive statistics and estimate variability             | Hazard ratio versus warfarin (95%CI)                           | 0.87 (0.79 to 0.96)                                            | 0.95 (0.87 to 1.05)                                            | -                                                              |
| Descriptive statistics and estimate variability             | MACE (rate per 100 patient-years)                              | 4.41% per year (827 subjects)                                  | 4.90% per year (913 subjects)                                  | 4.43% per year (926 subjects)                                  |

<div style=\"page-break-after: always\"></div>

| Hazard ratio versus warfarin (95%CI)                                                         | 0.89 (0.81 to 0.97)           | 0.98 (0.90 to 1.08)           | -                              |
|----------------------------------------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------------|
| Stroke, SEE or all-cause mortality (rate per 100 patient-years) Hazard ratio versus warfarin | 5.01% per year (949 subjects) | 5.23% per year (985 subjects) | 4.57% per year (1046 subjects) |
| (95%CI)                                                                                      | 0.90 (0.82 to 0.98)           | 0.94 (0.86 to 1.02)           | -                              |

*Ischemic stroke/SEE, Per-protocol, on-treatment ( EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation (EMA/CHMP/341363/2014 )) (excluding haemorrhagic stroke).

**97.5% CI was not calculated by the sponsor for this outcome.

## Table E-46. Summary of efficacy for trial Hokusai VTE

| Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban versus (LMW)Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism   | Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban versus (LMW)Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism                                                  | Title: A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multi-Center, Multi-National Study for the Evaluation of Efficacy and Safety of (LMW) Heparin/Edoxaban versus (LMW)Heparin/Warfarin in Subjects with Symptomatic Deep-Vein Thrombosis and/or Pulmonary Embolism                                                  |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                                                                            | DU176B-D-U305 (HOKUSAI VTE)                                                                                                                                                                                                                                                                                                                | DU176B-D-U305 (HOKUSAI VTE)                                                                                                                                                                                                                                                                                                                |
| Design                                                                                                                                                                                                                                                                                      | This was an event-driven, Phase 3, multi-national, multicenter, randomized, double-blind, matching placebo, parallel-group, non-inferiority study to evaluate the benefits and risks of edoxaban in reducing the risk of recurrent venous thromboembolism (VTE) complications in subjects with documented acute symptomatic DVT and/or PE. | This was an event-driven, Phase 3, multi-national, multicenter, randomized, double-blind, matching placebo, parallel-group, non-inferiority study to evaluate the benefits and risks of edoxaban in reducing the risk of recurrent venous thromboembolism (VTE) complications in subjects with documented acute symptomatic DVT and/or PE. |
|                                                                                                                                                                                                                                                                                             | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                                                                                             | Event driven: The study continued until ≈ 220 primary efficacy endpoint events (i.e., recurrent VTE) were recorded (mITT set). Treatment: maximum of 12 months. First subject, first visit date: 28-Jan-2010. Last subject, last follow-up date: 12-Jun-2013. not applicable not applicable                                                |
| Hypothesis                                                                                                                                                                                                                                                                                  | Non-inferiority (recurrent VTE, mITT, overall study period; HR < 1.5), then superiority (recurrent                                                                                                                                                                                                                                         | Non-inferiority (recurrent VTE, mITT, overall study period; HR < 1.5), then superiority (recurrent                                                                                                                                                                                                                                         |
| Treatments groups*                                                                                                                                                                                                                                                                          | Edoxaban (60 or 30 mg OD)†                                                                                                                                                                                                                                                                                                                 | VTE+all-cause death, mITT, overall study period). Randomized: 4143 Treated: 4118 patients (60 mg OD: 3385; 30 mg OD: 733) Treatment duration (median): 265 days.                                                                                                                                                                           |
| Treatments groups*                                                                                                                                                                                                                                                                          | Warfarin (dose-adjusted)                                                                                                                                                                                                                                                                                                                   | Randomized: 4149. Treated: 4122. Treatment duration (median): 261 days.                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

Endpoints and definitions

Primary endpoint

Secondary endpoint

Secondary endpoint

Database lock

26 Jun 2013

## Results and Analysis

| Analysis description                            | Primary Analysis for non-inferiority                           | Primary Analysis for non-inferiority                           | Primary Analysis for non-inferiority                  | Primary Analysis for non-inferiority                  |
|-------------------------------------------------|----------------------------------------------------------------|----------------------------------------------------------------|-------------------------------------------------------|-------------------------------------------------------|
| Analysis population and time point description  | mITT, overall study period                                     | mITT, overall study period                                     | mITT, overall study period                            | mITT, overall study period                            |
| Descriptive statistics and estimate variability | Treatment group                                                | Treatment group                                                | Edoxaban                                              | Warfarin                                              |
| Descriptive statistics and estimate variability | Number of subject                                              | Number of subject                                              | 4118                                                  | 4122                                                  |
| Descriptive statistics and estimate variability | Symptomatic recurrent VTE(%)                                   | Symptomatic recurrent VTE(%)                                   | 3.2% (130 subjects)                                   | 3.5% (146 subjects)                                   |
| Descriptive statistics and estimate variability | Hazard ratio versus warfarin (95%CI)                           | Hazard ratio versus warfarin (95%CI)                           | 0.89 (0.70 to 1.13; p < 0.0001 for non-inferiority)   | -                                                     |
| Analysis description                            | Primary analysis for superiority                               | Primary analysis for superiority                               | Primary analysis for superiority                      | Primary analysis for superiority                      |
| Analysis population and time point description  | mITT, overall study period                                     | mITT, overall study period                                     | mITT, overall study period                            | mITT, overall study period                            |
| Descriptive statistics and estimate variability | Treatment group                                                | Treatment group                                                | Edoxaban                                              | Warfarin                                              |
| Descriptive statistics and estimate variability | Number of subject                                              | Number of subject                                              | 4118                                                  | 4122                                                  |
| Descriptive statistics and estimate variability | Symptomatic (non-fatal) recurrent VTE + all-cause mortality(%) | Symptomatic (non-fatal) recurrent VTE + all-cause mortality(%) | 5.5% (228 subjects)                                   | 5.5% (228 subjects)                                   |
| Descriptive statistics and estimate variability | Hazard ratio versus warfarin (95%CI)                           | Hazard ratio versus warfarin (95%CI)                           | 1.00 (0.83 to 1.20; p = 0.9933 for superiority)       | -                                                     |
| Analysis description                            | Net clinical endpoint (PP analysis set, on treatment)          | Net clinical endpoint (PP analysis set, on treatment)          | Net clinical endpoint (PP analysis set, on treatment) | Net clinical endpoint (PP analysis set, on treatment) |
| Descriptive statistics and estimate variability | Treatment group                                                | Edoxaban                                                       | Edoxaban                                              | Warfarin                                              |
| Descriptive statistics and estimate variability | Number of subject                                              | 4057                                                           | 4057                                                  | 4078                                                  |

Symptomatic

Documented recurrent VTE

Symptomatic documented

recurrent VTE

+ all-cause mortality

Net clinical outcome

The composite of DVT, non-fatal PE, and fatal

PE, documented by objective methods during the 12-month study period. CEC adjudication

results were the basis for the final analyses.

The composite clinical outcome of symptomatic recurrent DVT, non-fatal

symptomatic recurrent PE, and all-cause mortality during the 12-month study period.

The composite of symptomatic (non-fatal)

recurrent VTE, (non-fatal) major bleeding and all-cause mortality.

<div style=\"page-break-after: always\"></div>

| Symptomatic (non-fatal) recurrent VTE + (non-fatal) major bleeding + all-cause mortality (%)   | 3.4% (138 subjects)   | 3.9% (158 subjects)   |
|------------------------------------------------------------------------------------------------|-----------------------|-----------------------|
| Hazard ratio versus warfarin (95%CI)                                                           | 0.87 (0.70 to 1.10)   | -                     |

*All patients received initial parenteral treatment with LMWH or UFH for at least 5 days.

†Edoxaban 60 mg OD in most patients. Dose was halved to 30 mg OD in any of the following cases: Body weight

≤ 60 kg; CrCL between 30-50 mL/min; and/or concomitant use of P-glycoprotein (P-gp) inhibitors (e.g.: verapamil or quinidine).

## Analysis performed across trials (pooled analyses and meta-analysis) N/A

## Clinical studies in special populations

A  clinical  study  in  93  patients  with  several  degrees  of  renal  function,  including  severe  renal impairment (study C-J307) has already been described and discussed under section 3.3 (dose-finding studies). No other studies in special populations have been submitted. For available efficacy data in special populations see also ancillary analyses subsection (subgroup analyses of the pivotal studies).

## Supportive studies

N/A

## 2.5.3. Discussion on clinical efficacy

## 2.5.3.1. Phase II studies

The totality of the data from the edoxaban clinical development program support the selection of the edoxaban 60 mg dose for phase III studies in NVAF and treatment of acute VTE, the dose reduction criteria and the magnitude of the dose reduction to 30 mg in subjects with reduced renal function, low weight and some of the identified P-gp inhibitors. In ENGAGE AF the primary efficacy endpoint (stroke + SEE) was superior for the 60 mg QD as compared to the 30 mg QD regimen albeit the rate of haemorrhagic strokes was lower in the 30 mg QD group. On the other hand, for the secondary 'net clinical benefit endpoint' (stroke, SEE, major bleeding events, mortality) the 30 mg QD dose was better than the 60 mg group due to the lower bleeding rates despite of lower efficacy.

Efficacy and B/R of a BID vs. a QD dosing regimen were further requested by the CHMP during the procedure however lacking data on efficacy for a BID regimen, modelling of B/R of an adapted bid dose were not possible to be provided post hoc.

## 2.5.3.2. ENGAGE AF: Prevention of stroke and SEE in patients with non-valvular atrial fibrillation

ENGAGE AF enrolled male or female subjects ≥21 years of age with documented NVAF (including paroxysmal,  persistent,  or  permanent  AF)  within  the  preceding  12  months  and  in  whom anticoagulation therapy was indicated and planned for the duration of the study.

## · VKA naïve/VKA experienced patients

<div style=\"page-break-after: always\"></div>

Subjects who were receiving or had received prior anticoagulant (e.g.: VKA experienced) and/or antiplatelet  therapies  were  eligible,  as  well  as  subjects  who  were  naive  to  anticoagulant  and/or antiplatelet therapy. In addition, eligible subjects were required to have a CHADS2 index score ≥ 2. VKA experienced was defined as current users as well as former users who took VKA for greater than 2 months. VKA naïve were those subjects who received ≤ 2 months of VKA therapy before study entry. Given that these definitions are not homogeneous across trials in NVAF, current EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events  in  patients  with  non-valvular  atrial  fibrillation  (EMA/CHMP/341363/2014) recommends sensitivity analyses using different definitions of VKA-naïve users in order to be able to compare the studies. Ancillary analyses provided by the applicant using different definitions of VKA experienced patients yielded very similar results to those of the primary analysis.

## · Bio-prosthetic heart valves

Patients  with  a  mechanical  heart  valve  were  excluded  from  ENGAGE  AF,  but  subjects  with bioprosthetic heart valves and/or valve repair could have been included. A total 321 subjects with a history  of bio-prosthetic  heart  valves or  valve  surgery  were  treated  with  study  drug  (either edoxaban or warfarin) in ENGAGE AF with 277 to 286 subject-year follow-up. Rates of stroke/SEE and major bleeding (main outcomes) in this subgroup were similar than in the overall study population. A further  clarification  whether  patients  with  bioprosthetic  heart  valves  were  included  in  the  first  3 months after surgery for valve implantation was requested, as during the first 3 months, the tissue valve is in contact with the blood and cannot be treated like native valve disease. The Applicant was unable to identify the proportion of subjects with a recent history of bioprosthetic heart valve surgery and  a  non-recommendation  of  edoxaban  use  during  the  first  3  months  after  implantation  of  a bio-prosthetic heart valve was included in the SmPC accordingly.

## · Patients CHADS2 score = 1

Patients with CHADS2 index score=1 were excluded from the single pivotal study ENGAGE-AF but were included in the wording of the indication (e.g.: patients with only one of the following risk factors: age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II), the applicant was requested to justify why the extrapolation of the available data from high risk CHADS2 score ≥2 to CHADS2 score =1 could be acceptable. It could not be confirmed nor ruled out that the effect of edoxaban is different from that of warfarin in patients CHADS2 score = 1 using CHA2DS2VASc= 2 as a proxy, due to the limited amount of patients and events in this pos-hoc subgroup. However, compared with no treatment in patients with CHADS2 = 1, edoxaban 60 mg is still projected to reduce the rate of ischemic stroke/SEE by 2.5%/yr at a cost of a 0.7%/yr increase in major bleeding. The benefit in mortality versus no treatment is projected to be &gt; 10%/yr. However, the results were hampered by its exploratory nature and by the combination of data from different studies/sources. The CHMP agreed that anticoagulation with edoxaban may provide additional benefit versus no treatment in patients with CHADS2 =1, and that the extrapolation is acceptable, as it has been accepted for similar compounds. With respect to the optimal dose to be used in this subgroup, considering that the edoxaban 60 mg dose was more effective than the 30 mg dose in preventing ischemic stroke/SEE in ENGAGE and that a significant proportion of patients with CHADS2 =1 has normal renal function and edoxaban exposure is consequently decreased, it seems reasonable to recommend the 60 mg dose over the 30 mg dose in these patients, as in the overall population. The applicant clarified that no further studies are planned with edoxaban to generate clinical data in these patients at lower risk of stroke. This was considered acceptable.

## · Treatment regimes tested in the ENGAGE AF

In ENGAGE-AF, eligible subjects were randomized to edoxaban 30 mg or 60 mg, or warfarin (1:1:1 ratio) using stratified randomization. Within each CHADS2 stratum, subjects were further stratified with respect to factors requiring edoxaban dosage reduction[moderate renal impairment (CrCL ≥ 30

<div style=\"page-break-after: always\"></div>

mL/min and ≤ 50 mL/min as calculated using the Cockroft-Gault formula), low body weight (≤ 60 kg) or  for  subjects  on  specified  concomitant  medications  (verapamil,  quinidine,  dronedarone)]. Treatment regimes tested in the ENGAGE AF study were deemed appropriate . The ENGAGE study used a double-blind design, which is the one recommended by the EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation (EMA/CHMP/341363/2014) .

## · Results of the primary endpoint with the thromboembolic events excluding haemorrhagic strokes

As in other similar trials, the primary efficacy endpoint in ENGAGE-AF was a net clinical endpoint mixing  thromboembolic  events  (ischemic/undefined  stroke,  SEE)  and  haemorrhagic  stroke.  As  a result, there has been double-counting of primary efficacy/safety events (thromboembolism/major bleeding)  regarding  haemorrhagic  stroke  (included  in  both  main  efficacy  and  safety  endpoints). Current EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation (EMA/CHMP/341363/2014 ) stresses  the  importance  of  excluding  haemorrhagic  stroke  from  the  main  efficacy  endpoint.  The applicant  provided  the results  of  the  primary  endpoint  with  the  thromboembolic  events excluding  haemorrhagic  strokes ,  in  line  with  the  above  mentioned  guideline.  The  rates  of ischemic stroke/SEE in the PP population, on-treatment was 0.93%/yr with edoxaban 60 mg and 1.01 %/yr with warfarin (HR: 0.92; 95% CI: 0.73 to 1.15; 97.5%CI: 0.71 to 1.23) thus supporting the non-inferiority  of  edoxaban  60  mg  versus  warfarin  in  the  prevention  of  ischemic  stroke/SEE (excluding  hemorrhagic stroke) at different  CIs.  The  applicant  clarified  that,  in  ENGAGE  AF,  the time-based definition was used to differentiate between ischaemic stroke and TIA. There were few TIA events with abnormal imaging only (25 events: 10 on edoxaban 60 mg and 15 on warfarin) and the analysis of ischemic stroke using time-based definition (excluding TIA with positive neuroimaging as being an ischemic stroke) (HR: 0.99; 95%CI: 0.82-1.18) or using tissue-based definition (sensitivity analysis including TIA with positive neuroimaging) (HR: 0.97; 95%CI: 0.81-1.16) were very similar.

## · Statistical methods applied in the ENGAGE AF study

ENGAGE AF was an event driven trial . A total of at least 448 events were required. Sample size calculation was endorsed by the CHMP. The non-inferiority margin (HR &lt;1.38) was comparable to that used in ARISTOTLE study with apixaban and more strickter than the 1.46 used in the RE-LY and ROCKET-AF studies with dabigatran and rivaroxaban. The time to first stroke/SEE event (primary endpoint) in ENGAGE-AF was analyzed using the Cox proportional hazards model including treatment groups and 2 dichotomized stratification factors as covariates (CHADS2 2-3 versus 4-6; full dose versus  reduced  dose  in  a  given  treatment  group).  The  applicant  focused  its  main  analysis (non-inferiority)  in  a  modified  ITT  population  during  the  'on-treatment  period'.  However,  the applicant also tested non-inferiority in the PP population during the overall study period according to CHMP  recommendations  obtained  during  the  scientific  advice  procedure,  as  well  as  in  the  PP population  'on-treatment',  which  is  in  agreement  with  the  recent EMA  Guideline  on  clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with NVAF (EMA/CHMP/341363/2014) that states that 'the analysis to show non-inferiority should include the primary endpoint events while taking study drug including a period of 3 days after study drug discontinuation (on-treatment analysis). Statistical methods applied in the ENGAGE AF study were considered acceptable.

## · Protocol Amendments

There were 7 amendments with extensive major changes in the protocol of the ENGAGE-AF study. In particular,  amendments 3 and could have implications in the quality of management in warfarin control group and dosing errors. Ancillary analyses of efficacy and safety suggest that implementation

<div style=\"page-break-after: always\"></div>

of Protocol  Amendments 3 and 4 may have led to an improvement in warfarin management. However, for both periods (before and after implementation of protocol amendments), edoxaban was associated with a lower rate of stroke or SEE events compared with warfarin.

## · Non-inferiority of edoxaban 30 mg versus warfarin in sensitivity analysis

Non-inferiority of edoxaban 60 mg was shown in the primary sponsor's analysis of all strokes/SEE (mITT, on-treatment) as well as in the sensitivity analysis for ischemic stroke/SEE according to EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with NVAF (EMA/CHMP/341363/2014) (PP, on-treatment), but superiority was not shown for the previous mentioned endpoints in the ITT population in the overall study period. On the contrary, although the main sponsor's analysis suggested non-inferiority of edoxaban 30 mg versus warfarin  on  all  strokes/SEE,  the  sensitivity  analysis  using  ischemic  stroke/SEE  (as  per  above guideline) showed inferiority of the low edoxaban dose versus warfarin .

## · Study drug interruptions

The percentage of subjects with 1 or more study drug interruptions (&gt; 3 consecutive days during which the subject did not take study drug) was 62.5%, 61.8%, and 65.5%, respectively, among the edoxaban 60 mg, edoxaban 30 mg, and the warfarin treatment groups. Thromboembolic events occurring during temporary interruptions (starting Day 4 of each interruption period to resumption of study drug after each interruption) were not included in the 'on-treatment analysis' of non-inferiority, but  off-treatment  events  on  the  first  3  days  study  drug  interruption  were  included  in  the \"on-treatment analysis\". Theoretically, temporary interruptions are more dangerous for edoxaban than for warfarin, due to its shorter half-life. There were 117 stroke/SEE events on edoxaban 60 mg and  112  stroke/SEE  events  on  warfarin  during  temporary  interruptions  (starting  Day  4  of  each interruption period to resumption of study drug after each interruption). However, when corrected by exposure, the yearly event rate was quite similar (edoxaban 3.06 %/yr vs. warfarin 3.04 %/yr). All-cause, cardiovascular mortality events, hemorrhagic strokes and intracranial bleed events were lower  in  the  edoxaban  60-mg  group  compared  with  the  warfarin  group  during  temporary interruptions.  Considering  various  reasons  and  circumstances  for  study  drug  interruptions  and varying duration and nature of 'off-study drug' antithrombotic therapies that may have been used by the investigators during interruptions, these data may need to be interpreted with caution.

## · Adjudicated events after study drug discontinuation in ENGAGE AF

After the end of study , the percentage of subjects with adjudicated events within 3 days was low and similar in the three treatment groups (0.2%). From day 4 to 30 after end of study, the percentage of patients with stroke was 1.3%, 1.8% and 1.4% in the edoxaban 60 mg OD, edoxaban 30 mg OD and warfarin, respectively. These data indicate that the management of oral anticoagulation after study drug discontinuation in ENGAGE AF was appropriate.

## · Consistency of the analyses for 60mg OD

Analyses of composite (first-event) endpoint of stroke, SEE, and CV mortality, the endpoint of MACE, and the composite endpoint of stroke, SEE, and all-cause mortality were generally consistent with the  analysis  of  the  main  endpoint  of  all  strokes/SEE . The trend for superiority of the high edoxaban dose ( 60 mg OD ) versus warfarin for the primary endpoint was supported by secondary analyses of patients with fatal strokes (80 vs. 86), disabling strokes (54 vs. 57), recurrent stroke/SEE events (5 vs. 8; mITT analysis set on-treatment period) and analysis of the composite of stroke, SEE and TIA (edoxaban 60 mg 1.69% per year vs. warfarin 1.92% per year; HR: 0.88; 95%CI: 0.746 to 1.042; mITT on-treatment period; main sponsor's analysis).

## · Efficacy of 30mg OD strength

<div style=\"page-break-after: always\"></div>

On the contrary, the edoxaban 30 mg dose showed a trend for inferiority versus warfarin in the analysis of pure thromboembolic events (ischemic stroke/SEE as well as in MI). The trend for inferior efficacy of edoxaban 30 mg OD versus warfarin was also supported by the higher number of disabling strokes (82 and 57 subjects in edoxaban 30 mg group and the warfarin group, respectively), in the number of patients with who had ≥ 2 occurrences of the primary efficacy endpoint (21 and 8 subjects in  edoxaban 30 mg group and the warfarin group, respectively; mITT analysis set on-treatment period) as well as by the high number of events when TIA was added to stroke and SEE (edoxaban 30 mg event rate 2.28% per year vs warfarin 1.92% per year; HR: 1.19; 95%CI: 1.021 to 1.389; mITT on-treatment period; primary sponsor's analysis). However, there was  a trend for superiority of edoxaban 30 mg versus warfarin in the reduction of haemorrhagic stroke and CV mortality (mainly due to the reduction in fatal bleedings), which might be of interest in patients at high risk of bleeding. In post hoc analyses submitted together with D121 responses in subjects with high risk of bleeding, the edoxaban 30-mg regimen (30 mg with reduction to 15 mg) did not reduce ischemic events with HR more than 1.0 compared with warfarin. Based on the data on ischemic strokes/SEE, it was difficult to justify edoxaban 30-mg regimen (with the exception of those patients with increased exposure where 30mg OD dose is recommended: (1) moderate renal impairment and/or (2) low body weight ≤ 60 kg and/or (3) concomitant use with some P-gp inhibitors) for patients with high risk of bleeding. The analysis by HAS-BLED score did not identify a group who would benefit from the lower dose of 30 mg. Therefore, ancillary analyses did not support the use of the edoxaban 30 mg dose, even in patients at high risk of bleeding.

## · Number of strokes and undefined strokes

There was an apparent discrepancy in numbers of primary endpoint events across tables, which was  due  to  the inclusion  of  either  first  events  or  all  events .  The  primary  endpoint  in  the ENGAGE-AF study was time to first stroke/SEE. A total of 292 primary endpoint events were recorded for the edoxaban 60-mg group (made up of 278 strokes and 14 SEE) and 336 primary endpoint events were recorded for the warfarin group (made up of 315 strokes and 21 SEEs) (mITT population, overall study period). However, 18 subjects in the edoxaban 60-mg group and 29 in the warfarin group experienced ≥ 2 adjudicated strokes. Thus more events were counted in the components of the primary endpoint analysis than in the primary analysis where only the first event was counted for a subject.  Regarding  confirmation  of  primary  events,  for  all  events  adjudicated  as  strokes  (either primary ischemic or primary hemorrhagic stroke), the images were available. All primary stroke (efficacy  or  hemorrhagic)  events were adjudicated based on the clinical description of the event accompanied  with  neuroimaging  studies.  However,  there  were  also  \"undefined  strokes\"  during ENGAGE-AF,  but  these  were  excluded  from  the  analysis,  mainly  for  not  having  confirmatory neuroimaging tests available. Numerically, there were more unconfirmed events with edoxaban than with warfarin (113 vs 104). Combining these events to those included in the study reported primary endpoint  as  sensitivity  analysis  yields  to  324  events  in  the  edoxaban  group  (event  rate  of 1.72%/year) vs. 372 (event rate of 2.00%/year) in the warfarin group with a hazard ratio of 0.86 (0.74,  1.00),  thus  still  favouring  edoxaban  60  mg  versus  warfarin.  Therefore,  the  inclusion  of unconfirmed non-adjudicated events did not change the primary study results indicating non-inferiority of edoxaban 60 mg versus warfarin.

## · Adjudicated versus investigator-reported events

With respect to adjudicated versus investigator-reported events , the number of Clinical Events Committee (CEC) adjudicated strokes (ischemic or hemorrhagic) was lower than the investigator reported primary events. However, in both cases, the events were lower with edoxaban than with warfarin  (adjudicated:  edoxaban  278.  vs  warfarin  316;  investigator-reported:  edoxaban  288  vs warfarin 329). Of interest, the CEC adjudicated a slightly lower number of ischemic strokes with edoxaban than the investigators (233 vs 235), but a higher number of ischemic strokes with warfarin than the investigator (234 vs 220). The main reason for the discrepancy seems a combination of

<div style=\"page-break-after: always\"></div>

chance and a lower number of TIAs that were upgraded to ischemic strokes by the CEC in the edoxaban group than in the warfarin group (13 vs 21). This small imbalance in the adjudication of TIA was considered by the CHMP unlikely to alter the conclusion of non-inferiority of edoxaban versus warfarin. In addition, investigators reported more SEE than the adjudicating committee, because they reported DVT and PE in addition to the arterial embolic events on the SEE form, but in both cases there were less SEE with edoxaban than with warfarin. If primary ischemic stroke and SEE as reported by the investigators are combined, the numbers are similar in both groups: edoxaban 305 (235+70) vs. warfarin 301 (220+81). Therefore, when counting all strokes, or the sum of ischemic stroke + SEE, there are no major discrepancies between investigator-reported and adjudicated primary endpoint events.

## Exploratory analyses of subgroups in ENGAGE-AF

Exploratory analyses of subgroups in ENGAGE-AF were conducted by INR/TTR level by centre and quartiles as well as by at least 14 patient/study characteristics. Efficacy data in subgroups were difficult  to  be  interpreted due to the inclusion of haemorrhagic stroke in the analyses. Subgroup analyses of stroke/SEE by INR/TTR level suggest that the effect size (reduction of stroke/SEE by edoxaban) decreases as the quality of anticoagulation in the control group increases (i.e.: in centers with TTR &gt; 60% and when INR/TTR is above the fourth quartile, &gt;73.9%). When the TTR data are examined by quartiles for the edoxaban 60 mg group compared to warfarin, the HR for the primary endpoint in the 1st, 2nd, and 3rd quartile was 0.80, 0.73, and 0.74, respectively, and for the 4th quartile was 1.07 (95%CI: 0.65-1.75). For the edoxaban 30 mg group compared to warfarin, the HR  for  1st,  2nd,  3rd,  and  4th  quartiles  were  0.82,  1.02,  1.22,  and  1.30  (95%CI:  0.81-2.09), respectively.  These  data  are  within  expected  on  the  light  of  previous  studies  with  novel  oral anticoagulants in NVAF.

Subgroup  analyses  by  patient/study  characteristics  showed  a  generally consistent  effect  of edoxaban  in  most  subgroups,  with  the  exception  of  subgroups  by  renal  function and geographic region (for both edoxaban doses versus warfarin). The HR for the edoxaban 60 mg group compared with the warfarin group for Western Europe was 1.47 (95%CI: 0.89-2.45; mITT, on-treatment) and for the subgroup with CrCL ≥ 80 mL/min was 1.41 (95%CI: 0.97-2.06).

## · Results by geographical region in the ENGAGE-AF study

The main primary endpoint results in ENGAGE-AF study seem to be driven by an increased stroke/SEE rate with warfarin in Asia/Pacific/South Africa and Latin America (2.33% and 2.60%, respectively), which contrasts with the 1.13% yearly rate of stroke/SEE found in Western Europe. In general, subgroup analyses of ENGAGE-AF for INR level and geographic region were consistent with a recent meta-analysis  of  subgroups  of  RE-LY  (dabigatran  vs.  warfarin),  ROCKET-AF  (rivaroxaban  vs. warfarin) and ARISTOTLE (apixaban vs. warfarin) ( Gómez-Outes et al. Thrombosis. 2013; 640723 ). In all these studies, the good results of the new anticoagulants were mainly at expenses of increased stroke/SEE rates with warfarin in Asia and Latin America. However, the  interaction  by  region seems  more  pronounced  in  the  ENGAGE-AF  study than  in  the  other  studies.  Although  the interpretation of the results in Western Europe is hampered by the limitations of subgroup analyses and the low event rates, additional information provided by the Applicant suggest that the cause of the poorer results of edoxaban in Western Europe than in other regions could be multifactorial, due to a combination of increased ischemic stroke/SEE rates in the edoxaban arms (a result of decreased exposure due to good renal function and increased body weight in many Western Europe patients in comparison  with  other  regions),  and  a  low  rate  of  ischemic/hemorrhagic  stroke  and  SEE  in  the warfarin arm, due to a good quality of oral anticoagulation in Western Europe centres in comparison with other regions. Nevertheless, it should be taken into account that ENGAGE AF demonstrated non-inferiority of edoxaban 60 mg versus a well-controlled warfarin regime in the overall population.

<div style=\"page-break-after: always\"></div>

All-cause and CVS mortalities were broadly similar in the overall vs. on-treatment analysis in both the edoxaban and warfarin groups in Western Europe, with point estimates of HR close to 1. Therefore, no safety signal was apparent in Western Europe. In addition, when the analysis was made in the region of the EEA + Switzerland, the results on ischemic stroke/SEE were broadly similar in the edoxaban and warfarin groups (HR 0.94 and 0.99 point estimates in the overall study period and on-treatment analyses, respectively). In summary, although the hazard ratios for the on-treatment and overall periods may show some variability, given in excess of 100 combinations of regions and endpoints this minor level of inconsistency in ischemic stroke/SEE is considered to be due to a combination of chance due to the extreme multiplicity of testing and probably due to a trend towards a better control of warfarin treatment in Western Europe and North-America than in other regions. The overal study results are deemed representative for the EEA.

## · Poorer results of edoxaban in the group of normal renal function

In addition, the poorer results  of  edoxaban  in  the  group  of  normal  renal  function versus impaired renal function for the primary endpoint is a novel finding. Sub -group analysis of ENGAGE-AF identified the increase in renal function as a significant predictor for increase in risk of stroke/SEE with edoxaban 60 mg versus warfarin (interaction p = 0.0002) and edoxaban 30 mg versus warfarin (interaction p = 0.0077). Patients with normal renal function (CrCl ≥ 80 mL/min) in the edoxaban 60 mg tended to have a higher risk of stroke/SEE than warfarin-treated patients (HR: 1.41, 95% CI: 0.97 -2.06). The interpretation of that finding is hampered by the exploratory nature of subgroup analyses and the relatively low number of events and patients with normal renal function. Comparing the  within-treatment  groups,  there  was  no  indication  that  a  better  creatinine  clearance  was associated with a higher rate of events with edoxaban, as the events rates of stroke/SEE, CV mortality and MACE were lower in the normal renal function patients than in patients with impaired renal function  in  both  treatment  groups.  In  the  edoxaban  group,  stroke/SEE  rates  were  1.26%/yr  in patients  with  normal  renal  function,  lower  than  the  1.49%/yr  stroke/SEE  rate  in  mild  renal insufficiency  and  2.29%/yr  in  patients  with  moderate  renal  insufficiency  (see  Table  1  below). However, the lower event rates in patients with normal renal function could also be due to differences in demographic characteristics as patients with normal renal function tend to be younger and with a lower thrombotic risk as shown by lower CHADS2 scores than patients with renal impairment.The finding may also be due, at least in part, to a surprisingly low event rate with warfarin in patients with normal  renal  function,  with  strokes  rates  of  less  than  1%/yr,  while  in  contemporary  AF  trials (ARISTOTLE, RELY, ROCKET-AF), the rate of stroke/SEE in patients with normal renal function was always above 1%/yr (1.05%/yr to 1.42%/yr). This finding could be related to the fact that the quality of anticoagulation with warfarin in ENGAGE was best compared to other contemporary AF trials.

<div style=\"page-break-after: always\"></div>

Table 1: Key Efficacy Endpoints by CrCL Category for Edoxaban 60 mg vsWarfarininENGAGEAF,mITTOverallStudyPeriod

| CrCLsubgroup (mL/min)   | Edoxaban 60 mg (N = 7012)   | Edoxaban 60 mg (N = 7012)   | Edoxaban 60 mg (N = 7012)   | Warfarin (N = 7012)   | Warfarin (N = 7012)   | Warfarin (N = 7012)   | Edoxaban 60mg Vs Warfarin   |
|-------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------|-----------------------|-----------------------|-----------------------------|
| CrCLsubgroup (mL/min)   | M                           |                             | [] 1/%                      | M                     |                       | [四] .11/%             | HR (95% C1)                 |
| Stroke/SEE              |                             |                             |                             |                       |                       |                       |                             |
| CrCL ≥30 to ≤50         | 1302                        | 76                          | 2.29                        | 1305                  | 87                    | 2.68                  | 0.86 (0.632, 1.169)         |
| CrCL >50 to <80         | 3007                        | 121                         | 1.49                        | 3048                  | 176                   | 2.18                  | 0.68 (0.538,0.854)          |
| CrCL ≥ 80               | 2633                        | 91                          | 1.26                        | 2608                  | 70                    | 0.97                  | 1.31 (0.958, 1.787)         |
| IschemicStroke/SEE      | IschemicStroke/SEE          |                             |                             |                       |                       |                       |                             |
| CrCL≥30to≤50            | 1302                        | 63                          | 1.89                        | 1305                  | 67                    | 2.05                  | 0.93 (0.660, 1.314)         |
| CrCL>50to<80            | 3007                        | 105                         | 1.29                        | 3048                  | 129                   | 1.59                  | 0.80 (0.622,1.041)          |
| CrCL ≥ 80               | 2633                        | 76                          | 1.05                        | 2608                  | 55                    | 0.76                  | 1.39 (0.983,1.968)          |
| IschemicStroke          |                             |                             |                             |                       |                       |                       |                             |
| CrCL ≥30 to ≤50         | 1302                        | 58                          | 1.74                        | 1305                  | 59                    | 1.81                  | 0.97 (0.677, 1.398)         |
| CrCL>50to<80            | 3007                        | 99                          | 1.22                        | 3048                  | 121                   | 1.49                  | 0.81 (0.620, 1.055)         |
| CrCL ≥ 80               | 2633                        | 73                          | 1.01                        | 2608                  | 52                    | 0.72                  | 1.41 (0.990, 2.018)         |
| HemorrhagicStroke       | HemorrhagicStroke           |                             |                             |                       |                       |                       |                             |
| CrCL≥30 to≤50           | 1302                        | 13                          | 0.38                        | 1305                  | 23                    | 0.70                  | 0.54 (0.276, 1.071)         |
| CrCL>50 to <80          | 3007                        | 19                          | 0.23                        | 3048                  | 51                    | 0.62                  | 0.37 (0.220,0.631)          |
| CrCL ≥ 80               | 2633                        | 16                          | 0.22                        | 2608                  | 16                    | 0.22                  | 1.00 (0.501,2.008)          |
| MyocardialInfarction    | MyocardialInfarction        |                             |                             |                       |                       |                       |                             |
| CrCL ≥30 to ≤ 50        | 1302                        | 32                          | 0.95                        | 1305                  | 34                    | 1.03                  | 0.92 (0.567,1.494)          |
| CrCL>50to<80            | 3007                        | 63                          | 0.77                        | 3048                  | 63                    | 0.77                  | 1.00 (0.707, 1.422)         |
| CrCL ≥ 80               | 2633                        | 35                          | 0.48                        | 2608                  | 40                    | 0.55                  | 0.88 (0.557,1.381)          |
| CV Mortality            | CV Mortality                | CV Mortality                | CV Mortality                |                       |                       |                       |                             |
| CrCL ≥30 to ≤50         | 1302                        | 165                         | 4.79                        | 1305                  | 204                   | 6.02                  | 0.80 (0.654, 0.985)         |
| CrCL >50 to <80         | 3007                        | 193                         | 2.32                        | 3048                  | 259                   | 3.10                  | 0.75 (0.620,0.900)          |
| CrCL ≥ 80               | 2633                        | 155                         | 2.10                        | 2608                  | 134                   | 1.82                  | 1.16 (0.920, 1.462)         |
| MACE                    | MACE                        | MACE                        | MACE                        | MACE                  | MACE                  | MACE                  | MACE                        |
| CrCL≥30 to≤50           | 1302                        | 239                         | 7.23                        | 1305                  | 273                   | 8.42                  | 0.86 (0.727,1.028)          |
| CrCL>50to<80            | 3007                        | 317                         | 3.93                        | 3048                  | 427                   | 5.32                  | 0.73 (0.635,0.849)          |
| CrCL ≥ 80               | 2633                        | 247                         | 3.44                        | 2608                  | 210                   | 2.93                  | 1.18 (0.982,1.419)          |

Note:TheHR and two-sided CIforpairwise comparisons versus warfarin arebased on the Cox

[a]: The event rate (% per yr) is calculated as number of events/subject-year exposure.

proportional hazard model including treatment and the two stratification factors as covariates: dichotomizedCHADS2score anddichotomizeddoseadjustmentfactor.

Source:TableR55-007

Table 7: KeySafetyEndpointsbyCrCLEdoxaban60mgvsIWarfarinin ENGAGEAF,SafetyAnalysisSet

| CrCL(mL/min)         | Edoxaban 60 mg (N=7012)   | Edoxaban 60 mg (N=7012)   | Edoxaban 60 mg (N=7012)   | Warfarin (N =7012)   | Warfarin (N =7012)   | Warfarin (N =7012)   | Edoxaban 60 mg vs Warfarin   |
|----------------------|---------------------------|---------------------------|---------------------------|----------------------|----------------------|----------------------|------------------------------|
| CrCL(mL/min)         | M                         | n                         | %/yr [a]                  | M                    | n                    | %/yr [a]             | HR (95% CI)                  |
| On-TreatmentPeriod   | On-TreatmentPeriod        | On-TreatmentPeriod        | On-TreatmentPeriod        | On-TreatmentPeriod   | On-TreatmentPeriod   | On-TreatmentPeriod   | On-TreatmentPeriod           |
| Major Bleed          |                           |                           |                           |                      |                      |                      |                              |
| CrCL ≥30 to ≤ 50     | 1302                      | 96                        | 3.91                      | 1305                 | 128                  | 5.23                 | 0.75 (0.575, 0.975)          |
| CrCL>50to<80         | 3007                      | 209                       | 3.20                      | 3048                 | 237                  | 3.55                 | 0.90 (0.747,1.084)           |
| CrCL≥80              | 2633                      | 109                       | 1.77                      | 2608                 | 154                  | 2.52                 | 0.71 (0.552,0.903)           |
| Major or CRNMI Bleed | Major or CRNMI Bleed      | Major or CRNMI Bleed      | Major or CRNMI Bleed      | Major or CRNMI Bleed | Major or CRNMI Bleed | Major or CRNMI Bleed | Major or CRNMI Bleed         |
| CrCL≥30to≤50         | 1302                      | 304                       | 13.74                     | 1305                 | 404                  | 19.18                | 0.72 (0.625,0.841)           |
| CrCL >50 to <80      | 3007                      | 725                       | 12.40                     | 3048                 | 802                  | 13.71                | 0.91 (0.820, 1.004)          |
| CrCL ≥80             | 2633                      | 490                       | 8.68                      | 2608                 | 547                  | 9.91                 | 0.88 (0.779, 0.995)          |
| Overall StudyPeriod  | Overall StudyPeriod       | Overall StudyPeriod       | Overall StudyPeriod       | Overall StudyPeriod  | Overall StudyPeriod  | Overall StudyPeriod  | Overall StudyPeriod          |
| Fatal Bleed          |                           |                           |                           |                      |                      |                      |                              |
| CrCL ≥30 to ≤50      | 1302                      | 10                        | 0.30                      | 1305                 | 29                   | 0.87                 | 0.34 (0.166, 0.704)          |
| CrCL >50 to <80      | 3007                      | 21                        | 0.25                      | 3048                 | 40                   | 0.48                 | 0.53 (0.310,0.891)           |
| CrCL ≥ 80            | 2633                      | 17                        | 0.23                      | 2608                 | 19                   | 0.26                 | 0.90 (0.466, 1.722)          |
| All-Cause Mortality  | All-Cause Mortality       | All-Cause Mortality       | All-Cause Mortality       | All-Cause Mortality  | All-Cause Mortality  | All-Cause Mortality  | All-Cause Mortality          |
| CrCL ≥30 to ≤ 50     | 1302                      | 229                       | 6.64                      | 1305                 | 280                  | 8.27                 | 0.81 (0.683, 0.968)          |
| CrCL>50to<80         | 3007                      | 306                       | 3.68                      | 3048                 | 352                  | 4.21                 | 0.87 (0.748,1.017)           |
| CrCL ≥80             | 2633                      | 215                       | 2.92                      | 2608                 | 187                  | 2.55                 | 1.15 (0.948, 1.404)          |

Note:TheHRand two-sidedCIforpairwisecomparisonsversuswarfarinarebased ontheCox

[a]: The event rate (% per yr) is calculated as number of events/subject-year exposure.

proportional hazard model including treatment and twostratification factors as covariates:

dichotomizedCHADS2score andthedichotomizeddoseadjustmentfactor.

Source:TableR55-008,TableR55-009,TableR55-010

<div style=\"page-break-after: always\"></div>

The CHMP agreed that in NVAF, although the overall benefit risk in the AF indication is considered positive  across  the  continuum  of  renal  function  at  the  population  level,  there  are  indications  of reduced efficacy of edoxaban compared to well-managed warfarin therapy that could be of relevance at the individual level in patients with increased creatinine clearance. The data in patients with normal renal function appear to be sufficiently robust, making a chance adverse finding unlikely. They may be explained by a combination of a lower exposure to edoxaban 60 mg in patients with normal renal function (in comparison with the exposure to 60 mg in patients with mild renal impairment) and a well-managed warfarin therapy resulting in a low stroke/SEE rate in the control group, particularly in patients  with  high  creatinine  clearances. In  this  respect,  a  warning  has  been  included  in section  4.4  of  the  SmPC that  a trend  towards  decreasing  efficacy  with  increasing creatinine  clearance  was  observed  for  edoxaban  compared  to  well-managed  warfarin. Therefore,  edoxaban  should  only  be  used  in  patients  with  NVAF  and  high  creatinine clearance after a careful evaluation of the individual thromboembolic and bleeding risk. In addition, a warning was also included in the SmPC that CrCL should be monitored at the beginning of the treatment in all patients and afterwards when clinically indicated. The applicant  has  also  been  committed  to  further  evaluate  post-marketing  whether  a  higher  QD  dose would provide a further improvement of the benefit-risk relationship in patients with high creatinine clearance

## · Monitoring of anti-Xa activity

Monitoring  of  anti-Xa  activity  may  be  helpful  to  individualise  the  treatment  and  dose  in  certain circumstances  (e.g.:  at  the  beginning  of  the  treatment  in  patients  with  cumulative  risk  factors  for decreased  exposure,  such  as  high  renal  clearance  combined  with  high  body  weight  or  in  case  of emergency or overdose). The Applicant has submitted a plan for developing a validated anti-Xa test to measure edoxaban's anticoagulant activity.

<div style=\"page-break-after: always\"></div>

## · Additional subgroups analyses

During the procedure, the Applicant was requested to show the analyses of subgroups of efficacy in ENGAGE-AF by subgroups excluding haemorrhagic stroke (i.e.: including only ischemic stroke and SEE). The event rate for composite of ischemic stroke and SEE was lower in the edoxaban 60-mg group than in the warfarin group for most subgroups, with the HR less than 1.0 for the overall study period, but in some of the sub-groups the HR was more than 1.0. However, there were several significant (p&lt;0.05) interactions:

(1) for the type of atrial fibrillation: The HR was 0.79 and 0.85 for subjects with persistent and permanent AFs and 1.73 for subjects with paroxysmal AF . However, this finding was based on a relatively low number of events and patients in this subgroup. The variations in stroke/SEE rates in the warfarin group was the main responsible for the interaction (1.23%/yr in paroxysmal AF versus 2%/yr for other types of AF). This also holds true for contemporary AF studies, in which stroke/SEE with warfarin was lower in patients with paroxysmal AF than in those with permanent/persistent AF. No safety signal was apparent in this subgroup, and CV mortality numerically favoureds edoxaban. In the subgroups by type of AF there was no question of differences in exposure as the renal function of each subgroup was essentially the same. The interaction by type of AF is probably multifactorial, more related to variations in stroke/SEE rates with warfarin (unexpectedly low stroke/SEE rates in some subgroups) than corresponding variations with edoxaban, in line with the interactions reported by treatment region and by renal function.

(2)  for  the  VKA-naïve  versus  VKA  experienced  subjects :  The  HR  was 0.75 for  VKA naïve subjects and 1.17 for VKA experienced subjects. VKA-experienced patients comprise the majority of patients enrolled in ENGAGE-AF (59%) and suggest that switching from warfarin to edoxaban was not associated woth a benefit in efficacy. Considering the primary endpoint of stroke/SEE, a significant interaction was found for the overall study period for prior VKA use (p=0.0253) but this was not observed for the on-treatment period (p=0.3545). The most important patient characteristics of the VKA-experienced subjects was the increased TTR which at 70% is very high in the ENGAGE AF study. None-the-less for the primary endpoint of stroke/SEE, edoxaban 60 mg did show similar efficacy and even for ischemic stroke, any gap in efficacy was less than 0.5%/year and is offset by a clinically significant decrease in major bleeds, and demonstrating similar net clinical outcome and all-cause mortality. Therefore, edoxaban 60 mg showed a positive benefit-risk balance in absolute terms and a similar benefit-risk balance to VKA with very good TTR control, which was the rule in VKA-experienced patients and is not expected to be the rule in many EU countries in standard practice (a poorer INR is expected), with some exceptions in specific centers and/or countries. Therefore, the CHMP was of the opinion that there is no need to include the information about this finding in the label, especially given its  similar  performance  to  other  direct  oral  anticoagulants  (DOACs)  when  the  differences  in background risk and TTR are taken into account;

(3) for the verapamil subgroup: The HR was 0.92 for subjects without concomitant verapamil and 2.59  for  subjects  who  took  concomitant  verapamil.  Verapamil  use  was  very  low  (&lt;5%  of  total population)  and  number  of  events  were  low  (18  vs.  7).  Notwithstanding,  it  suggests  that  the edoxaban 30 mg dose used in these patients was insufficient. Consequently, the applicant proposed not to reduce the edoxaban 60 mg to 30 mg when edoxaban is coadministered with verapamil or quinidine, which was endorsed.

Other issues that were discussed during the procedure regarding the ENGAGE AF study are following:

a)  There  were  728  subjects  for  whom  treatment  allocation  was  unblinded  because  of  SUSARs. Ancillary analysis indicated that there is no indication that unblinding of the data to the independent Data Analysis Group and the Data Monitoring Committee had an impact on the overall study results;

<div style=\"page-break-after: always\"></div>

b) Dose adjustment rules for patients ≤ 60 kg came into place in Protocol Amendment 7. However, none of the 66 patients randomized before amendment 7 had a body weight ≤60 kg, and therefore none of them received the unadjusted 60 mg edoxaban dose;

c) Ancillary analyses suggested that for those patients with the best quartile for center based results for INR numerically efficacy was slightly better for warfarin than for edoxaban 60 mg (ischaemic stroke, SEE, myocardial infarction). For haemorrhagic strokes, CV mortality, 'net clinical outcome', MACE and all cause mortality numerically the effects were still in favour of Edoxaban 60 mg. For major bleeds, major bleeds, CRNM bleeds and fatal bleeds the results were inconsistent. Taken the data together the CHMP agreed that edoxaban performs better, when compared to a suboptimal therapy with warfarin;

d) All cause mortality and CV mortality rates were numerically lower with the 30 mg regimen as compared to the 60 mg treatment. Therefore, the CHMP agrees that where the risk of bleeding events outweighs the risk of ischaemic strokes and SEEs the 30 mg QD dose might be an option. This could be the case for patients with a low CHADS2 score and/or patients with contraindications for VKA therapy. However, no data comparing low dose edoxaban e.g. with aspirin or aspirin/clopidogrel are available for patients with contraindications for VKA therapy and the issue could not be answered within this procedure;

e) Overall, the number of strokes, SEE and particular disabling strokes was higher in the 30 mg QD group as compared to warfarin, but the number of fatal strokes was lower. Haemorrhagic strokes are more likely to be fatal than ischaemic strokes. In the edoxaban 60 mg group more haemorrhagic strokes occurred and haemorrhagic strokes were even more likely to be fatal than in the edoxaban 30 mg group. The net effect was a lower rate of disabling strokes (53 vs. 81) in the 60 mg group at the expense of a higher rate of fatal strokes (79 vs. 73). In about 7000 patients 81 additional strokes, of these 28 disabling strokes, could be prevented at the cost of 6 additional fatal strokes with the 60 mg compared to the 30 mg dose;

f) The event rate in the edoxaban group decreased with increasing TTR INR. The Applicant provided a potential explanation to this observation. On one hand, a better center specific INR control for warfarin may indicate a better overall level of care that is per se associated with a lower event rate in the  edoxaban  group.  Such  factors  may  contribute  to  the  association  between  outcome  in  the edoxaban  group  and  control  of  INR  values  in  the  warfarin  group.  In  addition,  center  specific characteristics of patients included influenced INR control on one hand and the outcome on the other hand. e.g. center specific previous VKA use and region were highly correlated with INR control and may be relevant for the outcome.

g) For edoxaban 60 mg group, non-inferiority vs. warfarin can be assumed at least for those patients with TTR INR up to about 74%. However, for the highest quartile, the point estimate of the HR was in favour of warfarin (1.07; 95%CI: 0.65, 1.75). The data support the impression that non-inferiority of efficacy of edoxaban 60 mg vs. warfarin is questionable for those centers with optimal warfarin INR control. Ischaemic strokes, ischaemic strokes or SEE and all strokes + SEE were numerically in favour of warfarin in the highest quartile group. For bleeding events, MACE, MI and 'net clinical outcome' the event rates were largely similar and the rate of haemorrhagic strokes and CV deaths were numerically in favour of edoxaban. INR control may relate to two factors: I) general level of medical support and II) patient characteristics that may not be changeable. Albeit the primary statistical analysis was not based  on  quartiles  of  INR  control,  for  individual  treatment  decisions  it  was  agreed  to  briefly summarize the key data per quartile in the SmPC to provide reassurance to the physician that no benefit can be expected by switching a well controlled patient on warfarin to edoxaban.

<div style=\"page-break-after: always\"></div>

## 2.5.3.3. HOKUSAI VTE: Treatment of VTE including DVT and PE, and prevention of recurrent VTE

The efficacy and safety of edoxaban in reducing the risk of symptomatic recurrent VTE in subjects with documented acute symptomatic DVT and/or PE is primarily based upon the large Phase 3 Hokusai VTE study in which 4118 subjects were treated with edoxaban 60 mg (30 mg reduced) and 4122 with warfarin  for  3-12  months  (all  patients  received  heparin-based  initial  treatment  for  5-12  days). Hokusai VTE was Phase 3, multinational, multicenter, randomized, double-blind, matching placebo, parallel-group, non-inferiority study to evaluate the benefits and risks of edoxaban in reducing the risk of symptomatic recurrent VTE in subjects with documented acute symptomatic DVT and/or PE. At least 40% of subjects had to present with PE.

## · Dosing in the experimental group in HOKUSAI-VTE

HOKUSAI-VTE enrolled male or female adult subjects with symptomatic DVT and/or PE documented by objective methods. In HOKUSAI-VTE, eligible subjects were randomized to (LMW) heparin/edoxaban or (LMW) heparin/warfarin using stratified randomization. All patients received initial therapy with open-label enoxaparin or unfractionated heparin for at least 5 days. Edoxaban or warfarin was administered in a double-blind, double-dummy fashion. Edoxaban (or placebo) was started after discontinuation of initial heparin. Edoxaban was administered at a dose of 60 mg orally once daily, taken with or without food, or at a dose of 30 mg once daily in patients with a creatinine clearance of 30 to 50 ml per minute or a body weight of 60 kg or less or in patients who were receiving concomitant  treatment  with  potent  P-glycoprotein  inhibitors.  Dosing  in  the  experimental  group (heparin lead-in followed by edoxaban) was similar to the dosing selected for dabigatran trials in acute VTE (RE-COVER I and II), but different from the single drug approach (no need for heparin lead-in, using higher doses of the new anticoagulant during the first weeks and followed by a lower maintenance dose) used in rivaroxaban trials (EINSTEIN DVT and PE) and apixaban pivotal trial in acute VTE (AMPLIFY). This was considered to be an important difference in dosing between edoxaban and the other Factor Xa inhibitors. Consequently, a statement was included in section 4.2 of the SmPC that Lixiana is to be started following initial use of a parenteral anticoagulant for at least 5 days.

## · Treatment duration in HOKUSAI-VTE

Study duration was left to the investigator. Although it was endorsed that this approach may mimic standard practice, it would be preferable to plan for a second randomisation, or a second study in patients having received anticoagulation after 3-6 months, in order to generate randomised clinical data  versus  placebo  or  active  comparator  in  the  setting  of  extended  treatment  of  VTE  (i.e.:  as conducted in the EINSTEIN-ext with rivaroxaban, RE-MEDY and RE-SONATE study with dabigatran or the  AMPLIFY-ext  study  with  apixaban).  However,  the  design  and  analysis  (mITT  Overall  versus On-Treatment)  of  the  study  allowed  for  assessment  of  the  extension  of  therapy/the  secondary prevention of VTE without the need for a formal 'extension' study. Furthermore this 'extension' study within Hokusai was performed with an active comparator-warfarin rather than placebo allowing a more robust comparison as to the real world risk benefit if continued therapy. As such the indication for  both  the  active  treatment  of  acute  VTE  and  secondary  prevention  of  recurrent  VTE  were demonstrated with the Hokusai VTE study with up to 12 months of therapy. Therefore, it is agreed that  a  separate  \"extension\"  study  is  not  warranted.  The  Kaplan-Meier  curves  of  recurrent  VTE provided further support that continued exposure, remaining on therapy (on treatment versus overall population) is associated with decreased recurrence and both analyses (on treatment and overall population)  favored  edoxaban  versus  warfarin.  The  main  issue  during  HOKUSAI-VTE  regarding duration of therapy, looking at post-treatment recurrences, is that it seems that many patients would have benefited from longer treatment durations of anticoagulation. Furthermore, the Kaplan-Meier curves  are  linear  data  and  there  is  long-term  safety  data  from  ENGAGE  AF.  Due  to  the  above

<div style=\"page-break-after: always\"></div>

mentioned reasons, it was agreed not to limit the duration of treatment of VTE to 1 year tested with edoxaban in HOKUSAI-VTE.

Optimal treatment duration with edoxaban after acute VTE is unclear. According to clinical practice guidelines, the duration of therapy for treatment of VTE including DVT and PE, and prevention of recurrent VTE should be individualised after careful assessment of the treatment benefit against the risk for bleeding. Short duration of therapy (at least 3 months) should be based on transient risk factors  (e.g.  recent  surgery,  trauma,  immobilisation)  and  longer  durations  should  be  based  on permanent risk factors or idiopathic DVT or PE. This information was included in the SmPC.

The HOKUSAI-VTE study used a double-blind design, which is in line of the one used in the recent RE-COVER  studies  with  dabigatran  and  AMPLIFY  study  with  apixaban  (EINSTEIN  studies  with rivaroxaban followed an open-label design). HOKUSAI-VTE study was stratified by: (1) diagnosis at presentation (PE and DVT only), (2) baseline risk factors (temporary risk factors vs. all others), and (3)  need  for  edoxaban  dose  reduction  to  30  mg  (yes,  no).  The  primary  efficacy  outcome  in HOKUSAI-VTE was symptomatic recurrent VTE (i.e., the composite of DVT, non-fatal PE, and fatal PE). The applicant confirmed that approximately 8% of primary efficacy events were adjudicated events without confirmatory imaging. These events mainly included VTE-related deaths. However, the events were equally distributed in both groups and sensitivity analysis excluding these events (HR: 0.90: 95%CI: 0.69-1.16) yielded very similar results than the main analysis (HR: 0.89; 95%CI: 0.70-1.13), thus supporting non-inferiority of edoxaban under different assumptions.

## · Statistical considerations in HOKUSAI-VTE

HOKUSAI-VTE was event driven study. A total of at least 220 events were required. Sample size calculation was endorsed. The primary efficacy analysis of the HOKUSAI-VTE study was based on a modified Intent-to-Treat (mITT) Analysis Set (subjects who are randomized and received at least one dose of study drug) using all primary efficacy events (symptomatic recurrent VTE) that occurred in the 12-month study period. The time to the first event of the composite primary efficacy outcome was analyzed using a Cox proportional hazards model including treatment and the stratification factors as covariates. The experimental regime was considered non-inferior to the comparator if the upper limit of  the  95%CI  for  the  HR  was  less  than  1.5.  The  non-inferiority  margin  (HR  &lt;1.50)  is  the  most restrictive one compared to recent studies with novel oral anticoagulants in the treatment of VTE (1.80 in AMPLIFY; 2.0 in EINSTEIN studies; 2.75 in RE-COVER studies).

## · Study conduct

A  total  of  8292  subjects  were  randomized  and  assigned  to  the  edoxaban  (N=4143)  or  warfarin (N=4149) treatment groups, and a total of 8240 subjects were treated with edoxaban (N=4118) or warfarin (N=4122) (mITT set). There was no screening period in Hokusai VTE, which is consistent with the acute and serious nature of the event to be treated. The critical study qualification work-up was  conducted  outside  of  the  study  as  a  matter  of  routine  for  the  management  of  VTE.  These procedures were deemed acceptable if done within 48 hours before randomization. Of the 8,240 mITT subjects, 65 (0.8%) subjects withdrew consent and 11 (0.1%) were lost to follow up. Major protocol deviations were reported in 23% of patients (Table 14.1.2.1 of the HOKUSAI-VTE study report). Most of them (16%) corresponded to the use of disallowed medications (mainly disallowed NSAIDs) that impacts the evaluation of main efficacy/safety endpoints, followed by pretreatment for more than 48 hours with therapeutic dosages of anticoagulant treatment before randomisation (4%). The applicant was  requested  to  show  the  main  efficacy/safety  analyses,  on-treatment,  conducting  a  'pure' per-protocol analysis (i.e.: excluding the 23% of patients with major protocol deviations, in addition to those already excluded for not having a baseline VTE event confirmed by the CEC). In the revised \"true\" PP analysis (excluding all major protocol violations) there were 3116 patients on edoxaban and 3143 patients on warfarin. The HR of edoxaban versus warfarin for recurrent VTE was 0.95 (0.68 to

<div style=\"page-break-after: always\"></div>

1.33;  treatment+30  days),  thus  confirming  non-inferiority  (p-value  0.0040).  In  summary,  the original  PP  analysis  of  the  applicant  (not  excluding  all  major  protocol  violations)  favoured  the demonstration of non-inferiority of edoxaban versus warfarin in efficacy. However, non-inferiority was also demonstrated after conducting a \"true\" PP analysis (excluding all major protocol violations). Only 11 patients (0.1%) were lost to follow-up. However, a total of 24 patients (16 patients in the edoxaban group and only 8 patients from warfarin group) were excluded at sites for which subject data  authenticity  was  suspect  and  could  not  be  confirmed.  Ancillary  analyses  provided  by  the Applicant supported in conclusion that the inclusion/exclusion of these patients did not change study results. Approximately 17% of subjects required the 30 mg edoxaban at randomization due to body weight ≤ 60 kg (10%), CrCL 30-50 mL/min (4%), or for the use of quinidine/verapamil (0.5%). Postrandomization requirement for 30 mg edoxaban/edoxaban placebo occurred in 123 subjects (68 for edoxaban and 55  for  edoxaban  placebo  (active  warfarin),  respectively.  Approximately  17.6%  of subjects had their dose adjusted at randomization. Approximately 8% of the dose reductions were due to concomitant medication with P-gp inhibitors.

## · Main study results

Non-inferiority of edoxaban 60 mg was shown in the primary sponsor's analysis of symptomatic recurrent VTE (mITT, overall study period) as well as in the sensitivity analysis for symptomatic recurrent  VTE  (PP,  on-treatment),  but  superiority  was  not  shown  for  the  secondary  endpoint  of symptomatic recurrent VTE and all-cause death (mITT, overall study period. In addition, there was a huge  difference in the number  of  VTE  events  'on-treatment'  and  'overall  study period' (approximately half of total primary events occurred post-treatment).

Net clinical outcome (composite of symptomatic recurrent DVT, nonfatal symptomatic recurrent PE, Major bleeding, and All-cause mortality) occurred in 138 subjects (3.4%) in the edoxaban group and 158 subjects (3.9%) in the warfarin group (HR: 0.87; 95% CI: 0.696, 1.099; p = 0.2515). However, these results correspond to a secondary PP analysis on-treatment, and not to the main analysis in the mITT, overall study period. For the shake of consistency, the applicant was requested to show the results of net clinical outcome in HOKUSAI-VTE using the same approach as in the main analysis of the primary endpoint (i.e.: in the mITT population, overall study period). The HR and 95% CIs for the net clinical outcome using this approach (HR: 1.00; 95%CI: 0.85-1.18) suggest that both edoxaban and warfarin (both with lead in parenteral anticoagulant) are equivalent strategies for VTE treatment. The SmPC, section 5.1, has been amended accordingly .

## · Subgroup analyses

The efficacy of edoxaban was generally consistent across subgroups tested in the HOKUSAI-VTE study. Overall, of the 55 comparisons presented from 18 subgroup analyses, most (45) resulted in a point estimate favouring edoxaban. Statistically significant interaction was only found for fragile vs. non-fragile patients. Edoxaban effect was better in fragile than in non-fragile patients. In general, the effects of edoxaban were also better (although not statistically significant interaction was found) in index PE, age &gt; 75 years and history of cancer, which was reassuring. Regarding the quality of oral anticoagulation, the edoxaban group had a relative reduction in risk for recurrent VTE compared to warfarin for subjects at centers TTR &lt; 60% (HR: 0.89; 95% CI: 0.574, 1.364) and also at centers with TTR ≥60% (HR: 0.87; 95% CI: 0.653, 1.153). The Hazard Ratio for the edoxaban group for centers with INR-TTR &gt;55.8 ≤64.0% was 0.77 (95% CI: 0.496, 1.205).

## · DMS, SMCC, and CEC

DMS, SMCC, and CEC: The large difference between peak and trough values and the close relation between plasma concentration and factor Xa activity raiseed a question, whether a lower dose bid dose (e.g. 15 or 20 mg BID) would have been preferable over a qd dosing. However, it may not be

<div style=\"page-break-after: always\"></div>

possible to draw final conclusions from the phase 3 Hokusai VTE study, whether a lower bid dose adapted to a similar overall duration of suppression of FXa activity to 15% or less would have changed the B/R ratio. The DMC but not the SMCC had access to INR measurements that could have led to partial unblinding. A high risk patient that dies due to any reason will not have an index event of the primary  endpoint.  The  applicant  provided  a  competing  risk  analysis  upon  request  with  non-VTE related deaths as competing risk. The overall result was similar to the result of the primary analysis and did not change the conclusions.

## · Transition between LMW heparin and edoxaban treatment

The excess of index recurrent VTE events in the edoxaban group during the first 30 days raised a question, whether the transition between LMW heparin and edoxaban treatment could be improved (intensified to achieve a more potent anticoagulation; e.g. by an overlapping treatment initiation with a reduced dose or an initial parenteral therapy longer than 5 days). However, subgroup analyses did not show a consistent better efficacy in patients initially treated with LMWH for more than 5 days than in those treated for 5 days or less. Therefore, the recommended posology (Lixiana 60 mg once daily following initial use of parenteral anticoagulant for at least 5 days) was considered acceptable.

## · Possibility of a rebound effect

There was a slight increase in recurrent VTE rates in the edoxaban group after Day 360, especially after Day 390. This is mainly due to the low number of subjects at these timepoints. The change in the curve after Day 390 in the edoxaban group is due to 3 events which occurred after the subjects had stopped study drug. The data do not indicate a general rebound effect on MACE or VTE events after cessation of edoxaban.

## · Asymptomatic patients with DVT

Asymptomatic patients with DVT (e.g. with malignant disease) were not included in the study. The transferability of Hokusai VTE to patients with asymptomatic DVT is difficult to establish. However, as the indication should include the population studied in pivotal trials (symptomatic patients only, in Hokusai VTE) and on the other hand, asymptomatic patients with incidental extensive thrombosis are usually anticoagulated according to established clinical practice guidelines (Kearon et al. Chest. 2012; 141(2 Suppl): e419S-e494S), there is no reason to include in the SmPC neither a recommendation or a non-recommendation of use in asymptomatic patients with VTE.

## 2.5.3.4. Both pivotal studies

Only few black patients were included in both pivotal trials. The sparse data do not indicate concerns for efficacy and safety but the low number of black patients included in the studies has been reflected in the SmPC.

Cox's  proportional  hazards  model  was  used  for  primary  analysis  of  the  pivotal  trials  for  both indications, which assumes a constant HR over time. The applicant provided further clarifications that were accepted by the CHMP.

## 2.5.4. Conclusions on the clinical efficacy

In NVAF, the ENGAGE AF study provided evidence of non-inferiority for edoxaban 60 mg QD versus warfarin for the composite of all strokes and SEE (primary endpoint recommended in SA) and for the composite  of  ischemic  strokes  and  SEE  (primary  endpoint  recommended  currently  in  the EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events  in  patients  with  NVAF  [EMA/CHMP/341363/2014] ).  On  the  contrary,  although  the  low edoxaban  dose  (30  mg  QD)  showed  non-inferiority  versus  warfarin  for  all  strokes/SEE  (study endpoint),  it  was  inferior  to  warfarin  for  the  composite  of  ischemic  stroke/SEE.  Therefore,  the

<div style=\"page-break-after: always\"></div>

Applicant's proposal of recommending the edoxaban 60 mg dose for prevention of stroke and SEE in patients with NVAF was endorsed.

The effect of edoxaban 60 mg dose was consistent in most subgroups analysed. However, stroke/SEE rates tended to favour warfarin in patients recruited in Western Europe and those with normal renal function. The interpretation of the results in Western Europe was hampered by the limitations of subgroup  analyses  and  the  low  event  rates.  These  regional  variations  in  the  context  of  the heterogeneous countries of EEA region were discussed by the CHMP, and the CHMP took also into account that ENGAGE AF demonstrated non-inferiority of edoxaban 60 mg versus a well-controlled warfarin regime in the overall population. All-cause mortality and CV mortality were broadly similar in the overall vs. on-treatment analysis in both the edoxaban and warfarin groups in Western Europe, with point estimates of HR close to 1. Therefore, no safety signal was apparent in Western Europe. In addition,  when  the  analysis  was  made  in  the  region  of  the  EEA  and  Switzerland,  the  results  on ischemic stroke/SEE were broadly similar in the edoxaban and warfarin groups (HR 0.94 and 0.99 point estimates in the overall study period and on-treatment analyses, respectively). In summary, although the hazard ratios for the on-treatment and overall periods may show some variability, given in excess of 100 combinations of regions and endpoints this minor level of inconsistency in ischemic stroke/SEE was considered to be due a combination of chance due to the extreme multiplicity of testing  and  a  trend  towards  a  better  control  of  warfarin  treatment  in  Western  Europe  and North-America than in other regions. The overal study results were deemed hence representative for the EEA.

A positive B/R in patients with AF and normal renal function (CrCL ≥ 80 mL/min) was  questioned and extensively discussed but at the end considered positive across the continuum of renal function at the population level. More than 2000 patients were included in each arm in this analysis, there was consistency over a wide range of efficacy endpoints, the results were essentially consistent in the 60/30 mg arm and in the 30/15 mg arm, INR control in the warfarin arm was independent of renal function, there was external support since the event rates on edoxaban in ENGAGE AF were higher as compared to the event rates in the respective warfarin arms in additional 2 out of 3 studies, there was replication  since  also  in  Hokusai  VTE  there  was  a  clear  correlation  between  renal  function  and comparative  efficacy  with  a  HR  numerically  in  favour  of  warfarin  in  patients  with  normal  renal function.  Taken  all  these  considerations  together  and  balancing  the  apparent  robustness  of  the findings for the clinical endpoints on one hand and the fact that PK considerations cannot entirely explain the findings on the other hand, the level of concern remained high enough to make prescribing physicians clearly aware of the signal in patients with normal renal function. Therefore, a warning was included in section 4.4 of the SmPC that a trend towards decreasing efficacy with increasing creatinine clearance was observed for edoxaban compared to well-managed warfarin. Therefore, edoxaban should only be used in patients with NVAF and high creatinine clearance after a careful evaluation of the individual thromboembolic and bleeding risk.

In the treatment of acute VTE, HOKUSAI VTE provided evidence of non-inferiority of edoxaban 60 mg versus  warfarin  (both  regimes  preceded  by  heparin  lead-in  treatment).  The  non-inferiority  was consistent in the ITT and PP populations, as well as in the on-treatment and overall study period analysis. No specific VTE extension studies have been conducted with edoxaban. However, the design and  analysis  of  the  study  allowed  the  applicant  to  assess  extension  of  therapy/the  secondary prevention of VTE without the need for a formal 'extension' study. Furthermore this 'extension' study within Hokusai was performed with an active comparator-warfarin rather than placebo allowing a more robust comparison as to the real world risk benefit if continued therapy. As such the indication for  both  the  active  treatment  of  acute  VTE  and  secondary  prevention  of  recurrent  VTE  were demonstrated with the Hokusai VTE study with up to 12 months of therapy. The main issue during HOKUSAI-VTE regarding  duration of  therapy,  looking  at  post-treatment  recurrences,  was  that  it seems that many patients would benefit from longer treatment durations of anticoagulation. That is

<div style=\"page-break-after: always\"></div>

why it was agreed not to limit the duration of treatment of VTE to the 1 year tested with edoxaban in HOKUSAI-VTE.

During pivotal studies, dose reductions were made in patients concomitantly receiving P-gp inhibitors. However, the totality of the data did not support diminishing the dose when edoxaban 60 mg is concomitantly administered with verapamil, quinidine or amiodarone. However  in patients concomitantly  taking  edoxaban  and  the  following  P-gp  inhibitors:  ciclosporine,  dronedarone, erythromycin, or ketoconazole, the recommended dose is 30mg of edoxaban once daily.

Finally, the applicant's intention for applying for the authorisation of the 15 mg QD was endorsed but restricted to the process of switching from edoxaban to VKA for patients currently on edoxaban 30 mg. The information in the SmPC has been amended to reflect more accurately the switching process used in ENGAGE-AF study. An additional warning was included in the SmPC to prevent from treatment with suboptimal 15 mg dose in monotherapy and to make clear that the 15 mg dose is only indicated in  the  process  of  switching  from  edoxaban  30  mg  to  VKA  (patients  with  presumed  increased exposure), together with an appropriate VKA dose.

## 2.6. Clinical safety

## Patient exposure

Exposure: The exposure in the Pooled Phase 3 studies amounts to 18,010 patients treated with edoxaban for approximately 1.9 years (more than 34000 subject-years for edoxaban: approximately 18200 subject-years for edoxaban 60 mg and 15800 subject-years for edoxaban 30 mg) and and 11,010  patients treated with warfarin for approximately 1.7 years (approximately  18350 subject-years).

Table S-01: Numbers of Subjects in Analysis Sets in Phase 3 Studies

|                     | Edoxaban TotalExposure   | Edoxaban 30mg       | Edoxaban 60mg       | Warfarin            |
|---------------------|--------------------------|---------------------|---------------------|---------------------|
| PooledPhase3Studies | PooledPhase3Studies      | PooledPhase3Studies | PooledPhase3Studies | PooledPhase3Studies |
| Safety              | 18010                    | 7002                | 11008               | 11010               |
| ENGAGEAF            | ENGAGEAF                 | ENGAGEAF            | ENGAGEAF            | ENGAGEAF            |
| Safety              | 14014                    | 7002                | 7012                | 7012                |
| mITT                | 14014                    | 7002                | 7012                | 7012                |
| ITT                 | 14069                    | 7034                | 7035                | 7036                |
| HokusaiVTE          | HokusaiVTE               | HokusaiVTE          | HokusaiVTE          | HokusaiVTE          |
| Safety              | 4118                     | NA                  | 4118                | 4122                |
| mITT                | 4118                     | NA                  | 4118                | 4122                |

NA=notapplicable

Source:ISSAppendix12.6.2,TableS4,U301,Tab1e14.1.1.5andU305,Table14.1.1.5

Exposure  to  treatment  in  ENGAGE  AF  dominates  the  total  exposure,  with  total  subject-years  of treatment of &gt;15400 being accumulated on each of edoxaban 30 mg, edoxaban 60 mg and warfarin in  this  NVAF  study.  The  subjects  in  ENGAGE  AF  and  Hokusai  VTE  were  enrolled  globally. Approximately half of the subjects were recruited from Europe (Eastern and Western). Total exposure to edoxaban is approximately 1.7 times as high in males as in females and more than twice as high in subjects aged over 65 years than in younger subjects. These differences in exposure are largely accounted for by the dominant ENGAGE AF dataset, which comprised a notably older population than the Hokusai VTE set. An appreciable number of patients aged &gt;75 years (edoxaban 6153 vs warfarin 3319) and &gt;85 years (edoxaban 661 vs warfarin 374) were included in the pooled phase III trials. The available exposure to edoxaban is deemed appropriate for the assessment of frequent adverse events in the target population.

<div style=\"page-break-after: always\"></div>

The number of overall AEs and patients with at least one AE was initialy unknown as the applicant has only shown disaggregated data of 'bleeding' and 'non-bleeding AEs'. The applicant provided during the procedure summarized tables of overall adverse events (not disagreggated into 'bleeding' and 'non-bleeding' adverse events), showing: total adverse events and patients with at least one adverse event; serious and non-serious AEs; related and not related AEs) in the pooled phase III trials and by trial. The rate of patients with TEAEs/SAEs as well as drug-related TEAEs/SAEs favoured edoxaban in most categories, in both pivotal studies, separately and pooled, thus indicating a better safety profile of edoxaban in comparison with warfarin.

## Adverse events

Overall  adverse  events  in  ENGAGE-AF  (NVAF  indication): A  summary  of  overall  TEAEs  is provided in the following table, which includes bleeding events, hepatic events, bone fractures, and malignancies. The rates of patients with TEAE/SAE were lower with edoxaban than with warfarin for most categories and similar for TEAE that caused drug permanent discontinuation.

Table S-02: ENGAGE AF: Overview of All TEAEs (Bleed and Non-Bleed TEAEs), On-treatment Period

|                                                                   | Edoxaban 30 mg (N = 7012)   | Edoxaban 60 mg (N = 7002)   | Warfarin (N = 7012)   |
|-------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------|
|                                                                   | n (%)                       | n (%)                       | n (%)                 |
| Subjects With TEAE                                                | 5988 (85.5)                 | 6044 (86.2)                 | 6068 (86.5)           |
| Subjects With TESAE                                               | 2552 (36.4)                 | 2530 (36.1)                 | 2788 (39.8)           |
| Subjects With Drug-Related TEAE                                   | 1654 (23.6)                 | 1974 (28.2)                 | 2251 (32.1)           |
| Subjects With Drug-Related TESAE                                  | 230 (3.3)                   | 332 (4.7)                   | 461 (6.6)             |
| Subjects With TEAE Leading to Fatal Outcome                       | 290 ( 4.1)                  | 311 (4.4)                   | 362 (5.2)             |
| Subjects With TEAE That Caused Study DrugPermanentDiscontinuation | 889 (12.7)                  | 1059 (15.1)                 | 1054 (15.0)           |

Source:TableS3.10.13.1

Overall adverse events in Hokusai VTE (VTE treatment indication): A summary of overall TEAEs is provided in the following table, all of which include bleeding events, hepatic events, bone Fractures,  malignancies  and  Investigator-confirmed  endpoint  events.  The  rates  of  patients  with TEAE/SAE were lower with edoxaban than with warfarin for most categories and similar for TEAE leading to fatal outcome and TEAT that caused drug permanent discontinuation.

Table S-03: Hokusai VTE: Overview of All TEAEs (Bleed and Non-Bleed TEAEs), On-treatment Period

|                                                              | Edoxaban (N =4118)   | Warfarin (IN = 4122 )   |
|--------------------------------------------------------------|----------------------|-------------------------|
| SubjectsWith TEAE                                            | 2973 (72.2)          | 3085 (74.8)             |
| Subjects With SAE                                            | 625 (15.2)           | 698 (16.9)              |
| SubjectsWithDrug-Related TEAE                                | 1021 (24.8)          | 1349 (32.7)             |
| Subjects With Drug-Related SAE                               | 106 (2.6)            | 210 (5.1)               |
| SubjectsWithTEAE LeadingtoFatal Outcome                      | 80 (1.9)             | 76 (1.8)                |
| SubjectsWithTEAEThatCausedStudyDrugPermanent Discontinuation | 294 (7.1)            | 284 (6.9)               |

Source:U305.Table14.3.1.152

Bleeding events in ENGAGE-AF (NVAF indication): The risk of bleeding was lower for edoxaban 60 mg than warfarin for all categories. HR were below 1 and p values showed the reductions to be highly statistically significant: major bleeds (HR 0.80, p=0.009), fatal bleeds (HR 0.55, p=0.0059), non-fatal (HR 0.83, p=0.0087), life-threatening (HR 0.51, p &lt; 0.0001), CRNM (HR 0.86, p=0.0001),

<div style=\"page-break-after: always\"></div>

major or CRNM (HR 0.86, p &lt; 0.0001), minor (HR 0.84, p=0.0023) and any confirmed bleed (HR 0.87, p &lt; 0.0001). The lower risk of major intracranial hemorrhage (ICH) was particularly marked (HR 0.47, p &lt; 0.0001). A dose-response was apparent for edoxaban, as the rates of adjudicated bleeds were even lower with edoxaban 30 mg than with edoxaban 60 mg, but this advantage with regard to bleeding is offset by the notably lower efficacy of this dose (30 mg OD).

Table  S-04:  Adjudicated  Bleeding  Events,  Safety  Analysis  Set  -  On-Treatment  Period (ENGAGE AF)

<!-- image -->

|                                     | Edoxaban30 (N=7002) mg   | Edoxaban30 (N=7002) mg   | Edoxaban60 (N=7012) mg   | Edoxaban60 (N=7012) mg   | Warfarin (N=7012)   | Warfarin (N=7012)   | Edoxaban30mgvsWarfarin   | Edoxaban30mgvsWarfarin   | Edoxaban60mgvsWarfarin   | Edoxaban60mgvsWarfarin   |
|-------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|---------------------|---------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| BleedingCategory-First Event        |                          | Event Rate (%6/yr)       |                          | Event Rate (%/yr)        |                     | Event Rate (%o/yr)  | HR(95% C1)               | p-value                  | HR(95%C1)                | p-value                  |
| Major                               | 254                      | 1.61                     | 418                      | 2.75                     | 524                 | 3.43                | 0.47 (0.406, 0.548)      | <0.0001                  | 0.80 (0.707, 0.914)      | 0.0009                   |
| ICH                                 | 41                       | 0.26                     | 61                       | 0.39                     | 132                 | 0.85                | 0.30 (0.215, 0.433)      | <0.0001                  | 0.47 (0.344, 0.631)      | <0.0001                  |
| Non-ICH                             | 214                      | 1.36                     | 359                      | 2.36                     | 398                 | 2.60                | 0.52 (0.444, 0.619)      | <0.0001                  | 0.91 (0.788, 1.049)      | 0.1906                   |
| Fatal                               | 21                       | 0.13                     | 32                       | 0.21                     | 59                  | 0.38                | 0.35 (0.212, 0.574)      | <0.0001                  | 0.55 (0.355, 0.840)      | 0.0059                   |
| ICH[b]                              | 12                       | 0.08                     | 24                       | 0.15                     | 42                  | 0.27                | 0.28 (0.147, 0.532)      | 0.0001                   | 0.58 (0.349, 0.951)      | 0.0312                   |
| Non-ICH                             | 9                        | 0.06                     | 8                        | 0.05                     | 17                  | 0.11                | 0.52 (0.231, 1.162)      | 0.1105                   | 0.47 (0.204, 1.095)      | 0.0804                   |
| Non-Fatal(Afajor)                   | 234                      | 1.49                     | 386                      | 2.54                     | 466                 | 3.05                | 0.49 (0.418, 0.572)      | <0.0001                  | 0.83 (0.729, 0.955)      | 0.0087                   |
| ICH[b]                              | 29                       | 0.18                     | 37                       | 0.24                     | 90                  | 0.58                | 0.32 (0.208, 0.481)      | <0.0001                  | 0.41 (0.283,0.608)       | ≤0.0001                  |
| Non-ICH                             | 205                      | 1.30                     | 351                      | 2.31                     | 381                 | 2.49                | 0.52 (0.443, 0.622)      | <0.0001                  | 0.93 (0.803, 1.074)      | 0.3166                   |
| BleedingCategory-First Event        |                          | Event Rate (%/yr)        |                          | Event Rate (%/yr)        |                     | Event Rate (%/yr)   | HR(95%C1)                | p-value                  | HR (95% C1)              | p-value                  |
| Life-Threatening                    | 40                       | 0.25                     | 62                       | 0.40                     | 122                 | 0.78                | 0.32 (0.225, 0.460)      | <0.0001                  | 0.51 (0.377, 0.695)      | <0.0001                  |
| ClinicallyRelevantNon- Major        | 696                      | 6.60                     | 1214                     | 8.67                     | 1396                | 10.15               | 0.66 (0.605,0.712)       | ≤0.0001                  | 0.86 (0.795, 0.927)      | 0.0001                   |
| MajororClinically RelevantNon-Major | 1161                     | 7.97                     | 1528                     | 11.10                    | 1761                | 13.02               | 0.62 (0.575,0.666)       | <0.0001                  | 0.86(0.800,0.918)        | ≤0.0001                  |
| Mfinor                              | 533                      | 3.52                     | 604                      | 4.12                     | 714                 | 4.89                | 0.72 (0.647, 0.809)      | <0.0001                  | 0.84 (0.758, 0.941)      | 0.0023                   |
| AnyConfirmedBleed                   | 1499                     | 10.68                    | 1865                     | 14.15                    | 2114                | 16.40               | 0.66 (0.619,0.706)       | <0.0001                  | 0.87 (0.816, 0.924)      | <0.0001                  |

Note:ICHincludesprimaryhemorrhagicstroke,subarachnoidhemonhage,epi/subduralhemorhage,andischemicstrokewithmajorhemorhagic conversion.AllICHsreportedontheAdjudicatedCerebrovascularand Non-IntracranialbleedeCRFformsconfirmedbytheAdjudicatorsareincludedin ICH counts.

Note:Theeventrate(%/yr)iscalculatedas#ofevents/subject-yearexposure.

Note:Life-threateningbleedsaredefinedasall non-fatalICHandnon-fatalnon-intracranialmajorbleedswithhemodynamiccompromiserequiring intervention.

Note:Asubjectcanbeincluded inmultiplesub-categories.Thefirsteventofeach category isincluded intheanalysis.

Note:'AnyConfirmedBleed'includesthosethattheadjudicatordefinedasclinicallyovert.

Source:Module2.7.4Table2.1

Major bleeding was lower in most locations in the edoxaban groups compared with the warfarin group. However, there were more Major GI bleeds in the edoxaban 60 mg group than in the warfarin group (1.51% and 1.23% per year, respectively).

Table S-05: Adjudicated Major Bleeding by Treatment Group and Location, Safety Analysis Set - On-Treatment Period

<!-- image -->

I1301T-hle129

<div style=\"page-break-after: always\"></div>

Adjudicated CRNM bleeding was also lower in most locations in the edoxaban groups than the warfarin group. However, again there was more CRNM GI bleeds in the edoxaban 60 mg OD group than in the warfarin group (2.17% and 1.31% per year, respectively).

Table S-06: Adjudicated Clinically Relevant Non-Major Bleeding by Treatment Group and Location, Safety Analysis Set - On-Treatment Period

Abbreviations:DosAdj=DoseAdjusted,yr=year.

|                                       | Edoxaban30mg (15mgDosAdj) (=7002)   | Edoxaban30mg (15mgDosAdj) (=7002)   | Edoxaban60mg (30mgDosAdj) (N=7012)   | Edoxaban60mg (30mgDosAdj) (N=7012)   | Warfarin (=7012)   | Warfarin (=7012)    |
|---------------------------------------|-------------------------------------|-------------------------------------|--------------------------------------|--------------------------------------|--------------------|---------------------|
|                                       | #of events                          | EyentRate [e]( /%)                  | #of events                           | EventRate [](/%)                     | #of events         | EyentRate (%o/ym[a] |
| AnyClinicallyRelevant Non-MajorBleed  | 969                                 | 6.60                                | 1214                                 | 8.67                                 | 1396               | 10.15               |
| Gastrointestinal                      | 232                                 | 1.49                                | 328                                  | 2.17                                 | 201                | 1.31                |
| UpperGastrointestinal                 | 46                                  | 0.29                                | 52                                   | 0.34                                 | 34                 | 0.22                |
| LowerGastrointestinal                 | 187                                 | 1.19                                | 282                                  | 1.86                                 | 169                | 1.10                |
| CutaneousSoftTissue                   | 299                                 | 1.93                                | 309                                  | 2.04                                 | 613                | 4.13                |
| Macroscopic Hematuria'Urethral        | 178                                 | 1.14                                | 262                                  | 1.73                                 | 219                | 1.43                |
| Epistaxis                             | 174                                 | 1.11                                | 248                                  | 1.63                                 | 242                | 1.58                |
| Other                                 | 57                                  | 0.36                                | 68                                   | 0.44                                 | 121                | 0.78                |
| Oral Pharyngeal                       | 33                                  | 0.21                                | 57                                   | 0.37                                 | 93                 | 0.60                |
| Hemoptysis                            | 48                                  | 0.30                                | 56                                   | 0.36                                 | 70                 | 0.45                |
| Surgical Site                         | 23                                  | 0.15                                | 36                                   | 0.23                                 | 44                 | 0.28                |
| Vaginal[b]                            | 35                                  | 0.58                                | 32                                   | 0.58                                 | 25                 | 0.44                |
| Intramuscular, No CompartmentSyndrome | 2                                   | 0.01                                | 8                                    | 0.05                                 | 8                  | 0.05                |
| PunctureSite                          | 11                                  | 0.07                                | 3                                    | 0.02                                 | 15                 | 0.10                |
| Intraocular                           | 0                                   | 0.00                                | 2                                    | 0.01                                 | 0                  | 0.00                |

[a]:Theeventrate(°o/yr)iscalculatedas#ofevents/subject-yearexposure. Thesubjectyearexposureis the sum, across subjects,ofthe number of'at risk'years up tothe event or censoring. [b]:Forgender specific category(vaginal bleeding),the eventrate isbased on thegender specific

subjectnumbers.

Note:Asubjectmaybecountedinmultiplesubcategorieswhenmultipleeventsoccured

Note:Events aresortedindescendingorderof frequencyin theEdoxaban60mggroup.

Sourcedata:Tables14.3.1.1and14.3.1.13

The benefit in overall major bleeding risk was consistent in most subgroups analysed, particularly in fragile patients with renal insufficiency, age &gt; 75 yrs or body weight &lt; 60 kg. However, there was no difference between edoxaban 60 mg and warfarin with regard to overall major bleeds when warfarin treatment is optimally managed (i.e.: in centers with TTR &gt; 66.4% or in the 4 th quartile of INR/TTR), which is the rule in many European centers.

Table S-07: Adjudicated Major Bleeds by Center-Level INR Control: Safety Analysis Set On-Treatment Period (ENGAGE AF)

|                               | Edoxaban 30 mg (N=7002)   | Edoxaban 30 mg (N=7002)   | Edoxaban 60 mg (N=7012)   | Edoxaban 60 mg (N=7012)   | Warfarin (N=7012)   | Warfarin (N=7012)   | Edoxaban30mgvs Warfarin   | Edoxaban60mgvs Warfarin   |
|-------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------|---------------------|---------------------------|---------------------------|
|                               | n/M[c]                    | EventRate [](/%)          | n/[c]                     | EventRate [](1/%)         | []N                 | EventRate [](1/%)   | HR(95%C1)[b]              | HR (95%C1)[b]             |
| CenterswithTTR>66.4% (Median) | 122/3273                  | 1.62                      | 225/3277                  | 3.15                      | 273/3402            | 3.51                | 0.47 (0.377,0.578)        | 0.90 (0.752,1.071)        |
| CenterswithTTR≤66.4% (Median) | 116/3509                  | 1.49                      | 177/3517                  | 2.33                      | 251/3602            | 3.35                | 0.44 (0.357,0.554)        | 0.70 (0.576,0.847)        |
| p-valuefortheinteraction[b]   |                           |                           |                           |                           |                     |                     | 0.7559                    | 0.0607                    |

Note:OnlyINRstakenwhileonstudymedicationandafterthefirst7daysofstudymedicationareincluded.

[a]:Theeventrateiscalculatedasn/subject-yearexposure

[b]: The HR and two-sided CI for pairwise comparisons versus warfarin are based on the Cox regression model with counting

processapproachincludingtreatment and thetwostratificationfactors ascovariates:thedichotomizedCHADS2score and thedichotomized dose-reduction factor.The p-value for interaction is based on the Cox regression model with counting process approach for on treatment including treatment,thetwostratificationfactorsascovariates:dichotomizedCHADS2scoreanddichotomizeddose-adjustmentfactor,subgroup,treatmentand subgroupinteraction.

[c]: M is the total number of subjects on whom the informationis available for that subgroup.

Source:U301.Table12.12

<div style=\"page-break-after: always\"></div>

Table S-08: Adjudicated Major Bleeds by Quartiles of INR TTR, Safety Analysis Set - On Treatment Period

Abbreviations:DosAdj =DoseAdjusted,HR=HazardRatioversusWarfarin,CI=ConfidenceInterval,yr=year,INR=IntemationalNormalized Ratio, TTR=TimeinTherapeuticRange.

|                               | Edoxaban30mg (15mgDosAdi) (N=7002)   | Edoxaban30mg (15mgDosAdi) (N=7002)   | Edoxaban60mg (30mgDosAdi) (N=7012)   | Edoxaban60mg (30mgDosAdi) (N=7012)   | Warfarin (N=7012)          | Warfarin (N=7012)          | Edoxaban30mg (15mgDosAdi)vs Warfarin   | Edoxaban60mg (30mgDosAdj)vs Warfarin   |
|-------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|--------------------------------------|----------------------------|----------------------------|----------------------------------------|----------------------------------------|
|                               | n/MI[c]                              | EventRate (%/yr)[a]                  | n/[[c]                               | EventRate [以](1/%)                   | n/[[c]                     | EventRate [e](14/%)        | HR (95% CD]                            | HR (95% CD[]                           |
| 57.7%) 1stQuartile(<=         | 48/1406                              | 1.59                                 | 78/1413                              | 2.60                                 | 102/1406                   | 3.77                       | (0.295, 0.587) 0.42                    | (0.516,0.932) 0.69                     |
| 2ndQuartile (>57.7%to< 66.4%) | 68/2103                              | 1.43                                 | 99/2104                              | 2.15                                 | 149/2196                   | 3.12                       | 0.46 (0.348, 0.617)                    | 0.70 (0.540,0.898)                     |
| BrdQuartile 73.9%) （>66.4%to< | 69/1906                              | 1.59                                 | 119/1908                             | 2.84                                 | 165/2038                   | 3.59                       | (0.337,0.590) 0.45                     | (0.628, 1.007) 0.80                    |
| 4thQuartile(>73.9%)           | 53/1367                              | 1.67                                 | 106/1369                             | 3.58                                 | 108/1364                   | 3.39                       | 0.50 (0.358,0.692)                     | 1.05 (0.803,1.371)                     |
| pvaluefortheinteraction[d]    | pvaluefortheinteraction[d]           | pvaluefortheinteraction[d]           | pvaluefortheinteraction[d]           | pvaluefortheinteraction[d]           | pvaluefortheinteraction[d] | pvaluefortheinteraction[d] | 0.8941                                 | 0.1102                                 |

[a]:The eventrate(%/yr)is calculatedas#ofevents/subject-yearexposure.The subjectyearexposure is the sum,acrosssubjects,of the number of'atrisk'yearsuptotheeventorcensoring.

[c]:M isthetotal numberofsubjectsonwhomtheinformationis availableforthat subgroup.

[b]:TheHRand two-sidedCIforpairwise comparisonsversusWarfarin arebased on theCoxregressionmodelwith countingprocess approachfor ontreatmentperiodincludingtreatmentandthe2stratificationfactorsascovariates:thedichotomizedCHADS2scoreandthedichotomizeddose-adjustment factor.

[d]:Thep-valueforinteractionisbasedontheCoxregressionmodelwithcountingprocess approachforontreatmentperiodincludingtreatment,the 2 stratificationfactors:dichotomizedCHADS2scoreanddichotomizeddose-adjustmentfactor,subgroup,treatmentandsubgroupinteraction

Sourcedata:Table14.3.1.23

Note:AllINRstakenwhileon-treatment,excludingtheinitial 7daysof studymedication areconsidered.

Bleeding  events  in  HOKUSAI-VTE: In  Hokusai  VTE, the reduction in bleeding risk was highly significant for Major/CRNM bleeding (8.5% VS. 10.3%; HR 0.81; 95%CI: 0.71-0.94; p=0.0040) but not for major bleeds (1.4% vs. 1.6%; HR: 0.84; 0.59-1.21; p=0.3521). There were fewer critical site Major/CRNM bleeds on edoxaban than warfarin treatment (13 vs. 32), fewer intracranial bleeds in the edoxaban group than the warfarin group (5 vs. 18) and fewer fatal bleeds (2 vs. 10). It seems that the more important benefit of edoxaban, as with other new anticoagulants, is the reduction in ICH.

Table S-09: Adjudicated Bleeding Events, Safety Analysis Set - On-Treatment Period (Hokusai VTE)

[a]TheHR(versuswarfarin)andtwo-sided CIarebasedontheCoxproportionalhazardsregressionmodel includingtreatmentandthefollowingrandomizationstratificationfactorsascovariates:presentingdiagnosis (PEwithorwithoutDVT,DVTonly),baselineriskfactors（temporaryfactors,allothers),andtheneedfor 30mgedoxaban/edoxabanplacebodose atrandomization(yes,no),p-valueα=0.01[two-sided].

| AdjudicatedBleeding              | Edoxaban (N=4118)   | Warfarin (N=4122)   |
|----------------------------------|---------------------|---------------------|
| Major/CRNIMBleeding.n(%)         | 349 (8.5)           | 423 (10.3)          |
| HREdoxabanvs.Warfarin(95%C1)[a]  | 0.81(0.705,0.936)   | 0.81(0.705,0.936)   |
| p-value [a]                      | 0.0040              | 0.0040              |
| MajorBleeding.n(°)               | 56 (1.4)            | 66 (1.0)            |
| HREdoxabanvs.Warfarin(95%。C1)[a] | 0.84(0.592,1.205)   | 0.84(0.592,1.205)   |
| p-value[a]                       | 0.3521              | 0.3521              |
| Fatal,n (%) [b]                  | 2 (<0.1)            | 10 (0.2)            |
| CRNMBleeding.n(%)                | 298 (7.2)           | 368 (8.9)           |
| NuisanceBleeding.n(%)            | 663 (16.1)          | 787 (19.1)          |
| All Bleeding.n(%)                | 895 (21.7)          | 1056 (25.6)         |

[b]Ofthe2fatalbleedingeventsthatoccurredinthesubjectsontheedoxabanarm,neitherhadyetreceived edoxabanstudydrug(ie,eventocciurredduringtheinitialheparintreatment)

Source:Module2.7.4Table2.7.

On the contrary, there was an increase in major/CRNMB associated with a fall in hemoglobin &gt; 2 g/dL (40 vs. 33) and needing a transfusion ≥ 2 units (28 vs. 22), which was mainly due to an increase in 'mucosal  bleedings',  including  major/CRNM  gastrointestinal  bleedings  (2.4%  in  edoxaban  group versus 2.3% of warfarin group) and vaginal bleeds (4.6% in the edoxaban group versus 3.2% in the warfarin group).

<div style=\"page-break-after: always\"></div>

Table S-10: Adjudicated Major or Clinically Relevant Non-Major Bleeding Event Characteristics: Safety Analysis Set - On-Treatment Period (Hokusai VTE)

| Adjudicated MajororCRNMBleeding   | Edoxaban 60mg (N=4118) n (%)   | Warfarin (N=4122) n (%)   |
|-----------------------------------|--------------------------------|---------------------------|
| Event Characteristic [a]          |                                |                           |
| FatalBleed                        | 2 (≤0.1)                       | 10 (0.2)                  |
| Clinically Overt                  | 349 (8.5)                      | 423 (10.3)                |
| Fall in Hemoglobin ≥2 g/dL        | 40 (1.0)                       | 33 (0.8)                  |
| Transfusions≥2units               | 28 (0.7)                       | 22 (0.5)                  |
| HemodynamicCompromise             | 1 (<0.1)                       | 6 (0.1)                   |
| Requiring Surgery                 | 3 (<0.1)                       | 2 (≤0.1)                  |

Source:U305,Table12.8

When all adjudicated confirmed bleeds were considered, gastrointestinal bleeds were recorded for 4.2%  and  3.6%  in  the  edoxaban  and  warfarin  groups,  respectively,  with  the  majority  of  these affecting the lower GI tract (3.4% and 3.1% of subjects in each treatment group). The incidence of all vaginal bleeds was 9.0% for edoxaban and 7.1% for warfarin. The increase in GI bleedings with edoxaban 60 mg OD was consistent with the increase in risk of GI bleeding seen in the ENGAGE-AF study and the results obtained with other NOAC. The higher rate of occurrence of vaginal bleeds (mainly menorrhagia) in this study compared with ENGAGE AF may be a reflection of the younger age of the population. The benefit in major bleeding risk was consistent in most subgroups analysed, particularly in fragile patients with renal insufficiency, age &gt; 75 yrs or body weight &lt; 60 kg. However, there was no difference between edoxaban 60 mg and warfarin with regard to MB/CRNMB bleeds at centres with TTR &gt; 60% (HR: 0.91; 95% CI: 0.770, 1.077), which is the rule in many European centers, and in centers with TTR &gt;70.41% (HR: 1.06; 95%CI: 0.79 to 1.44).

Table S-11: Primary Safety Endpoint (Adjudicated Major/CRNM Bleeding) by Center Level Percent Time in Therapeutic Range (TTR), Safety Analysis Set, On-Treatment Study Period

|                                                | Edoxaban m/M (%)   | Warfarin m/M (%)   | Edoxaban vs. Warfarin HR(95%C1) [a]   |
|------------------------------------------------|--------------------|--------------------|---------------------------------------|
| AdjudicatedMajororCRNMBleeding                 |                    |                    |                                       |
| CenterswithTTR<60%                             | 83/1199(6.9)       | 139/1271(10.9)     | 0.61(0.468,0.805)                     |
| CenterswithTTR>=60%                            | 265/2876 (9.2)     | 284/2845(10.0)     | 0.91 (0.770,1.077)                    |
| CenterswithTTR<25thPercentile (55.82%)         | 47/713 (6.6)       | 92/748(12.3)       | 0.52(0.366,0.738)                     |
| CenterswithTTR>=25thto<50th Percentile(64.03%) | 117/1329 (8.8)     | 140/1291(10.8)     | 0.80 (0.627, 1.024)                   |
| CenterswithTTR>=50thto<75th Percentile（70.41%) | 95/1115(8.5)       | 109/1180(9.2)      | 0.90 (0.686,1.189)                    |
| CenterswithTTR>=75thPercentile                 | 89/918 (9.7)       | 82/897(9.1)        | 1.06 (0.786. 1.439)                   |

[a]TheHRand two-sided CIarebasedontheCoxproportionalhazardsregressionmodelincluding treatmentandthefollowingrandomization stratificationfactorsascovariates:presentingdiagnosis(PE withorwithoutDVT,DVTonly),baselineriskfactors（temporaryfactors,allothers),andtheneedfor 30mgedoxaban/edoxabanplacebodoseatrandomization(yes,no).

Abbreviations:CI=ConfidenceInterval,CRNM=ClinicallyRelevantNonMajor,HR=Hazard Ratio, M=number ofsubjectsAnalysisSetforeachindividualsubgroup,m=number ofsubjectsineach individual subgroupwith an event,TTR=TimeinTherapeuticRange.

## Ancillary analyses of bleeding events across studies

Intracranial  hemorrhage  (ICH): Ancillary analyses provided by the Applicant showed that the benefits of edoxaban versus warfarin in ICH were consistent in the worst case (high TTR and Western European population). It was consistent with results observed with other NOACs. The class benefit seems to be driven by an intrinsically risk of ICH with VKAs, which is seen even at high TTR. The

<div style=\"page-break-after: always\"></div>

absolute benefit of edoxaban versus warfarin is difficult to establish due to low number of events, but could be around 3 ICH avoided per 1,000 patients treated per year in the European AF population (edoxaban 3 ICH vs warfarin 6  ICH/1,000/yr).  In  the  overall  ENGAGE  AF  study  population,  the projected  benefit  is  around  5  ICH  per  1,000  patients  treated  (edoxaban  4  ICH  vs.  warfarin  9 ICH/1,000/yr). In the overall Hokusai VTE study population, the absolute benefit of edoxaban versus warfarin in ICH may be similar, around 3 ICH avoided per 1,000 patients treated for acute VTE (edoxaban 1 ICH/1,000 vs. warfarin 4 ICH/1,000), but difficult to establish due to low number of events and shorter durations of treatment (usually lasting less than 1 year).

Baseline  characteristics  of  patients  with  major  bleeding: Patients  who  experienced  major bleedings  had  older  age,  higher  proportion  of  renal  impairment  and  concomitant  ASA  use  than patients  without  major  bleedings.  These  patients  were  more  represented  in  ENGAGE  AF  than  in Hokusai VTE. In both ENGAGE AF and Hokusai VTE, demographic characteristics in subjects with adjudicated  major  bleeds  were  generally  comparable  between  treatment  groups,  except  for concomitant aspirin use in Hokusai VTE which was higher in the edoxaban than the warfarin group.

Clinical  management  of  major  bleeding: In  ENGAGE  AF  the  rate  of  patients  needing hospitalization for major bleeding was less frequent in edoxaban than in warfarin in ENGAGE AF (1.54%/yr vs 1.81%/yr), transfusion ≥ 2 units was similar (1.05%/yr in both groups), as well as need for surgery (0.20%/yr vs 0.29%/yr). Hospitalization with intensive care was lower with edoxaban (0.7%/yr  vs  1.4%/yr).  In  Hokusai  VTE,  the  rate  of  patients  requiring  hospitalization  for  major bleeding (1.2% vs. 1.2%), transfusion ≥ 2 units (0.7% vs 0.5%), need for surgery (&lt;0.1 vs &lt; 0.1% and  hospitalization  with  inensive  care  unit  (0.3  vs  0.4%)  was  generally  comparable  between edoxaban and warfarin treatment groups.

Major bleeding outcomes: there was lower 30-day all-cause mortality after major bleeding in the edoxaban 60-mg than the warfarin group (ENGAGE AF: 0.5% vs. 1.0%; Hokusai VTE: 0.1% vs. 0.3%). Major bleed outcome of resolved with sequelae was lower with edoxaban than with warfarin in ENGAGE AF (0.7% vs 1.2%), but not in Hokusai VTE (0.2% vs. 0.1%).

Major and CRNM GI bleeding: In ENGAGE AF, edoxaban 60-mg subjects had a higher rate of Major/CRNM GI bleed than warfarin subjects (3.54%/yr vs. 2.42%/yr), including those requiring hospitalization (1.61%/yr vs. 1.27%/yr) and transfusion (0.97%/yr vs. 0.84%/yr). However, the more severe bleedings, resulting in death of hospitalisation in intensive care unit, are more often reported with warfarin than with edoxaban. The increase in GI bleedings (HR≈ 1.46) mimic those reported with dabigatran 150 mg BID in RE-LY study (HR: 1.52) and rivaroxaban 20 mg OD in ROCKET AF (HR ≈ 1.26) for CRNM GI bleed. Further SmPC changes in sections 4.4 and 4.8 have been included to warn about this increase in risk.

Common non-bleeding TEAEs (pooled Phase III trials): Comparison of total edoxaban and edoxaban 60 mg with warfarin revealed only small differences in incidence for the majority of events (Pooled  Phase  3  studies).  However,  anaemia  was  reported  for  a  higher  proportion  of  edoxaban subjects (4.2%) than warfarin subjects (2.9%). Gastrointestinal TEAEs (diarrhoea, nausea, gastritis and dyspepsia) was also reported for a higher proportion of edoxaban subjects than warfarin subjects (6.3% vs 6% for diarrhoea; 3.4% vs. 2.8% for nausea; 2.1% vs. 1.9% for gastritis and 1.8% vs. 1.6% for dyspepsia, respectively). The most notable difference was for INR increased which was, as anticipated, much more common on warfarin than edoxaban treatment (4.7% compared with 0.5%).

Treatment-related  non-bleeding  TEAEs: In  the  Pooled  Phase  3  studies,  treatment-related non-bleeding  TEAEs  were  recorded  for  11.6%  of  the  edoxaban  60  mg  group  and  14.6%  of  the

<div style=\"page-break-after: always\"></div>

warfarin group over the modified on-treatment period. 'Anaemia' and 'hepatic enzyme increased' was more frequent in edoxaban 60 mg group than in the edoxaban 30 mg group or warfarin group (anemia: 0.9% versus 0.8% and 0.6%) (hepatic enzyme increased: 0.8% vs. 0.2% and 0.6%).

Table S-13: Common Treatment-related Non-Bleeding TEAEs in ≥0.5% of Subjects in Pooled ENGAGE AF and Hokusai VTE Studies: Safety Analysis Set; Modified On-Treatment Period

|                                       | Edoxaban Total (=18010) n(9)   | Edoxaban 30mg (N=7002) n (%6)   | Edoxaban 60mg (N=11008) n(6)   | Warfarin (=11010) n(96)   |
|---------------------------------------|--------------------------------|---------------------------------|--------------------------------|---------------------------|
| BloodandLymphaticSystem Disorders     | 239 (1.3)                      | 86 (1.2)                        | 153 (1.4)                      | 117 (1.1)                 |
| Anaemia                               | 156 (0.9)                      | 57 (0.8)                        | 99 (0.9)                       | 62 (0.6)                  |
| GastrointestinalDisorders             | 358(2.0)                       | 139 (2.0)                       | 219 (2.0)                      | 211 (1.9)                 |
| Diamhoea                              | 69(0.4)                        | 32(0.5)                         | 37(0.3)                        | 38(0.3)                   |
| Investigations                        | 600(3.3)                       | 204 (2.9)                       | 396(3.6)                       | 781 (7.1)                 |
| HepaticEnzymeIncreased                | 101 (0.6)                      | 16 (0.2)                        | 85 (0.8)                       | 67(0.6)                   |
| CreatinineRenalClearance Decreased    | 86 (0.5)                       | 40 (0.6)                        | 46 (0.4)                       | 33 (0.3)                  |
| IntenationalNonmalisedRatio Increased | 46 (0.3)                       | 15 (0.2)                        | 31 (0.3)                       | 450(4.1)                  |

Note:Invesfigator-confimedbleedingeventsandemicacyendpointeventssuchasDVT,PE,MI,SEE andstrokeareexcluded.IfPTisdeath,theAEisalsoexcluded

Note:TableincludesPTswithfrequencyof≥O.S%inatleastonegroup.SOCrepresentsallTEAEcounts forthatSOC,includimgPTsthatwerereportedby&lt;0.5%6ofsubjects.

Soiurce:ISSAppendix12.6.2.TableS16

Hepatic safety: There was a small imbalance against edoxaban 60 mg versus warfarin (pooled phase 3 studies) in: a) the cases of hyperbilirubinaemia (edoxaban 60 mg 0.3% vs warfarin 0.1%); b) in concurrent elevation of ALT or AST ≥ 3 x ULN &amp; Total Bilirubin ≥ 2 x ULN (edoxaban 60 mg 0.4% vs warfarin 0.3%, corresponding to 43 and 29 cases, respectively; Pooled Phase 3 trials); c) In the percentage of subjects in the edoxaban 60 mg group versus warfarin that were characterized by an independent hepatologist as having a hepatocellular injury (1.1% vs. 1.0%, respectively); d) In the percentage of cases of liver injury possible/probable related to study drug [(edoxaban 60 mg 0.4% (48 of 11008 subjects) versus warfarin 0.3% (30 of 11010 subjects)]; e) in the percentage of liver injury adjudicated as severe (edoxaban 60 mg 0.4% vs warfarin 0.3%); f) and in the number of Hy's law cases adjudicated as severe hepatocellular liver injury possibly/probably related to study drug (edoxaban any dose 2 vs warfarin 1), which is of concern. A similar concern has been arisen with other factor Xa inhibitors. A definitive association between these novel oral factor Xa inhibitors and risk of hepatic injury has not been definitively confirmed.

Hepatic  events: All  suspected  hepatic  events  were  blindly  adjudicated  by  two  hepatologists independently. There were no hepatic events adjudicated as 'unassessable'. Of all hepatic events sent for adjudication, there were 4 cases that the adjudicators had insufficient data for severity only; nature of liver injury and causality were determined for all cases. In both ENGAGE AF and Hokusai VTE, an independent adjudication process by expert hepatologists was established to provide an unbiased  and  systematic  assessment  of  individual  cases  in  a  blinded  fashion.  There  were  82 concurrent combination abnormalities (69 from ENGAGE AF: 22 on edoxaban 30 mg, 28 on edoxaban 60 mg, 19 on warfarin; and 11 from Hokusai VTE: 7 on edoxaban 60 mg and 4 on warfarin). From independent adjudication using the CEC Charter definition (consistent with the FDA's DILI Guidance) and  blinded  to  study  drug,  there  were  8  adjudicated  as  having  hepatocellular  injury  and probably/possibly related, of which 5 met Hy's Rule criteria (1 edoxaban 30 mg, 3 edoxaban 60 mg, 2  warfarin-treated).  There  were  3  additional  cases  (2  edoxaban  30  mg,  1  edoxaban  60  mg,  0 warfarin) assessed as related per investigator (assessed as unlikely/unrelated per adjudication), all which  revealed  confounding  factors.  When  adding  these  3  additional  cases  to  those  already adjudicated by the independent hepatologists, it would result in 3 total Hy's law cases with edoxaban

<div style=\"page-break-after: always\"></div>

30 mg, 3 total cases with edoxaban 60 mg and 2 total cases with warfarin. Therefore, the addition of these cases do not change the overall conclusion about hepatic safety of edoxaban, as the overall number  of  Hy's  law  cases  would  still  be  insufficient  for  a  meaningful  conclusion.  The  observed discrepancies between the investigator-reported and hepatologist-adjudicated Hy's law cases can be judged as within normal variability expected in these kind of assessments, where hepatologists tend to be more strict than investigators by applying pre-defined criteria for Hy's law cases. In addition, both pivotal studies were declared GCP compliant. Therefore, the validity of the adjudication process by the hepatologists was endorsed. There was a numerical excess of adjudicated hepatic events in the edoxaban arm compared with warfarin (15 versus 6) when coadministered with macrolides, with associated event rates of 1.31%/year and 0.53%/year. However, the number of subjects receiving macrolides was low (edoxaban 60 mg 459 subjects versus warfarin 451 subjects). Although the hazard ratio for those taking macrolides was in favour of warfarin, the 95% CI was very wide and included unity, while the p-value for interaction was not significant. The Applicant considered that the imbalance between the two groups (edoxaban 60 mg and warfarin) may be a chance finding, to which the CHMP agreed. The Applicant has not performed specific studies on the effect of edoxaban on mitochondrial extracts. The rationale for this was the lack of evidence from the nonclinical studies, specifically the long-term toxicology studies in which there were no apparent hepatotoxicity-related responses associated with this test compound. The Applicant shared the draft study protocol of the mitochondrial inhibition assay that was endorsed by the CHMP.

The liver function tests (LFTs) evaluated in the various single and repeated dose toxicity studies were consistently not positive for toxicologically significant LFT elevations and histopathology examinations. In addition, female rats at the doses that showed even higher edoxaban exposure did not present liver lesions. Regarding the observed secondary liver degeneration/necrosis in a cohort of dead  or  moribund/sacrificed  male  rats  in  the  high  dose  group  in  the  carcinogenicity  study,  the Applicant believed that it is associated with well-studied phenomena that hepatocytes are particularly vulnerable  to  necrotizing  insults  such  as  severe  metabolic  disturbances  including  hypoxia. Hepatocellular lesion in the high-dose male group is considered related to the moribund condition of animals  given  600/400 mg/kg/day  which  clearly  exceeded  the  MTD.  Therefore,  the  Applicant concluded that hepatocellular finding observed in the rat carcinogenicity study is of no toxicological significance and was not considered relevant to human, which was agreed by the CHMP.

There  were  no  concurrent  combination  abnormality  cases  for  which  a  biopsy  was  performed  in ENGAGE AF. In Hokusai VTE, two subjects with combination abnormalities had a liver biopsy, one edoxaban-treated and one warfarin-treated subject. The edoxaban patient had a history of chronic cholecystitis that, on Day 47 of study had adenocarcinoma in the liver tissue. This case was classified as  severe  cholestasis,  unlikely/unrelated  to  study  drug  per  CEC  hepatologists  adjudication.  The additional case occurred during warfarin treatment. After six months of treatment with warfarin, the patient  developed  liver  enzyme  elevations  that  progressed  to  fulminant  hepatitis  requiring  liver transplant  (post-operative  fatality)  while  off  study  drug.  This  event  was  adjudicated  as  severe hepatocellular liver injury, probably/possibly related to study drug and meeting Hy's Rule based on the CEC hepatologists adjudication. Therefore, the very scarce data on liver biopsies were insufficient to draw any meaningful conclusion, but did not raise any major concern on edoxaban.

SmPC changes related to liver safety: It was agreed to add to the SmPC a recommendation of use with caution in patients with mild or moderate hepatic impairment and use with caution in patients with elevated liver enzymes ALT/AST &gt; 2xULN or total bilirubin ≥ 1.5xULN and a recommendation to perform liver function testing prior to initiation of treatment. The Applicant also agreed to add that periodic monitoring of hepatic function is recommended for patients on edoxaban treatment beyond 1 year.

<div style=\"page-break-after: always\"></div>

Malignancies and bone fractures: Overall the reporting frequency of events of neoplasms was low and no significant imbalance was observed between groups in both pivotal studies. The percentage of subjects with new bone fractures was comparable among treatment groups in both pivotal studies. The most common bone fracture was hip/pelvis/proximal.

MACE: In ENGAGE, MACE rates and its components (stroke, MI, fatal bleeding and CV death) were consistently lower with edoxaban 60 mg than with warfarin. In HOKUSAI-VTE, MI was numerically more frequent with edoxaban (60 mg/d standard dose) compared to warfarin. Furthermore, overall MACE was numerically increased with edoxaban as were the rare individual events CV death, fatal ischaemic stroke and SEE. Additional analyses showed that the difference in MI between edoxaban and warfarin was numerically larger in the CAD subpopulation (2.9% vs. 0.9%) than in the total study population (0.5% vs. 0.3%), but due to the low number of events (6 vs. 2) firm conclusions are not possible. In the AF study no such imbalance disfavouring edoxaban was observed (edoxaban 60 mg 72 MI vs. warfarin 85 MI in the CAD subpopulation). Mechanistic data supporting or rebutting the assumption that edoxaban might favour development of MI in CAD patients compared to warfarin are not available. In summary, the CHMP agreed that there was no need to exclude CAD patients from treatment with edoxaban.

Other  adverse  events  of  interest: For  some SMQs, including acute renal failure (both pivotal studies), acute polyneuropathies (ENGAGE-AF), anaphylactic reactions (HOKUSAI-VTE)  and interstitial lung disease (ILD) (HOKUSAI-VTE), a small increase is seen for edoxaban in comparison with warfarin:

a) Acute renal failure: the imbalance is noticed in both edoxaban clinical trials with the edoxaban 60 mg OD dose. There is no evidence that edoxaban may be associated to a worsening of acute renal failure  or  nephrotoxic  effect.  However,  there  is  evidence  that  patients  with  severe  bleeding  with edoxaban may experience worsening CrCL or even acute renal failure in the overall data from clinical trials and post-marketing experience. This finding has been included in section 4.8 of the SmPC;

b)  Acute  polyneuropathies: An  imbalance  has  been  reported  on  the  incidence  of  acute polyneuropathies with edoxaban in the ENGAGE-AF study. There was a low incidence of GBS/ALS throughout the edoxaban program with only 1 (serious) ALS case and no GBS case during edoxaban treatment/treatment + 30 days. The small imbalance in the Acute Polyneuropathy Clinical Event group  in  ENGAGE  AF  was  primarily  driven  by  the  PT  'polyneuropathy',  which  is  not  specific  for ALS/GBS as the majority of the reported cases had confounding etiological factors and were unrelated to study medication and the differences are thus not suggestive of neurologic toxicity. No cases for GBS/ALS were found from post marketing data up to 30 June 2014;

c) Allergic reactions: in HOKUSAI-VTE the numbers of anaphylactic reactions on-treament were higher with edoxaban than with warfarin (230 vs 197) as well as the cases of angioedema (48 vs. 38). There are some allergic reactions (hypersensitivity, allergic oedema and anaphylaxis) during pivotal trials with at least possible/probable relationship with edoxaban (Anaphylactic reactions: Hokusai-VTE-61423070, Hokusai-VTE-35004296, ENGAGE-AF-12060006; Angioedema: Hokusai-VTE-10680073, Hokusai-VTE-401115473, ENGAGE-AF-42100001; Severe cutaneous reaction:  ENGAGE-AF-10070071)  and  a  post-marketing  case  of  eyelid  oedema/angioedema (DSJ-2013-20575).  These  cases  are  within  reported  with  other  direct  oral  factor  Xa  inhibitors (Xarelto,  Eliquis)  and  have  been  included  in  section  4.8  of  the  SmPC  in  alignment  with  these compounds.  In  addition,  \"pruritus\"  (common)  and  \"urticaria\"  (uncommon)  were  reported  with edoxaban in pivotal trials and have been added to \"rash\" in the subsection of \"Skin and Subcutaneous Tissue Disorders\" with the said frequencies.

d) Gastrointestinal symptoms: Nausea (common) has been included in section 4.8 of the SmPC, as it was reported as related to edoxaban by the investigators in both pivotal studies. The findings in

<div style=\"page-break-after: always\"></div>

both pivotal studies for the remaining GI adverse events (gastritis, dyspepsia, diarrhoea) are not as consistent as for nausea and it is agreed not to include them in section 4.8 of the SmPC.

## Serious adverse events and deaths

Deaths: The overall death rate was lowest for edoxaban 60 mg (8.0%) and highest for edoxaban 30 mg (10.4%), with the rate for warfarin being 8.6% (pool analysis of Phase 3 Trials). The majority of deaths were classed as cardiovascular; the rate of cardiovascular deaths was lowest for edoxaban 60 mg (4.6%) and highest for edoxaban 30 mg (6.8%), with the rate for warfarin being 5.1%. The edoxaban 30 mg group included only subjects from ENGAGE AF. The death rate in edoxaban 30 mg was largely driven by ischemic events (suggesting a lack of effective anticoagulation). However, there was heterogeneity in the causes of death in both pivotal studies.

Table S-22: Adjudicated Deaths in Pooled ENGAGE AF and Hokusai VTE Studies: Safety Analysis Set; Overall Study Period

|                        | Edoxaban Total (N=18010) n (%)   | Edoxaban 30mg (N=7002) n (%)   | Edoxaban 60mg (N=11008) n (%)   | Warfarin (N=11010) n (%)   |
|------------------------|----------------------------------|--------------------------------|---------------------------------|----------------------------|
| Total                  | 1613 (9.0)                       | 731 (10.4)                     | 882 (8.0)                       | 952 (8.6)                  |
| CardiovascularDeaths   | 984 (5.5)                        | 478 (6.8)                      | 506 (4.6)                       | 559 (5.1)                  |
| Non-Hemorrhagic Stroke | 98 (0.5)                         | 53 (0.8)                       | 45 (0.4)                        | 47 (0.4)                   |
| SystemicEmbolicEvent   | 4 (≤0.1)                         | 4 (<0.1)                       | 0                               | 3 (≤0.1)                   |
| MyocardialInfarction   | 37 (0.2)                         | 20 (0.3)                       | 17 (0.2)                        | 19 (0.2)                   |
| PulmonaryEmbolism      | 12 (<0.1)                        | 8 (0.1)                        | 4 (≤0.1)                        | 7 (≤0.1)                   |
| Sudden Death           | 467 (2.6)                        | 224 (3.2)                      | 243 (2.2)                       | 263 (2.4)                  |
| Other Cardiac Death    | 366 (2.0)                        | 169 (2.4)                      | 197 (1.8)                       | 220 (2.0)                  |
| Bleeding               | 115 (0.6)                        | 54 (0.8)                       | 61 (0.6)                        | 110 (1.0)                  |
| OtherDeaths            | 514 (2.9)                        | 199 (2.8)                      | 315 (2.9)                       | 283 (2.6)                  |
| Malignancy             | 230 (1.3)                        | 90 (1.3)                       | 140 (1.3)                       | 136 (1.2)                  |
| Infection              | 182 (1.0)                        | 64 (0.9)                       | 118 (1.1)                       | 91 (0.8)                   |
| Other Death            | 102 (0.6)                        | 45 (0.6)                       | 57 (0.5)                        | 56 (0.5)                   |

Source:ISSAppendix 12.6.2,Table S23

In ENGAGE-AF, a positive trend was found in favour of edoxaban 60 mg for all-cause death and CV death on-treatment and overall study period, mainly at expenses of lower CV death rates (7.5% vs. 8.7%).

Table S-23: Adjudicated Deaths - mITT/Safety Analysis Set, Modified On- Treatment and Overall (ENGAGE AF)

<div style=\"page-break-after: always\"></div>

|                                                            | Edoxaban 30mg (N=7002) n (%)   | Edoxaban 30mg (N=7002) n (%)   | Edoxaban60mg (N=7012) n (%)   | Edoxaban60mg (N=7012) n (%)   | Warfarin (N=7012) n (%)   | Warfarin (N=7012) n (%)   |
|------------------------------------------------------------|--------------------------------|--------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|
|                                                            | Modified On- Treatment         | Overall                        | Modified On- Treatment        | Overall                       | Modified On- Treatment    | Overall                   |
| Total                                                      | 386 (5.5)                      | 731 (10.4)                     | 379 (5.4)                     | 769 (11.0)                    | 432 (6.2)                 | 836 (11.9)                |
| Primary Cause                                              |                                |                                |                               |                               |                           |                           |
| Cardiovascular                                             | 307 (4.4)                      | 522 (7.5)                      | 296 (4.2)                     | 527 (7.5)                     | 348 (6.2)                 | 608 (8.7)                 |
| Sudden/UnwitnessedDeath                                    | 159 (2.3)                      | 229 (3.3)                      | 167 (2.4)                     | 246 (3.5)                     | 179 (2.6)                 | 269 (3.8)                 |
| CongestiveHeart Failure/Cardiogenic Shock                  | 59 (0.8)                       | 117 (1.7)                      | 51 (0.7)                      | 129 (1.8)                     | 62 (0.9)                  | 142 (2.0)                 |
| OtherCardiovascular                                        | 8 (0.1)                        | 48 (0.7)                       | 11 (0.2)                      | 45 (0.6)                      | 6 (≤0.1)                  | 50 (0.7)                  |
| Ischemic Stroke                                            | 38 (0.5)                       | 55 (0.8)                       | 22 (0.3)                      | 43 (0.6)                      | 26 (0.4)                  | 47 (0.7)                  |
| IntracranialHemorrhage                                     | 10 (0.1)                       | 16 (0.2)                       | 25 (0.4)                      | 30 (0.4)                      | 44 (0.6)                  | 53 (0.8)                  |
| Dysrhythmia                                                | 12 (0.2)                       | 20 (0.3)                       | 11 (0.2)                      | 16 (0.2)                      | 9 (0.1)                   | 15 (0.2)                  |
| AtheroscleroticVascular Disease                            | 4 (<0.1)                       | 11 (0.2)                       | 3 (≤0.1)                      | 5 (≤0.1)                      | 5 (<0.1)                  | 8 (0.1)                   |
| DirectlyRelatedtoCABGor Percutaneous Coronary Intervention | 2 (<0.1)                       | 3 (<0.1)                       | 3 (<0.1)                      | 5 (<0.1)                      | 1 (<0.1)                  | 4 (<0.1)                  |
| Non-IntracranialHemorrhage                                 | 6 (≤0.1)                       | 9 (0.1)                        | 3 (≤0.1)                      | 5 (<0.1)                      | 10 (0.1)                  | 12 (0.2)                  |
| PulmonaryEmbolism                                          | 4 (≤0.1)                       | 9 (0.1)                        | 0                             | 3 (≤0.1)                      | 4 (<0.1)                  | 5 (≤0.1)                  |
| Systemic Arterial Embolic Event                            | 5 (≤0.1)                       | 5 (≤0.1)                       | 0                             | 0                             | 2 (<0.1)                  | 3 (<0.1)                  |
| Malignancies                                               | 23 (0.3)                       | 93 (1.3)                       | 25 (0.4)                      | 94 (1.3)                      | 23 (0.3)                  | 84 (1.2)                  |
| Malignancies Clin Evid Before Rand                         | 0                              | 0                              | 0                             | 0                             | 1 (<0.1)                  | 2 (≤0.1)                  |
| Malignancies ClinEvid After Rand                           | 23 (0.3)                       | 93 (1.3)                       | 25 (0.4)                      | 94 (1.3)                      | 22 (0.3)                  | 82 (1.2)                  |
| Non-CV/Non-Malignancy                                      | 56 (0.8)                       | 116 (1.7)                      | 58 (0.8)                      | 148 (2.1)                     | 61 (0.9)                  | 144 (2.1)                 |
| Infection                                                  | 30 (0.4)                       | 69 (1.0)                       | 37 (0.5)                      | 94 (1.3)                      | 42 (0.6)                  | 92 (1.3)                  |
| OtherNon-Cardiovascular/ Non-Malignancy                    | 16 (0.2)                       | 30 (0.4)                       | 14 (0.2)                      | 36 (0.5)                      | 10 (0.1)                  | 30 (0.4)                  |
| Accidental/Trauma                                          | 4 (≤0.1)                       | 5 (<0.1)                       | 3 (<0.1)                      | 10 (0.1)                      | 6 (≤0.1)                  | 10 (0.1)                  |
| Renal                                                      | 5 (<0.1)                       | 9 (0.1)                        | 1 (<0.1)                      | 4 (<0.1)                      | 2 (<0.1)                  | 8 (0.1)                   |
| Suicide                                                    | 1 (<0.1)                       | 1 (≤0.1)                       | 2 (<0.1)                      | 3 (<0.1)                      | 0                         | 1 (<0.1)                  |
| Hepatobiliary                                              | 0                              | 2 (<0.1)                       | 1 (<0.1)                      | 1 (≤0.1)                      | 1 (<0.1)                  | 3 (<0.1)                  |

Source:U301,Table14.2.6.2andTableS2.6.15.1

On the contrary, in HOKUSAI-VTE, numerically more deaths were reported with edoxaban than with warfarin on-treatment + 30 days (79 vs 71) and during overall study period (136 vs. 130), including an imbalance in CV deaths on-treatment + 30 days (12 vs 6) and death due to infectious disease in the overall study period (25 vs 12). Among the latter, lung infections constituted a large proportion. These pneumonias were not related to PE but were due to the reduced general condition of the study patients with high co-morbidity. The most likely explanation for the observed difference is therefore a chance finding. For the numerically increased CV events in the VTE study, a causal relationship is difficult to delineate from the individual events but some uncertainty remains. It is reassuring that there is no hint for a higher rate with edoxaban of recurrent PEs or deaths in patients with a more severe index event, i.e. in patients with potentially higher risk for a (severe) recurrent VTE. The all-cause mortality in the safety data set is listed in the SmPC, which is endorsed. Although the patient population is different, it is reassuring that mortality was numerically decreased with edoxaban in the ENGAGE AF trial.

Table S-24: Adjudicated Primary Cause of Death - Safety Analysis Set, Treatment + 30 days and Overall Study Period (Hokusai VTE)

<div style=\"page-break-after: always\"></div>

| CauseofDeath                                 | Edoxaban 60 mg (N=4118) n (%)   | Warfarin (N=4122) n(%)   | Edoxaban 60 mg (N=4118) n (%)   | Warfarin (N=4122) n(%)   |
|----------------------------------------------|---------------------------------|--------------------------|---------------------------------|--------------------------|
|                                              | Treatment + 30 days             | Treatment + 30 days      | Overall                         | Overall                  |
| All Causes                                   | 79 (1.9)                        | 71 (1.7)                 | 136 (3.3)                       | 130 (3.2)                |
| VTE-RelatedDeath                             | 18 (0.4)                        | 16 (0.4)                 | 27 (0.7)                        | 28 (0.7)                 |
| PE                                           | 3 (<0.1)                        | 2 (<0.1)                 | 4 (>0.1)                        | 3 (<0.1)                 |
| Unexplained Death (and VTE cannot be (no pem | 15 (0.4)                        | 14 (0.3)                 | 23 (0.6)                        | 25 (0.6)                 |
| CardiovascularDeath                          | 12 (0.3)                        | 6 (0.1)                  | 15 (0.4)                        | 13 (0.3)                 |
| MI                                           | 2 (≤0.1)                        | 2 (<0.1)                 | 2 (≤0.1)                        | 2 (≤0.1)                 |
| Ischemic stroke                              | 4 (≤0.1)                        | 1 (<0.1)                 | 6 (0.1)                         | 3 (≤0.1)                 |
| SEE                                          | 0                               | 0                        | 0                               | 0                        |
| Other CardiacDeath                           | 6 (0.1)                         | 3 (<0.1)                 | 7 (0.2)                         | 8 (0.2)                  |
| OtherKnown Cause                             | 49 (1.2)                        | 49 (1.2)                 | 94 (2.3)                        | 89 (2.2)                 |
| Cancer                                       | 22 (0.5)                        | 28 (0.7)                 | 51 (1.2)                        | 59 (1.4)                 |
| Bleeding (including Hemorrhagic Stroke)      | 2 (≤0.1)                        | 9 (0.2)                  | 6 (0.1)                         | 10 (0.2)                 |
| Infectious Disease                           | 17 (0.4)                        | 8 (0.2)                  | 25 (0.6)                        | 12 (0.3)                 |
| Other                                        | 8 (0.2)                         | 4 <0.1)                  | 12 (0.3)                        | 8 (0.2)                  |

Note: Deaths are included in the Overall Study Period if they occurred on or after the date of first dose of any study drug. All deaths that occurred prior to last study follow-up contact are considered for the Overall Study Period.

Note: Percentages are based on N, the total number of subjects.

Source:U305.Table12.21andTable14.2.6.2

Finally, ancillary analyses of deaths in both pivotal studies show that all-cause mortality and CV mortality are not reduced by edoxaban 60 mg as compared with warfarin, particularly in centres above the median TTR and in original regions with a good quality of warfarin anticoagulation, like in Western Europe. In the overall European population (EEA + Switzerland), the point estimates slightly favour edoxaban in ENGAGE-AF and warfarin in Hokusai VTE, but the CIs for the HRs are wide and no significant differences in all-cause mortality or CV mortality are expected between edoxaban 60 mg and warfarin in AF or treatment of VTE in Europe.

Other serious adverse events: The serious adverse events reported in edoxaban 60 mg and warfarin groups were generally well balanced. Cardiac disorders SOC including atrial fibrillation and cardiac failure were less frequent TESAEs on edoxaban 60 mg than warfarin. The edoxaban 30 mg group had a higher frequency of events of the Cardiac system, particularly of atrial fibrillation, as previously noted for all TEAEs, and cardiac failure. TESAEs of anaemia and iron-deficiency anaemia were more frequent with edoxaban 60 mg (and edoxaban 30 mg) than warfarin treatment. TESAEs of gastritis were also more frequent with edoxaban 60 mg than warfarin treatment (24 vs 11).

## Laboratory findings

There was a clear increase with edoxaban versus warfarin in the number of patients with Hb drop from baseline &gt;2 g/dl in the ENGAGE-AF study (edoxaban 20.6% vs. warfarin 16.4%) (Table 3.2 of the Summary of Clinical Safety). The imbalance is also apparent, although of a lesser magnitude, in the HOKUSAI VTE study (6.2% vs 4.2%). From both studies, approximately half of the imbalance in subjects with hemoglobin drop &gt; 2 g/dL is accounted for by increased mucosal bleeds in edoxaban subjects compared with warfarin, which is consistent with the pathophysiology of mucosal bleeding that is associated with higher volume loss over time (compared with ICH). From ENGAGE AF, bleed events with very high volume loss (transfusion ≥ 4 units, ≥ 5 g/dL adjusted hemoglobin loss) were lower (total number of subjects and percentage) in edoxaban 60-mg than warfarin subjects.

No imbalances in creatinine, platelet count or leucocyte count are evident in the pooled phase III studies. Hepatic events have been assessed in previous sections.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

Non-bleeding  adverse  events  in  special  populations: Post-hoc  analyses  of  non-bleeding adverse events in subpopulations (by gender, age, race, renal or hepatic impairment, pregnancy and lactation) of pooled phase III trials, with some methodological limitations (e.g.: exclusion of some subpopulations in pivotal trials, low numbers and post-hoc nature of the analysis) did not reveal any safety concern in a particular population.

Elderly: The following table provides a summary of the number of older subjects included in PK, controlled and non-controlled clinical studies bv age ranges.

Table S-25. Summary of Older subjects included in Clinical studies

| Clinical studies           | Age 65-74 yrs (N Older/N Total)   | Age 75-84 yrs (N Older/N Total)   | Age≥85 yrs (N Older/N Total)   |
|----------------------------|-----------------------------------|-----------------------------------|--------------------------------|
| PK studies [a]             | 52/1427                           | 2/1427                            | 0/1427                         |
| Controlled Studies [b]     | 10576/34401                       | 9606/34401                        | 1096/34401                     |
| Non Controlled Studies [c] | 184/662                           | 63/662                            | 5/662                          |
| Total studies              | 10812 /36490                      | 9671 /36490                       | 1101 /36490                    |

[a]: PK Trials include all completed Phase 1 studies.

[b]: Controlled studies include: PRT018, J225, J226, U301 (ENGAGE AF), U305 (Hokusai VTE), PRT011, J302,

J303, J04, and J209.

[c]: Uncontrolled studies include J03, J05, and PRT-007.

Source: Table T-Age-pooled

Events of special interest in the elderly: The following tables show non-bleedings AEs of interest in  the  elderly,  by  age  range,  separately  for  each  pivotal  study.  Data  pooling  was  not  deemed appropriate due to differences in study designs, patients' characteristics  and  different  treatment durations. Bleeding events by age subgroups were already included in subgroup analyses shown previously in the corresponding safety section and therefore are not presented here. As anticipated, regarless of treatment group, there was a higher rate of events in the older age groups compared with the younger age groups, but edoxaban compared favourably to warfarin for most types of adverse events and age groups. The exception is the numerical increase in SAEs in Hokusai VTE study in patients 85 years, which is due to increased number of infections (see also assessment of Q143). However, this increase was not seen in ENGAGE-AF and is hampered by the low number of subjects (n= 74) and events (27). Therefore, it is likely to be a chance finding.

Table S-26: Overview of Non-Bleeding TEAEs by Age, Safety Analysis Set; Modified On-Treatment Period: ENGAGE AF

<div style=\"page-break-after: always\"></div>

|                                                                                      | Edoxaban 30 mg (N=7002) n(%)   | Edoxaban 30 mg (N=7002) n(%)   | Edoxaban 30 mg (N=7002) n(%)   | Edoxaban 30 mg (N=7002) n(%)   | Edoxaban 60 mg (N=7012) n (%)   | Edoxaban 60 mg (N=7012) n (%)   | Edoxaban 60 mg (N=7012) n (%)   | Edoxaban 60 mg (N=7012) n (%)   | Warfarin (N=7012) n (%)   | Warfarin (N=7012) n (%)   | Warfarin (N=7012) n (%)   | Warfarin (N=7012) n (%)   |
|--------------------------------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|--------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
|                                                                                      | <65y M=1784                    | 65-74y MI= 2429                | 75-84y M=2502                  | ≥85y M=287                     | <65y M=1830                     | 65-74 y I=2344                  | 75-84 y M=2528                  | ≥85y M=310                      | <65y M=1869               | 65-74y MI=2338            | 75-84y M=2508             | ≥85y M=297                |
| Total with AEs                                                                       | 1434 (80.4)                    | 2046 (84.2)                    | 2179 (87.1)                    | 254 (88.5)                     | 1480 (80.9)                     | 1951 (83.2)                     | 2204 (87.2)                     | 286 (92.3)                      | 1493 (79.9)               | 1954 (83.6)               | 2196 (87.6)               | 280 (94.3)                |
| Subjects Serious AEs-Total                                                           | 578 (32.4)                     | 960 (39.5)                     | 1030 (41.2)                    | 128 (44.6)                     | 563 (30.8)                      | 855 (36.5)                      | 1012 (40.0)                     | 141 (45.5)                      | 622 (33.3)                | 901 (38.5)                | 1089 (43.4)               | 151 (50.8)                |
| -Fatal                                                                               | 65 (3.6)                       | 123 (5.1)                      | 124 (5.0)                      | 28 (9.8)                       | 76 (4.2)                        | 116 (4.9)                       | 141 (5.6)                       | 25 (8.1)                        | 80 (4.3)                  | 106 (4.5)                 | 159 (6.3)                 | 34 (11.4)                 |
| -Hospitalization/prolong existinghospitalization                                     | 532 (29.8)                     | 880 (36.2)                     | 980 (39.2)                     | 116 (40.4)                     | 525 (28.7)                      | 793 (33.8)                      | 945 (37.4)                      | 132 (42.6)                      | 564 (30.2)                | 823 (35.2)                | 1000 (39.9)               | 134 (45.1)                |
| -Life-threatening                                                                    | 19 (1.1)                       | 35 (1.4)                       | 33 (1.3)                       | 4 (1.4)                        | 22 (1.2)                        | 28 (1.2)                        | 30 (1.2)                        | (61)9                           | 18 (1.0)                  | 35 (1.5)                  | 39 (1.6)                  | 14 (4.7)                  |
| -Disability/incapacity                                                               | 8 (0.4)                        | 8 (0.3)                        | 14 (0.6)                       | 3 (1.0)                        | 6 (0.3)                         | 10 (0.4)                        | 16 (0.6)                        | 2 (0.6)                         | 3 (0.2)                   | 9 (0.4)                   | 9 (0.4)                   | 4 (1.3)                   |
| -Other(medically significant)                                                        | 195 (10.9)                     | 322 (13.3)                     | 366 (14.6)                     | 47 (16.4)                      | 198 (10.8)                      | 309 (13.2)                      | 358 (14.2)                      | 46 (14.8)                       | 213 (11.4)                | 317 (13.60                | 394 (15.7)                | 57 (19.2)                 |
| AE leading to drop-out [a]                                                           | 103 (5.8)                      | 220 (9.1)                      | 323 (12.9)                     | 63 (22.0)                      | 114 (6.2)                       | 231 (9.9)                       | 364 (14.4)                      | 75 (24.2)                       | 111 (5.9)                 | 205 (8.8)                 | 370 (14.8)                | 82 (27.6)                 |
| Psychiatric disorders (SOC)                                                          | 117 (6.6)                      | 179 (7.4)                      | 249 (10.0)                     | 35 (12.2)                      | 115 (6.3)                       | 176 (7.5)                       | 243 (9.6)                       | 27 (8.7)                        | 111 (5.9)                 | 167 (7.1)                 | 219 (8.7)                 | 37 (12.5)                 |
| Nervous system disorders (SOC)                                                       | 290 (16.3)                     | 524 (21.6)                     | 621 (24.8)                     | 91 (31.7)                      | 288 (15.7)                      | 475 (20.3)                      | 656 (25.9)                      | 78 (25.2)                       | 319 (17.1)                | 478 (20.4)                | 637 (25.4)                | 93 (31.3)                 |
| Accidents and injuries (SMQ)                                                         | 210 (11.8)                     | 346 (14.2)                     | 559 (22.3)                     | 90 (31.4)                      | 210 (11.5)                      | 330 (14.1)                      | 545 (21.6)                      | 85 (27.4)                       | 255 (13.6)                | 396 (16.9)                | 608 (24.2                 | 100 (33.7)                |
| Cardiacdisorders(soc)                                                                | 458 (25.7)                     | 647 (26.6)                     | 691 (27.6)                     | 76 (26.5)                      | 461 (25.2)                      | 596 (25.4)                      | 637 (25.2)                      | 95 (30.6)                       | 479 (25.6)                | 630 (26.9)                | 673 (26.8)                | 103 (34.7)                |
| Vascular disorders (SOC)                                                             | 225 (12.6)                     | 365 (15.0)                     | 397 (15.9)                     | 51 (17.8)                      | 237 (13.0)                      | 330 (14.1)                      | 421 (16.7)                      | 44 (14.2)                       | 219 (11.7)                | 363 (15.5)                | 408 (16.3)                | 57 (19.2)                 |
| disorders (SMQ) Cerebrovascular                                                      | 12 (0.7)                       | (71)67                         | 20 (0.8)                       | 5 (1.7)                        | 12 (0.7)                        | 27 (1.2)                        | 24 (0.9)                        | 0(0.0)                          | 9 (0.5)                   | 25 (1.1)                  | 31 (1.2)                  | 7 (2.4)                   |
| Infections and infestations (SOC)                                                    | 721 ( 40.4)                    | 1097 (45.2)                    | 1239 (49.5)                    | 149 (51.9)                     | 732 (40.0)                      | 1082 (46.2)                     | 1236 (48.9)                     | 154 (49.7)                      | 753 (40.3)                | 1077 (46.1)               | 1235 (49.2)               | 164 (55.2)                |
| Anticholinergic syndrome (SMQ)                                                       | 170 (9.5)                      | 315 (13.0)                     | 435 (17.4)                     | 67 (23.3)                      | 183 (10.0)                      | 300 (12.8)                      | 446 (17.6)                      | 62 (20.0)                       | 207 (11.1)                | 308 (13.2)                | 436 (17.4)                | 72 (24.2)                 |
| Qualityoflifedecreased (PT)                                                          | 0                              | 0                              | 0                              | 0                              | 0                               | 0                               | 0                               | 0                               | 0                         | 0                         | 0                         | 0                         |
| Sum of postural hypotension, falls, black outs, syncope, dizziness, ataxia,fractures | 232 (13.0)                     | 471 (19.4)                     | 663 (26.5)                     | 103 (35.9)                     | 242 (13.2)                      | 420 (17.9)                      | 679 (26.9)                      | 87 (28.1)                       | 265 (14.2)                | 485 (20.7)                | 701 (28.0)                | 105 (35.4)                |
| Other AEs appearing more frequently in older subjects [b]                            |                                |                                |                                |                                |                                 |                                 |                                 |                                 |                           |                           |                           |                           |

[b]PleaserefertoTable2

[a]AEs leading to drop out =Subjects with non-bleedingTEAEthat caused study drugpermanent discontinuation.

Source:TableT-Q147-001,Table T-Q147-002,Table T-Q147-003,Table T-Q147-004,Table T-Q147-005

Table S-27: Overview of Non-Bleeding TEAEs by Age, Safety Analysis Set; Treatment + 30 Days Period: Hokusai VTE

|                                                                                  | Edoxaban (N = 4118) n (%)   | Edoxaban (N = 4118) n (%)   | Edoxaban (N = 4118) n (%)   | Edoxaban (N = 4118) n (%)   | Warfarin (N =4122) n (%)   | Warfarin (N =4122) n (%)   | Warfarin (N =4122) n (%)   | Warfarin (N =4122) n (%)   |
|----------------------------------------------------------------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|
|                                                                                  | <65y M= 2784                | ≥65<75y M=774               | ≥75-<85 y M=486             | ≥85+y M=74                  | <65y M= 2752               | ≥65<75y M= 826             | ≥75-<85y M=463             | ≥85+y M=81                 |
| Total with AEs                                                                   | 1882 (67.6)                 | 573 (74.0)                  | 363 (74.7)                  | 61 (82.4)                   | 1972 (71.7)                | 598 (72.4)                 | 358 (77.3)                 | 61 (75.3)                  |
| Serious AEs - Total Subjects                                                     | 298 (10.7)                  | 134 (17.3)                  | 108 (22.2)                  | 27 (36.5)                   | 350 (12.7)                 | 135 (16.3)                 | 104 (22.5)                 | 21 (25.9)                  |
| -Fatal                                                                           | 39 (1.4)                    | 22 (2.8)                    | 19 (3.9)                    | 6 (8.1)                     | 40 (1.5)                   | 22 (2.7)                   | 14 (3.0)                   | 4 (4.9)                    |
| -Hospitalization/prolongexisting hospitalization                                 | 260 (9.3)                   | 118 (15.2)                  | 93 (19.1)                   | 26 (35.1)                   | 279 (10.1)                 | 114 (13.8)                 | 86 (18.6)                  | 19 (23.5)                  |
| - Life-threatening                                                               | 14 (0.5)                    | 10 (1.3)                    | 6 (1.2)                     | 4 (5.4)                     | 7 (0.3)                    | 3 (0.4)                    | 3 (0.6)                    | 0                          |
| -Disability/incapacity                                                           | 2(<0.1)                     | 3 (0.4)                     | 3 (0.6)                     | 0                           | 3 (0.1)                    | 1 (0.1)                    | 2 (0.4)                    | 0                          |
| -Other(medically significant)                                                    | 119 (4.3)                   | 42 (5.4)                    | 45 (9.3)                    | 11 (14.9)                   | 169 (6.1)                  | 63 (7.6)                   | 44 (9.5)                   | 7 (8.6)                    |
| AE leading to drop-out[a]                                                        | 105 (3.8)                   | 41 (5.3)                    | 34 (7.0)                    | 15 (20.3)                   | 98 (3.6)                   | 44 (5.3)                   | 40 (8.6)                   | 3 (3.7)                    |
| Psychiatric disorders (SOC)                                                      | 138 (5.0)                   | 60 (7.8)                    | 30 (6.2)                    | 4 (5.4)                     | 121 (4.4)                  | 36 (4.4)                   | 24 (5.2)                   | 6(7.4)                     |
| Nervous system disorders (SOC)                                                   | 344 (12.4)                  | 105 (13.6)                  | 72 (14.8)                   | 12 (16.2)                   | 333 (12.1)                 | 88 (10.7)                  | 61 (13.2)                  | 11 (13.6)                  |
| Accidents and injuries (SMQ)                                                     | 208 (7.5)                   | 78 (10.1)                   | 58 (11.9)                   | 13 (17.6)                   | 239 (8.7)                  | 90 (10.9)                  | 69 (14.9)                  | 15 (18.5)                  |
| Cardiac disorders (SOC)                                                          | 105 (3.8)                   | 50 (6.5)                    | 39 (8.0)                    | 10 (13.5)                   | 100 (3.6)                  | 45 (5.4)                   | 45 (9.7)                   | 9 (11.1)                   |
| Vascular disorders (SOC)                                                         | 178 (6.4)                   | 62 (8.0)                    | 31 (6.4)                    | 10 (13.5)                   | 204 (7.4)                  | 80 (9.7)                   | 44 (9.5)                   | 7 (8.6)                    |
| Cerebrovasculardisorders(SMQ)                                                    | 15 (0.5)                    | 18 (2.3)                    | 9 (1.9)                     | 2 (2.7)                     | 16 (0.6)                   | 16 (1.9)                   | 12 (2.6)                   | 1 (1.2)                    |
| Anticholinergic syndrome (SMQ)                                                   | 161 (5.8)                   | 61 (7.9)                    | 50 (10.3)                   | 9 (12.2)                    | 156 (5.7)                  | 57 (6.9)                   | 51 (11.0)                  | 10 (12.3)                  |
| Infectionsandinfestations(SoC)                                                   | 721 (25.9)                  | 224 (28.9)                  | 138 (28.4)                  | 31 (41.9)                   | 736 (26.7)                 | 221 (26.8)                 | 158 (34.1)                 | 22 (27.2)                  |
| Quality of life decreased (PT)                                                   | 0                           | 0                           | 0                           | 0                           | 0                          | 0                          | 0                          | 0                          |
| Sum of postural hypotension,falls,black outs,syncope,dizziness,ataxia, fractures | 128 (4.6)                   | 56 (7.2)                    | 50 (10.3)                   | 10 (13.5)                   | 148 (5.4)                  | 67 (8.1)                   | 57 (12.3)                  | 12 (14.8)                  |
| Other AEs appearing more frequently in older subjects[b]                         |                             |                             |                             |                             |                            |                            |                            |                            |

[b]PleaserefertoTable 4

[a]AEs leading to drop out=Subjects with non-bleeding TEAE that caused study drug permanent discontinuation.

Source:TableAE100A6575,TableAE100A7585,TableAE100AGE85,TableAE100ALT65,TableAE101A6575,TableAE101A7585,TableAE101AGE85 TableAE101ALT65,TableAE201A6575,TableAE201A7585,TableAE201AGE85,TableAE201ALT65,TableAESA6575,TableAESA7585,Table AESAGE85,TableAESALT65,TableSSAE460LT65,TableSSAE460GE65TO75,TableSSAE460GE75TO85,TableSSAE460GE85,Table ACHOLLT65,TableACHOLGE65TO75,TableACHOLGE75T085,TableACHOLGE85

<div style=\"page-break-after: always\"></div>

## Renally impaired patients:

The Applicant provided the safety evaluation in renally impaired patients (moderate-severe renal impariment: baseline CrCl ≤ 50 mL/min) separately for the two large phase 3 studies. No relevant imbalances (edoxaban vs, warfarin) were observed. Hence, the data provide no hint that safety and tolerability of edoxaban in renally impaired patients is worse than in the general study population. Pneumonia was more frequent with edoxaban in the VTE study (2.6% vs. 0.7%). This was also true for the general study population as discussed under \"Serious Events and Deaths\" subsection.

## Safety related to drug-drug interactions and other interactions

Concomitant medications and bleeding risk: Subgroup analysis of major bleedings in ENGAGE AF  indicated  that  subjects  receiving  concomitant  aspirin  (use  was  permitted  with  a  dose  &lt;100 mg/day), other antiplatelet agents, and thienopyridines had an approximately 2-fold higher annual event  rate  for  major  bleeding  than  those  not  receiving  such  medications.  Additional  SmPC amendments have been implemented in this regard. In most subgroups, the HR for major bleeds for the comparison of the edoxaban 60 mg and edoxaban 30 mg groups with the warfarin group was less than 1. Some small increases above 1 were seen in patients receiving concomitant amiodarone and those not receiving concomitant ACEI/ARB. However, these variations are within expected when many subgroups are analysed.

## Discontinuation due to adverse events

Permanent discontinuations: In the ENGAGE-AF, the percentage of subjects who permanently discontinued study drug was comparable among the edoxaban 30 mg, edoxaban 60 mg, and warfarin treatment  groups  (33.0%,  34.4%,  and  34.5%,  respectively).  The  most  common  reason  for permanent discontinuation of study drug in the edoxaban 30 mg, edoxaban 60 mg, and warfarin treatment groups was AE or suspected endpoint event (15.6%, 17.2% and 16.7%, respectively). In HOKUSAI-VTE,  the  percentage  of  subjects  who  permanently  discontinued  study  drug  was  also comparable between the edoxaban and warfarin treatment groups (16.9% and 17.4%, respectively). The most common reason for permanent discontinuation of study drug in the edoxaban and warfarin treatment groups was non-target endpoint AE (5.7% and 5.4%, respectively). Suspected target endpoints (specified efficacy or safety endpoints) accounted for 3.4% and 3.8%, respectively.

Discontinuations due to bleeding adverse events: In ENGAGE-AF, bleeding leading to study drug interruption was 13.2% in the edoxaban 60 mg group vs. 15.3% in the warfarin group. Bleeds that led to study drug permanent discontinuation were 3.9% in the edoxaban 60 mg group vs. 4.1% in the warfarin group. In HOKUSAI-VTE, bleeding leading to study drug interruption was 2.9% in the edoxaban  group  vs.  5.2%  in  the  warfarin  group.  Bleeds  that  led  to  study  drug  permanent discontinuation were 1.4% in both groups.

Discontinuations  due  to  non-bleeding  AEs: There  were  no  marked differences  between  the treatment groups with regard to the TEAEs leading to permanent treatment discontinuation in pooled phase 3 studies (edoxaban 60 mg 8.6% vs warfarin 8.3%). In summary, in phase 3 trials there were no marked  differences between the treatment groups with regard to overall permanent discontinuations, or those related to bleeding or non-bleeding AEs.

## Post marketing experience

Edoxaban was approved in Japan on 22 Apr 2011 for the prevention of VTE following total knee arthroplasty (TKA), total hip arthroplasty (THA), and hip fracture surgery (HFS). For the purpose of this  MAA,  a  cumulative  output  from  the  global  safety  database  was  generated  from  launch  of

<div style=\"page-break-after: always\"></div>

edoxaban in Japan through to 30 Sep 2013. To obtain the estimated of number of patients exposed to edoxaban, the distribution data between the launch and September 2013 were used. Assuming a dosing period per patient of 14 days regardless of strength, the number of patients exposed to LIXIANA was estimated and the number of total and the most frequent AEs was assessed during post-marketing  experience.  These  events  are  within  expected  in  patients  undergoing  major orthopaedic surgery. No specific clinical data have been generated on the use of activated charcoal to reduce absorption in case of edoxaban overdose.

## 2.6.1. Discussion on clinical safety

The safety database was mainly derived from two Phase 3 studies (ENGAGE-AF in NVAF and Hokusai VTE  in  patients  with  acute  VTE),  which  amounts  to  18,010  patients  treated  with  edoxaban  for approximately 1.9 years. In these studies, edoxaban showed a generally lower rate of adverse events than warfarin,  mainly  driven  by  a  lower  risk  of  major  and  CRNMB  than  warfarin.  The  benefit  in bleedings was consistent across most subgroups analysed, including fragile patients, but was not significant in centers where warfarin was managed optimally. Depending on localisation, edoxaban showed a consistent lower risk of ICH than warfarin but an augmented risk of mucosal bleeding (e.g.: gastrointestinal bleedings and vaginal bleedings), which was associated to a significant number of patients experiencing a drop in Hb &gt; 2 g/dl as compared to baseline.

Major and CRNMB was the more frequent AE with edoxaban (11.1 events per 100 patient-year in NVAF  and  8.5%  in  acute  VTE;  corresponding  MB  rates  were  2.75  %  patient-year  and  1.3%, respectively).  Anaemia  was  reported  for  a  higher  proportion  of  edoxaban  subjects  (4.2%)  than warfarin subjects (2.9%).

Intracranial hemorrhages: Ancillary analyses provided by the Applicant showed that the benefits of edoxaban versus warfarin in ICH were consistent in the worst case (high TTR and European, mainly Western Europe, population). This benefit was consistent with those observed with other similar compounds. The class benefit  seems  to  be  driven  by  an  intrinsically  risk  of  ICH  with  vitamin  K antagonists, which is seen even at high TTR. The absolute benefit of edoxaban versus warfarin was difficult to be established due to low numbers of events, but could be estimated to be around 3 ICH avoided per 1,000 patients treated per year in the European AF population (edoxaban 3 ICH vs warfarin 6 ICH/1,000/yr). In the overall ENGAGE AF study population, the projected benefit was around 5 ICH per 1,000 patients treated (edoxaban 4 ICH vs. warfarin 9 ICH/1,000/yr). In the overall Hokusai VTE study population, the absolute benefit of edoxaban versus  warfarin in ICH may be similar, around 3 ICH avoided per 1,000 patients treated for acute VTE (edoxaban 1 ICH/1,000 vs. warfarin 4 ICH/1,000), but difficult to establish due to low number of events and shorter durations of treatment (usually lasting less than 1 year).

Major bleeding : Patients who experienced major bleedings had older age, higher proportion of renal impairment and concomitant ASA use than patients without major bleedings. These patients were more  represented  in  ENGAGE  AF  than  in  Hokusai  VTE.  In  both  ENGAGE  AF  and  Hokusai  VTE, demographic characteristics in subjects with adjudicated major bleeds were generally comparable between treatment groups, except for concomitant aspirin use in Hokusai VTE which was higher in the edoxaban than the warfarin group. In ENGAGE AF the rate of patients needing hospitalization was less frequent in edoxaban than in warfarin in ENGAGE AF (1.54%/yr vs 1.81%/yr), transfusion ≥ 2 units was  similar  (1.05%/yr  in  both  groups),  as  well  as  need  for  surgery  (0.20%/yr  vs  0.29%/yr). Hospitalization with intensive care was lower with edoxaban (0.7%/yr vs 1.4%/yr). In Hokusai VTE, the rate of patients requiring hospitalization (1.2% vs. 1.2%), transfusion ≥ 2 units (0.7% vs 0.5%), need for surgery (&lt;0.1 vs &lt; 0.1% and hospitalization with inensive care unit (0.3 vs 0.4%) was generally comparable between edoxaban and warfarin treatment groups. There was lower 30-day

<div style=\"page-break-after: always\"></div>

all-cause mortality after major bleeding in the edoxaban 60-mg than the warfarin group (ENGAGE AF: 0.5% vs. 1.0%; Hokusai VTE: 0.1% vs. 0.3%). Major bleed outcome of resolved with sequelae was lower with edoxaban than with warfarin in ENGAGE AF (0.7% vs 1.2%), but not in Hokusai VTE (0.2% vs. 0.1%).

Gastrointestinal  bleedings: In  ENGAGE  AF,  edoxaban  60-mg  subjects  had  a  higher  rate  of Major/CRNM GI bleed than warfarin subjects (3.54%/yr vs. 2.42%/yr), including those requiring hospitalization (1.61%/yr vs. 1.27%/yr) and transfusion (0.97%/yr vs. 0.84%/yr). However, the more severe bleedings, resulting in death of hospitalisation in intensive care unit, are more often reported with warfarin than with edoxaban. The increase in GI bleedings (HR≈ 1.46) mimic those reported with dabigatran 150 mg BID in RE-LY study (HR: 1.52) and rivaroxaban 20 mg OD in ROCKET AF (HR ≈ 1.26) for CRNM GI bleed. Further SmPC changes in sections 4.4 and 4.8 have been implemented to warn about this increase in risk.

Other adverse events: Gastrointestinal TEAEs (diarrhoea, nausea, gastritis and dyspepsia) were also reported for a higher proportion of edoxaban subjects than warfarin subjects (6.3% vs 6% for diarrhoea; 3.4% vs. 2.8% for nausea; 2.1% vs. 1.9% for gastritis and 1.8% vs. 1.6% for dyspepsia, respectively). The most notable difference was for INR increase which was, as anticipated, much more common on warfarin than edoxaban treatment (4.7% compared with 0.5%). The rates of deaths and serious adverse events were similar with edoxaban and warfarin, as where the rates of patients that discontinued study drug. However, some imbalances were found in hepatic events, cases of acute renal failure, acute polyneuropathies and allergic reactions.

From the safety database all the adverse reactions reported in clinical trials have been included in the Summary of Product Characteristics.

## 2.6.2. Conclusions on the clinical safety

Edoxaban was generally associated to a lower risk of adverse events than warfarin, mainly driven by a lower risk of major and CRNMB in pivotal studies. The benefit was consistent across most subgroups analysed, including fragile patients, but was not significant in centers where warfarin was managed optimally. Edoxaban showed a lower risk of ICH than warfarin but an augmented risk of mucosal bleeding (e.g.: gastrointestinal bleedings and vaginal bleedings). Gastrointestinal TEAEs (diarrhoea, nausea, gastritis and dyspepsia) was also reported for a higher proportion of edoxaban subjects than warfarin subjects (6.3% vs 6% for diarrhoea; 3.4% vs. 2.8% for nausea; 2.1% vs. 1.9% for gastritis and 1.8% vs. 1.6% for dyspepsia, respectively). No significant imbalances were found in rates of death or SAEs.

## 2.7. Pharmacovigilance

## Detailed description of the pharmacovigilance system

The CHMP considers that the Pharmacovigilance system as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

## 2.8. Risk Management Plan

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

<div style=\"page-break-after: always\"></div>

The PRAC considered that the risk management plan version 5 could be acceptable if the applicant implements the changes to the RMP as described in the PRAC endorsed PRAC Rapporteur assessment report.

The applicant implemented the changes in the RMP as requested by PRAC.

The CHMP endorsed the Risk Management Plan version 6 with the following content:

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                            |
|------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks   | Bleeding due to: · drug interaction in combination with other drugs known to increase the risk of bleeding eg, aspirin, NSAIDS,  inappropriate administration of 60 mg dose /inadvertent overdose by use of 60-mg dose, eg in combination with use of strong P-gp inhibitors; in patients with low body weight ≤ 60 kg; and in patients with moderate to severe renal impairment (CrCL 15-50 mL/min). |
| Important potential risk     | HepaticDysfunction                                                                                                                                                                                                                                                                                                                                                                                    |
| Important potential risk     | Trend towards decreasing efficacy in NVAF subjects with high Creatinine Clearance                                                                                                                                                                                                                                                                                                                     |
| Missing information          | Lack of reversal agent                                                                                                                                                                                                                                                                                                                                                                                |
| Missing information          | Paediatric use                                                                                                                                                                                                                                                                                                                                                                                        |
| Missing information          | Reproductive and development toxicity [Pregnancy and lactation]                                                                                                                                                                                                                                                                                                                                       |
| Missing information          | Patients with hepatic impairment                                                                                                                                                                                                                                                                                                                                                                      |
| Missing information          | Patients with severe renal impairment (CrCL < 30 mL/min) or end-stage renal disease (CrCL < 15 mL/min or on dialysis)                                                                                                                                                                                                                                                                                 |
| Missing information          | Patients with mechanical heart valves                                                                                                                                                                                                                                                                                                                                                                 |
| Missinginformation           | Combination with dual antiplatelet therapy                                                                                                                                                                                                                                                                                                                                                            |
| Missing information          | Off-label use in Europe in populations or indications outside the approved indications per European SmPC                                                                                                                                                                                                                                                                                              |

<div style=\"page-break-after: always\"></div>

## Pharmacovigilance plan

| Study/activity Type, title and category (1-3)                                                                                                                        | Objectives                                                                                                                                                                                                                                                        | Safety concerns addressed               | Status (planned, started)   | Dateforsubnission of interimorfinal reports (planned or actual)                                                                                                                                                                                                                                            |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Drug utilization study: characterize actual prescribing pattern and assess off- label use (category 3)                                                               | Prescription patterns, assess off-label use in Europe                                                                                                                                                                                                             | Off-label use                           | [Planned]                   | Study design: protocol for EMA comments within 3months of marketing authorization of edoxaban. Study execution and final report within 18 months post-EMA approval of protocol and minimum 1 year post-launch and depending on results may be repeated 1 year later in at least 5 major EEA markets.       |
| PASS: Non- interventional study on Edoxaban treatment in routine clinical practise for patients with non valvular atrial fibrillation (ETNA-AF- Europe) (category 3) | To collect real- world safety data on bleeding events including intracranial haemorrhage, drug related adverse events such as liver adverse events, cardiovascular (CV) and all- cause mortality in AF patients treated with edoxaban up to 4 years. Furthermore, | Safety of edoxaban in clinical practice | [Planned]                   | Execution following approval of protocol by authorities. Submission of full study protocol within 3 months of positive CHMP opinion. Interim reports: Regular interim status reports, yearly data snapshots, pooled safety analysis after 1.5 years (combined with ETNA- VTE-Europe) Final Report: Q4 2021 |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)                                                                                                                      | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | Safety concerns addressed                                                  | Status(planned, started)   | Dateforsubmissionof interimorfinal reports(plannedor actual)                                                                                                                                                                                                                                                         |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                    | subgroup analyses will be performed in predefined patient populations, such aspatients with renal or hepatic impaiiment.                                                                                                                                                                                                                                                                                                                                                                          |                                                                            |                            |                                                                                                                                                                                                                                                                                                                      |
| Non-interventional study onEdoxaban treatmentin routine clinical practice for patientswith acute yenous thromboembolism in Europe (ETNA- VTE-Europe). (category 3) | The co-primary objective isto collectreal world safety safety data on bleeding events, drugrelated adverseevents such asliver adverse events, and mortality (VTE-related and all-cause)in VTEpatients treatedwith edoxaban. Furthermore, safety analyses im pre-specified subpopulations such aspatients with renal impairmentand patients with hepatic impairmentwill beperformed. Primary objectiveisthe analysis of the overall symptomatic VTErecurrence rate during an overall observational | Safety of edoxaban in clinicalpractice VTErecuirence in clinical practice. | [Planned]                  | Execution following approval of protocol by authorities.Submission of full study protocol within3monthsof positive CHMP opinion. ApproximateInterim reports: Regular interim statusreports,yearly data snapshots,pooled safetyanalysisafter1.5 years(combinedwith ETNA-AF-Europe) Final report: Approximately Q22020 |

<div style=\"page-break-after: always\"></div>

| Study/activity Type,title and category (1-3)                                                                                                                                                                                                                                                    | Objectives                                                                                | Safetyconcerns addressed                  | Status(planned, started)                                  | Dateforsubmissionof interimorfinal reports(planned or actual)   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------------|
|                                                                                                                                                                                                                                                                                                 | periodof 18 months in unselected patients with acute VTE.                                 |                                           |                                                           |                                                                 |
| This study is sponsored by companyPortola supported by the applicant: ARandomized Double Blind, Vehicle-Controlled MultipleDose Studyto Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic sofIntravenously Administered PRT064445After Dosing toSteady State with Edoxaban | To identify whether PRT064445can reversethe effectofFactor Xa inhibitors                  | Reversibility of edoxabaneffect inhumans  | Ongoing                                                   | TBD                                                             |
| This study is sponsored by company Perosphere, supported by the applicant: A \"phase II Randomized, Sequential Group, Evaluation of Ascending Reversal Dosesof PER977 Administeredto Subjects with SteadyState Edoxaban Dosing and Re-                                                           | To identify whether PER977can effectively reversethe effectofFactor Ia and Xa inhibitors. | Reversibility of edoxabaneffect in humans | Ongoing. Clinical completionis anticipatedin December2014 | CSR planned for July 2015                                       |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)                                                                                                                                                                                  | Objectives                                                          | Safetyconcerns addressed              | Status (planned, started)   | Datefor'submissionof interim orfinal reports(plannedor actual)                  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------|-----------------------------|---------------------------------------------------------------------------------|
| anticoagulation withEdoxaban FollowingPER977 Reversal\" (category 3)                                                                                                                                                            |                                                                     |                                       |                             |                                                                                 |
| Stago is planning toconductafor- registration study in March 2015.It isplanned tofile for CE Marking of the anti-FXa assay in Q1 2016. Commercially available assay planned to be available approximately Q2 2016 (category 3) | To develop a commercial calibrated quantitative anti FactorXa assay | Measurementof edoxabanlevels inhumans | Planned                     | Commerciallyavailable anti-FXa assayplanned tobe available approximately Q22016 |

## Risk minimisation measures

| Safetyconcern                                                               | Routineriskminimization measures         | Additionalriskminimization measures                             |
|-----------------------------------------------------------------------------|------------------------------------------|-----------------------------------------------------------------|
| Bleeding                                                                    | SmPC/PIL Prescription onlymedicine (POM) | EducationalPackageincluding Prescriber's guide PatientAlertcard |
| HepaticDysfunction                                                          | SmPC/PIL POM                             | None                                                            |
| Trendtowardsdecreasing efficacyinNVAF subjectswith high CreatinineClearance | SmPC POM                                 | None                                                            |
| Missinginformation                                                          | SmPC/PIL POM                             | EducationalPackageincluding Prescriber's guide                  |

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Package leaflet

The Applicant proposed to include a Quick Response (QR) code in the Package leaflet that links to a patient website. The home page will require the patient to select their country and whether they are taking Lixiana for NVAF or VTE.

<div style=\"page-break-after: always\"></div>

The CHMP considered that the information initialy proposed to be included within the product website via QR code was not acceptable. The CHMP agreed with the inclusion of a QR code as long as it only links to the statutory information approved (i.e. SmPC, Package leaflet or educational material agreed in the RMP).

## 3. Benefit-Risk Balance

## Benefits

## Beneficial effects

The ENGAGE AF was a large (n=21,105 patients) double-blinded, event-driven, non-inferiority clinical trial  where  patients  with  NVAF  were  randomised  to  either  edoxaban  30mg  once  daily  treatment group, or edoxaban 60mg once daily treatment group or warfarin.

The  study  provided  evidence  of  non-inferiority  for  edoxaban  60  mg  OD  versus  warfarin  for  the composite of all strokes and SEE (HR: 0.79; 97.5% CI: 0.632, 0.985; non-inferiority margin: 1.38; p&lt;0.0001 for non-inferiority; mITT, on treatment) and for the composite of ischemic strokes and SEE (HR:  0.92;  95%CI:  0.73-1.15;  PP,  on-treatment)  (endpoint  recommended  in  the  current EMA Guideline on clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with NVAF [EMA/CHMP/341363/2014]) ).

The mean time in therapeutic range (TTR) (INR: 2-3) was 64.9% (median 68.4%), the highest across the contemporary AF studies, and the rate of stroke/SEE event rate in the warfarin arm (1.5%/yr) was the lowest.

Analyses of composite (first-event) endpoint of stroke, SEE, and CV mortality, the endpoint of MACE, and the composite endpoint of stroke, SEE, and all-cause mortality were consistent with the analysis of the primary endpoint. The trend for superiority of the high edoxaban dose (60 mg OD) versus warfarin for the primary endpoint was supported by secondary analyses of patients with fatal strokes (80 vs. 86) disabling strokes (54 vs. 57), recurrent stroke/SEE events (5 vs. 8; mITT, on-treatment period) and analysis of the composite of stroke, SEE and TIA (HR: 0.88; 95%CI: 0.746 to 1.042; mITT on-treatment period).

Given  that  NVAF  population  and  AF  management  were  heterogeneous,  exploratory  analyses  of subgroups in ENGAGE-AF were conducted by INR/TTR level by centre and quartiles as well as by at least 14 patient/study characteristics. Subgroup analyses by patient/study characteristics showed a generally consistent effect of edoxaban in most subgroups, but not in some relevant ones (see: Uncertainty in the knowledge about the beneficial effects).

## HOKUSAI VTE: Treatment of VTE including DVT and PE, and prevention of recurrent VTE

HOKUSAI VTE was a large (n=8292) double-blinded, event-driven, non-inferiority comparative trial (edoxaban  60  mg  OD  vs  warfarin)  in  patients  with  acute  VTE.  Approximately  41%  of  patients presented with PE as index event. Intended treatment duration was 3 months in 6% of patients, 6 months in 37% of patients and 12 months in 57% of patients. Edoxaban and warfarin regimes were preceded by heparin lead-in treatment for at least 5 days.

The study showed evidence of non-inferiority with regard to the composite endpoint of documented symptomatic recurrent VTE (HR: 0.89; 95% CI: 0.70-1.13; non-inferiority margin = 1.5; p&lt;0.0001 for non-inferiority; mITT, overall study period). For subjects presenting with PE (with or without DVT), 50 (1.2%) edoxaban and 58 (1.4%) of warfarin subjects had a recurrent VTE [HR (95% CI): 0.85 (0.64, 1.14)].

<div style=\"page-break-after: always\"></div>

The effect of edoxaban was generally consistent across subgroups tested in the HOKUSAI-VTE study. Overall, of the 55 comparisons presented from 18 subgroup analyses, most (45) resulted in a point estimate favouring edoxaban. Edoxaban effect was (significantly) better in fragile than in non-fragile patients. In general, the effects of edoxaban were also better (although no statistically significant interaction was found) in index PE, age &gt;75 years and history of cancer, which is reassuring.

Regarding the quality of oral anticoagulation, the mean TTR was 63.5%, which is higher than that reported in other contemporary studies with NOACs in this indication (from 57% in RE-COVER II to 62.7% in EINSTEIN PE). The edoxaban group had a relative reduction in risk for recurrent  VTE compared to warfarin for subjects at centers TTR &lt; 60% (HR: 0.89; 95% CI: 0.574, 1.364) and also at centers with TTR ≥60% (HR: 0.87; 95% CI: 0.653, 1.153).

## Uncertainty in the knowledge about the beneficial effects.

The utility of the lowest edoxaban dose (15 mg) was restricted to the process of switching from Lixiana to VKA for patients currently on edoxaban 30 mg (reduced dose in patients with presumed increased exposure). It was unclear whether dose reduction from 30 mg OD to 15 mg was necessary in this process and if the 15 mg dose will provide a sufficient level of anticoagulation. The applicant modelled factor Xa activity over the 24-hour dosing period for the doses used in the ENGAGE AF study and showed that even the 15 mg dose has some antithrombotic effect, although lower than that of a full  therapeutic  dose,  as  expected.  However,  edoxaban  15  mg  is  not  to  be  administered  in monotherapy, but only concomitantly with warfarin during the switching procedure. The ENGAGE AF protocol included 15 mg strength as provision intended to mitigate the risk of bleeding expected for those patients who were taking two oral anticoagulants concomitantly.

## ENGAGE AF: Prevention of stroke and SEE in patients with non-valvular atrial fibrillation

Although  the low  edoxaban  dose (30  mg  OD)  showed  non-inferiority  versus  warfarin  for  all strokes/SEE (HR: 1.07; 97.5% CI: 0.87-1.31; p=0.0055 for non-inferiority; mITT, on-treatment), it was inferior to warfarin for the composite of ischemic stroke/SEE 1.47 (HR: 95% CI: 1.20 to 1.80; PP, on-treatment).  The  trend  for  inferior  efficacy  of  edoxaban  30  mg  OD  versus  warfarin  was  also supported by the analysis of pure thromboembolic events (ischemic stroke/SEE as well as MI), by the higher number of disabling strokes (82 and 57 subjects in edoxaban 30 mg group and the warfarin group, respectively), by the number of patients who had ≥ 2 occurrences of the primary efficacy endpoint (21 and 8 subjects in edoxaban 30 mg group and the warfarin group, respectively; mITT analysis set, on-treatment period) as well as by the high number of events when TIA was added to stroke and SEE (edoxaban 30 mg event rate 2.28% per year vs warfarin 1.92% per year; HR: 1.19; 95%CI: 1.021 to 1.389; mITT on-treatment period).

Exploratory analyses of subgroups in ENGAGE-AF were conducted by INR/TTR level by centre and quartiles as well as by at least 14 patient/study characteristics. However, stroke/SEE rates tended to favour warfarin in patients recruited in Western Europe and those with normal renal function .

The interpretation of the results in Western Europe was hampered by the limitations of subgroup analyses and the low event rates. Whether these regional variations may be acceptable in the context of the heterogeneous countries of EEA region was discussed taking into account the fact that ENGAGE AF demonstrated non-inferiority of edoxaban 60 mg versus a well-controlled warfarin regime in the overall population. In addition, all-cause mortality and CV mortality were broadly similar in the overall vs. on-treatment analysis in both the edoxaban and warfarin groups in Western Europe. In summary, the overal study results were considered representative for the European population.

In NVAF, although the overall benefit risk in the AF indication was considered positive across the continuum of renal function at the population level, there were indications of reduced efficacy of

<div style=\"page-break-after: always\"></div>

edoxaban compared to well-managed warfarin therapy that could be of relevance at the individual level  in  patients  with  increased  creatinine  clearance.  In  general,  a  trend  towards decreasing efficacy  with  increasing  creatinine  clearance was  observed  for  edoxaban  compared  to well-managed  warfarin.  The  data  in  patients  with  normal  renal  function  were  considered  to  be sufficiently robust, making a chance adverse finding unlikely. They may be explained to a combination of a lower exposure to edoxaban 60 mg in patients with normal renal function (in comparison with the exposure to 60 mg in patients with mild renal impairment) and a well-managed warfarin therapy resulting in a low stroke/SEE rate in the control group, particularly in patients with high creatinine clearances. Therefore, a warning has been included regarding this trend in the SmPC.

Subgroup analyses of stroke/SEE by INR/TTR level suggest that the effect  size  (reduction  of stroke/SEE by edoxaban) decreases as the quality of anticoagulation in the control group increases (i.e.:  in  centers  with  TTR  &gt;  60%  and  when  INR/TTR  was  above  the  fourth  quartile, &gt;73.9%). When the TTR data were examined by quartiles for the edoxaban 60 mg group compared to warfarin, the HR for the primary endpoint in the 1st, 2nd, and 3rd quartile was 0.80, 0.73, and 0.74, respectively, and for the 4th quartile was 1.07 (95%CI: 0.65-1.75). For the edoxaban 30 mg group compared to warfarin, the HR for 1st, 2nd, 3rd, and 4th quartiles were 0.82, 1.02, 1.22, and 1.30 (95%CI: 0.81-2.09), respectively. These data were expected in the light of similar results in previous studies with novel oral anticoagulants in NVAF and were presented in the SmPC.

The analyses of efficacy in ENGAGE-AF by subgroups excluding haemorrhagic stroke were provided (i.e.: including only ischemic stroke and SEE). The event rate for composite of ischemic stroke and SEE was lower in the edoxaban 60-mg group than in the warfarin group for most subgroups, with the HR less than 1.0 for the overall study period, but in some of the sub-groups the HR was more than 1.0. However, there were several significant (p&lt;0.05) interactions:

-for the type  of  atrial  fibrillation : The HR was 0.79 and 0.85 for subjects with persistent and permanent AFs and 1.73 for subjects with paroxysmal AF. However, this finding was based on a relatively low number of events and patients in this subgroup. The variations in stroke/SEE rates in the warfarin group was the main responsible for the interaction.

- for the VKA-naïve versus VKA experienced subjects: The HR was 0.75 for VKA naïve subjects and 1.17 for VKA experienced subjects. VKA-experienced patients comprised the majority of patients enrolled in ENGAGE-AF (59%). The finding indicated that switching from warfarin to edoxaban was not associated with a benefit in efficacy. Considering the primary endpoint of stroke/SEE, a significant interaction was found for the overall study period for prior VKA use (p=0.0253) but this was not observed for the on-treatment period (p=0.3545). The most important patient characteristics of the VKA experienced subjects in the ENGAGE AF study was the high TTR at 70%. Nonetheless, for the primary endpoint of stroke/SEE, edoxaban 60 mg did show similar efficacy and even for ischemic stroke, any gap in efficacy was less than 0.5%/year and was offset by a clinically significant decrease in major bleeds, resulting in similar net clinical outcome and all-cause mortality.

- for the verapamil subgroup : The HR was 0.92 for subjects without concomitant verapamil and 2.59  for  subjects  who  took  concomitant  verapamil.  Verapamil  use  was  very  low  (&lt;5%  of  total population) and number of events were low (18 vs. 7). Nevertheless, it suggests that the edoxaban 30 mg dose used in these patients was insufficient and 60mg dose was recommended for these patients.

No data were available on subjects during the first 3 months after implantation of a bioprosthetic heart valves , and therefore a non-recommendation of use was included in the product information.

The extrapolation of the data to patients with CHADS2 index score=1 (included in the indication) was accepted.

<div style=\"page-break-after: always\"></div>

## HOKUSAI VTE: Treatment of VTE including DVT and PE, and prevention of recurrent VTE

Although recurrent VTE (DVT or PE) (main efficacy endpoint) favoured numerically edoxaban over warfarin in the overall study period, there was a numerical imbalance in the number of all-cause deaths in the overall study period of the HOKUSAI-VTE study (edoxaban 122 vs warfarin 106), thus leading to a hazard ratio of 1.00 in the superiority analysis of recurrent VTE and all-cause death for the overall study period (HR: 1.00; 95%CI: 0.83-1.20; p=0.9933). Analysing the time-course of deaths, the imbalance was not attributed to the on-treatment deaths (edoxaban 35 vs warfarin 33) but to an excess in deaths due to infectious diseases in the edoxaban arm after treatment had been stopped. This imbalance was not seen in the ENGAGE-AF study in a population with AF.

No specific VTE extension studies have been conducted with edoxaban. However, the design and analysis (mITT Overall versus On-Treatment) of the study allowed assessing extension of therapy/the secondary  prevention  of  VTE  without  the  need  for  a  formal  extension  study.  The  main  issue  in HOKUSAI-VTE regarding duration of therapy was that many patients may have benefited from longer anticoagulative treatment durations. Therefore, it was agreed not to limit the duration of treatment of VTE to the 1 year study duration of HOKUSAI-VTE.

During  pivotal  studies,  dose  reductions  were  made  in  patients  concomitantly  receiving P-gp inhibitors . However, the totality of the data does not support diminishing the dose when edoxaban 60 mg is concomitantly administered with verapamil, quinidine or amiodarone, and this was reflected in the SmPC.

## Risks

## Unfavourable effects

The safety database is mainly derived from two Phase 3 studies (ENGAGE-AF in NVAF and Hokusai VTE in patients with acute VTE), which amounts to 18,010 patients treated with edoxaban for a mean of approximately 1.9 years. Major and clinically-relevant nonmajor (CRNM) bleeding was the most frequent AE with edoxaban (11.1 events per 100 patient-year in NVAF and 8.5% in acute VTE; corresponding  major  bleeding  (MB)  rates  were  2.75  %  patient-year  and  1.3%,  respectively). Anaemia was reported for a higher proportion of edoxaban subjects (4.2%) than warfarin subjects (2.9%) in the pooled Phase 3 studies. In these studies, edoxaban showed a generally lower risk of MB and CRNMB than warfarin. The benefit was consistent across most subgroups analysed, including fragile patients, but was not significant in centers where warfarin was managed optimally. Depending on localisation, edoxaban showed a consistently lower risk of ICH than warfarin but an augmented risk of mucosal bleeding (e.g.: gastrointestinal bleedings and vaginal bleedings), which was associated with a significant number of patients experiencing a drop in Hb &lt; 2 g/dl as compared to baseline. Gastrointestinal TEAEs (diarrhoea, nausea, gastritis and dyspepsia) was also reported for a higher proportion of edoxaban subjects than warfarin subjects (6.3% vs 6% for diarrhoea; 3.4% vs. 2.8% for nausea; 2.1% vs. 1.9% for gastritis and 1.8% vs. 1.6% for dyspepsia, respectively). The most notable difference was for INR increased which was, as anticipated, much more common on warfarin than edoxaban treatment (4.7% compared with 0.5%). The rates of deaths and serious adverse events were similar with edoxaban and warfarin, as where the rates of patients that discontinued study drug. However, some imbalances were found in hepatic events, cases of acute renal failure, acute polyneuropathies and allergic reactions, and MACE (Hokusai VTE study only) (see Uncertainty in the knowledge about the unfavourable effects).

## Uncertainty in the knowledge about the unfavourable effects Bleeding events

<div style=\"page-break-after: always\"></div>

It seems that an important benefit of edoxaban, as with other NOACs, was the reduction in ICH. However, the projected benefit in ICH may be highly dependent on the expected rate of ICH with warfarin in standard practise. For example, the rates of ICH with warfarin in patients with NVAF in standard practice in North-America and Europe are low (approximately 0.4 per 100 patients-year in both), which is much lower than the 0.85 per 100 patient-year incidence found with warfarin in ENGAGE-AF. In addition, in ENGAGE-AF, there was no difference between edoxaban 60 mg and warfarin with regard to overall major bleedings when warfarin treatment was optimally managed (i.e.: in centers with TTR &gt; 66.4%), which is the rule in many European centers. Similar results were found in Hokusai-VTE with respect to the lack of reduction in bleeding events when warfarin was optimally managed. The consequences of major bleedings seemed more benign with edoxaban than with warfarin as shown by a lower 30-day all-cause mortality after major bleeding in the edoxaban 60-mg than the warfarin group in both trials, and by a lower rate of hospitalization due to major bleeding in AF patients. Ongoing development plans for assay to measure the anticoagulant activity and potential specific reversal agents have been included in the agreed RMP.

## Hepatic safety

There were some imbalances against edoxaban 60 mg versus warfarin  in pooled phase 3 studies in: a) the cases of hyperbilirubinaemia (edoxaban 60 mg 0.3% vs warfarin 0.1%); b) and concurrent elevation of ALT or AST ≥ 3 x ULN &amp; Total Bilirubin ≥ 2 x ULN (edoxaban 60 mg 0.4% vs warfarin 0.3%, corresponding to 43 and 29 cases, respectively; Pooled Phase 3 trials); c) the percentage of subjects in the edoxaban 60 mg group versus warfarin that were characterized by an independent hepatologist as having a hepatocellular injury (1.1% vs. 1.0%, respectively); d) In the percentage of cases of liver injury possibly/probably related to study drug [(edoxaban 60 mg 0.4% (48 of 11008 subjects)  versus  warfarin  0.3%  (30  of  11010  subjects)];  e)  in  the  percentage  of  liver  injury adjudicated as severe (edoxaban 60 mg 0.4% vs warfarin 0.3%) ; f) and in the number of Hy's law cases  adjudicated  as  severe  hepatocellular  liver  injury  possibly/probably  related  to  study  drug (edoxaban any dose 2 vs warfarin 1). It was agreed to add important safety information related to hepatic  safety  to  the  SmPC.  The  issue  will  be  further  investigated  in  the  non-interventional post-authorization safety study (PASS) in patients with AF.

There were other non-bleeding events reported during phase 3 studies, including: acute renal failure, acute polyneuropathies, anaphylactic reactions, interstitial lung disease, and MACE in which a small numerical increase was seen for edoxaban in comparison with warfarin. It was agreed that some of these numerical imbalances like acute polyneuropathies and MACE, are likely due to chance. Acute renal failure could be associated with some severe bleedings, and allergic reactions were within what has been reported for other NOACs.

## Benefit-risk balance

## Importance of favourable and unfavourable effects

Strokes in association with AF are often fatal, and those patients who survive are left more disabled by their stroke and more likely to suffer a recurrence than patients with other causes of stroke. Edoxaban 60 mg OD showed at least similar efficacy compared to warfarin in reducing stroke rates in NVAF. This was supported by secondary analyses of patients with fatal strokes, disabling strokes (54 vs. 57) and recurrent stroke/SEE events. Venous thromboembolism (VTE), encompassing deep vein thrombosis  (DVT)  and  pulmonary  embolism  (PE),  is  the  third  leading  cause  of  mortality  due  to circulatory diseases, only behind myocardial infarction and stroke. Edoxaban 60 mg OD also showed similar efficacy compared to warfarin in preventing recurrent VTE.

With respect to safety, an important benefit of edoxaban, as with other new anticoagulants, is the reduction in ICH. However, the projected benefit in ICH may be highly dependent on the expected

<div style=\"page-break-after: always\"></div>

rate of ICH with warfarin in different conditions in standard practise. In addition, edoxaban showed an augmented risk of mucosal bleeding (e.g.: gastrointestinal bleedings and vaginal bleedings), which was associated with a significant number of patients experiencing a drop in Hb &gt; 2 g/dl as compared to baseline. It was reassuring that the most severe bleedings were less frequent with edoxaban than with warfarin. The information about increase in mucosal bleedings was added as warning in the SmPC. Finally, no differences in overall number of deaths were found between warfarin and edoxaban in pivotal studies.

All  these  data  suggest  that  edoxaban  is  non-inferior  to  warfarin  in  both  indications,  with  some advantages related to ICH but disadvantages related to mucosal bleedings.

## Benefit-risk balance

The overall benefit-risk balance of edoxaban was considered positive.

## Discussion on the benefit-risk balance

In NVAF, although the overall benefit-risk balance in the NVAF indication was considered positive across the continuum of renal function at the population level, there were indications of reduced efficacy of edoxaban compared to well-managed warfarin therapy that could be of relevance at the individual level in patients with increased creatinine clearance.

In general, a trend towards decreasing efficacy with increasing creatinine clearance was observed for edoxaban compared to well-managed warfarin. A warning has been included in section 4.4 of the SmPC  to  create  awareness  about  this  observation.  The  applicant  agreed  to  further  evaluate post-marketing whether a higher QD dose would provide a further improvement of the benefit-risk relationship in patients with high creatinine clearance This was included in the agreed version of the RMP  as  MEA  to  address  potential  risk:  'trend  towards  decreasing  efficacy  in  patients  with  high creatinine clearance

Monitoring  of  anti-Xa  activity  may  be  helpful  to  individualise  the  treatment  and  dose  in  certain circumstances  (e.g.:  at  the  beginning  of  treatment  in  patients  with  cumulative  risk  factors  for decreased exposure, in case of high renal clearance combined with high body weight; in case of emergency or overdose). The Applicant has submitted a plan for developing a validated anti-Xa test to measure edoxaban's anticoagulant activity. The anti-Xa assay will be first validated retrospectively by using anti-Xa, efficacy/safety data from pivotal trials, and then prospectively in future clinical trials.

In the treatment of acute VTE, HOKUSAI VTE provided evidence of non-inferiority of edoxaban 60 mg versus warfarin (both regimes preceded by heparin lead-in treatment). No specific VTE extension studies have been conducted with edoxaban. However, the design and analysis (mITT Overall versus On-Treatment) of the study allowed assessing extension of therapy/the secondary prevention of VTE without the need for a formal 'extension' study. It was also agreed not to limit the duration of treatment of VTE to the 1 year study duration of HOKUSAI-VTE but to leave the decision to the treating physician taking into account clinical practice guidelines, which recommend that the duration of therapy be individualised.

In both pivotal studies, edoxaban showed a generally lower risk of MB and CRNMB than warfarin. The benefit  was  consistent  across  most  subgroups  analysed,  including  fragile  patients,  but  was  not significant in centers where warfarin was managed optimally. Again, it was debated whether the safety advantage found in these studies can be extrapolated to many European centers in which warfarin treatment is optimal. Depending on localisation, edoxaban showed a lower risk of ICH than warfarin,  which  was  considered  a  major  benefit,  consistent  with  that  reported  for  other  NOACs. Edoxaban  showed  an  augmented  risk  of  mucosal  bleeding  (e.g.:  gastrointestinal  bleedings  and

<div style=\"page-break-after: always\"></div>

vaginal bleedings), which was associated with a significant number of patients experiencing a drop in Hb &lt; 2 g/dl as compared to baseline.

There were some imbalances in hepatic events not favouring edoxaban 60 mg versus warfarin. A definitive association between these novel oral factor Xa inhibitors and risk of hepatic injury has not been confirmed. The uncertainties have been solved with SmPC ammendments and an RMP plan to further investigate this potential risk postauthorisation.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Lixiana in the

Prevention  of  stroke  and  systemic  embolism  in  adult  patients  with  nonvalvular  atrial  fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).

Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).

is favourable and therefore recommends  the granting of the marketing authorisation subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to medical prescription.

## Conditions and requirements of the Marketing Authorisation

## · Periodic Safety Update Reports

The marketing authorisation holder shall submit the first periodic safety update report for this product within 6 months following authorisation. Subsequently, the marketing authorisation holder shall submit periodic safety update reports for this product in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## · Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the Marketing Authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

If the dates for submission of a PSUR and the update of a RMP coincide, they can be submitted at the

<div style=\"page-break-after: always\"></div>

same time.

## · Additional risk minimisation measures

Prior to launch of Lixiana in each Member State, the Marketing Authorisation Holder (MAH) must agree the content and format of the educational programme, including communication media, distribution modalities, and any other aspects of the programme, with the National Competent Authority.

The educational programme is aimed at mitigating the risk of serious bleeds or haemorrhage in patients treated with Lixiana by ensuring prescriber awareness and providing guidance on appropriate patient selection, correct dosing as well as management of the risk.

The programme is also aimed at ensuring that the healthcare professionals who intend to prescribe Lixiana are aware of the Patient alert card and that the card is to be given to and reviewed with all patients treated with Lixiana.

The MAH shall ensure that in each Member State where Lixiana is marketed, all healthcare professionals who are expected to use Lixiana are provided with the following educational material:

- The Summary of Product Characteristics
- Prescriber Guide for healthcare professionals
- Patient alert card

The Prescriber Guide for healthcare professionals shall contain the following key elements:

- Relevant information on the risk of bleeding
- Details of the population potentially at higher risk of bleeding
- Contraindications
- Recommendations for dose adjustment in at risk populations, including patients with renal or hepatic impairment, low body weight and concomitant use of some P-gp inhibitors
- Guidance on switching from or to Lixiana treatment
- Guidance regarding surgery or invasive procedure, and temporary discontinuation
- Management of overdose situations and haemorrhage
- Use of coagulation tests and their interpretation
- That all patients should be provided with a Patient alert card and be counselled about:
-  The signs or symptoms of bleeding and when to seek attention from a healthcare provider
-  Importance of treatment compliance
-  Necessity to carry the Patient alert card with them at all times
-  The need to inform Health Care Professionals that they are taking Lixiana if they need to have any surgery or invasive procedure

The Patient alert card should contain the following key safety messages:

- The signs or symptoms of bleeding and when to seek attention
- Importance of treatment compliance
- Necessity to carry the Patient alert card with them at all times
- The need to inform Health Care Professionals that they are taking Lixiana if they need to have any surgery or invasive procedure

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.

These conditions fully reflect the advice received from the PRAC.

## New Active Substance Status

Based on the CHMP review of data on the quality properties of the active substance, the CHMP

<div style=\"page-break-after: always\"></div>

considers that edoxaban tosilate is qualified as a new active substance.

## Paediatric Data

Furthermore,  the  CHMP  reviewed  the  available  paediatric  data  of  studies  subject  to  the  agreed Paediatric  Investigation  Plan  P/0028/2014and  the  results  of  these  studies  are  reflected  in  the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

In  accordance  with  Article  45(3)  of  Regulation  (EC)  No  1901/2006,  assessment  of  studies significance, in the agreed paediatric investigation plan P/0028/2014 is not applicable, as none of the studies were initiated before entry into force of the Regulation and completed after this.